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Antimalarial drug resistance has always been an obstacle in the fight against malaria. 
Malaria parasites have developed resistance to most available antimalarial drugs and, 
more recently resistance to artemisinins, the first-line treatment for malaria, is 
emerging and spreading in Southeast Asia. Artemisinin resistance is characterized by  
delayed parasite clearance times observed in malaria patients. For now this resistance 
is considered to be partial by the WHO and artemisinin-combination therapies remain 
as the mainstay of antimalarial treatment. 
In vitro assays are of paramount importance to detect and monitor drug resistance. 
Several in vitro drug assays exist,	however their inherent characteristics, such as the 
use of radioactive or expensive reagents and their long turn-around times limit their 
application.  
The project developed in the context of this thesis aimed to develop a novel drug 
assay for Plasmodium spp. that would overcome some of the limitations of currently 
available drug assays. The underlying idea was to use hemozoin, a crystal produced 
by malaria parasites, to measure their own growth or maturation which would allow to 
detect drug effects.  
The hemozoin content increases as parasites mature inside the erythrocytes. Thus, 
hemozoin constitutes an optimal parasite maturation biomarker. Moreover, it is a 
birefringent crystal, and as such it is able to depolarize light. The resulting light 
depolarization can be easily detected by optical methods such as flow cytometry. It 
was previously shown by our laboratory that in a rodent model of malaria 
depolarization caused by hemozoin inside infected erythrocytes could be detected 
using a simple flow cytometric set-up. Moreover, the inhibitory effect of commonly 
used antimalarial drugs could also be determined after only 6-8 hours of incubation. 
The main objectives of the work developed during this thesis was to further develop 
the flow cytometric detection of hemozoin assay using P. falciparum in vitro cultures 





A benchtop flow cytometer (Cyflow SL) was modified to allow the detection of light 
depolarization and it was used for all studies. Other commercially available 
cytometers (MoFlo, Accuri C6, Attune) were also easily adapted to detect light 
depolarization, showing that the measurement of this additional parameter can be 
accomplished in different instruments.   
In vitro cultures of P. falciparum were established and allowed to further investigate 
the potential of this novel method. Ring-stage synchronized cultures of P. falciparum 
were incubated with several antimalarial drugs (chloroquine, mefloquine, quinine, 
artemisinin, artesunate and pyrimethamine). Analysis of depolarizing events, 
corresponding to parasitized erythrocytes containing hemozoin, allowed the detection 
of parasite maturation. Furthermore, chloroquine resistance and the inhibitory effect 
of all antimalarial drugs tested, except for pyrimethamine, could be determined as 
early as 18 - 24 hours of incubation. The 50% inhibitory concentrations (IC50) 
obtained at 24 hours of incubation were comparable to previously reported values. 
However, these values were most of the times higher than the ones obtained with the 
already validated HRP2 ELISA assay. Indeed, IC50 values may differ considerably 
between assays. Different assays measure different parameters to assess parasite 
growth, at different time-points. Moreover, variations in parasite density and 
hematocrit as well as the stage-dependent action of antimalarial drugs, may influence 
these values. Altogether, explaining the differences in IC50 values that are commonly 
observed. 
The performance of the hemozoin detection assay in the field was assessed during a 6-
month trial performed in Gabon, a malaria endemic country. The trial was conducted 
in the Centre de Recherches Médicales de Lambaréné – Albert Schweitzer Hospital. 
On site, an existing flow cytometer (Cyflow SL) was modified to detect light 
depolarization caused by hemozoin. A total of 46 samples from malaria patients were 
analyzed during this study. Blood samples were incubated with increasing 
concentrations of chloroquine, artesunate and artemisinin. The percentage of 
depolarizing cells was used as maturation indicator and measured at 24, 48 and 72 
hours of incubation to determine parasite growth and drug effects. Analysis of ex vivo 
cultures of parasites obtained from blood samples of malaria patients showed four 
different growth profiles. The flow cytometric detection of hemozoin allowed to 
detect drug effects in 39/46 (85%) of samples. In 25 samples drug effects were 
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measurable at 24 hours. In the remaining 14 samples parasite maturation was delayed, 
and thus drug effects were only detected at 48 hours of incubation. Obtained IC50 
values showed that chloroquine-resistant parasites were still common and present in 
Lambaréné, Gabon but they were fully sensitive to artesunate and artemisinin.  
Finally, the usefulness of the hemozoin detection assay in the investigation of 
artemisinin resistance in vitro was also assessed. Artemisinin-resistant (MRA-1240) 
and sensitive (MRA-1239, 3D7) strains were cultured in vitro. Parasite maturation 
was determined based on the flow cytometric detection of hemozoin-containing cells. 
Two different drug assays were performed: 1) standard drug assay: where ring-stage 
parasites were continuously incubated with increasing concentrations of 
dihydroartemisinin (DHA) for 48 hours; and 2) pulse assay: where tightly ring-stage 
synchronized parasites were incubated with a single high-dose (700 nM) of DHA for 
6 hours. 
Results showed that at 24 hours of incubation artemisinin-resistant parasites had 
increased IC50 values, in comparison to the artemisinin-sensitive strains (15 nM and 
8 nM, respectively). Moreover, when parasites were exposed to a high-dose of DHA 
for 6 hours, increased survival rates associated with artemisinin resistance could be 
detected after only 30 hours of incubation.  
Interestingly, it was also observed that artemisinin-resistant parasites do not seem to 
enter dormancy, as it has been previously suggested by others. Microscopic 
assessment performed after 72 hours of incubation showed that parasites that survived 
to a 6-hour exposure to DHA were very close in terms of parasite development to the 
ones found in the drug free control. Further investigation using more artemisinin-
resistant strains is required to determine whether increased IC50 values correlate with 
the delayed parasite clearance times observed in the patients; and if the underlying 
mechanisms of artemisinin resistance is or not related to dormancy.  
 
Overall, the work presented in this thesis shows that hemozoin detection by flow 
cytometry is an alternative, reagent-free and rapid drug assay that overcomes some of 
the limitations of currently available drug assays for P. falciparum. Moreover, it may 
also be a useful tool in the study of artemisinin resistance both in culture-adapted 
strains and, possibly in strains obtained directly from patients. 




tools to assess drug effects and monitor drug resistance in Plasmodium spp. Several 
novel hemozoin detection platforms are available or under development and should 
definitely be further explored for their potential to be used as antimalarial drug assays. 
Furthermore, combination of hemozoin detection with the measurement of other 
parameters, such as DNA and RNA content and parasite viability may even provide 
additional important information to reliably determine the developmental stage and 
metabolic status of parasites and, consequently, detect drug effects. Hopefully, this 
would lead to the development of an optimal antimalarial drug assay that could play 
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O número de casos e mortes por malária tem vindo a diminuir, de forma considerável, na 
última década, devido principalmente à disponibilidade de fármacos eficazes no tratamento 
desta doença e à implementação de medidas de controlo vetorial. No entanto, o parasita da 
malária desenvolveu resistência à maioria dos fármacos anti-maláricos. Na atualidade, a 
situação mais alarmante ocorre no Sudeste Asiático e está relacionada com o surgimento 
de parasitas resistentes à artemisinina, o fármaco base da terapêutica de primeira linha para 
a malária. A resistência à artemisinina é diferente das resistências observadas 
anteriormente para outros anti-maláricos e caracteriza-se por um atraso na eliminação do 
parasita do sangue observado em doentes com malária. Apesar destas observações, é 
importante referir que esta resistência é considerada pela Organização Mundial de Saúde 
(OMS) como sendo parcial e as terapêuticas combinadas, baseadas na artemisinina, 
continuam a ser o pilar do tratamento da malária.  
Neste contexto, os testes de suscetibilidade in vitro são ferramentas essenciais para detetar 
e monitorizar o aparecimento de parasitas resistentes. Atualmente, existem vários testes de 
suscetibilidade in vitro para Plasmodium spp., o agente etiológico da malária, mas a sua 
aplicação é limitada por características, como a utilização de reagentes radioativos e 
dispendiosos, além dos longos tempos de resposta.   
O projeto realizado no âmbito desta tese teve como objetivo desenvolver um novo teste de 
suscetibilidade para Plasmodium spp. capaz de ultrapassar algumas das limitações dos 
testes existentes. A ideia subjacente baseia-se na detecção da hemozoína como método 
indireto de determinação do efeito de anti-maláricos na maturação do parasita. 
A hemozoína é produzida em quantidades crescentes pelos parasitas da malária, durante a 
sua maturação no interior dos eritrócitos, sendo um cristal birrefringente capaz de 
despolarizar a luz, constituindo assim um ótimo bio-marcador da maturação do parasita. 
Por sua vez, a despolarização da luz pode ser detetada por métodos óticos, como a 
citometria de fluxo. Trabalhos realizados anteriormente no nosso laboratório num modelo 
animal de malária demonstraram que a despolarização da luz causada pela hemozoína, que 
se encontra no interior de eritrócitos infectados, pode ser detetada utilizando um protocolo 
simples baseado em citometria de fluxo. Verificou-se ainda que este método permitiu 
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detetar a maturação dos parasitas no interior dos eritrócitos, bem como o efeito inibitório 
dos fármacos anti-maláricos testados, em apenas seis/oito horas de incubação. 
O principal objetivo do trabalho realizado, durante este projeto de doutoramento, consistiu 
em desenvolver este novo teste de suscetibilidade baseado na deteção de hemozoína por 
citometria de fluxo, utilizando culturas in vitro de parasitas de malária que infetam 
humanos, nomeadamente o P. falciparum. Posteriormente, o desempenho deste novo teste 
foi avaliado ex vivo, no campo, utilizando amostras de doentes com malária. 
Para isso, um citómetro de fluxo de bancada (Cyflow SL) foi modificado para permitir a 
deteção da despolarização da luz causada pela hemozoína. Outros citómetros (MoFlo, 
Accuri C6, Attune), disponíveis no mercado, também foram adaptados, sem dificuldade, 
para detetar este parâmetro adicional. Não obstante, o Cyflow SL modificado foi o 
instrumento usado na maioria dos estudos realizados durante este projeto.  
Estabeleceram-se culturas in vitro de P. falciparum que permitiram investigar o potencial 
da deteção de hemozoína por citometria de fluxo como teste de suscetibilidade aos anti-
maláricos. Neste sentido, as culturas de P. falciparum foram sincronizadas e os parasitas 
em forma de anel foram incubados com vários fármacos anti-maláricos (cloroquina, 
mefloquina, quinino, artemisinina, artesunato e pirimetamina). A análise das células que 
despolarizam a luz, correspondentes a eritrócitos parasitados que contêm hemozoína, 
permitiu detetar a maturação do parasita ao longo do tempo, assim como o efeito inibitório 
de todos os anti-maláricos testados em apenas dezoito/vinte e quatro horas de incubação, à 
exceção da pirimetamina, cujo efeito foi detetado somente após setenta e duas horas. As 
concentrações inibitórias de 50% (IC50), calculadas às vinte e quatro horas de incubação, 
eram comparáveis com os valores previamente reportados usando outros métodos, embora 
estes valores fossem, na maioria das vezes, superiores aos valores obtidos com o teste de 
ELISA-HRP2. Sabe-se que os valores de IC50 podem variar de modo considerável entre 
testes, maioritariamente porque os parâmetros de medição e os tempos de incubação são 
diferentes consoante o teste usado. Além disso, variações da parasitémia e de hematócrito, 
bem como a especificidade do fármaco em determinados estadios de desenvolvimento do 
parasita, também podem influenciar estes valores.  
O desempenho do teste de deteção de hemozoína por citometria de fluxo, em amostras de 
doentes com malária, foi avaliado durante um estudo de seis meses, realizado no Gabão, 
um país onde a malária é endémica. Neste estudo, o citómetro de fluxo existente no local 
(Cyflow SL) foi modificado para detetar a despolarização da luz causada pela hemozoína, 
tendo sido analisado um total de quarenta e seis amostras de doentes com malária. As 
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amostras de sangue foram incubadas com concentrações crescentes de cloroquina, 
artesunato e artemisinina e a percentagem de células que despolarizam a luz foi utilizada 
como indicador de maturação do parasita, tendo sido medida às vinte e quatro, quarenta e 
oito, e setenta e duas horas de incubação, para determinar o crescimento do parasita e os 
efeitos dos anti-maláricos testados.  
Após a realização de culturas ex vivo de parasitas obtidos de amostras de sangue de 
doentes com malária, observou-se que existiam quatro perfis de crescimento diferentes. 
Independentemente desta observação, a deteção da hemozoína por citometria de fluxo 
permitiu determinar o efeito dos fármacos anti-maláricos em trinta e nove das quarenta e 
seis (85%) amostras. Em vinte e cinco amostras, o efeito dos fármacos foi detetado às vinte 
e quatro horas. Nas catorze amostras restantes, os parasitas apresentaram um atraso na sua 
maturação e, por isso, o efeito dos fármacos anti-maláricos foi detetado apenas às quarenta 
e oito horas de incubação. Os valores de IC50 obtidos revelaram que ainda existem 
naquela região do Gabão (Lambaréné) parasitas resistentes à cloroquina, mas estes 
continuam a ser totalmente sensíveis ao artesunato e à artemisinina.   
Por último, investigou-se a deteção de hemozoína por citometria de fluxo no estudo da 
resistência à artemisinina in vitro. Para isso, estirpes resistentes (MRA-1240) e sensíveis 
(MRA-1239, 3D7) à artemisinina foram cultivadas in vitro. Uma vez mais, a maturação do 
parasita foi determinada com base na deteção de eritrócitos com hemozoína por citometria 
de fluxo. Neste caso, foram realizados dois tipos de ensaios: 1) ensaio de suscetibilidade 
padrão, no qual os parasitas em forma de anel são incubados com concentrações crescentes 
de dihidroartemisinina (DHA), durante quarenta e oito horas;  2) ensaio de pulso, em que 
os parasitas sincronizados em forma de anel são incubados com uma única dose (700 nM) 
de DHA, durante seis horas. 
Os resultados mostraram que, às vinte e quatro horas de incubação, os parasitas resistentes 
à artemisinina têm valores de IC50 superiores aos observados para as estirpes sensíveis à 
artemisinina ( quinze nM e oito nM, respetivamente). Nos ensaios de pulso, observou-se 
um aumento na taxa de sobrevivência associado à resistência à artemisinina, após somente 
trinta horas de incubação. É de salientar que a avaliação microscópica, realizada às setenta 
e duas horas de incubação, revelou que os parasitas, expostos durante seis horas à DHA, 
são muito semelhantes, a nível de desenvolvimento, aos parasitas encontrados no controlo 
sem fármaco. Tal indica que os parasitas resistentes à artemisinina não parecem entrar num 
estado de dormência, ao contrário do que foi descrito noutros estudos. Será necessária 
investigação adicional, utilizando mais estirpes resistentes à artemisinina, para determinar: 
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1) se os valores aumentados de IC50 estão correlacionados com o atraso nos tempos de 
eliminação do parasita observados nos doentes; 2) se o mecanismo de resistência à 
artemisinina está ou não relacionado com um processo de dormência. 
 
O trabalho apresentado nesta tese demonstra que a deteção de hemozoína por citometria de 
fluxo pode ser uma alternativa aos testes de suscetibilidade aos anti-maláricos existentes. 
Esta abordagem não requer a utilização de reagentes adicionais para a deteção dos 
parasitas e é um teste relativamente rápido, superando algumas das limitações dos testes de 
suscetibilidade atualmente disponíveis. Além disso, também pode ser uma ferramenta útil 
no estudo da resistência à artemisinina, tanto em estirpes adaptadas a crescer in vitro, como 
em estirpes obtidas diretamente de doentes com malária.  
Convém referir que atualmente estão disponíveis, ou em desenvolvimento, novas 
plataformas de deteção de hemozoína que devem ser exploradas relativamente ao seu 
potencial para utilização como testes de suscetibilidade aos anti-maláricos. Para além 
disso, a combinação da deteção de hemozoína com a medição de outros parâmetros, como 
o conteúdo de DNA e RNA e viabilidade do parasita, pode fornecer informações 
adicionais e relevantes na determinação do efeito inibitório dos fármacos anti-maláricos.  
Em conclusão, esperamos que os resultados obtidos durante este projeto possam conduzir 
ao desenvolvimento do teste de suscetibilidade ideal para Plasmodium spp. e que este 




The present thesis describes the development and validation of a novel, rapid and 
reagent-free antimalarial sensitivity assay for Plasmodium falciparum.  
In Chapter I, an overview of the main subjects discussed in this thesis is done to 
contextualize the theme. The problematic of malaria as a public health disease, the 
importance of antimalarial drug resistance and the in vitro detection of drug resistance 
is introduced. Furthermore, several aspects about the subject of study (hemozoin) and 
the technique that was investigated (flow cytometry) are also presented.   
In Chapter II, the detection of light depolarization caused by hemozoin by flow 
cytometry is presented and discussed in the context of malaria research. Specific 
explanations on how to modify different commercially available flow cytometers to 
detect this additional parameter are given.  
Chapter III, describes how the flow cytometric detection of hemozoin can be used to 
assess drug effects in P. falciparum laboratory-adapted strains. Results presented in 
this chapter show that the inhibitory effect of all antimalarial drugs tested could be 
detected. Therefore, indicating that the reagent-free and real-time hemozoin detection 
assay could become a novel assay for the detection of drug effects on P. falciparum.  
 In Chapter IV, the performance of the hemozoin detection assay is investigated in 
the field using samples from malaria patients. Results presented here were obtained 
from a study conducted in a malaria-endemic country (Gabon) where samples from 
malaria patients were cultured ex vivo with several antimalarial drugs. Drug effects 
and parasite resistance could be detected in blood samples from malaria patients using 
the hemozoin detection assay.  
In Chapter V, the usefulness of the hemozoin assay to detect artemisinin resistance, 
as characterized by a delay in parasite clearance times in the patients, in vitro is 
investigated. Results are still preliminary but they seem to indicate that increased 50% 
inhibitory concentrations can be detected in artemisinin-resistant parasites, as well as 
increased survival rates.  
Finally, in Chapter VI, an overview, general discussion and conclusions of major 
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1. MALARIA  
a. Epidemiology and the Disease 
Malaria is the most important parasitic disease. In 2015, it was responsible for the death of 
438000 people, mainly children under 5 years of age. It is transmitted over 96 countries 
where 3.2 billion people are at risk [1]. Most cases and deaths occur in Africa, where P. 
falciparum the deadliest of all malaria parasites is dominant.  There are five species of the 
genus Plasmodium spp. capable of causing malaria in human beings. Most cases are 
caused by P. falciparum and P. vivax, yet P. malariae, P. ovale and P. knowlesi also cause 
human infections [2]. 
Malaria is transmitted by Anopheles mosquitos. The Plasmodium spp. life cycle begins 
with the inoculation of sporozoites into the skin by infected mosquitos. Through the 
bloodstream parasites reach the liver, infect hepatocytes and multiply into thousands of 
parasites, called merozoites. The merozoits will be released into the bloodstream, leading 
to the blood stage of infection that is characterized by continuous cyclic asexual 
replication. The liver stage is clinically silent, and symptoms of malaria appear only during 
the blood stage  (Figure I.1).  
The symptoms of malaria are nonspecific. They include: headache, fatigue, abdominal 
discomfort usually followed or accompanied by fever, chills and vomiting. There is no 
combination of signs and symptoms that distinguish malaria from other causes of fever.  
At the early stage of infection, when symptoms start to appear, if prompt effective 
antimalarial treatment is given full recovery is expected. On the other hand, if treatment is 
ineffective due to wrong prescription or the use of poor-quality medicines, treatment is 
delayed, and in the case of P. falciparum, progression to severe and potentially lethal 
malaria can occur. This progression to severe malaria can happen in a matter of hours. 
Severe malaria manifests with one or more of the following: coma (cerebral malaria), 
severe anemia, hypoglycemia, metabolic acidosis, acute renal failure or acute pulmonary 
edema, as reviewed elsewhere [2]. 
Malaria can also occur during pregnancy and it can have serious consequences both for the 
unborn child and the mother. Both P. falciparum and P. vivax can cause placental malaria. 
Yet, severe cases of P. vivax malaria during pregnancy are rare [3]. Placenta malaria can 
cause low-birth weight (< 2.5 kg), which is associated with increased infant mortality [4]. 
In high transmission settings mothers may have exacerbated parasitemia but they remain 
asymptomatic, even though high numbers of infected erythrocytes are accumulated in the 
placenta. Congenital malaria is rare, but once it happens it clears spontaneously in 62% of 
CHAPTER I – GENERAL INTRODUCTION 
 
 2 
the cases [5]. In regions of unstable malaria transmission, there is increased risk of 
pregnant women to develop severe P. falciparum malaria associated with a mortality rate 
of roughly 50%. In case of severe disease fetal distress, premature labor and stillbirth can 
occur. The risk of infant death is high, particularly if maternal malaria occurs during the 
late pregnancy [6].   
 
Figure I.1: Plasmodium spp. life cycle.  
During a blood meal, an anopheline mosquito injects Plasmodium spp. sporozoites that will reach 
the liver through the bloodstream (A). After traversing several hepatocytes—they invade a final 
one (B). Inside the hepatocyte sporozoites will develop into thousands of merozoites which will be 
released into the bloodstream (C). Merozoites infect red blood cells and develop from ring-forms to 
throphozoits and, finally, to schizonts. Schizonts will rupture, releasing merozoits that will re-
invade more red blood cells giving rise to a new cycle of asexual replication (D). Occasionally, 
replication cycles originate female and male gametocytes (E).  Through another blood meal, a 
mosquito ingests gametocytes (F). Fertilization of gametes occurs in the mosquito midgut with the 
formation of ookinetes and later the oocysts (G). Sporozoites released from the oocyst will migrate 
to the salivary glands of the mosquito and will be released during the next blood meal. (Adapted 
from Portugal 2011 - [7]) 
 
P. vivax can also lead to severe and sometimes fatal disease. In the last decade, there was 
an increase in the number of reports describing severe manifestations in P. vivax 
infections. High prevalence of severe anemia associated with P. vivax malaria have been 
described [8–10]. Other severe manifestations including coma, renal failure, hemodynamic 
shock, severe jaundice, abnormal bleeding and frequent hypoglycemia can occur as well 
[11–15].  
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b. Threats to Malaria Control  
Even thought the number of malaria deaths remain considerably high one must recognize 
that the scenario of malaria has been worse not too long ago. In 15 years the number of 
deaths and the incidence of malaria has been reduced by 48% and 18%, respectively [1]. 
This has mainly been due to cost-effective interventions such as: vector control, 
chemoprevention and case management. 
Vector control strategies reduce the transmission of parasites from humans to mosquitos 
and then back to humans. This is achieved by the use of use of insecticide-treated mosquito 
nets (ITNs) or indoor residual spraying (IRS).  Chemoprevention will suppress or treat 
blood-stage infection in humans and case-management includes prompt diagnosis and 
treatment. These strategies altogether will greatly contribute for the reduction of 
transmission and mortality caused by malaria. For instance, a report from a village in 
Senegal showed that, introduction of effective diagnosis, treatment and vector control 
(using ITNs) strategies reduced the prevalence of parasites in children from 87% to 0.3% 
in 12 years [16]. 
Unfortunately, nature seems to be always a step ahead - some mosquitos have become 
resistant to some insecticides and malaria parasites have also developed resistance to 
antimalarial drugs.  
P. falciparum resistance to the first-line treatment of malaria, the artemisinins, has now 
been reported in five countries in the Greater Mekong subregion: Cambodia, Lao People’s 
Democratic Republic, Myanmar, Thailand an Vietnam [17]. This resistance is 
characterized by a delay on parasite clearance in patients treated with and ACT 
(artemisinin-combination therapy). Yet patients still respond to treatment, when the partner 
drug remains effective.  
For P. vivax malaria, at least one true case of chloroquine resistance has been confirmed in 
10 countries: Bolivia, Brazil, Ethiopia, Indonesia, Malaysia, Myanmar, Papua New 
Guinea, Peru, the Solomon Islands and Thailand [1].  
Malaria mosquito vectors are developing resistance to the insecticides used in insecticide-
treated mosquito net (ITNs) and indoor residual spraying (IRS), threatening the 
effectiveness of insecticide-based vector control [1]. Current efforts in global malaria 
control rely heavily on a single insecticide class: pyrethroids. This is the only class of 
insecticides used in long-lasting insecticidal net (LLINs) [1, 18]. Pyrethroid resistance was 
detected in all major malaria vectors [1, 19]. Nevertheless, despite the observed resistance 
long-lasting insecticidal nets remain effective. 
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To address remaining threats and emerging challenges, the WHO has developed a Global 
technical strategy for malaria 2016–2030. This strategy sets the very ambitious targets for 
reductions in malaria cases and deaths and it was developed in close alignment with the 
Roll Back Malaria (RBM) Partnership’s Action and Investment to Defeat Malaria 2016–
2030 – for a malaria-free world.   
Strong political commitment, robust financing and increased multi-sectorial collaboration 
are essential if the goals of this agenda are to be meet. The previously mentioned threats 
will have to be continuously addressed and thus, novel tools and optimized approaches are 
required for the effective and successful accomplishment of malaria elimination by 2030.  
 
Table I.1: Goals, milestones and targets of the Global technical strategy for Action and 
Investment to defeat malaria 2016–2030 [1]. 
 
 
c. TREATMENT OF MALARIA   
i. Antimalarial Drugs – Historical Overview 
The very first drug used to treat malaria was quinine. Quinine, occurs naturally in the bark 
of Chinchona trees, that are found in South America. The cinchona bark was introduced 
into Europe in the 17th century by a Jesuit priest that was returning from a mission in Peru. 
This miraculous bark relieved feverish symptoms and agues. In fact, this drug has had an 
extremely important role in colonialism, by reducing the colonial mortality allowing 
“white men” to establish and survive in the tropics [20]. Because of this quinine was even 
called as one of the “tools for empire”.  Quinine was used for centuries and in fact, it is still 
an effective drug. However, novel and better drugs have been developed and the use of 
quinine to cure malaria has decreased. 
Synthetic compounds were made available later in the 19th century. By that time the need 
CHAPTER I – GENERAL INTRODUCTION 
 5 
for new antimalarial drugs led to the development and search for new effective 
compounds. Interestingly, methylene blue more commonly known as a dye, was the first 
synthetic antimalarial. Its antimalarial effect was noticed by Paul Elrich, his reasoning was 
if the dye is able to stain the malaria parasites it may be also toxic to the parasites in vivo. 
In 1891, two patients suffering from malaria were cured using methylene blue – this was 
the first time that a synthetic drug was ever used in humans [21]. 
In 1925, plasmoquine was developed by Bayer, this was the first 8-aminoquinoline which 
proved to be effective in preventing relapses caused by P. vivax infections. Later in 1932, 
mepacrine was developed and showed to be effective against P. falciparum malaria. In 
1934, H. Andersag, developed a compound known as resochin [22]. This compound 
seemed promising but it seemed to be too toxic. During the World War II huge efforts 
were made by American, British and Australian scientists to cooperate in large-scale with 
the aim of developing new synthetic antimalarial drugs. Around 16000 compounds were 
synthetized and tested. Interestingly, one of the first compounds to be tested was resochin, 
which for the second time was considered too toxic. It was only in 1946 that an US clinical 
trial showed that resochin, now known as chloroquine, had a great activity against malaria 
parasites. Indeed, chloroquine was then massively used and it was the drug of choice in the 
WHO Global Eradication Programme of the 1950s and 1960s. Due to its efficacy, 
affordability and safety chloroquine was considered the best treatment for malaria for 
many years [23]. 
During the World War II, several significant scientific advances in the context of 
antimalarial drugs were made. Soon after the war, primaquine was introduced and proved 
to be the drug of choice for the prevention of relapses in P. vivax malaria, and it still is 
nowadays [22].  
Proguanil was also developed during the war by the British. It actually served as a 
prototytpe for the development of pyrimethamine [22].  
The antimalarial activity of amodiaquine was discovered in the 1950s. In the mid 1980s, 
fatal adverse drug reactions were described [24, 25]. However, because of chloroquine 
resistance amodiaquine was used in Africa and Asia. Currently it is mainly administered in 
combination with artesunate.  
In the 1970’s pyrimethamine was introduced in combination with sulfadoxine (Fansidar). 
This combination is still used today, particularly in intermittent preventative malaria 
treatment during pregnancy in Africa [26]. The development of mefloquine and 
atovaquone was also based on prototype compounds that were discovered during the 
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Vietnam war. Mefloquine was introduced in mid 1970’s and was widely used around the 
world. Resistance to atovaquone can easily emerge and thus, it is used in combination with 
another drug, namely proguanil (Malarone) [27] . 
The current first-line treatment for malaria is based on the artemisinins [26]. Artemisinin is 
found in a plant called Artemisia annua (known as qinghao in China). This plant has been 
used in traditional Chinese medicine for over 2000 years. It was during the Vietnam War, 
when a governmental program to screen a library of Chinese plants for their potential 
antimalarial effect was launched, that the potent antimalarial effect of artemisinin was 
discovered. Indeed, this research program was initially planned because more militaries 
were dying of malaria than from fighting the war. In 1972, Tu You You, who has been 
awarded with a Nobel Prize in 2015, extracted the principal ingredient from the plant and 
called it qinghaosu (which means essence of qinghao). Artemisinins are the quickest drugs 
in terms of parasite clearance, affecting up to 10.000-fold reductions in parasite burden 
every 48 hours [28]. In fact, this feature is of critical benefit in treating severe malaria and 
reversing its otherwise lethal course [2]. 
Indeed, it is remarkable that two herbal treatments, cinchona bark and qinghao, were used 
to treat malaria effectively for hundreds of years before even understanding of the parasite 
life cycle. Today both quinine (derived from the cinchona bark) and artemisinin (from 
qinghao) remain of prime importance in the treatment and control of malaria. 
 
ii. Current Guidelines for the Treatment of Malaria 
The control of malaria largely depends on drug therapies, and, to a lesser extent, 
prophylaxis. Table I.2 summarizes the available drugs to treat and/or prevent malaria.  
Antimalarial drugs target different stages of the life cycle of malaria parasite and they can 
be classified as:  blood schizonticides (act on the asexual intraerythrocytic stages), tissue 
schizonticides (kill hepatic schizonts), hypnozoiticides (kill hypnozoites), gametocytocides 
(destroy intraerythrocytic sexual forms). The majority of the drugs act on the blood 
(intraerythrocytic) stage. 
The choice of the most appropriate treatment is influenced by several factors such as: the 
causative species, the severity of signs and symptoms, the patients age, immunity status 
and other risk determining factors (acute or chronic conditions, pregnancy and/or immune 
impairment). Nevertheless, the primary objective of treating severe malaria is to save life. 
Other considerations such as minor toxicity or preventing recrudescence are secondary.  
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Table I.2: Currently used antimalarial drugs (adapted from [29]) 
Class Drug Use Half-life 
4-aminoquinolines 
chloroquine Treatment of non-falciparum malaria 60 days 
amodiaquine Partner drug for ACT 9–18 days* 
piperaquine Partner drug for ACT 5 weeks 
8-aminoquinolines primaquine 
Radical cure and terminal 
prophylaxis of P. vivax and           




quinine Treatment of P. falciparum and severe malaria 
8 – 10 
hours 
mefloquine Prophylaxis or partner drug for ACT 
14 – 18 
days 
lumefantrine Partner drug for ACT 3 – 5 days 
Sesquiterpene lactone 
endoperoxides 
artemether ACT: combination with lumefantrine 0.5 – 1.4 
hours artesunate Treatment of severe malaria 
dihydroartemisinin ACT: combination with piperaquine 
Manich base antifolates 
pyronaridine Combination with artesunate ACT 12 – 14 days 
pyrimethamine-
sulfadoxine 
Treatment of some chloroquine-
resistant parasites or combination 
with artesunate as ACT 
4 – 5 
days 
Naphtoquinone/antifolate Atovaquone-proguanil 
Combination for prophylaxis and 
treatment of P. falciparum malaria 
2 – 3 
days 
Antibiotics 
doxycycline Chemoprophylaxis or treatment of 
P. falciparum malaria 
16 – 22 
hours 
clindamycin 2 -3 hours 
*3 hours (but the antimalarial activity is thought to be exerted by the primary metabolite, 
monodesethylamodiaquine, which has a half-life of 9–18 days; 
 
The latest guidelines for the treatment of uncomplicated malaria is the use of artemisinin-
based combination therapy (ACT). To treat severe malaria the use of several antimalarial 
drugs, such as artesunate, quinine, artemether, as a single-therapy during 24 hours and, 
thereafter, complete the treatment with ACTs or with combination therapy of antimalarial 
drugs with antibiotics (doxycycline, clindamycin) is recommended [26, 30]. More detailed 
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Table I.3: Current guidelines to treat malaria (adapted from [26]) 
Treatment of severe malaria  
Adults and children with severe malaria (including infants, pregnant women in all trimesters and 
lactating women) should be treated with intravenous or intramuscular artesunate for at least 24 
hours until oral medication can be tolerated. Once the patient has received at least 24 hours of 
parental therapy and is now able to tolerate oral therapy, treatment should be completed with a 3 
day regimen of ACT.  If artesunate is not available, artemether in preference to quinine should be 
used instead.  
Treatment of uncomplicated P. falciparum malaria 
All children and adults with P. falciparum uncomplicated malaria should be treated with one of the 
following ACT for 3 days: artemether/lumefantrine, artesunate/amodiaquine, 
artesunate/mefloquine, dihydroartemisinin/piperaquine or artesunate/sulfadoxine-pyrimethamine. 
In low-transmission settings, to reduce transmission, a single dose of primaquine with the ACT 
should be given to patients as well (except pregnant women, infants aged < 6 months and women 
breastfeeding infants < 6 months).  
Treatment regimens have to be adjusted in special risk groups, including: first trimester pregnancy, 
infants with less than 5kg of body weight, patients co-infected with HIV, non-immune travellers 
and patients with uncomplicated hyerparasitemia. 
Treatment of uncomplicated non- P. falciparum malaria  
If the malaria species is not know patients should be treated as if they had uncomplicated P. 
falciparum malaria.  
In areas where chloroquine is still effective adults and children should be treated with either an 
ACT or chloroquine. In areas where chloroquine resistance exists, adults and children should be 
treated with an ACT. Pregnant women in their first trimester who have chloroquine-resistant 
malaria should be treated with quinine. 
Preventing relapse of P. vivax and P. ovale malaria  
To prevent relapse either from P. vivax or P. ovale malaria children and adults should be treated 
with a 14 day course of primaquine, in all transmission settings.  
The G6PD status of all patients should be used to guide administration. In people with G6PD 
deficiency, treatment should be done with a higher dose for a shorter period of 8 days. In this case 
close medical supervision is required.  
In women who are pregnant or breastfeeding a weekly prophylaxis with chloroquine until delivery 
or until breastfeeding is completed should be considered.  
Chemoprevention for special risk groups 
In malaria endemic areas in Africa, intermittent preventive treatment (iPTP) with sulfadoxine-
pyrimethamine (SP) should be given do all women in their first or second pregnancy as part of 
antenatal care. Doses should start in the second trimester and be given at least one month apart, 
ensuring that at least 3 dosses are received.  
In areas of moderate-to-high malaria transmission in Africa, where SP is still effective, all infants 
(<12 months of age) should receive SP-IPTi at the time of second and third rounds of vaccination.  
In areas with highly seasonal malaria transmission in Africa, all children aged <6 years should 
receive seasonal malaria chemoprevention with a monthly dose of amodiaquine/SP, during each 
transmission season. 
 
iii. New Antimalarial Drugs  
New antimalarial drugs are needed for several reasons. First, available drugs may be 
limited by drug resistance. It is important to note that even though resistance has been 
described for most used antimalarial drugs, including artemisinins, the current first line 
treatment for malaria based on ACTs remains effective. Moreover, effective treatment 
requires multiple doses. A single-dose effective regimen would offer improved compliance 
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and allowed to reduce costs. Besides this, most drugs only act on the blood stage and other 
parasite life-cycle stages such as non-erythrocytic and sexual stages are not affected. More 
importantly, some drugs have safety limitations. Ideally, antimalarial drugs should be safe 
in young children and pregnant women. Therefore, investigation and development of novel 
drugs that may address these issues is crucial to successfully control malaria.  
Since the World War II strong efforts were made to discover novel and better antimalarial 
drugs. However, in the early 1990s many companies have stopped attempting to develop 
new antimalarial drugs [27]. Between 1975 and 1999 only four of more than a thousand 
new drugs developed worldwide were antimalarials [31]. In 1999, Medicines for Malaria 
Venture (MMV) begun and the scenario has changed considerably. This public-private 
partnership aims to investigate and develop novel, effective drugs against malaria. In fact, 
MMV has been the main driver of antimalarial drug research and development projects.  
The pipeline of drugs targeting malaria include: 1) novel medicines that are based either on 
already known antimalarial drugs that are now being investigated as potential novel partner 
drugs for ACTs or new formulations of these compounds for a different route of 
administration; and 2) completely novel classes of molecules, with potentially different 
mechanisms of action (Figure I.2).  
There are promising new classes of compounds in the pipeline: the KAE069 (cipargamin), 
KAF156 and ACT-451840.  
KAE609 is a spiroindolone antimalarial compound that showed to have a rapid parasite 
clearence rate in the treatment of P. falciparum and P. vivax malaria [32]. In fact, it seems 
to be even more rapid in clearing parasitemia than artemisinins. Moreover, this compound 
also has gametocytocidal activity detected in vitro against P. falciparum and thus, may 
have transmission-blocking properties [33]. 
The KAF156 represents a new class of antimalarial agents (imidazolopiperazines) [34, 35]. 
KAF156 has shown potent in vitro activity against both asexual and sexual blood stages 
and against liver stages as well. In a recent clinical study, the rates of parasite clearance 
after treatment with KAF156 were slightly lower than those associated with artemisinin 
treatment but still higher than the ones associated with treatment with sulfadoxine–
pyrimethamine, atovaquone–proguanil, quinine, or mefloquine [36].  
ACT-451840 belongs to a new chemical class of potent antimalarial compounds with a 
novel mode of action. This novel compound is effective against both P . falciparum  and P. 
vivax and also against all asexual and sexual stages of P. falciparum. It has been shown  to 
have a fast parasite clearance and it has a longer half-life (34 hours) in comparison to 
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Figure I.2: Global Portfolio of Antimalarial Medicines (as of 30th June 2016).  
Several 3-day cure artemisinin based combination therapies are in developments (yellow bars) 
OZ439/FQ, KAE609, KAF156 and tafenoquine are new compounds to contribute to SERCAP 
(single-exposure radical cure and prophylaxis) or multiple exposure treatment for multi-drug 
resistance (orange bars). Tafenoquine has also been shown to be effective against hipnozoites. New 
treatments for severe malaria under investigation include rectal artesunate and artesunate for 
injection (Artesun®). A new combination of sulfadoxine-pyrimethamine + amodiaquine (SP+AQ) 
is being investigated for seasonal malaria chemoprophylaxis. (http://www.mmv.org/research-
development/interactive-rd-portfolio accessed 28/09/16)  
 
d. Mechanisms of Action of Antimalarial Drugs 
The mechanism of action of antimalarial drugs may greatly influence the determination of 
drug effects in in vitro drug assays. Specially, in the context of the work developed in this 
thesis. As discussed in section 6, the subject of this study is hemozoin, which is the target 
of action of most antimalarial drugs.  
Antimalarial drugs can be grouped, according to its mechanism of action, into compounds 
that: 1) inhibit the formation of hemozoin 2) inhibit the synthesis of nucleic acid 3) inhibit 
the mitochondrial respiratory chain and 4) which are not completely understood. 
1) Most available antimalarial drugs share the same mechanism of action: inhibition of 
hemozoin formation. Examples are quinine, chloroquine, amodiaquine, mefloquine, 
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piperaquine and lumefantrine. The exact mechanism of how these drugs inhibit hemozoin 
formation is far from being resolved, yet it is known that their interaction with heme is 
essential for the antimalarial activity of these compounds [38, 39]. In this case the death of 
the parasite results from the accumulation of cytotoxic free heme. 
From all the abovementioned drugs the one that has been more extensively investigated is 
chloroquine, where several mechanism have been proposed to explain how it interferes 
with heme detoxification. The first studies suggested that chloroquine cause alkalinization 
of the food vacuole [40]. Another study challenged this observation and reported that 
therapeutically achievable levels of chloroquine would induce rather minimal changes in 
the pH [41] and that such a change could not inhibit hemoglobin degradation [42].  
Another explanation was based on the inhibition of peroxidase degradation of heme [43]. It 
was shown that when heme reacts with H2O2 it has catalase and peroxidase activities that 
contribute to heme degradation [44]. This would be prevented by chloroquine thus, leading 
to increased levels of H2O2 that would cause peroxidative damage to the parasite.  
It was also suggested that chloroquine would inhibit heme sequestration by the parasite.  
Indeed it was shown that quinoline drugs inhibit the formation of both synthetic and native 
hemozoin [45]. Chloroquine seems to form quinoline-heme complexes that inhibit further 
extension of hemozoin chains [46]. Thus, it is reasonable to consider that quinolines act by 
preventing further crystallization of hemozoin, leaving enough free toxic heme to harm the 
parasite.  
2) Folate antagonists, such as sulfadoxine and pyrimethamine, inhibit enzymes of the 
folate pathway and thus, the synthesis of nucleic acids in the malaria parasite is blocked 
[39]. Selectivity of action of the malarial enzymes is due to structural and functional 
differences between them and their human counterparts. The parasite can either synthesize 
or salvage folate precursors, whereas mammals have no de novo synthesis and rely on 
dietary sources.  
3) Atovaquone acts on the mitochondrial electron transfer chain. It was shown to inhibit 
the respiratory chain of malarial mitochondria at the cytochrome bc1 complex [47], leading 
to the collapse of the mitochondrial membrane potential [48].  
4) The mechanism of action of some drugs is still not fully understood. In the case of the 
artemisinins no consensus have been found yet. The most widely accepted view is that 
artemisinins are pro-drugs which are activated upon cleavage of the endoperoxide ring, 
after reacting with heme and/or ironII oxide [49]. The resulting free radicals are thought to 
react with susceptible groups within a range of parasite proteins, leading to cellular 
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damage and killing. 
Whether the actual activator of artemisinins is heme or free ferrous iron; or perhaps 
unstable hemoglobin is still not fully understood [50]. Both iron [51–53] and heme-
mediated [54] activation can occur but it seems that the potent activity of artemisinin 
against trophozoites is likely due to heme-mediated activation. In fact, in the presence of 
hemoglobinase inhibitors the activity of artemisinins is almost completely abolished [54].  
Other modes of action/activation have been proposed. The sarco/endoplasmic reticulum 
Ca2+ ATPase (PfSERCA) was suggested as potential direct target [55, 56]. Yet, its role in 
artemisinin mechanism of action has been questioned [57, 58]. 
It was also reported that iron-mediated activation in the mitochondria could lead to 
inhibition of the electron transport chain and mitochondrial depolarization [59].  Other 
studies suggested the direct interaction with cofactors involved in maintaining redox 
homeostasis as an iron-independent pathway of artemisinins activation [60]. 
More recently, P. falciparum phosphatidylinositol-3-kinase (PfPI3K) has been proposed as 
a direct target of the artemisinins during the ring stage [61]. Nevertheless, other critical 
targets, including heme, lipids and other proteins, must have a role particularly in other 
stages of parasite development.  
 
2. ANTIMALARIAL DRUG RESISTANCE  
The classical definition of antimalarial drug resistance is “ the ability of a parasite strain to 
survive and/or multiply despite the administration and absorption of a drug given in doses 
equal or higher than those usually recommended but within tolerance of the subject”. This 
definition was modified to specify that the drug in question “must gain access to the 
parasite or the infected erythrocyte for the duration necessary for its normal action” [62].  
Resistance has been documented for most antimalarial drugs and thus, it is, and has always 
been, a subject of great concern and a major obstacle in the fight against malaria. Drug 
resistance is complicated with the phenomena of cross-resistance that can occur among 
drugs that belong to the same chemical family or which have similar modes of action. P. 
falciparum multidrug resistance occurs when the parasite is resistant to more than two 
antimalarial compounds of different chemical classes and modes of action.  
Several factors, summarized in Table I.4, influence the development and spread of drug 
resistance. One of the most important factors is the inappropriate and widespread use of 
antimalarial drugs, which will exert a strong selective pressure on malaria parasites.  
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Table I.4: Factors that influence the development of antimalarial drug resistance (adapted 
from [63]) 
1. The frequency with which the resistance mechanism arises 
2. The fitness cost to the parasite associated with the resistance mechanism 
3. The number of parasites in the human host that are exposed to the drug 
4. The concentrations of drug to which these parasites are exposed (i.e., the doses used and 
pharmacokinetic properties of the antimalarial drug or drugs) 
5. The pharmacodynamic properties of the antimalarial drug or drugs 
6. The degree of resistance (the shift in the concentration-effect relationship) that results from 
the genetic changes 
7. The level of host defense (nonspecific and specific immunity) 
8. The simultaneous presence of other antimalarial drugs or substances in the blood that will 
still kill the parasite if it develops resistance to one drug (i.e., the use of combinations). 
9. Transmission intensity. 
 
Interestingly, antimalarial drug resistance often emerges in the same region, in the Greater 
Mekong Sub region in Southeast Asia. The reason for this phenomenon is not completely 
understood but there might be several explanations for this. One of them is the fact that, 
contrary to Africa, malaria infections are much less common, which allows resistant 
parasites to survive and reproduce more easily without having much competition from 
other parasite populations. Another possible explanation is that in Africa most people 
develop natural immunity to malaria, and in fact only a small number of malaria infected 
people gets to be treated or exposed to antimalarial drugs.  This certainly translates into a 
much lower drug pressure on the parasite in comparison to Southeast Asia where 
antimalarial drugs are more widely distributed [64]. In low-transmission settings, as the 
ones found in Southeast Asia, most infections are symptomatic and thus, more people 
receive treatment, leading to a greater chance for selection of resistant parasites.  
Antimalarial drug resistance greatly affects the global control of malaria in different ways, 
in terms of: disease burden [8, 65], economic costs [66], distribution of malaria species 
[67] and access to high-quality treatment [64].  
 
a. Current Status of Antimalarial Drug Resistance 
Resistance to antimalarial drugs has been described P. falciparum, P. vivax and P. 
malariae [64, 68]. While P. falciparum has developed resistance to most of antimalarial 
drugs in current use (Table I.5) [63], P. vivax has shown to be resistant to chloroquine [69, 
70], primaquine [71] and sulfadoxine-pyrimethamine [72]. Resistance of P. malariae to 
chloroquine was reported in a single study from Indonesia [73].  
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Table I.5: Years of introduction of antimalarial drugs and of their first reports of resistance 
(adapted from [74]) 
Antimalarial drug Year of introduction 
First reported 
resistance Location 
Quinine 1632 1910 • Thai-Cambodia Border 
Chloroquine 1945 1957 • Thai-Cambodia Border 
• Columbia 
Sulfadoxine-
pyrimethamine 1967 1967 
• Thai-Cambodia Border 
 
Mefloquine 1977 1982 • Thai-Cambodia Border  
Artemisinin* 1980s 2008-2009 • Thai-Cambodia Border  
* artemisinin resistance as characterized by delayed parasite clearance time.  
 
Resistance of P. falciparum to quinine was first described in Brazil [75] and later in 
Southeast Asia [76]. Yet, resistance to quinine only occurs sporadically in Southeast Asia 
and Oceania. 
Chloroquine-resistant P. falciparum malaria has been described in all regions where P. 
falciparum is endemic, except Central America and the Caribbean. However, since its 
withdrawal there have been signs of decrease of chloroquine resistance in some areas, for 
instance in Malawi [77, 78], Kenya [79] and Tanzania [80]. While this phenomenon is 
interesting, caution is still required and widespread reintroduction of chloroquine is not 
recommended.  
Resistance to sulfadoxine-pyrimethamine emerged only 6 months after its introduction and 
has been reported in Southeast Asia, South America and in Africa. Mefloquine resistance 
is frequent in Southeast Asia and has also been reported in the Amazon region of South 
America. Sporadically it occurs in Africa [81].  
More recently, resistance to artemisinin, characterized by prolonged parasite clearance 
times, has been described [82, 83]. Firstly it was reported in Cambodia and Thailand but it 
has now spread to Myanmar and Vietnam (Figure I.3). The observed delayed parasite 
clearance phenotype does not translate into increased 50% inhibitory concentrations (IC50) 
determined by standard in vitro assays [83, 84]. In fact, most patients who have delayed 
parasite clearance following treatment with an ACT still manage to clear their infections. 
Recently, a molecular marker for artemisinin resistance has been described [85]. Mutations 
in the kelch13 (K13)-propeller domain are associated with delayed parasite clearance, both 
in vitro and in vivo.  Even though, further validation is still required, the WHO has updated 
the definition of artemisinin resistance into: suspected artemisinin resistance, defined as a 
high prevalence of the delayed parasite clearance phenotype or high prevalence of K13 
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mutants; and confirmed artemisinin resistance, defined as a combination of both delayed 
parasite clearance and K13 resistance-validated mutations for the same patient) [86]. 




Figure I.3: Location of study sites and proportions of patients with artemisinin resistance. 
Artemisinin resistance was defined by a parasite clearance half-life longer than 5 hours, with some 
Plasmodium falciparum isolates having kelch13 polymorphisms (at or beyond amino acid position 
441) (adapted from [17]). 
 
P. vivax resistance to chloroquine was first reported in Papua New Guinea and Indonesia 
but it has also been detected in South America and Asia [87]. Resistance to primaquine has 
been reported as well, but the data must be interpreted with caution because of many 
confounding factors, including geographical variations in relapse patterns, unsupervised 
therapy, parasite tolerance, the risk for reinfection and the difficulty of finding a valid 
control group [88]. Resistance to sulfadoxine-pyrimethamine in P. vivax have also 
appeared in Asia and the Pacific Islands, where both P. falciparum and P. vivax coexist 
[89–91].  
In the case of P. ovale, P. malariae resistance is not well-characterized and it is considered 
that these parasite remain sensitive to chloroquine. There was only one study in Indonesia 
that reported resistance of P. malariae to chloroquine [73]. Nevertheless, chloroquine is 
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b. Mechanisms of Antimalarial Drug Resistance 
Resistance to antimalarial drugs arises because parasites with genetic changes that confer 
reduced susceptibility to a specific drug are selected. These genetic changes are either 
mutations or alterations in the copy number of genes encoding for the parasite target of the 
drug or for influx/efflux pumps, which influence the concentration of the drugs inside the 
parasite. In some cases just a single genetic event may be all that is required, in other 
multiple independent events may be necessary [94].  
 
Chloroquine Resistance 
Chloroquine resistance was first noted in the Thai-Cambodian Region in 1957, 
approximately a decade after its introduction. In Africa, chloroquine resistance was first 
reported in 1978. By 1989 it had spread throughout the whole African continent. 
Chloroquine resistance reached the endemic regions in South America in 1980 and in 1989 
it was reported in Asia and Oceania.  It is now known that the appearance of chloroquine 
resistance in Africa was not due to a new mutation but instead it was caused by the slow 
and gradual spread of chloroquine-resistant parasites from Southeast Asia [95].  
Resistance to chloroquine is related to an increased capacity of the parasite to expel 
chloroquine from its digestive vacuole, not allowing the drug to reach the required levels to 
inhibit the formation of hemozoin [96]. In fact, resistance to chloroquine can be reversed 
by drugs which interfere with this efflux system [97]. Yet, it remains unclear if parasites 
resistant to other quinoline drugs have similar mechanisms.  
Two genes have been implicated with chloroquine resistance: pfcrt (P. falciparum 
chloroquine-resistance transporter) [98] and the pfmdr1 (P. falciparum multi-drug resistant 
transporter 1) [99].  The pfcrt gene is located on chromosome 7 and codes for a vacuolar 
membrane transporter protein (pfCRT). The pfcrt polymorphisms, in particular the K76T 
mutation has been associated with chloroquine resistance [100] and is a strong marker for 
predicting it [99, 101]. Cross-resistance of other drugs, such as amodiaquine and quinine, 
with chloroquine is also influenced by pfcrt mutations [99].  The PfCRT K76T 
polymorphism is thus a validated marker for chloroquine resistance and should also be 
considered as an indicator for amodiaquine resistance. 
The pfmdr1 gene is localized on chromosome 5 and encodes an ATP-binding cassette 
(ABC) protein [102].  A point mutation in the pfmdr1 gene has been linked to chloroquine 
resistance in some studies [101, 103–105] but not in others [106–108].  
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Resistance to sulfadoxine-pyrimethamine 
Sufadoxine and pyrimethamine acts synergistically by inhibiting two enzymes that are 
involved in folate synthesis: dihydropteroate synthetase (DHPS) and 
dihydrofolatereductase (DHFR), respectively.  Mutations in the genes enconding for these 
enzymes (pfdhfr and pfdhps genes) are implicated with resistance to sulfadoxine-
pyrimethamine [109, 110]. These markers have been useful for tracking sulfadoxine-
pyrimethamine resistance across the globe.  
 
Resistance to quinine 
Quinine resistance is associated with polymorphisms in several transporters. 
Polymorphisms in pfmdr1, pfcrt, and pfnhe1 genes are related to decreased sensitivity to 
quinine [111].  
 
Resistance to mefloquine 
Molecular studies have shown that mefloquine resistance arose in several different places 
[112]. Resistance to mefloquine is associated with increased copy numbers of the pfmdr1 
gene [113, 114].  
 
Resistance to artemisinins 
Resistance to artemisinins differs from what has been observed in resistance against other 
antimalarial drugs. It is characterized by a delay in parasite clearance time rather than by 
treatment failure. Furthermore, commonly used in vitro assays do not show altered 50% 
inhibitory concentrations (IC50).  
Recently, a potential molecular marker for artemisinin resistance has been described. 
Genome-wide association studies using field isolates identified regions on chromosome 13 
associated with delayed parasite clearance [85, 115]. A mutation in the propeller domain of 
the P. falciparum kelch (K13) gene was associated with delayed parasite clearance after 
artemisinin therapy in Southeast Asia.  Definite evidence that asexual blood-stage parasites 
harbouring kelch13 mutations are less susceptible to artemisninis was provided by genome 
editing study [116].  Non-synonymous polymorphism at the following specific positions: 
Y493H, R539T, I543T, and C580Y in the kelch repeat region of K13 propeller domain 
have been associated with artemisinin resistance [85].  
Recent studies showed that delayed clearance and K13 mutations are common in parts of 
Cambodia, Thailand, Myanmar, and Vietnam, but not in other areas of Asia or Africa 
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[117]. Indeed, in Africa, specific mutations associated with artemisinin resistance were not 
detected, even though K13 gene polymorphisms and mutations in the propeller domain are 
also common in African parasites [117]. The molecular function of K13 is still not known. 
Recently, it was suggested that K13 could be a regulator of polyubiquitination (and thus 
degradation) of PfPI3K, a recently described potential target of artemisinins [61]. PfPI3K 
phosphorylates phosphatidylinositol (PI) to produce phosphatidylinositol 3-phosphate 
(PI3P) in ring-stage parasites.  Increased PfPI3K levels were associated with the C580Y 
mutation in PfKelch13 and were proposed to allow ring-stage parasites survival in the 
presence of artemisinins [61]. However, this increase is rather modest (2-4 fold) while 
mutant parasites have shown more than 70-fold resistance to artemisinin [118]. Thus, it is 
likely that additional factors must be involved in this mechanism of resistance to 
artemisinin. 
 
3. ASSESING ANTIMALARIAL DRUG EFFICACY 
a. Importance of Assessing Antimalarial Drug Efficacy 
Resistance to antimalarial drug is of great concern and it hinders the control of malaria. 
Surveillance is needed in order to facilitate the monitoring and containment of resistant 
parasites. In fact, monitoring the changing patterns of drug resistant malaria parasites is an 
essential key component for an efficient control and case management.  Recommendations 
to control the therapeutic efficacy of antimalarial drugs have been made for P. falciparum, 
but also for P. vivax [119]. 
 
b. Therapeutic Efficacy Trials  
In 1965, shortly after chloroquine resistance has emerged the first standardized systems to 
assess drug responses in vivo were developed [120]. These tests were originally developed 
for chloroquine. In 1996, the WHO developed a new protocol for assessing antimalarial 
drug efficacy in high transmission areas [121]. Since then, therapeutic efficacy protocols 
have been updated on a regular basis for high transmission areas and have been validated 
for low-to-moderate transmission regions as well. The most recent version is from 2009 
[122]. 
In clinical therapeutic efficacy trials a drug is administered to a malaria patient, blood 
samples are collected at pre-determined times and parasitemia is assessed by microscopic 
observation of Giemsa-stained blood smear, or less commonly by PCR. Day 0 is 
traditionally set as the day that the patient is enrolled in the trial and had received the first 
CHAPTER I – GENERAL INTRODUCTION 
 19 
dose of medicine.  In the case of P. falciparum malaria monitoring therapeutic efficacy 
involves the assessment of clinical and parasitological outcomes for 28 days, in the case of 
drugs that have an elimination half-life of less than 7 days (chloroquine, amodiaquine, 
artemisinin derivatives, atovaquone–proguanil, halofantrine, lumefantrine, quinine and 
sulfadoxine–pyrimethamine), or for 42 days, in the case of drugs with longer half-lives 
(mefloquine, piperaquine) [123]. Standard physical examination will be done on days 0, 1, 
2, 3, 7, 14, 21, 28, (35 and 42) [122]. 
Monitoring of re-appearance of parasites in the blood has to be performed as well. In these 
cases, PCR genotyping should be used to distinguish recrudescence, associated with 
treatment failure, from a new infection.  
In P. vivax malaria assessment of therapeutic responses is more challenging [122]. These 
parasites produce a dormant liver-stage that causes relapses, which cannot be distinguished 
from recrudescence or re-infection. In this case, early relapses, which may occur 3 weeks 
after treatment, or any newly acquired infections should be suppressed by therapeutic 
doses of antimalarial drugs with longer half-lives, such as chloroquine, mefloquine and 
piperaquine. Thus, reappearance of parasitemia within 28 days of treatment, whether 
relapse, recrudescence or re-infection, can still be used as a proxy measure of resistance. 
The WHO has classified the potential treatment outcomes on the basis of parasitological 
and clinical assessments performed after a drug had been administered. Accordingly, all 
patients will be classified as having early treatment failure, late clinical failure, late 
parasitological failure or an adequate clinical and parasitological response (Table I.6).  
The proportion of patients experiencing therapeutic failure during the follow-up period will 
be used to estimate the efficacy of the drug in question [26]. Once the data has been 
validated it should be made available to drug policy-makers for action. An antimalarial 
medicine that is recommended in the national malaria treatment policy should be changed 
if the total treatment failure rate exceeds 10%. The decline in efficacy can be indeed 
indicative of drug resistance. Yet, it may also due to several other reasons thus, 
complementary studies of pharmacokinetics, in vitro drug assays and molecular 
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Table I.6: WHO classification of responses to treatment  (adapted from [122])	
Early treatment failure (ETF) 
• danger signs or severe malaria on day 1, 2 or 3, in the presence of parasitemia; 
• parasitemia on day 2 higher than on day 0, irrespective of axillary temperature; 
• parasitemia on day 3 with axillary temperature ≥ 37.5 °C;  
• and parasitemia on day 3 ≥ 25% of count on day 0. 
Late clinical failure (LCF) 
• danger signs or severe malaria in the presence of parasitemia on any day between day 4 
and day 28 (day 42) in patients who did not previously meet any of the criteria of early 
treatment failure; 
• and presence of parasitemia on any day between day 4 and day 28 (day 42) with axillary 
temperature ≥ 37.5 °C in patients who did not previously meet any of the criteria of early 
treatment failure. 
Late parasitological failure (LPF) 
• presence of parasitemia on any day between day 7 and day 28 (day 42) with axillary 
temperature < 37.5 °C in patients who did not previously meet any of the criteria of 
early treatment failure or late clinical failure 
Adequate clinical and parasitological response (ACPR) 
• absence of parasitemia on day 28 (day 42), irrespective of axillary temperature, in 
patients who did not previously meet any of the criteria of early treatment failure, late 
clinical failure or late parasitological failure. 
 
c. In Vitro Assays for Antimalarial Drug Testing 
Undoubtedly, in vivo tests are essential to provide relevant data to clinicians and health 
authorities. However, tests of therapeutic efficacy not only require a challenging long 
follow-up of patients, for at least 28 days, but its outcome might be confounded by the 
immunity of the patient, pharmacokinetics differences and even possible re-infections. 
Moreover, ethical considerations preclude the evaluation of new drugs until initial phases 
of clinical trials are complete and the drug has been approved for clinical use. In vitro 
assays avoid many of these confounding factors and can be used for different purposes, 
such as: 
- for drug development: screening of new compounds, in vitro interaction of drug 
combinations, cross-resistance studies, phenotypic comparisons of pre-treatment and 
post-treatment isolates, baseline sensitivity to new drugs; 
- as a complementary test to determine if drug resistance is the probable cause of 
therapeutic failure; 
- to validate candidate molecular markers of drug resistance; 
- to monitor drug resistance: emergence of drug resistance, changing trends of drug 
sensitivity or resistance over time and space, in vitro responses of individual drugs that 
are currently administered in combination therapies, in particular for drugs that do not 
have yet a validated molecular marker.  
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i. Overview  
All current antimalarial drug assays are based on in vitro culturing of malaria parasites. 
This technique of culturing P. falciparum parasites in vitro was only developed in 1976, by 
Trager and Jensen. Yet, the very first assay to determine antimalarial drug effects in vitro 
was performed in 1922. An isolated P. falciparum sample from a patient was incubated in 
vitro and exposed to a single concentration of quinine for 29 hours to demonstrate its 
schizoncidal effect [124]. In the late 1960s, when the problem of drug resistant malaria 
emerged, Rieckmann developed the “macrotest” to detect and follow the evolution of 
chloroquine-resistant P. falciparum [125, 126]. The principle of this test was based on sub-
optimal short-term cultured method that has been described in 1912, where the crucial 
point was the maturation from rings to schizonts, without necessarily attaining the ring 
stage of the second intraerythrocytic cycle [127].  
In 1976, in vitro culture method for P. falciparum underwent a major change and this 
technical improvement led to an improved version of the “macrotest”, called the 
microstest. Since then, several novel in vitro assays were developed and most of them are 
still being used nowadays.   
 
ii. Microscopy – The Schizont Maturation Test (WHO microtest) 
Microscopy is indeed the technique that has been available for longer and the first in vitro 
drug sensitivity test for P. falciparum was based on microscopy, it was known as the 
microtest [128]. This test was developed by Rieckmann in 1978, shortly after in vitro 
culturing methods for P. falciparum had been described. Finger prick capillary blood was 
collected and incubated with different concentrations of drugs. The amount of young 
parasite forms that matured into schizonts is assessed after 30-48 hours by microscopy.  
A field-applicable standard kit based on Rieckmann’s microtechnique was developed by 
Wernsdorfer, under WHO sponsorship [129]. Thereafter this assay was known as the 
WHO microtest. Nowadays, the WHO kit is no longer being produced, yet microscopic 
assessment of schizont maturation is still used.  Nevertheless, microscopic methods are 
likely to be tedious, time-consuming and more importantly subjective because the decision 
of whether a parasite is viable or not tends to differ between different examiners. Because 
of these limitations, several other approaches that rely on specific indicators of parasite 
growth have been investigated.  
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iii. Radioisotope Methods 
The use of radiolabeled DNA precursors to assess parasite maturation was the first 
alternative to be investigated. In cultures containing malaria parasites, uninfected 
erythrocytes and platelets do not synthesize DNA, RNA, proteins or membranes and 
human leukocytes do not multiply and tend to disintegrate over a few days. Thus, the only 
actively dividing cells are the parasites themselves. Of the several DNA precursors 
investigated [3H]Adenosine, [3H]Xanthine and [3H]Hypoxanthine were shown to be 
incorporated into the nucleic acids of Plasmodium spp. parasites.  However, 
[3H]Hypoxanthine is the main purine base used by P. falciparum and is the radioisotope 
used for in vitro drug sensitivity assays [130]. 
The incorporation of  [3H]Hypoxanthine  is directly proportional to the number of P. 
falciparum infected erythrocytes, when the initial parasitemia ranges between 0.1 and 1% 
[131, 132]. If the initial parasitemia is higher than 1% incorporation becomes non-linear 
and is lower than expected. Moreover, it is stage-dependent and follows DNA replication 
and nuclear division, meaning that during the ring-stage the incorporations is low and it 
starts increasing as parasites developed into mature throphozoites reaching a maximum 
with schizont formation [131, 132].  
The first radioisotope and semi-automated assay was developed by Desjardins [133] and it 
still remains as the reference method for in vitro antimalarial drug sensitivity testing. Even 
though it allows an accurate and sensitive determination of drug effects on parasite growth, 
its main limitation is the use of a radioactive compound that requires sophisticated 
infrastructure for handling and disposal. Other assays that may overcome this limitation 
were further investigated and developed. 
 
iv. Fluorometric Assays 
This type of assays is based on the principle of DNA labeling with fluorochromes.  
Infected erythrocytes are incubated with drugs for 48 hours after which erythrocytes are 
lysed by addition of distilled water or saponin. After centrifugation, the packed pellets are 
stained with DNA-binding fluorochromes such as Hoechst 33258, PicoGreen®, SYBR® 
Green I [134–137]. The fluorescence intensity, which is proportional to the amount of 
DNA in individual samples, is measured with a minifluorometer, fluorescence 
spectrophotometer or fluorescence activated microplate reader. This procedure may require 
an additional step of DNA extraction in chloroform to eliminate hemozoin which can cause 
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quenching. This protocol must be optimized to ensure complete recovery of the total 
amount of DNA in each sample. Moreover, contaminating human leukocytes must be 
removed completely. This assay is accurate, rapid but less sensitive in comparison to other 
methods and it requires an experienced technician to execute it.  
 
v. Antigen Detection by ELISA 
Two enzyme-linked immunosorbent assays (ELISAs) based on two different antigens 
(HRP2 and pLDH) have been developed to assess drug effects in P. falciparum. In fact 
these antigens have been initially investigated for their potential use in the context of 
malaria diagnosis.  
The histidine-rich protein 2 (HRP2) appears to be produced exclusively by P. falciparum 
in the course of its growth and multiplication. It is most actively secreted into the host 
erythrocyte and to the extracellular environment (plasma, culture medium) during the late 
ring and trophozoites stages [138]. The levels of HRP2 are closely related with parasite 
density and development [139]. However, the HRP2 is a stable antigen that persists in 
patients up to two weeks after effective treatment, despite parasite and fever clearance. In 
synchronized laboratory-adapted strains levels of HRP2 remain low during the first 48 
hours, reaching high levels only at 60 – 72 hours [140]. Assessment of the HRP2 
concentration by the end of the 72 hours of incubation represents the cumulative effect of 
parasite metabolism and it does not seem to increase in parallel with parasite maturation 
during the first cycle.  
A commercial ELISA kit to measure HRP2 is available, however it is expensive (800 
USD/10 microtitre plates). Yet, the cost can be reduced by 80% (i.e. about US$ 100 for 10 
plates) by preparing the antibody coated plates in-house [141].  
This assay is easy to perform and neither highly specialized equipment nor personnel are 
required. Moreover, it has a low limit of detection of 0.05% parasitemia. ELISA-based 
assays can be tedious and time-consuming to perform because they require numerous 
washing steps. Another limitation is the rather long turn-around time, since it is mandatory 
for samples to be incubated for 72 hours before the ELISA can be performed.  
Another ELISA assay based on the detection and quantification of parasite lactate 
dehydrogenase (pLDH) was developed. pLDH is a terminal enzyme in the Embden–
Meyerhof pathway (glycolysis) of the malaria parasite. The enzymatic activity of pLDH 
reflects the general metabolic activity of viable parasites. In 1993, Makler et al. developed 
an assay where by measuring the enzymatic activity of pLDH it was possible to determine 
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drug activity [142]. Rather high initial parasite densities of 1-2% are required. Subsequent 
tests with fresh isolates showed that this assay was not sensitive for field application [143]. 
These limitations led to the development of a new pLDH-based assay. This new approach 
measures pLDH levels in a double-site enzyme-linked LDH immunodetection (DELI) 
assay, which was made possible by the development of monoclonal antibodies. This new 
format is considerably more sensitive and is also field applicable [144]. Nevertheless, 
limited supplies of monoclonal antibodies constrained the further validation and 
application of this assay. 
 
vi. Flow Cytometric Methods 
By 1987, it had been shown that flow cytometry of DNA and RNA content of parasitized 
erythrocytes could differentiate stages and, in some cases, species [145, 146]. Since then 
flow cytometry has been used to study parasite physiology and also response to 
antimalarial drugs [147–152]. Most of the described flow cytometry methods for drug 
testing in malaria use fluorescent DNA and RNA stains to detect the parasites [153, 154]. 
The principle behind this approach is the contrast between host erythrocytes, which most 
of them lack DNA/RNA, and the malaria parasites, which have DNA/RNA and are thus, 
readily stained with fluorescent stains. The fluorescent intensity increases in direct 
proportion to parasite maturation which allows to different asexual development stages. 
More recent work has also included the use of maturation/viability markers in the context 
of drug testing [155, 156]. 
A range of different fluorochromes have been used, such as: thiazole orange, acridine 
orange, Hoechst 33258 or 33342, SYBR Green I, among others (Table I.7). The latter has 
been pointed out as the best choice because, contrary to Hoechst 33258 or 33342, it does 
not require flow cytometers equipped with an ultraviolet laser, which are expensive. 
Unlike thiazole and acridine orange that bind both to DNA and RNA, SYBR green I is a 
specific-double stranded DNA dye, therefore excluding the problem of the RNA present in 
retycolocytes (immature erythrocytes) [137]. This technique is rapid, accurate, highly 
sensitive, automated and non-radioactive. On the other hand the flow cytometric analysis 
requires expensive equipment and specialized technicians for maintenance. Even though, 
nowadays simpler and more affordable flow cytometers have been developed. Another 
limitation for the use of such method in resource-limited settings is the fact that most flow 
cytometric approaches rely on the use of nucleic acid stains which are expensive and 
certainly not readily available in those settings. 
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Table I.7: Summary of dyes used to study Plasmodium spp. by flow cytometry (adapted from 
[153]) 
Stain Marker of Excitation maximum Reference 
Acridine orange RNA/DNA 460 nm (RNA) 500 nm (DNA) 
[145]  
[157] 
Ethidium bromide RNA/DNA  
[158]  
[159]  
Dihydroethidium DNA Live cells 
535 nm (DNA) 
610 nm (live) [160] 
Hoechst 33258 double-stranded DNA 345 nm 
[146] 
[157] 




Propidium iodide RNA/DNA 535 nm [162] 
SYTO-9 RNA/DNA 486 nm (RNA) 485 nm (DNA) [157] 
SYTO-16 DNA/RNA 494 nm (RNA) 488 nm (DNA) 
[163] 
[164] 
SYTO-61 DNA/RNA 628 nm [165]  












SYTOX green DNA/RNA (distinguish live from dead cells) 504 nm [169]  





536 nm  





355 nm  












Hoechst 33342 DNA 488 nm + 305 nm [173]  
Dihydroethidium + 
SYBR green I DNA 488 nm [173] 
Dihydroethidium + 
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d. Interpretation of In Vitro Results – Comparison of Different In Vitro Assays 
In vitro assays can be complex and so does their interpretation. Each test has a different 
end-point and measures the parasite growth differently using: incorporation of radioactive 
nucleotides or fluorescent stains and production of parasite-specific enzymes or secretion 
of soluble antigens.  
Results from in vitro drug assays can be expressed in different ways. Most of them are 
expressed in terms of which concentration is required to inhibit a specific percentage of 
parasite growth.  Generally, the 50% inhibitory concentration (IC50) is used, but IC90 or 
the minimal inhibitory concentration (MIC) (synonymous with IC100) can also be used. 
IC50 values are deduced from a sigmoid dose-response curve where the parasite growth is 
a function of the drug concentration (Figure I.4).  
 
Figure I.4: A representative dose-response curve. 
The 50% inhibitory concentration is found on the steepest 
part of the curve and bisects the distance on the Y-axis 






In fact, in malariology the MIC value is a less precise measure than the IC50. This is 
mainly due to the characteristic growth of malaria parasites and to the inherent limitations 
of available sensitivity assays. Unlike bacteria, were MIC values are commonly 
determined, malaria parasites replicate rather slowly in 48 hours cycles. As a consequence, 
available assays fail to detect small changes in parasites sensitivity to a specific drug. 
Thus, these small differences in growth inhibition are more reliably detected when 
determined at the steepest region of the curve, by calculating IC50 values instead of 
calculating the MIC. Unlike the estimation of IC50 values, the MIC is a fixed cut-off value 
[130]. Moreover, available assays measure parasite “viability” indirectly and there is no 
objective measure of growth inhibition like it may happen in bacteriology where the 
diameter of area cleared of bacterial growth on an agar plate is measured [130].  
Even though IC50 values are recommended to assess drug effects it is important to note 
that results can still differ considerably between different assays or even when using the 
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due to the fact that several different factors, such as hematocrit/erythrocyte volume 
fraction, initial parasitemia, volume present in the wells will influence parasite growth, 
both in the presence and absence of drug (Table I.9). Differences observed when using the 
same assay must be a consequence to inherent differences that exist among different 
laboratories. 
 
Table I.8: Antimalarial activities of several antimalarial drugs determined by different in 






SYBR green I 
plate assay HRP2 assay 
Quinine 
47.1 nM [175] 
59.9 nM [176]  
63 nM [177]  
102.3 nM [178] 
35 nM [177] 6.9 nM [179] 5.9 nM [179] 
Mefloquine 
6.1 nM [178]  
18.2 nM [175]  
34.5 nM [176] 
42.6 nM [180] 
12.1 nM [181]  
9.4 nM [179] 
9.5 nM [182]  
40.7 nM [183] 
8.4 nM [179] 
Chloroquine 
6 nM [184]  
9.6 nM [185] 
9.7 nM [178] 
11.3 nM [175] 
15.7 nM [180] 
18.7 nM [176] 
29.6 nM [186] 
14.79 nM [185] 
8.1 nM [179]  
11.54 nM [185]  
16 nM [187] 
22.2 nM [188] 
7.5 nM [179] 
9.7 nM [185]  
Amodiaquine 20.3 nM [189] 7.8 nM [177] 
  Artemisinin 10.1 nM [190]  
22 nM [180] 
 
9 nM [182] 
  
Dihydroartemisinin 4.2 nM [186]  5.3 nM [180] 
 
3.78 nM [188]  
22.1 nM [183]  2.3 nM [191] 
Artesunate 
0.4 nM [175]  
0.9 nM [176] 
1.1 nM [185] 
9.4 nM [189] 
3.7 nM [185] 
5.4 nM [183] 
1.9 nM [185] 
3.6 nM [188] 
1.5 nM (48h) 
[185] 
2.4 nM [191] 
2.5 nM (72h) 
[185] 
Atovaquone 
0.06 nM [185] 
1.1 nM [189] 
1.3 nM [180] 
0.11 nM [185] 0.06 nM [185] 0.8 nM [185] 
Pyrimethamine 
 
5 nM [184] 
19.3 nM (48h) [185] 
19.4 nM (72h) [185] 
78.4 nM [178] 
26.3 nM (72h) [185] 
32.2 nM (48h) [185] 
 
 > 100 nM (48h) [185] 
23.9 nM (72h) [185] 
7.2 nM [182] 
26.6 nM (48 h) 
[185] 
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25 - 100 μL 
 
10 – 200 μL 
 
100 μL 
Hematocrit 1.5 – 20% 1 – 2.5% 2.5% 1.5 – 2.5% 1.5% 
Parasitemia:      
Laboratory 
strains 
1% 0.5% 0.25 – 1% 0.5 -1% 0.05% 
Clinical 
isolates 
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e. Molecular Methods 
Molecular assays rely on molecular markers to predict drug resistance. Several molecular 
markers have been described for some antimalarial drugs including chloroquine, 
mefloquine, sulfadoxine-pyrimehamine, atovaquone (Table I.10). More recently, a 
molecular marker for artemisinin resistance, as characterized by delayed parasite 
clearance, has also been reported but further validation is still required [85].  Similarly to 
in vitro tests, molecular studies are also relevant and useful in monitoring the prevalence of 
a specific molecular marker in a certain region and thus, monitoring the potential spread of 
resistant parasites.  
Advantages of molecular methods include the need for small volumes of samples, the fact 
that it does not require in vitro incubation of samples with the drugs and it allows the 
assessment of a large number of samples in a relatively short period of time. More 
importantly, the transport and storing of samples for molecular analysis can be simply 
done by using dried blood spots in filter papers. As disadvantages there is the need for 
sophisticated equipment and training, and most importantly the fact that the number of 
currently known and validated markers is limited. Nevertheless, molecular methods are 
valuable surveillance tool for monitoring the occurrence, spread, or intensification of drug 
resistance. 
 
Table I.10: Molecular Markers for Antimalarial Drug Resistance 
 pfcrt pfmdr1 pfnhe1 cyt-b  pfdhfr pfdhps 
Quinine ! ! !    
Chloroquine ! !     
Mefloquine  !     
Amodiquine ! !     
Lumefantrine  !     
Piperaquine !      
Atovaquone    !   
Pyrimethamine-sulfadoxine     ! ! 
pfcrt (P. falciparum chloroquine resistance transporter); pfmdr1 (P. falciparum multidrug 
resistance transporter 1); pfnhe1 (P. falciparum sodium/proton exchanger 1); cyt-b (cytochrome b 




f. Key Practical Aspects of Antimalarial Drug Testing 
i. Culturing of P. falciparum 
In 1976, Trager and Jansen described a method to reliably culture asexual stages of malaria 
parasites [192]. Culturing of parasites is an essential step for in vitro antimalarial drug 
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testing because incubation of infected erythrocytes with the drugs is required to assess its 
inhibitory activity. In fact, vaccine development, investigation of mechanisms of 
pathogenesis, parasite development and the study of parasite genetics have been greatly 
impacted by use of in vitro cultivation of the malaria parasite.  
In vitro cultivation of P. falciparum generally requires human erythrocytes, a lipid source 
and a synthetic medium that provides suitable ionic environment and soluble nutrients. The 
culture medium for P. falciparum consists on RPMI 1640 supplemented with glucose, 
hypoxanthine, L-glutamine, sodium bicarbonate, HEPES and gentamycin [193].  
Detailed information about each culture-related factor that may influence in vitro drug 
testing is presented below.  
 
ii. Culture-related factors that influence in vitro drug sensitivity  
No standardize protocol for in vitro antimalarial drug testing exists. Different laboratories 
consider different factors, which can considerably influence the level of drug response 
(Table I.7 and I.8). Such factors include: modification to the culture medium, the type of 
serum substitute, the used hematocrit, the initial parasitemias and the incubation 
conditions.  
 
Culture medium and components 
The main in vitro assay affected by the culture medium components is the radioisotope 
assay based on the incorporation of [3H]Hypoxanthine. Unlabeled hypoxanthine is 
routinely supplemented into to RPMI 1640 medium to optimize the parasite growth in 
culture. This might influence the maximal incorporation of [3H]Hypoxanthine. At 
concentrations ≥ 2 μmol/l of unlabeled hypoxanthine the incorporation of 
[3H]Hypoxanthine decreases [130].  
The activity of antifolate drugs is also affected by the culture medium. Standard RPMI 
1640 contains folic acid (1 mg/l) and PABA (1 mg/l). Both these substrates antagonize the 
antimalarial activity of antifolate drugs, such as sulfonamides, sulfones, pyrimethamine, 
trimethoprim and cycloguanil (the biologically active metabolite of proguanil)  [130]. 
Although the “real inhibitory” effect of such drugs may be masked by the presence of folic 
acid and PABA in the culture medium, IC50 values can still be determined and compared 
between samples.  
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Hematocrit: erythrocyte volume fraction 
Uninfected erythrocytes are used in in vitro drug testing to adjust the initial parasitemia of 
blood samples. They are essential for the development of the parasite because they 
obviously provide the location/environment for asexual reproduction but also nutrients for 
parasite growth [194].  Any blood group can be used since all of them support the growth 
of erythrocytic stages of malaria [130]. Yet, the use of type O cells may be more adequate 
because of their compatibility with serum or plasma of all other blood groups. In vitro 
multiplication of P. falciparum is higher in freshly collected erythrocytes, independently of 
the anticoagulant used for its collection [195]. Nevertheless, erythrocytes can be used up to 
approximately one week after blood collection.   
The hematocrit refers to the percentage of volume of red blood cells per total volume of 
the sample. It is known that increases in the hematocrit, from 1% t 2.5% for example, will 
lead to an increase in IC50 values as well [196]. Furthermore, when the hematocrit is 
higher than 2.5% confounding factors can be observed. Because, when using this 
hematocrit in 96-well plates the parasite growth during 48 hours without medium change is 
suboptimal due to the depletion of nutrients, poor gas exchange in thick layer of 
erythrocytes, accumulation of lactic acid or a combination of all these factors [130]. 
Moreover, some specific assays are directly affected by differences in the hematocrit. For 
example, incorporation of [3H]Hypoxanthine increases when the hematocrit increases from 
1 to 2% but tends to reach a plateau at hematocrits equal or higher than 2.5% [196].  
 
Initial parasitemia  
When the parasitemia is higher, using the same hematocrit, the in vitro activity of drugs 
tends to decrease, resulting in higher IC50 values. This is referred as the inoculum effect, 
which is defined by an increase in the inhibitory drug concentration when greater numbers 
of parasites are inoculated. It is thought to be the consequence of some drug accumulating 
inside the parasitized erythrocyte [197] and has been described for most antimalarial drugs 
like artemisinin, artesunate, chloroquine and mefloquine [198].  
 
Leukocytes 
P. falciparum growth is not inhibited by the presence of leukocytes, when this leukocytes 
were obtained from non-immune healthy donors [199]. Therefore, elimination of 
leukocytes is unnecessary, and untreated erythrocytes (i.e. with leukocytes) can be used for 
routine culture. 
CHAPTER I – GENERAL INTRODUCTION 
 
 32 
Even though the presence of leukocytes does not inhibit parasite growth, it can interfere 
with several in vitro drugs assays. Mostly with assays that measure parasite DNA/RNA, 
such as fluorometry or flow cytometry. Because unlike erythrocytes, leukocytes will have 
high amounts of DNA/RNA that cannot, or are difficult to, be distinguished from the 
DNA/RNA of the parasite [153].  
In cases the absence of leukocytes is required, blood samples can be treated in order to 
remove these cells by using CF11 cellulose powder columns, cell affinity chromatography 
with protein A sepharose or commercial filters [130]. Yet, it should be taken in 
consideration that leukocyte-free blood prepared by passage over a powdered cellulose 
column can result in suboptimal parasite growth [199].  
 
Anticoagulants 
Several anticoagulants used to collect capillary or venous blood from patients like heparin, 
acid citrate dextrose and EDTA have been studied. Parasite growth is not affected by any 
of these anticoagulants if isolates are cultured immediately after blood collection [130]. 
Yet, others recommend the use of heparin or citrate phosphate dextrose solution (CPD) 
tubes, claiming that the use of EDTA blood does not support parasite survival [193]. In 
fact, several reports use EDTA-anticoagulated tubes to collect blood from malaria patients 
for ex vivo drug testing [200–204]. Heparin is also known to reversibly inhibit the invasion 
of uninfected erythrocytes by merozoites [205], thus as long as the blood is washed before 
culture it should not affect parasite growth in vitro. However, it is known to inhibit the 
action of taq DNA polymerase [130] and thus, its use should be avoided in molecular 
studies. Collection tubes containing acid citrate dextrose are designed to be filled 
completely, an thus the total volume of collected whole blood is altered. No clear 
consensus seems to exist and different reports mention and use different anticoagulants. 
 
Serum substitutes 
Serum factors influence the availability of drug in the blood. Once drugs are administered, 
the drug is absorbed and enters the bloodstream, some it is bound to blood proteins, in 
particular albumin, while the rest remains free in circulation. The free part of the drug is 
the one responsible for drug effects. Each drug will have different proportion of the bound 
and unbound fractions [130], therefore the type of serum substitute used for in vitro 
culturing of parasites may have a significant impact both on parasite growth but also on 
drug effect. 
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Several serum substitutes have ben investigated. Fetal calf serum is commercially available 
and is an affordable alternative to human serum. However, there is wide batch-to-batch 
variation in its ability to support P. falciparum growth in vitro [206]. Another alternative is 
the use of Albumax. This lipid-enriched bovine albumin preparation has been widely tested 
for culture of malaria parasites and antimalarial drug sensitivity assays. Even though it is 
the most currently used human serum substitute for P. falciparum in vitro cultures, it has 
also been associated with unpredictable growth of isolates and it may affect the IC50 
values obtained for different drugs [196, 206, 207].  
 
Incubation conditions: the period of incubation and the atmosphere 
Incubation periods of cultured parasites with the respective drug can differ from 24 to 96 
hours, depending on the assay being used and on the drug being tested (Table I.8).  
Most assays use as endpoint a period of incubation that precede the 48 hours. In this case 
drug effects are determined within the first erythrocytic cycle, this is the case of the 
schizont maturation test, the hypoxanthine assay and the fluorometric methods. On the 
other hand, other assays require a prolonged incubation time of 72 hours, such as the 
ELISA assays, or even 96 hours when drugs have a delayed inhibitory effect on the 
parasite (e.g. pyrimethamine or antibiotics) [185].  
In terms of atmospheres the CO2 level should be maintained always at 5%, while the O2 
may vary. The currently used culture medium was optimized to have a pH within the 
physiological range in an atmosphere containing 5% CO2. Alterations of this concentration 
will lead to an altered pH, which can influence the IC50 values of pH-dependent drugs like 
chloroquine.  Indeed, studies have shown that an increase in CO2 concentration will lead to 
significantly higher IC50 values [208].  
On the other hand, O2 concentrations seem not to affect the IC50 values. Generally, the 
recommended atmosphere for P. falciparum growth in vitro include the use of a low O2 
atmosphere, with 5% CO2 [193]. However, the use of such atmospheres requires gas 
cylinders and gas-mixing incubators which might not be available in many of the resource-
limited settings in malaria endemic countries. The influence of atmospheres on parasite 
survival after drug treatment has been addressed in a study where an ex vivo drug assay 
was performed using different atmospheres: trigas (5% CO2, 5% O2, 90% N2), 5% CO2, 
and candle jar. Results showed no differences in parasite survival using these three 
atmospheres [84].  
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iii. Synchronization of parasites 
One of the particular features of P. falciparum infection in humans is the fact that only 
young parasite forms (rings) are found in circulation. In in vitro cultures of P. falciparum 
all parasite developmental stages (ring-forms, throphozoites and schizonts) are present. 
Thus, several approaches have been used to synchronize in vitro parasite cultures. 
Generally, they involve combinations of treatments that include: selective killing of mature 
parasites by sorbitol lysis [209], harvesting of mature stages using a Percoll gradient [210] 
or using a magnetic column [211, 212].  
The use of a 5% sorbitol solution to eliminate mature parasite forms is the most commonly 
used method [209]. This protocol relies on the lysis of throphozoites and schizonts 
allowing the continued growth of ring-form parasites.  
Percoll density centrifugation can also be used to enrich for mature parasite forms, 
however separation of late trophozoites, early or late schizonts is not possible [210].  
Magnetic cell sorting systems are also used to separate mature forms containing hemozoin. 
Hemozoin is paramagnetic and thus, when an infected blood sample containing different 
parasite forms is subjected to a strong magnetic field late-stage parasites containing 
hemozoin will get retained, while uninfected erythrocytes or young parasites will flow 
through [211].  
Heparin, which reversible inhibits the invasion of erythrocytes by P. falciparum 
merozoites, has also been used to synchronize cultures [205]. In this case parasites are 
incubated in the presence of heparin, when almost all of them have progressed to the 
schizont stage, heparin is removed allowing merozoite invasion to occur. Thus, allowing to 
obtain parasite cultures with a specfic synchronization window. The duration of merozoite 
invasion can be limited by the addition or removal of heparin [213]. This method is rather 
recent and it has not been used very often. 
 
4. HEMOZOIN - THE MALARIA PIGMENT 
a. Overview 
Hemozoin, also known as malaria pigment, is produced by malaria parasites during their 
growth inside the erythrocytes. During the blood stage the parasites digest up to 80% of 
hemoglobin present in the erythrocyte [214, 215] in order to gain space to grow [216] and 
as a source of aminoacids [215]. As a result free toxic heme is produced. In order to 
detoxify it, the parasite converts it into hemozoin. The content of hemozoin increases as 
the parasite matures from ring-forms, to trophozoites and, finally to schizonts (Figure I.5). 
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Similarly to schizonts, gametocytes also have a high content of hemozoin. However, while 
schizonts have a single granule of hemozoin, in gametocytes the hemozoin is widely 
distributed.  
Figure I.5: Hemozoin as a parasite 
maturation indicator.  
The content oh hemozoin increases as the 
parasite matures (arrows). Hemozoin is able 
to depolarize light, thus using polarized 
microscopy hemozoin crystals exhibit a 







In fact, hemozoin had a crucial role in the discovery and understanding of malaria, as 
presented elsewhere [217]. In 1717 Lancini made the first observations of the presence of 
hemozoin in the spleen and brain in a necropsy of a patient with malaria. In 1847, Meckel 
made the same observation and assumed that this dark pigment was melanin. Later in 
1849, Rudolf Virchow associated this dark pigment with malaria. Yet, it was Laveran who 
made the ultimate casual relationship between the pigment and the parasite. The pigment 
was proved to be equivalent to hematin and not melanin in 1911 by Brown.   
Hemozoin has also been described in other organisms, such as the blood-sucking insect 
Rhodnius prolixus, in the parasitic worm Schistosoma mansoni and in the avian protozoan 
parasite Hemoproteus columbae [218, 219].  
Despite the early discovery of hemozoin its mechanism of formation is still not completely 
understood.  
 
b. Formation of Hemozoin  
During the blood stage, the parasite digests hemoglobin and converts the resulting free 
toxic heme into hemozoin inside its digestive vacuole (Figure I.6). Investigating the 
process of hemozoin formation inside the parasite is very challenging and thus, most 
studies have been focused on the structurally and chemically identical β-hematin [220].  




Figure I.6: Electron microscopic picture of a P. falciparum infected erythrocyte.  
Several hemozoin crystals (Hz) can be detected inside the digestive vacuole of the parasite.  
 
Hemozoin is thought to be formed by biomineralization [221, 222]. Biomineralization is 
the process where deposition of low molecular weight inorganinc materials within or 
outside the cells of living organisms occurs, leading to the formation of inorganic salts.  
Interestingly, other organisms also use this process as a detoxification mechanism. In the 
case of hemozoin formation, it has been suggested that the use of the term biocrystalization 
(instead of biomineralization) is more appropriate [223]. Both enzymes and lipids can be 
implicated in biomineralization processes.  In fact, histidine-rich proteins (HRP) have been 
suggested to be associated with hemozoin formation [224]. However, parasites that lack 
these proteins (e.g.: P. vivax) can still produce hemozoin [225] and HRPs have been found 
in small amounts in the parasite food vacuole, where hemozoin is produced [226].  Lipids 
have also been suggested to be involved in the process of hemozoin formation[227]. 
Several reports have shown that hemozoin is formed in lipid–aqueous interfaces, providing 
experimental evidences that support this hypothesis [227–230]. Yet, it was also observed 
that hemozoin crystals grow on the surface of other hemozoin crystals, suggesting that the 
process of hemozoin formation could be autocatalytic [218]. More recently, another 
protein (HDP – heme detoxification protein) that converts heme into hemozoin has been 
described [231]. 
In summary, it is still unclear which or if any of these mechanisms is involved in hemozoin 
crystallization processes in vivo. Further studies in this direction are needed to fully 
elucidate the mechanism of hemozoin production in Plasmodium spp. 
c. Biophysical Properties of Hemozoin and its Use for the Study of Malaria 
Hemozoin crystals are paramagnetic and birefringent. Therefore, they are able to generate 
small magnetic fields and to change the rotating plane of polarized light, respectively. Due 
to the fact that Hz is birefringent, it can be detected by optical methods, such as 
microscopy (Figure I.5) [232, 233] or flow cytometry [174, 234]. Its paramagnetic 
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property has mainly been used for separating infected erythrocytes from uninfected ones 
[211, 212]. More recently, systems that exploit both physical properties were developed as 
alternative malaria diagnosis methods [235–237].  
The idea of using hemozoin as a parasite maturation indicator to assess drug effects dates 
back to 1982. Rieckmann developed a drug assay based on the visual detection of 
hemozoin, where at the end of 48 hours of incubation the amount of dark-pigmented 
precipitate (hemozoin) was assessed [238]. However, this assay was not very accurate 
because of the interference in the final read-out caused by leukocytes agglutination.  
The use of hemozoin as a mean to detect the presence of malaria parasites or even its 
maturation and growth may be a unique opportunity to develop novel and better reagent-
free methods for the study of malaria.  
 
5. FLOW CYTOMETRY 
a. Principles of Flow Cytometry 
Flow cytometry is a powerful technique for the analysis of multiple parameters of 
individual cells within heterogeneous populations. Measured parameters include the 
relative size of a particle, granularity or internal complexity and fluorescence. This is 
accomplished by using an optical-to-electronic system that records how the cell scatters 
light or emits fluorescence.  
As the name indicates, this technique is based on a flow of cells that will pass one at the 
time through a laser beam. As a cell passes through the laser it will refract or scatter light 
at all angles. The forward scatter (FCS) refers to the amount of light scattered in the 
forward direction (less than 10º angles). The magnitude of FCS is proportional to the size 
of the cell. The side scatter (SSC) refers to the light that is scattered to the side (at a 90º 
angle). The side-scatter indicates the level of granularity and structural complexity of the 
cell. The scattered light will reach a detector, which will convert the light intensity into 
voltages. A combination of filters and beam splitters guide the scattered and fluorescent 
light to the appropriate detectors. 
A flow cytometer is constituted by three main systems: fluidics, optics and electronics. The 
fluidics system transports particles in a stream allowing them to pass through the lase one 
at the time. The optics system consists of one or more lasers, which will illuminate the 
particles passing in the stream, and of optical filters, that will direct the resulting light 
signals to the respective detectors. Finally, the electronics system will convert the detected 
light signals into electronic signals that can be processed by the computer (Figure).  
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Nowadays a wide range of different flow cytometers exist. From expensive and 
sophisticated instruments to small, simple and affordable versions.  
 
b. Flow Cytometry and Malaria 
In 1987 flow cytometry was used for the first time to detect infected erythrocytes (Janse 
1987). In this study quantification of DNA and RNA allowed to differentiate parasite 
species and stages without morphologic information [146]. Due to its speed and to the 
amount of information it provides, cytometry may become particularly important for the 
study of malaria parasite growth and invasion since it overcomes some of the limitations of 
existing methods. Especially, during the last decade flow cytometry has been increasingly 
used in malaria research with particular focus on the study of parasite physiology and its 
response to antimalarial drugs [147–149, 152, 239]. Most approaches rely on the use of 
nucleic acid stains to detect parasite’s DNA/RNA (Table I.10). Generally they require 
either complex multi-parameter analysis or complex protocols of staining to reliably 
distinguish infected erythrocytes from uninfected [153, 154]. In some they even require the 
use flow cytometers equipped with UV lasers or with more than one laser – increasing the 
cost of these methods.  
More recently flow cytometric methods based on the detection of hemozoin, produced by 
malaria parasites, have been described [174, 234, 240, 241]. These methods rely on the fact 
that hemozoin is able to depolarize light and thus, the resulting light depolarization can be 
detected by flow cytometry. The detection of hemozoin inside leukocytes have been used 
for diagnosis and immunological studies [242, 243], while hemozoin inside erythrocytes 
has mainly been assessed for drug testing purposes [174] and has been the main focus of 
the work presented in this thesis.   
 
c. Detection of Light Depolarization by Flow Cytometry  
In 1987, flow cytometric detection of depolarized light scatter was described for the first 
time [244]. Initially this was used as a simple and reagent-free mean to distinguish 
eosinophils from other leukocyte cell population based on the birefringence of the 
eosinophil granules [244].  This feature was only available on Cell-Dyn automated full-
blood-count analysers and other manufacturers of flow cytometers were not allowed to 
offer this measurement in their instruments because of a patent (US, Patent: 5017497: 
http://www.google.com/patents/US5017497 accessed on 02/12/2016). 
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In 1999, hemozoin-containing monocytes in a blood sample from a malaria patient was 
detected by a Cell-Dyn hematology analyser [245]. Later other studies reported the 
detection of hemozoin inside monocytes and neutrophils using the same instruments [234, 
240, 242]. In fact the use of hematology analyzers as an alternative tool to diagnose 
malaria, both in non-endemic and endemic countries, has been investigated and it is 
extensively reviewed elsewhere [246]. Interestingly, in some of these studies the 
possibility of detecting hemozoin inside erythrocytes was reported [240, 247] (Figure I.7). 
This was further investigated and developed in the context of the work presented here in 




Figure I.7: Granularity/Lobularity plots from the Cell-Dyn 3500.  
Granularity is a measure of depolarization (90º-depolarized) and lobularity of 90º light scatter. A 
normal FBC result is shown with the eosinophil population (green) separated from monocytes 
(purple), lymphocytes (blue) and neutrophils (orange) (A).  A FBC result from a patient with P. 
falciparum malaria (purple dots) shows hemozoin-containing monocytes in the eosinophil area 
(purple arrow) and an eosinophil population that is abnormally scattered (green arrow) (B). A P. 
vivax infection in a patient with increased osmotic resistance. In “normal lysis” mode many red 
dots (resistant erythrocytes) with strongly depolarizing content appear in the plot (red arrow) (C). 
The same sample, as in C, but re-analysed in the “extended lysis” mode where red dots events have 




6. A NOVEL ANTIMALARIA DRUG ASSAY FOR PLASMODIUM spp. BASED 
ON THE FLOW CYTOMETRIC DETECTION OF HEMOZOIN 
The idea of using hemozoin as a parasite maturation indicator was the basis of sensitivity 
assay developed in the 80’s [238]. Yet, the visual read-out was not ideal and results were 
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not reliable. However, reports indicating that hemozoin could be detected inside leukocytes 
by hematology analysers made us revisit Rieckmann’s work. This time the subjective 
visual read-out would be replaced by flow cytometry instead.   
Previously, during my master studies, the use hemozoin as a parasite maturation indicator 
and, consequently as a mean to detect drug effects was assessed in a malaria rodent model 
(C57BL/6 mice infected with Plasmodium berghei). Results showed that indeed it was 
possible to distinguish between infected and uninfected blood samples based on the flow 
cytometric detection of hemozoin. Depolarizing cells, which correspond to infected-
erythrocytes containing hemozoin, were present in the infected sample but absent in the 
uninfected one (Figure I.8A and B). Moreover, different degrees of depolarization 
corresponding to different stages of maturation were observed (Figure I.8B). Drug effects 
could be determined by assessing the percentage of events that had a high depolarization 
signal overtime (Figure I.8C) [243].  
These promising results led to the work presented in this thesis, where further 
investigation, development, and validation of the hemozoin detection assay were 
performed. 
 
Figure I.8: Flow cytometric 
detection of hemozoin and 
assessment of drug inhibitory 
effects in a malaria rodent model.  
Side scatter against depolarized side 
scatter plots of a blood sample from 
an uninfected (A) and a Plasmodium 
berghei-infected mouse (B). Solid 
pink line delineates the depolarizing 
erythrocyte population and the 
dashed pink line delineates the 
population of highly depolarizing 
events. Increasing concentrations of 
chloroquine (CQ) were incubated 
with P. berghei-infected 
erythrocytes. The inhibitory effect of 
chloroquine can be detected already 
after 2 hours of incubation. Each 
point represents the mean of 
triplicate measurements (± one SD) 
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1. Abstract 
The use of flow cytometry in malaria research has increased over the last decade. Most 
approaches use nucleic acid stains to detect parasite DNA and RNA and require complex 
multi-color, multi-parameter analysis to reliably detect infected red blood cells (iRBCs). 
We recently described a novel and simpler approach to parasite detection based on flow 
cytometric measurement of scattered light depolarization caused by hemozoin (Hz), a 
pigment formed by parasite digestion of hemoglobin in iRBCs.  Depolarization 
measurement by flow cytometry was described in 1987; however, patent issues restricted 
its use to a single manufacturer’s hematology analyzers until 2009.  
Although we recently demonstrated that depolarization measurement of Hz, easily 
implemented on a bench top flow cytometer (Cyflow), provided useful information for 
malaria work, doubts regarding its application and utility remain in both the flow 
cytometry and malaria communities, at least in part because instrument manufacturers do 
not offer the option of measuring depolarized scatter.  Under such circumstances, 
providing other researchers with guidance as to how to do this seemed to offer the most 
expeditious way to resolve the issue. 
 We accordingly examined how several commercially available flow cytometers (CyFlow 
SL, MoFLo, Attune and Accuri C6) could be modified to detect depolarization due to the 
presence of free Hz on solution, or of Hz in leukocytes or erythrocytes Hz from rodent or 
human blood. All were readily adapted, with substantially equivalent results obtained with 
lasers emitting over a wide wavelength range. Other instruments now available may also 
be modifiable for Hz measurement. 
Cytometric detection of Hz using depolarization is useful to study different aspects of 
malaria. Adding additional parameters, such as DNA content and base composition and 
RNA content, can demonstrably provide improved accuracy and sensitivity of parasite 
detection and characterization, allowing malaria researchers and eventually clinicians to 
benefit from cytometric technology. 
 
 
Keywords: polarization, depolarized side scatter, hemozoin, flow cytometry, malaria, and 
light depolarization. 
  




Malaria remains one of the most important parasitic diseases, killing around 700,000 
people each year [1]. Reliable detection of parasites and identification of the species are 
crucial for clinical diagnosis, as well as for many research applications. Both may require 
differentiation of asexual and sexual forms, determination of different maturation stages, 
and reliable quantification of parasite density (numbers per unit volume of blood or 
percentage of infected red blood cells).  Antimalarial drug development and assessment of 
resistance to drugs may additionally require evaluation of parasite metabolic state and 
viability. Cytometry could potentially provide an alternative to microscopy of Giemsa 
stained smear [2], the accepted method for diagnosis for over a century.  
Malaria parasites growing inside infected erythrocytes (iRBCs) catabolize hemoglobin, 
producing the strongly absorbing and birefringent pigment hemozoin (Hz). Once the 
parasite completes its growth cycle in the iRBC, Hz is released and, subsequently ingested 
by peripheral blood phagocytes [3]. The presence and form of Hz in iRBCs are useful 
characteristics for distinguishing various species and developmental stages; observation of 
Hz, known to be associated with malaria, in cells in unstained blood led Alphonse Laveran 
to the initial discovery of malaria parasites in 1880 [3]. Staining came later. 
In addition to strongly absorbing light at wavelengths between 300 and 700 nm, Hz is able 
to depolarize light and can, as has long been known, be detected by optical methods such 
as dark-field microscopy [4 – 7] or depolarization microscopy [8, 9]. In the latter, crossed 
polarizing filters are inserted in the illumination and observation paths of a microscope and 
bright spots indicate the presence of Hz.   
By 1987, it had been shown that flow cytometry of DNA and RNA content of iRBCs could 
differentiate stages and, in some cases, species [10, 11]. Flow cytometry has since been 
used to study parasite physiology and response to antimalarial drugs [12 – 17]. This is 
most often done using fluorescent DNA and RNA stains and complex multi-color, multi-
parameter analysis (2, 18); additional maturation/viability markers may also be measured 
[17, 19]. 
Also in 1987, it was reported that depolarized light scatter could also be detected by flow 
cytometry; this was initially recognized as providing a simple, reagent-free means to 
distinguish eosinophil from neutrophil leukocytes based on the birefringence of eosinophil 
granules [20]. A patent (US, Patent: 5017497: http://www.google.com/patents/US5017497 
accessed on 01/08/2014) on the procedure was licensed by Abbott Diagnostics (Santa 
Clara, CA) and used in their Cell-Dyn hematology analyzers; the patent also prevented 
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manufacturers of research flow cytometers from offering the measurement in their 
apparatus.  
In 1999, it was found that Hz-containing monocytes in the blood of malaria patients could 
be could be detected by the Cell-Dyn analyzers [21]. Since then, several other studies have 
reported the detection of Hz inside monocytes and neutrophils with both those instruments 
and user-modified research flow cytometers [22 – 25], and the use of hematology 
analyzers to diagnose malaria in non-endemic and endemic countries has been extensively 
reviewed elsewhere [26]. Of note, some of these studies reported the possibility of 
detecting Hz in iRBCs as well [22, 27].   
With the patent no longer in force, we recently implemented depolarized scatter 
measurement on a bench top flow cytometer (Cyflow SL, Partec/Sysmex). This permitted 
comparing cytometric detection of Hz-containing leukocytes using this cytometer and the 
Cell-Dyn instrument with microscopy [28, 29]. More importantly, it confirmed that Hz 
inside iRBCs could be detected, leading to further studies [30 – 31]. 
Although this work attracted some interest in both the malaria and the flow cytometry 
communities, questions remained as to whether and how readily depolarized scatter 
measurements could be easily installed and measured on other common instruments, what 
kind of Hz can be detected (e.g. free Hz, intraleukocytic Hz, intraerythrocytic Hz from 
rodent or human parasites), and to what extent aspects of instrument setup, e.g., the laser 
wavelengths, might interfere with measurements. Addressing these issues, we have now 
shown that light depolarization caused by Hz from different sources can be easily detected 
in a variety of flow cytometers. We hope that this will encourage malaria researchers and 
clinicians to make productive use of the technique. 
 
3. Material and Methods 
Samples 
Free synthetic Hz, Plasmodium berghei (rodent) and Plasmodium falciparum (human) 
infected RBC, as well as Hz containing human peripheral blood mononucleated cells 
(PBMCs) were analyzed (Table II.1).  
P. falciparum infected red blood cells were fixed with 2% paraformaldehyde (PFA) and 
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Flow cytometric detection of depolarized side scattered light 
Depolarized side scatter detection was implemented using the following flow cytometers 
(Figures II.1 and II.2):  
1) The CyFlow Blue (Sysmex/Partec, Munster, Germany), has a 488 nm excitation laser, 
and detectors for Forward Scatter (FSC), Side Scatter (SSC), green fluorescence – FL1 (BP 
535/35 nm), orange fluorescence – FL2 (BP 590/50 nm) and red fluorescence – FL3 (LP 
630 nm). For this study the instrument was modified as described elsewhere [30]. Briefly, 
two SSC detectors were created, with a 50/50 beam splitter between them.  A polarizing 
filter coupled with a 488 nm filter was placed in front of one of the SSC detectors with the 
filter’s axis of polarization horizontal and therefore orthogonal to the vertical polarization 
plane of the laser light, allowing the detection of depolarized side scatter. 
2) The MoFlo high speed cell sorter (Beckman Coulter, Fort Collins, USA) optical set-up 
was modified as described in Krämer 2001 and Frita 2011 (23, 30). Briefly, scattered light 
from a 488 nm laser (200 mW air-cooled Sapphire, Coherent) was split in two using a 95/5 
beam splitter to measure normal SSC (5% of the light) and depolarized SSC (95% of the 
light) by placing a polarization filter with its axis of polarization orthogonally to the 
Samples Protocol 
Plasmodium berghei  
infected red blood 
cells [30] 
 
BALB/c mice (Charles River, Spain) were infected with the 
transgenic P. berghei ANKA (259 cl2) that constitutively expresses 
GFP during the whole life cycle. Blood samples were collected by 




red blood cells [32] 
P. falciparum 3D7 strain was obtained from MR4 (ATCC, 
Manassas, VA) and kept in continuous culture according to the 
recommendations of the Malaria Research and Reference Reagent 
Resource Center (MR4) and as previously described elsewhere [32] 
. Cultures were maintained at 5% hematocrit, at 37ºC in an 
atmosphere of 5% CO2.  
Intraleukocytic 
hemozoin [30, 33] 
Human peripheral blood mononucleated cells (PBMCs) were 
incubated with synthethic Hz, as described elsewhere [30]. Briefly, 
PBMCs were isolated from blood collected from healthy volunteers 
and placed in a Ficoll gradient (Ficoll-Paque Plus, GE Healthcare, 
Uppsala, Sweden), where the interface containing the PBMCs was 
collected after centrifugation. PBMCs were washed, counted 
and ressuspended at a concentration of 5 x 
10^5 PBMC/ml. Synthetic Hz (obtained as explained below) was 
added at 50 uM (hme equivalent) and the plate was incubated for 6 
hours at 37°C in 5% CO2 [33]. 
Synthetic hemozoin  
[64, 65] 
Synthetic hemozoin was obtained by the method described by Slater 
et al. (Slater 1991), with some modifications previously reported.  
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polarization plane of the laser illumination. Both detectors had 488/10 nm bandpass filters; 
O.D. 1.0 and 2.0 neutral density (ND) filters were, respectively, fitted to the normal and 
depolarized SSC detectors. SYBR-Green fluorescence, diverted by a 505DCRX dichroic 
filter ahead of the polarizer, was detected through a 540/30 nm bandpass filter. 
3) The Attune Acoustic Focusing Cytometer (Life Technologies, Carlsbad, USA) is 
equipped with 488 nm and 405 nm lasers with detectors for: FSC, SSC, and six 
fluorescence regions (BP 530/30, BP 574/26, LP 640, BP 603/48, BP522/31 and BP 
450/40). Two SSC detectors were created, with a 50/50 beam splitter between them, and 
polarizing filters were placed orthogonally to the polarization plane of each laser light, one 
in front of a detector in the violet laser optical path (VL2) and the other in front of the 
fluorescence detector of the blue laser path (BL2). 
4) The Accuri C6 (BDBiosciences, La Jolla, USA) is equipped with a 488 nm solid state 
laser and a 640 nm diode laser, detectors for FSC, SSC and four fluorescence detectors 
with the following optical filters: BP 533/30 (FL1), BP 585/40 (FL2), LP 670 (FL3) and 
BP 675/25 (FL4). The BP 585/40A fluorescence filter in the FL2 detector was replaced by 
a 488 nm bandpass filter coupled with a plastic polarizing filter oriented orthogonally to 
the polarization plane of the laser light, allowing detection of depolarized side scatter. 
 
Measuring depolarized scatter with different wavelengths using a MoFlo 
Depolarized side scatter was measured at different wavelengths on a MoFlo using a 
Coherent Innova I90C Argon laser tuned to multiline UV at 1.10 W, 457 nm at 80 mW, 
488 nm at 80 mW, or 514 nm at 80 mW. Each laser line was used separately, but always 
simultaneously with the main 488 nm Sapphire laser as a control. A mounted Glan-
Thompson calcite polarizer with an extinction ratio greater than 100,000:1 (GTH10M, 
Thorlabs) was placed in front of each secondary laser line. Scattered light from the 
secondary laser was transmitted through the third instrument pinhole. Normal and 
depolarized SSC were measured using the corresponding bandpass filters (multiline UV: 
350/50 nm; 457 nm: 455/30 nm; 488 nm: 488/10 nm; 514 nm: 510/20 nm; and 640 nm: 
630/20 nm) after a 70/30 beam splitter and with an orthogonally positioned polarizer filter 
in the 70% end of the beam splitter.  
The separation Index (SI) (Median Positive - Median Negative)/(2 x StdDev Negative) 
between the Hz-containing cell population and the uninfected cells was calculated in order 
to evaluate the capacity of each laser wavelength to resolve these two populations, and 
compared with the SI measured with the main 488 nm laser. A ratio of 1 indicates there are 
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no differences in the capacity of the respective wavelength to resolve the Hz-containing 
cells compared to the main 488 nm laser. One-way ANOVA with n=4 for each wavelength 
was performed to assess whether there were statistical differences between each ratio. 
 
Microscopy 
In the P. berghei infected sample, sorted cells were centrifuged and transferred to a glass 
slide, which was then fixed in methanol and Giemsa-stained.  
In the case of P. falciparum, sorted cells were left to sediment overnight. Supernatant was 
discarded and a 10 μl drop of pelleted cells was placed into a glass slide which was 
immediately covered using a square coverslip. Leica DM5000B (Leica, Solms, Germany) 
and Leica DM2500 microscopes were used for fluorescence and depolarized microscopy, 
respectively. 
 
Cell Sorting using the MoFlo 
Populations with different levels of depolarization were sorted. The instrument was run at 
a pressure of 483 kPa (70 psi) with a 70 µm nozzle and a drop formation frequency of 
approximately 96 kHz. Sorting rates were typically c.a. 3.5×107 cells per hour. Cells were 
collected into approximately 1 ml of PBS maintained at 4◦C.  
 
Flow cytometry data analysis 
Flow cytometry results were analyzed using FlowJo software (version 9.0.2, Tree Star Inc., 
Oregon, USA). Depolarizing events were defined in plots of SSC versus depolarized-SSC 
as those with a signal above the background observed in the uninfected control.  
To assess if the depolarization level would reflect parasite development, parasites tagged 
with a green fluorescent protein (GFP) in the case of P. berghei ANKA or stained with a 
fluorescent DNA dye (SYBR green I) in the case of P. falciparum, were analyzed. To 
determine SYBR green I or GFP positive cells, green fluorescence (FL1) versus red 
fluorescence (FL3) plots were used. SYBR green I positive events were established based 
on a stained uninfected control. 
 
The study involving human samples was approved by the Ethical Committee of the Faculty 
of Medicine, University of Lisbon. All experiments involving animals were performed in 
compliance with the relevant laws and institutional guidelines. 
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4. Results 
Detection of light depolarization using different instruments 
The Attune, Accuri C6, CyFlow, and MoFlo could all be set up for depolarized side scatter 
by making a few simple changes to the optics, allowing restoration of the original 
configuration within a few minutes (Figure II.1). Hz from P. berghei iRBC could be 
successfully detected (Figures II.2, II.3A and SII.1). In fact, a CyFlow instrument located 
in the rather remote location of Lambaréné, Gabon, was also easily converted and used to 
investigate indigenous malaria parasites from local patients. 
 
Detection of light depolarization caused by different types of hemozoin 
All forms of Hz could be easily detected by measuring depolarized side-scattered light. 
Intraerythrocytic Hz from both the rodent malaria parasite P. berghei and the human 
malaria parasite P. falciparum were detected, although Hz-containing cells of these two 
species exhibited different levels of depolarized side scatter (Figure II.3B and SII.2). Hz in 
P. berghei iRBC showed higher levels and a wider distribution of depolarization than Hz 
in P. falciparum iRBC. PBMCs containing synthetic Hz also showed a high level of 
depolarization (Figure II.3C). Free crystals of synthetic Hz could be detected as well and 
showed a wide range of depolarized side-scatter (Figure II.3D). 
 
 
Figure II.1: Optical layout of three different bench top flow cytometers modified to detect 
light depolarization. Three bench top flow cytometers were adapted to detect light depolarization 
caused by hemozoin. The Cyflow (Partec) and the Attune (Life Technologies) were modified 
similarly, briefly: two sides-scatter detectors (SSC) (red boxes) were created by placing a 50/50 
beam splitter between them, and a horizontally polarized filter (H polar) was placed in front of one 
of the SSC detectors. In the Attune this was done twice: for the blue and violet lasers optical paths. 
The Accuri C6 (BDBiosciences) was easily modified by replacing the emission filter in front of the 
second detector of fluorescence with a 488 nm filter coupled with a polarizer filter with its axis in 
the horizontal plane; no further alterations were required. Boxes with the blue background 
represent the optical components that were modified in comparison to the original set up.  





Figure II.2: Detection of depolarizing side-scattered light by four different flow cytometers. 
Representative plots (side scatter versus depolarized side-scatter) of mouse uninfected red blood 
cells (RBCs) (top row) and RBCs infected with Plasmodium berghei (bottom row). Light 
depolarization caused by hemozoin was detected in four different cytometers: the Cyflow (A), the 
Attune (B), the Accuri C6 (C) and the MoFlo (D). Depolarizing cells were selected after 




Figure II.3: Detection of intraerythrocytic, intraleukocytic and free hemozoin (Hz). 
Representative plots (side scatter against depolarized side-scatter) of mouse red blood cells (RBCs) 
infected with Plasmodium berghei (A), human RBCS infected with Plasmodium falciparum (B), 
Hz-containing phagocytes (C) and free synthetic Hz (D), analyzed using a Cyflow. The resulting 
depolarization of light caused by Hz could be detected in these four different samples, however 
different degrees of depolarization were observed, possibly indicating a different distribution of Hz 
crystals within the cells.  
Note: Gain values had to be adjusted for the various samples, since they had inherently different 
characteristics. However, for the depolarized side-scatter parameter the gain values did not differ 
considerably, ranging from 230 to 280.  
 
Hemozoin induced depolarization at different wavelengths  
 When depolarized side scatter was measured at several different wavelengths commonly 
used in flow cytometers, the separation index (SI) ratio obtained with each wavelength in 
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indicating that there appears to be little difference in the detection of depolarizing events, 
statistically confirmed with one-way ANOVA test (n=4 for each wavelength). 
 
Figure II.4: Assessing hemozoin depolarization 
with different wavelengths. Bars represent ratios 
of Separation Index (SI; see Methods) obtained 
with each wavelength in comparison to the SI 
measured with the main 488 nm Sapphire laser. A 
ratio close to one indicates there is no difference, 
confirmed statistically with one-way ANOVA test 
(n=4 for each wavelength). Increasing laser power 
did not improve separation (data not shown). 
 
Identification of P. berghei and P. falciparum infected RBCs with different degrees of 
depolarization 
In the P. berghei-GFP infected RBCs four different populations were selected, designated 
as non, low, medium and high depolarizing (Figure SII.1). As the depolarization degree 
increases an increase in the GFP was observed, which indicates that more mature parasites 
have a higher level of depolarization (Figure SII.1A). Although some overlap in the GFP 
intensity signal could be observed, there was a clear difference between the highly-
depolarizing and non-depolarizing populations, with median values of GFP fluorescence of 
1063 and 129, respectively. Microscopic analysis of the sorted populations corroborated 
this observation, where infected RBCs with immature parasites with no observable Hz 
were only present in the non-depolarizing population. While, in the high-depolarizing 
population, only parasites with large amounts of dispersed Hz were present. Interestingly, 
mature parasites with a single but large clump of Hz could be found in the low and 
medium-depolarizing populations (Figure SII.1B). 
In the case of P. falciparum infected RBCs, only two gates were created, designated as 
SG+/Hz+ (depolarizing) and SG+/Hz- (non-depolarizing) (Figure SII.2). Results showed 
that the depolarizing population (SG+/Hz+) had a much higher intensity of SYBR green I 
fluorescence with a median value of 3735 compared to 514 median of the non-depolarizing 
population (SG+/Hz-), indicating more DNA and thus, reflecting their more advanced 
stage of development (Figure SII.2A). Bright-field and fluorescence microscopy of SYBR 
green I showed that mature, multinucleated schizonts were only detected in the 
depolarizing population, whereas single-nucleated young parasites were only found in the 
non-depolarizing population (Figure SII.2B).  
 




Malaria and Flow Cytometry 
Cytometry of malaria-infected RBC has been used for (i) monitoring of infected RBC, 
mainly in mouse models (33 - 38),  (ii) characterization of infected RBC (15), (iii) 
assessment of maturation and/or viability of parasites in infected RBC [10, 13, 14, 16, 17, 
39, 40], and (iv) to detect and count P. falciparum infected RBC in culture [14, 41 – 43] or 
from patient blood [44 – 46], with the possibility to distinguish species based on base 
composition [2, 17].  
Reliable discrimination of parasitized RBC from micro-nucleated RBC and/or 
reticulocytes can, however, be difficult [46]. Usually, this requires elaborate/laborious 
manipulation steps, such as removal of RNA [12, 33] or the use of a combination of 
different nucleic acid stains [13, 35], frequently requiring instruments with more than one 
light source, e.g., UV in the case of the frequently used Hoechst 33342 stain. More 
complex protocols can be more error-prone. 
Hemozoin is a useful and simple parameter to measure  
Hz measurement is attractive as an addition and/or an alternative to the range of cytometric 
measurements now made on malaria parasites. Detection by microscopy using simple 
polarizing filters [8, 9] or by cytometric depolarized scatter measurement is reagent-free 
and does not require extensive sample preparation, and thus can easily be done on native 
samples [31, 32]. Because it is produced throughout schizogony by growing parasites, Hz 
is an ideal maturation marker [48]. Hz distribution and amount also vary between species 
and parasite forms. For example, Hz is higher in gametocytes than in most asexual forms 
of P. falciparum, providing aid in identification [6]. Although Hz levels in early P. 
falciparum ring-forms are below the detection thresholds of both dark-field microscopy 
[49] and flow cytometry [31] when analyzing native samples, it may be detected in bulk in 
blood after rigorous lysis of the sample [50]. Even though we have shown that free 
synthetic Hz can be easily detected by flow cytometry (Figure II.3D), we have not 
investigated detection of free Hz obtained after blood sample lysis. The utility and possible 
applications of the cytometric Hz detection in phagocytes (Figure II.3C) have been 
reviewed elsewhere [51]. 
 
Detection of light depolarization caused by hemozoin using different flow cytometers 
 Compact bench top instruments, such as CyFlow SL or the Cube (Partec), the Attune (Life 
Technologies) or the Accuri C6 (BDBiosciences), which we show are easily modifiable for 
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Hz (Figures II.1 and II.2), are relatively easy to run in resource-limited environments, 
making it feasible for cytometric Hz measurement to be more widely used. 
The benchtop systems and a MoFlo sorter were all easily modified without any special 
training and it was easy to return them to their original configurations. 
Although patent issues no longer impede modification of flow cytometers for depolarized 
scatter, a major obstacle has arisen with the common use of fiber optic cables, which do 
not preserve the polarization of light, in the light collection path(s) for fluorescence and 
side scatter.  It should be noted that, unlike the model we used, the new Attune NxT is 
equipped with such fiber optics and is therefore not usable to detect depolarized scatter.  
The depolarized population detected with the Accuri C6 was not as clearly separated from 
the non-depolarized population, as was the case with the other instruments (Figure II.2E). 
The Accuri differs in design from the other systems in several respects; the light that is 
detected in the depolarized side scatter detector is not at 90º from its original path (Figure 
II.1), and the detector gains are not easily adjustable by the user. Moreover, the Accuri 
filters and filter holders are much smaller than those in the Attune, CyFlow, and MoFlo, 
limiting the choice of optical components initially available to us. We are awaiting arrival 
of parts for a new filter design that we expect will improve performance. 
The use of different beam splitters between the SSC and depolarized SSC seemed to have 
little, if any influence on the detected population (data not shown). It is noteworthy that 
placing a 1:100;000 Glan polarizer into the laser illumination path ahead of the cuvette 
also appeared to have little effect (data not shown).  We also found that depolarization was 
adequately detectable at different wavelengths (Figure II.4), corroborating the report from 
Krämer et al [23] that side scatter light polarization could be detected in a modified MoFlo 
at wavelengths of 488 nm, 633 nm and 647 nm. They noted that longer wavelengths 
produced marginally stronger signals. Results obtained from additional excitation 
wavelengths (UV multiline, 457 nm and 514 nm) did not differ significantly from those 
obtained using a 488 nm laser (Figure II.4). Indeed, although certain longer wavelengths 
and perhaps a 95/5 beam splitter or better polarization ratios might be expected to provide 
better results, the light sources and wavelengths commonly used in flow cytometers, 50/50 
beam-splitters, and simple polarizing filters appear sufficient for the measurement of Hz in 
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Flow cytometric detection of intraleukocytic and intraerythrocytic hemozoin 
At the end of the maturation cycle, schizonts rupture, releasing Hz which is phagocytized 
by circulating neutrophils and monocytes [52]. After detection of Hz leukocytes using the 
Cell-Dyn hematology analyzer was reported [21], several studies, reviewed elsewhere (26), 
addressed the performance and utility of this approach. 
Although finding Hz in leukocytes as part of an automated blood count might allow the 
detection of malaria even in the absence of clinical suspicion, this is still only possible 
using the Cell-Dyn instruments [53]. These “closed” platforms, which use proprietary 
reagents, fixed detection and analysis algorithms and provide no ready access to list-mode 
data are limited in adaptability [23, 26, 29]. However, their detection of intraleukocytic Hz 
has been correlated with malaria severity [54 – 56], and flow cytometric counts of Hz-
containing leukocytes have been shown to be a better marker of disease severity than 
microscopic counting [28]. Intraleukocytic Hz detection is also potentially applicable to 
the diagnosis of malaria during pregnancy [9]. 
Importantly, since Hz has immune modulating effects, as reviewed elsewhere [51], flow 
cytometric detection/sorting of Hz-containing leukocytes and non-containing leukocytes 
from the same host might help elucidate further details  [30, 51, 57].  
Hz detection by microscopy provides the foundation for the slide-based schizont 
maturation assay, still a mainstay in detecting antimalarial drug resistance in clinical 
settings. Several flow cytometric procedures analogous to the schizont maturation assay 
have been described by others [13, 16, 17, 39, 58]; since depolarized scatter measurements 
were not available on their apparatus, they could not use Hz content as a maturation 
indicator for stage determination. Instead a combination of DNA and RNA content was 
employed, providing more precise stage identifications than would be obtained by 
cytometric detection of DNA content alone but requiring two dyes and two fluorescence 
measurements.  
In a classic schizont maturation assay of P. falciparum, initial clinical samples contain 
little Hz because stages later than early trophozoites are removed from circulation. 
Parasites in drug-free medium and drug-resistant parasites form Hz as they continue to 
grow and mature, whereas Hz formation is diminished or absent in parasites cultured in 
effective concentrations of antimalarial agents. We have shown that schizonts in these 
contexts are easily distinguished from younger parasites solely based on their level of 
depolarization (Figure SII.2), measurable without addition of reagents. 
 We have demonstrated a field-suitable novel flow cytometric assay for antimalarial 
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susceptibility based on this rationale [30, 32]. This assay has also been shown to detect 
drug effects on parasite maturation much earlier than any other available technique [32, 
59].  
Unpublished preliminary experiments with flow cytometers equipped to measure DNA, 
RNA, and Hz simultaneously in parasitized RBC indicate that although both RNA content 
and Hz signals increase during maturation, these two parameters are not highly correlated 
and that measuring both may therefore provide more information about parasite physiology 
than would measuring only one or the other. 
P. berghei- and P. falciparum-infected RBC showed different populations with 
depolarized side scatter signals. It has long been known that the amount, appearance and 
location of pigment in different species of malaria parasites show wide variations [60]. In 
P. berghei Hz crystals are fine and dispersed granules which only clump together by the 
end of schizogony (Figure SII.1B, second and third panel from top), while in P. falciparum 
the Hz crystals aggregate as they start to appear (Figure SII.2B, lower panels). Thus, in P. 
falciparum forms with highly dispersed Hz and, consequently, high degree of 
depolarization are absent. This explanation also fits with the obtained depolarized side 
scatter signals because side scatter is also a measure of cell granularity [61]. Therefore, it is 
likely that a parasite containing several small but distributed Hz crystals will have a higher 
depolarized side scatter signal than a parasite containing a single large clump of Hz.   
Microscopy has shown that Hz is also more abundant and dispersed in gametocytes [6] and 
our analyses of P. berghei-infected blood samples showed higher levels of depolarized side 
scatter in gametocytes (Figure SII.2B). Thus, this approach can eventually be applied to 
aid in the detection of these sexual forms, which are responsible for transmission. 
Currently, in vitro assays to screen dugs for gametocytes are either based on labor-
intensive microscopy or on the analysis of transgenic fluorescent gametocytes by flow 
cytometry [62 – 64]. Hz detection may be useful to help and develop novel assays for the 
detection and quantification of gametocytes, with different applications such as, the 
development and investigation of novel transmission blocking drugs.   
Gametocytes differ from sexual forms in that, although their Hz signals are high and may 
even be higher than those of schizonts, their RNA content is relatively low; our 
preliminary experiments indicate that cytometry can resolve two gametocyte populations 
with higher and lower modal RNA content, presumably representing macrogametocytes 
(female) and microgametocytes (male), the former known to exhibit cytoplasmic 
basophilia in Giemsa-stained smears, characteristic of RNA staining. 
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Future Prospects: Malaria Cytometry in Simple Imaging Systems 
During the past few years, fluorescence imaging cytometers usable for some 
multiparameter analyses formerly only possible using flow cytometry, including CD4+ T 
cell counting in HIV patients and multiplexed bead PCR assays for malaria species 
identification, have come into use.  The DNA and RNA dye measurements typically done 
in malaria cytometry require less sensitivity, and could be implemented in similar 
apparatus. A recent report on spectral imaging of malaria-infected cells in a microscope 
illuminated by multiple LEDs suggests that Hz may be detected efficiently by transmission 
measurements in the 630-700 nm range [65] without a need to use polarized light; we have 
also found evidence for this. In addition to its substantially lower cost and complexity, a 
multiparameter imager for malaria cytometry would offer the considerable advantage of 




The old parameter of light depolarization measurements has found a new job in malaria. It 
allows to detect Hz, free in blood or inside iRBCs erythrocytes leukocytes all of which can 
be used in several applications, such as: (i) detection of Hz-containing leukocytes for 
diagnostic applications and to unravel malaria-associated immunopathology; (ii) detection 
of parasitized RBC and determination of species and stages for diagnosis and drug 
susceptibility determination; and (iii) discrimination of gametocytes and other low-
abundance parasite subpopulations. Depolarized light scatter measurements are easily 
implemented on common benchtop flow cytometers and work across a wide range of 
illumination wavelengths; equivalent optical measurements for Hz detection can also be 
made in imaging cytometers. Adding Hz detection to other parameters, such as DNA or 
RNA content, will provide improved accuracy and sensitivity of parasite detection and 
allow researchers to expand the use of cytometry in the field of malaria. 
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8. Supporting Information 
Figure SII.1: Degree of 
depolarization and 
developmental stage of P. 
berghei infected mouse red 
blood cells. Representative flow 
cytometric plot of side scatter 
versus depolarized side-scatter 
(upper plot) and GFP intensity 
(bottom histogram) of mouse red 
blood cells (RBCs) infected with 
Plasmodium berghei-GFP (A). 
Representative pictures of 
Giemsa-stained smears of FACS 
sorted cells analyzed by bright 
field and polarization microscopy 
are shown in the left and right 
panel in B, respectively (scale bar 
= 5 μm). Populations with 
increasing levels of 
depolarization (A, upper plot) 
show a correspondent increase in 
GFP intensity (A, bottom histogram). GFP positive cells were sorted (using a Moflo) based on their 
degree of depolarization (A). Immature forms were only observed in the non-depolarizing 
population while mature schizonts with a big clump of hemozoin (Hz) were found both in the low 
and medium-depolarizing population (arrows) (B). Also in the medium-depolarizing population 
other parasite forms (gametocytes) with distributed fine granules of Hz were present. However, 
these forms were more frequent in the high-depolarizing population (arrow heads) (B).  
 
Figure SII.2: Degree of 
depolarization and developmental 
stage of P. falciparum infected red 
blood cells culture. Representative 
plots of side scatter versus depolarized 
side-scatter (A, upper plot) and SYBR 
green I intensity (A, bottom histogram) 
of human red blood cells (RBCs) 
infected with Plasmodium falciparum 
and stained with SYBR green I (A). 
Representative pictures of unstained 
smears of sorted cells analyzed by 
bright field and fluorescence 
microscopy (left and right panel in B, 
respectively) (scale bar = 5 μm). 
SYBR green I positive cells were 
gated and FACS sorted (using a 
MoFlo) based on their depolarization 
(hemozoin – Hz): SG+/Hz- (non-
depolarizing) and SG+/Hz+ 
(depolarizing) cells  (A). The depolarizing population showed a higher SG intensity then the non-
depolarizing. Microscopic observation of the sorted populations showed that single-nucleated 
immature forms were present only in the non-depolarizing population (B), whereas multi-nucleated 
schizonts (bright fluorescence spots) with a large clump of Hz (arrows) were exclusively found in 
the depolarizing population (B).  
CHAPTER II  - FLOW CYTOMETRIC DETECTION OF HEMOZOIN 
	 79	
Hemozoin induced depolarization at different wavelengths 
Four different wavelengths were tested (Multiline UV, 457 nm, 488 nm, and 514 nm) 
using a MoFlo cytometer for the ease of switching optical configurations (see Fig 1). A 
sample was brought on each different day (total of 4 days) with different parasitemia and 
Hemozoin (Hz) depolarization was measured for the four tested wavelengths. To address 
the differences, for each wavelength we measured the sample simultaneously with the 
main 488 nm laser (Coherent Sapphire 200mW), which is mainly used for all our 














Figure SII.3: MoFlo Optical Layout for the 4 different tested wavelengths. The following 
figures show the acquisition plots and gate strategy of one representative day to measure the 
Median channel intensity of the depolarized and non-depolarized populations for the tested and 
control wavelengths, as well as the standard deviation of the non-depolarized population in the 
tested and control wavelengths. 
 









Figure SII.5: Acquisition plots and gating strategy for day 25-03-2014 using 457 nm. 
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sample Median SD Median SD Median SD Median SD Tested	Wav. Main	488
Tested	Wav. Power	(W) Date Parasitemia NDepol NDepol Depol Depol NDepol NDepol Depol Depol SI SI Ratio
Multiline	UV 1.10 04-02-2014 ~	20% 3 5.18 48 21.89 11 6.65 107 68.96 4.34 7.22 0.60
1.10 06-02-2014 ~	20% 5 5.11 67 34.83 11 7.04 103 71.05 6.07 6.53 0.93
1.10 13-02-2014 ~	3% 15 7.79 63 43.58 12 6.48 49 31.47 3.08 2.85 1.08
1.13 25-03-2014 ~	14% 18 9.76 139 65.23 16 7.00 107 77.35 6.20 6.50 0.95
457nm 0.08 04-02-2014 ~	20% 10 7.03 103 48.53 3 3.41 48 35.45 6.61 6.60 1.00
0.08 06-02-2014 ~	20% 1 1.75 53 32.18 1 2.25 44 30.48 14.86 9.56 1.55
0.08 13-02-2014 ~	3% 13 4.36 110 56.00 13 6.67 103 55.35 11.12 6.75 1.65
0.08 25-03-2014 ~	14% 14 6.70 104 77.19 18 6.01 168 79.94 6.72 12.48 0.54
488nm 0.08 04-02-2014 ~	20% 12 5.31 102 53.63 9 6.55 98 61.45 8.47 6.79 1.25
0.08 06-02-2014 ~	20% 7 4.01 85 54.84 3 4.00 65 50.38 9.73 7.75 1.25
0.08 13-02-2014 ~	3% 12 6.23 102 56.29 14 4.58 106 58.43 7.22 10.04 0.72
0.08 25-03-2014 ~	14% 14 6.64 117 80.65 18 5.66 161 79.81 7.76 12.63 0.61
514nm 0.08 04-02-2014 ~	20% 7 5.23 65 37.52 3 3.21 46 33.02 5.54 6.70 0.83
0.08 06-02-2014 ~	20% 2 3.25 57 39.32 1 2.02 44 31.95 8.46 10.64 0.79
0.08 13-02-2014 ~	3% 14 4.70 99 57.39 12 6.22 103 57.21 9.04 7.32 1.24
0.08 25-03-2014 ~	14% 19 6.10 127 76.77 15 7.25 108 77.37 8.85 6.41 1.38
Main	488nm	(Control)Tested	Wavelength
The values obtained with this strategy are shown in the following table SII for each of the 
four days, corresponding to four different samples. Separation Index was calculated 
according to the following equation: 
  
Separation Index = (MFISC depol Lin [Depol] - MFISC depol Lin [NDepol])/(2 x SDSC depol Lin 
[NDepol]) 
 
Table SII: Separation Index ratios calculated for each wavelength for four different samples 
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Resistance of Plasmodium falciparum to almost all antimalarial drugs, including the first-
line treatment with artemisinins, has been described, representing an obvious threat to 
malaria control.  In vitro antimalarial sensitivity testing is crucial to detect and monitor 
drug resistance. Current assays have been successfully used to detect drug effects on 
parasites. However, they have some limitations, such as the use of radioactive or expensive 
reagents or long incubation times. Here we describe a novel assay to detect antimalarial 
drug effects, based on flow cytometric detection of hemozoin (Hz), which is rapid and 
does not require any additional reagents. Hz is an optimal parasite maturation indicator 
since its amount increases as the parasite matures. Due to its physical property of 
birefringence, Hz depolarizes light, hence it can be detected using optical methods such as 
flow cytometry.  
A common flow cytometer was adapted to detect light depolarization caused by Hz. 
Synchronized in vitro cultures of P. falciparum were incubated for 48 hours with several 
antimalarial drugs.  Analysis of depolarizing events, corresponding to parasitized red blood 
cells containing Hz, allowed the detection of parasite maturation. Moreover, chloroquine 
resistance and the inhibitory effect of all antimalarial drugs tested, except for 
pyrimethamine, could be determined as early as 18 to 24 hours of incubation. At 24 hours 
incubation, 50% inhibitory concentrations (IC50) were comparable to previously reported 
values.  
These results indicate that the reagent-free, real-time Hz detection assay could become a 
novel assay for the detection of drug effects on Plasmodium falciparum.  
 
  





Resistance of Plasmodium falciparum to almost all antimalarial drugs has been observed 
[1]. In fact, resistance to commonly effective and useful drugs such as chloroquine or 
sulfadoxine/pyrimethamine has severely compromised their use for malaria control [2]. 
Alarmingly, resistance to the currently used first-line treatment compounds, the 
artemisinins, characterized by a prolonged parasite clearance time [3], has already been 
reported from South-East-Asia. Consequently, detection and monitoring of drug resistance 
is of paramount importance.  
Traditionally, therapeutic efficacy trials are the gold standard for assessing parasite 
response to antimalarial drugs. The obvious complexity of these trials led to the 
development of in vitro assays [4]. The major in vitro phenotypic assays include the WHO 
schizont maturation microtest [5], the isotope ([3H]-hypoxanthine) incorporation assay [6], 
the detection of the parasite antigens pLDH [7] or HRP2 [8] by ELISA, and assays using 
fluorescent DNA dyes, such as SYBR green I [9], YOYO [10], PicoGreen [11] and DAPI 
[12] with either spectrophotometric or cytometric readout (Table III.S1).  
The development of novel antimalarial compounds hinges on assays to determine the 
inhibitory effects of drugs on the parasite [13]. Although all these assays have been 
successfully applied to detect drug effects on the parasite, they all have relevant 
limitations. For example, the WHO microtest is based on the tedious and subjective 
microscopic observation of parasite maturation [14]. The [3H]-hypoxanthine assay 
requires expensive equipment as well as complex isotope handling precautions and 
radioactive waste management [6]. All these assays require reagents for parasite detection 
that are often rather expensive and frequently require a cold chain. Importantly, they also 
need incubation times of 48 up to 96 hours to reliably detect drug effects [15].  
Molecular methods are highly desirable, because they do not depend on viable parasites 
and have the capacity to provide rapid results. Their major drawback is the limited number 
of known and validated resistance markers [4]. It is important to note that there is currently 
no specific in vitro test to identify artemisinin resistance, as stated by an expert panel in the 
WHO Global Plan for Artemisinin Resistance Containment (GPARC) [16].  
In this scenario, alternative assays that may overcome the limitations previously mentioned 
are highly desirable. An assay that would not only allow real-time determination of drug 
effects during a single parasite cycle but could also detect drug effects in a second or even 
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third cycle would certainly be a useful tool, permitting the assessment of inhibitory effects 
of drugs with different times of action. 
Malaria pigment, i.e., hemozoin (Hz), is produced in increasing amounts by the parasite 
during the erythrocytic cycle and, therefore, constitutes an ideal maturation indicator. Hz, 
the end product of plasmodial hemoglobin metabolism, has been identified as an important 
modulator of the host’s immune response to Plasmodium spp., as a marker for disease 
severity and prognostic factor for disease outcome, and also as an adjuvant diagnostic tool, 
of particular use regarding the non-immune traveler [17-19]. Hz depolarizes light and can 
be easily detected thereby without reagents by optical methods including dark-field 
microscopy [20], polarization microscopy [21] and flow cytometry [22]. 
In 1999, a study reported that the flow cytometry based full-blood-count analyser, Cell-
Dyn® (Abbott, Santa Clara, CA), could detect Hz within leucocytes [23]. More 
importantly, studies reported that the Cell-Dyn® seemed to detect Hz inside parasitized red 
blood cells (RBC) [24], [25]. Based on the flow cytometric detection of depolarized side 
scatter [26], as used in the Cell-Dyn®, we showed that Hz could be detected inside 
parasitized RBC in P. berghei infected rodents [27]. Moreover, in vitro parasite 
maturation, as well as the inhibitory effect of chloroquine and quinine, could be detected 
after only 6 hours of incubation [27]. Later, we showed that maturation of P. falciparum in 
culture could also be determined [28].  
Our present data show how flow cytometric detection of Hz can be used as a novel, 
reagent-free, real time assay to assess antimalarial drug effects on P. falciparum.  
 
  




3. Material and Methods 
All reagents were obtained from Sigma Aldrich (St Louis, Mo, USA), unless stated 
otherwise.  
 
Flow cytometer modification (depolarized side scatter detection) 
The Cyflow® Blue (Partec, Münster, Germany) is a portable (Figure SIII.1), five 
parameter flow cytometer with blue laser (488 nm) excitation, and detectors for forward 
scatter (FSC), side scatter (SSC), green fluorescence (FL1), orange fluorescence (FL2) and 
red fluorescence (FL3). For this study the set-up was modified as described elsewhere [27]. 
Briefly, two SSC detectors were created, with a 50%/50% beam splitter between them. 
Then a polarization filter was placed orthogonally (horizontal) to the polarization plane of 
the laser light (vertical), in front of one of the SSC detectors, allowing the detection of 
depolarized side scatter (Figure SIII.1). The Cyflow® is equipped with an absolute cell 
count method (http://www.partec.com/instrumentation/flow-cytometry.html, accessed 
3/8/2012), which allows determination of the number of particles in 200 µl of sample. 




Parasitemia, parasite maturation and the synchronicity of parasites in culture were assessed 
by light microscopic examination of Giemsa-stained blood smears. Air-dried blood smears 
were fixed in absolute methanol and stained with Giemsa (Merck, Darsmstadt, Germany) 
in a 1:10 dilution in PBS 1x, for 20 minutes.  
 
Plasmodium falciparum continuous cultures 
The Plasmodium falciparum resistant (Dd2) and susceptible (3D7) strains were grown in 
recently collected donor erythrocytes in RPMI based complete malaria culture medium 
(CMCM) according to the recommendations of the Malaria Research and Reference 
Reagent Resource Center (MR4) [29]. Cultures were maintained at 5% hematocrit, at 37ºC 
in an atmosphere of 5% CO2. As uninfected controls, erythrocytes from healthy donors 
were cultured as described above. 
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Synchronizing Plasmodium falciparum continuous cultures 
Continuous cultures of P. falciparum were cultivated until they reached a parasitemia of 
>2% with a minimum of 50% rings. They were synchronized by adding 5% sorbitol for 10 
minutes at room temperature as described elsewhere [30]. Briefly, the culture medium was 
washed away by centrifuging the culture at 1800 rpm, for 5 minutes. Next, 10 mL of 5% 
sorbitol was added to the pelleted red blood cells and incubated for 10 minutes, at room 
temperature. Cultures were washed twice in PBS1x by centrifugation at 1800 rpm, for 5 
minutes. Finally, CMCM was added to the pelleted cells, and the synchronized culture was 
incubated for another 48 hours, at 37ºC in a 5% CO2 atmosphere.  
 
Hemozoin detection sensitivity assay  
Ring stage synchronized cultures (at least 90% of ring forms) at 2.5% hematocrit and at 
approximately 1% parasitemia were incubated with antimalarial drugs or with CMCM 
(used for the drug free and uninfected controls) in 24 or 96 well-plates, for 48 hours, at 
37ºC in a 5% CO2 atmosphere. 
Quinine, chloroquine, mefloquine, artemisinin, artesunate, and pyrimethamine were 
purchased from Sigma Aldrich (St Louis, Mo, USA). NITD246 was kindly provided by 
Dr. Bryan Yeung from the Novartis Institute for Tropical Diseases, Singapore. Stock 
solutions of chloroquine and quinine were prepared in distilled water, artemisinin and 
mefloquine in pure methanol (Merck, Darmstadt, Germany), pyrimethamine in absolute 
ethanol (Merck, Darmstadt, Germany), artesunate in 70% ethanol and NITD246 in pure 
DMSO.  
Doubling concentrations ranging from 6 to 200 nM for chloroquine, 10 to 160 nM for 
mefloquine, 12 to 200 nM for pyrimethamine and 4 to 64 nM for artesunate and 
artemisinin were tested. For NITD246 concentrations of 0.1, 0.2, 1 and 2 nM were used, 
while for quinine concentrations of 3, 12, 50, 200 and 800 nM were tested.  
For each flow cytometric measurement approximately 100,000 events were analyzed. A 
volume of 5µL of the blood suspension present in the wells was stained with SYBR green 
1x, as described below. To determine the best time point for IC50 calculation, 
measurements were done at 6-hour intervals over 48 hours for the majority of the drugs 
tested, except for pyrimethamine which was measured again at 72 hours. All samples were 
analyzed in triplicate and, for each drug, at least 3 different experiments were performed. 
In order to investigate possible inoculation effects, artesunate and artemisinin were also 
investigated at a lower parasitemia of 0.4 and 0.7%, respectively.  




To assess if renewing artesunate would influence its effect on parasite growth, cultures 
were washed and fresh artesunate, at a concentration of 8 nM, was added every 12 hours, 
during 48 hours of incubation. 
To investigate the detection limit of the novel Hz assay, ring-stage synchronized cultures 
with parasitemias of 0.05%, 0.1%, 0.3%, 0.5%, 0.6% and 1% were incubated for 48 hours. 
Finally, to assess the performance of the Hz assay with low parasitemias, ring-stage 
synchronized cultures at 0.3% parasitemia were incubated for 72 hours with increasing 
concentrations of chloroquine, artesunate and pyrimethamine (as mentioned above). Flow 
cytometric analysis was performed in 24 hours intervals. 
 
SYBR green I staining 
For each measurement 5 µl of the culture (approximately 800 000 cells) was stained with 
the DNA-specific dye SYBR green I (Invitrogen, Carlsbad, USA) at 1x. After 20 minutes 
of incubation, in the dark, the stained sample was immediately analyzed by flow cytometry 
using a 535/45 nm bandpass filter in front of the detector. 
CD235 (glycophorin A) staining 
A volume of 10 µL of a continuous P. falciparum culture, at 5% hematocrit, was 
transferred into a well of a 96 well plate, washed in cold FACS buffer (PBS 1x and 2% 
bovine albumin serum) and then centrifuged at 1400 rpm, for 3 minutes at 4ºC. A volume 
of 50 µL of a 1:500 dilution of CD235-Phycoerythrin antibody (eBioscience, San Diego, 
US) was added to the cells and incubated for 20 minutes on ice in the dark. After a final 
wash, the cells were re-suspended in PBS 1x and analyzed by flow cytometry using a 610 
nm long-pass filter.   
 
Flow cytometric analysis   
Flow cytometry results were analyzed using FlowJo software (version 9.0.2, Tree Star Inc., 
Oregon, USA). The gating scheme used is shown in Figure III.1. The red blood cells in 
uninfected and infected samples were detected by their characteristic forward (FSC) and 
side scatter (SSC) properties  (Figure III.1A and B).  
Staining with the anti-glycophorin A CD235 antibody was used to establish that all events 
detected represented red blood cells. The antibody was not used for routine analyses.   
Depolarizing events were defined in plots of SSC versus depolarized-SSC as those with a 
signal above the background observed in the uninfected control (Figure III.1C and D).  
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To determine SYBR green I positive cells, green fluorescence (FL1) versus red 
fluorescence (FL3) plots were used; these provide better separation between weakly 
stained and autofluorescent cells than can be obtained from one-dimensional histograms. 
SYBR green I positive events (Figure III.1F) were established based on a stained 
uninfected control (Figure III.1E) and had to be adjusted at each time point, always using 
the uninfected SYBR green stained sample from the corresponding time point.  
 
Histidine-rich protein-2 (HRP2) sensitivity assay   
A histidine-rich protein-2 (HRP2) enzyme-linked immunosorbent assay (ELISA) was 
established and performed according to standard procedures [8], also available on the 
internet website http://www.meduniwien.ac.at/user/harald.noedl/malaria/ (accessed 
3/8/2012) 
Ring-stage synchronized P. falciparum cultures, at an initial parasitemia of 0.05% and a 
1.5% hematocrit, were incubated with the antimalarial drugs for 72 hours, at 37ºC in a 5% 
CO2 atmosphere. At the end, samples were frozen at -20ºC until the HRP2 ELISA assay 
was performed.  
Briefly, after two freezing and thawing cycles, 100 µL of the lysed sample was transferred 
to a 96 well-plate pre-coated with MPFM-55A antibody (Immunology Consultants 
Laboratories, Portland, USA) and incubated for one hour.  The cells were washed three 
times and then incubated for another hour with the secondary antibody, MPFG-55P 
(Immunology Consultants Laboratories, Portland, USA). Cells were washed again and 
incubated for 5-10 minutes with the chromogen, TMB One (Biotrend, Köln, Germany). 
The reaction was stopped by adding sulphuric acid at 1M (Merck, Darmstadt, Germany) 
and the absorbance was immediately determined using the Infinite M200 plate reader 
(Tecan, Männedorf, Switzerland), at a wavelength of 450 nm.  
To assess a possible inoculum effect of artemisinin, the HRP2 assay was also performed 
using a parasitemia of 1%. 
 
Data analysis 
A nonlinear regression model (sigmoidal dose-response/variable slope) was used to 
calculate the IC50s, with SigmaPlot - Systat Software (Chicago, IL, USA). 
  





Depolarized side scatter detects parasitized red blood cells 
Staining with the red blood cell surface marker (CD235) antibody was used to establish 
that the events detected represented red blood cells. Figure III.1G shows that 99.5% of 
events detected are red blood cells. Representative dot plots of side scatter versus 
depolarized side scatter are shown in Figure III.1C and III.1D. At 24 hours of incubation, 
depolarizing events were very low in the uninfected control (0.027%) (Figure III.1C), but 
could easily be detected (0.46%) in the infected blood sample (Figure III.1D). The 
depolarizing events present in the infected sample were also positive for SYBR green I. 
Analysis of SYBR green I fluorescence intensity showed that the majority of these 
depolarizing events (79.4%) had high fluorescence (pink line in Figure III.1H) indicating 
high DNA content and thus, represented parasitized red blood cells with mature parasites.  
All subsequent results reported in this paper are based on the depolarizing events expressed 
as a percentage of all events analyzed. 
 
 
Figure III.1: Gating for detection of depolarizing parasitized red blood cells in a Plasmodium 
falciparum culture.  
Flow cytometric analysis of an uninfected and a synchronized P. falciparum (3D7) infected culture 
(1.5% parasitemia) after 24 hours of incubation, stained with SYBR green I. Plots of forward vs. 
side scatter for the uninfected and infected cultures appear in Figures A and B; corresponding plots 
of side scatter vs. depolarized side scatter appear in Figures C and D.  The gates in Figures C and D 
identify the depolarizing events. 
Figures E and F (see text) illustrate gates defining SYBR green-positive parasitized cells. The blue 
dots on Figure F represent the depolarizing events.  
Staining with the red blood cell surface marker (CD235) shows that 99.5% of events in a stained 
sample (red line) exhibit fluorescence above the highest level measured in an unstained control 
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(black line), indicating that the detected events are red blood cells (G). 
In the SYBR green I histogram (H) of the infected culture, the overall population (black line) 
shows a distinct peak with a high fluorescent intensity in the third decade. This peak corresponds 
mainly to the gated population of depolarizing events (pink line). Because SYBR green I intensity 
correlates with DNA content and thus with parasite level of maturation, the depolarizing population 
(pink line) consists mainly (79.4%) of mature parasites. The highly red- and green-fluorescent 
events visible outside the SYBR green gate just to the right of its apex represent contaminating 
white blood cells among the donor red cells.   
 
Depolarized Side Scatter detects parasite maturation 
We next sought to establish whether this type of analysis would discriminate among 
different Plasmodium falciparum stages. To that end, samples of 100,000 events were 
analyzed. Determination of the absolute number of cells at each time point showed no 
evidence for red blood cell lysis. Following the percentage of depolarizing events during 
48 hours of incubation, in a ring-stage, synchronized culture (1.4% parasitemia), showed 
an increase at 18 hours, with a peak at 30 hours and a subsequent decrease (Figure III.2A). 
The same sample stained with the DNA stain, SYBR green I, showed no change in the 
percentage of fluorescent events until 30 hours, followed by a steady increase until 48 
hours (Figure III.2B). Observation of Giemsa stained blood smears at all time points 
showed parasite maturation until 30 hours, which coincided with the peak of depolarizing 
events. Thereafter, from 36 to 48 hours, immature forms were observed, coinciding with a 
decrease of depolarizing events and an increase of fluorescent events (Figure III.2). These 
changes reflect parasite growth with the 30 hour peak of depolarization corresponding with 
the peak of maturation, after which erythrocytes rupture and daughter-merozoites are 
released along with Hz, explaining the decrease in depolarizing events and the increase in 
SYBR green I fluorescent events, observed after 30 hours.  
The increase in the percentage of depolarizing events over time and the inhibitory effect of 
chloroquine, artesunate and pyrimethamine could be detected at parasitemias down to 
0.3%. At lower parasitemias (0.05 and 0.1%) no clear increase above the background could 
be detected during the first 48 hours of incubation.  
 





Figure III.2: Growth curves of Plasmodium falciparum (3D7) in culture. 
Flow cytometric analysis of a synchronized P. falciparum (3D7) culture (1.4% parasitemia). The 
percentages of depolarizing events (A) and SYBR green I positive events (B) were followed for 48 
hours in uninfected (black lines in A and B) and infected red blood cells (red line in A and green 
line in B). Analysis of depolarizing events (Hz-containing parasitized erythrocytes) shows an 
increase at 18 hours, peaking at 30 hours (A). SYBR green I positive events (parasitized RBC) 
remain unchanged at 1.4% until 30 hours, after which a steady increase can be noted (B). Hz 
detection reflects parasite maturation with increasing amounts of Hz until 30 hours, while the 
parasitemia remains unchanged (SYBR green I positive events). After 30 hours, increasing SYBR 
green I positive events indicate replication and presence of immature forms, which explains the 
decrease observed in the depolarizing population. Each time point represents the mean value of 
triplicate samples ± one SD. Red blood cell lysis was excluded by absolute cell counts, which 
remained stable.  
 
Detection of inhibitory effects of chloroquine on sensitive (3D7) and resistant (Dd2) P. 
falciparum strains 
Using a chloroquine sensitive strain (3D7), the difference between inhibiting and non-
inhibiting concentrations was clearly visible after 18 hours, with the largest difference 
observed at 30 hours (Figure III.3A). The first sign of drug effect could be consistently 
detected at 18 hours, where at concentrations of 6 and 12 nM a percentage of 0.1% 
depolarizing events were observed, while at 25, 50 and 100 nM only 0.004% were detected 
(Figure III.3A). 
In the resistant P. falciparum strain (Dd2), chloroquine resistance could clearly be detected 
at 18 hours after drug exposure, with growth curves of all concentrations following the 
drug free control (Figure III.3B). At this time point (18 hours), in all drug concentrations 
around 0.1% depolarizing events were observed, compared to the 0.01% seen at the 
beginning of the incubation (Figure III.3B). 
 











Figure III.3: Effect of chloroquine on the growth curve of P. falciparum sensitive and 
resistant strains.  
Synchronous cultures of sensitive (3D7, parasitemia of 1.3%) and resistant (Dd2, parasitemia of 
1.4%) P. falciparum strains were incubated for 48 hours with doubling concentrations of 
chloroquine and analyzed at 6 hourly intervals. The inhibitory effect of chloroquine at higher 
concentrations (>25 nM) is clearly visible (arrow) after 18 hours of incubation (A). The resistant 
strain can easily be distinguished from the sensitive strain with growth curves of all drug 
concentrations being identical to the drug free control (B). Each time point represents the mean 
value of triplicate samples ± one SD. 
 
Detection of inhibitory effects of other antimalarial drugs 
Representative growth curves in the presence of different concentrations of quinine, 
mefloquine, artemisinin and the spiroindolone NITD246 are shown in Figure III.4. The 
curves for artesunate are shown in Figure III.5 and those for the slow acting drug, 
pyrimethamine, are shown in Figure III.6. As was the case with chloroquine, inhibitory 
concentrations showed a clear effect from 18 hours onwards in three different compound 
classes: quinolones (quinine and mefloquine), endoperoxides (artemisinin and artesunate) 
and a spiroindolone (NITD246). 
Interestingly, artemisinin showed a delayed growth curve at the 32 nM concentration in 
comparison to the drug free control (Figure III.4C). The same was observed for artesunate 
at a lower concentration of 4 nM (Figure III.5A). Of note, the artesunate growth curve at 
an intermediate concentration of 8 nM showed an initial inhibition with a delayed rise 
starting after 30 hours and an absence of the typical peak at 24 – 30 hours (Figure III.5A 
and B). By renewing the artesunate every 12 hours in the culture medium, this delayed rise 
was lost and the initial inhibition was maintained throughout the 48 hours of incubation 
(Figure III.5B). In both cases, however, the percentage of SYBR green I positive events 
remained largely unchanged over the 48 hours of incubation, indicating absence of parasite 
replication (Figure III.5C). The parasites, previously treated only once with artesunate at 8 
nM, were also re-cultured and observed for growth during four days. No growth was 




observed during these 4 days, as confirmed by flow cytometry, nor was an increase in 




Figure III.4: Effect of quinine, mefloquine, artemisinin and a spiroindolone (NITD246) 
on the growth curve of P. falciparum (3D7). 
Synchronous cultures of a P. falciparum 3D7 strain were incubated for 48 hours with increasing 
concentrations of quinine (A), mefloquine (B), artemisinin (C) and NITD246 (D). In all cases the 
dose-dependent inhibitory effect of the drugs could already be detected at 18 hours by comparing 
the treated samples (solid lines) with the drug free control (dotted red line). The curves allowed the 
determination of IC50 values at 24 hours. Of note, artemisinin at 32 nM showed a 6 hour delayed 
growth curve, from 18 to 42 hours, with the peak of maturation occurring at 36 hours. Each time 
point represents the mean value of triplicate samples ± one SD. DF ctrl – drug free control; UI ctrl 
– uninfected control.  
 




Figure III.5:  Effect of artesunate on the growth curve of P. falciparum (3D7) and the effect of 
12 hourly renewing of artesunate during incubation. 
Synchronous cultures of a P. falciparum 3D7 strain were incubated for 48 hours with doubling 
concentrations of artesunate (A) or with a single concentration of 8 nM of artesunate for the whole 
time or renewed at 12 hour intervals (B and C). Figures A and B show detection of Hz 
(depolarizing events) while Figure C shows detection of SYBR green I fluorescence (DNA in 
parasites). The inhibitory effect of artesunate was already detectable after 18 hours of incubation 
(A). Similar to artemisinin (Figure III.4C), the growth curve of artesunate at 4 nM showed a 6 
hourly delayed growth curve from 18 to 42 hours, including a 6 hour delay in the peak, occurring at 
36 hours. Interestingly, the growth curve at 8 nM seemed to show inhibition until 30 hours, when a 
slight increase was observed (A and B). However, renewing artesunate at 12 hourly intervals 
eliminates this effect (green line in B). The percentage of SYBR green I positive events remained 
approximately the same during the 48 hours of incubation (C). This indicates that parasites at the 
non-renewed 8 nM concentration showed some maturation as indicated by Hz detection but were 
unable to replicate. Each time point represents the mean value of triplicate samples ± one SD. 
 
 





Figure III.6: Growth curve of Plasmodium falciparum (3D7) after treatment with 
pyrimethamine.  
Synchronous cultures of a P. falciparum 3D7 strain were incubated for 72 hours with doubling 
concentrations of pyrimethamine. No inhibitory effect could be observed during the first 48 hours 
at any concentration (A). However, an inhibition was clearly visible at 72 hours (B). This could be 
explained by the fact that pyrimethamine is a slow acting drug and its effect can only be detected 
on the second generation, after 48 hours.  
Interestingly, the growth curves at all concentrations follow the drug free control after the 30 hour 
peak, while the curve for 200 nM shows a later peak at 36 hours with a higher number of 
depolarizing events, compared to the drug free control (A). See discussion for possible explanation. 
Each time point represents the mean value of triplicate samples ± one SD. DF ctrl – drug free 
control; UI ctrl – uninfected control. 
 
IC50 values obtained by the Hemozoin detection assay are comparable with other available 
assays  
To determine the earliest time-point that would allow us to reliably calculate IC50 values, 
results obtained from the Hz detection assay at different time-points (18, 24, 30 and 36 
hours) (Table III.1) were compared with those reported in the literature (Table SIII.2), as 
well as with results from the already validated HRP2 ELISA assay (Table III.2). This 
analysis led us to use the 24 hour time point for all subsequent IC50 calculations. The IC50 
results for our Hz assay and the HRP2 assay are shown in Table III.2.  
Concerning the inoculum effect, no reliable results could be obtained with the HRP2 assay 
at a parasitemia of 1%, because no differences were observed between the drug treated 
samples and the drug free control. Using a lower parasitemia in the Hz assay, discrepant 
results were observed for artemisinin and artesunate: while the IC50 of artesunate 
remained the same (4 nM) at a parasitemia of 1.3% and 0.4%, the IC50 value for 
artemisinin decreased from 32 nM at 1.0% parasitemia to 13.2 nM at a parasitemia of 
0.7%.  




Table III.1: Inhibitory concentrations (50%) of several antimalarial drugs against P. 
falciparum 3D7 strain determined by the Hemozoin detection assay at different times of 
incubation. 
 
Time of incubation 
 





























21.3 nM  
(± 7) 
33.5 nM  
(± 6.4) 
64.9 nM 

















< 4 nM 
 
6.4 nM 


















 (± 10.3) 
Mean inhibitory concentration values (50%) ± one standard deviation are presented.  
Standard deviation values are not shown for results that were not supported by at least three 
independent experiments. Time-points identified with (*) were not systematically analyzed, since 
the 24 hour time-point was used as the preferential time-point to reliably calculate IC50 values (as 
discussed in the manuscript). 
(X) values could not be determined; (n.d.) no data available. 
 
Table III.2: Antimalarial activities of several antimalarial drugs determined by the Hemozoin 
detection assay and the HRP2 assay. 
 Hemozoin 
detection* 24 hours 
of incubation 
HRP2 
72 hours of 
incubation 
Chloroquine 34.2 nM (± 8.1) 22 nM 
Quinine 54.6 nM (± 9) 52 nM 
Mefloquine 21.3 nM (± 7) 21 nM 
Artesunate 6.4 nM (± 2.3) 1.1 nM 
Artemisinin 25.6 nM (± 5.9) 11.5 nM 
Pyrimethamine 25.4 nM (± 10.3) 1) 30.5 nM 
NITD 246 0.8 nM 0.4 nM 
The averages of 50 % inhibitory concentration values ± one standard deviation are presented 
above. 
* For the Hemozoin detection assay each drug was tested at least three times (except for the novel 
compound NITD246).  
HRP2 – Histidine-rich protein 2. 
1) after 72 hours of incubation 
 
  





This study confirms that the optical detection of Hz can be easily achieved by a simple 
adaptation of a common flow cytometer to allow detection of light depolarization (Figure 
SIII.1).  This study also extends observations [27] that maturation of P. falciparum and 
inhibitory antimalarial drug effects can be assessed by the detection of Hz inside intra-
erythrocytic parasites. Although this novel approach is based on previous observations that 
Hz in parasitized RBC could be detected by flow cytometric methods [24], [27] it should 
be noted that the idea of using Hz for a sensitivity assay is not new and was described in 
the 1980s [31]. However, the assay format used a visual readout and appears to have been 
rather inaccurate because of nonspecific agglutination [32]. Recently, an improvement of 
this approach has been reported where the Hz produced is measured by a colorimetric 
method [33]. To do this, the Hz produced by the parasites after 72 hours of incubation is 
liberated and transformed back into heme before reading the absorbance at 405/750 nm. 
However, the assay involves multiple manipulation steps, including lysis and several 
washing steps, which are cumbersome and may introduce variability. In fact, in our hands, 
the isolation of Hz and quantification of heme requires meticulous attention to accurate 
pipetting to guarantee reproducible results [34]. 
 
Depolarization signal strength and detection limit 
The comparison of an uninfected RBC sample with a synchronized P. falciparum infected 
RBC sample at 24 hours of incubation showed a depolarizing population that could be 
easily identified and gated (Figure III.1C and D). However, the degree of depolarization of 
the whole population was much lower than previously described for P. berghei infected 
blood samples [27]. A possible explanation for this may be different side scatter signals, 
which are a measure of cell granularity [35], that could be caused by the different shape 
and distribution of the Hz crystals within these parasites. A parasite containing several 
small but distributed Hz crystals will have a higher depolarized side scatter signal than a 
parasite containing a single big Hz crystal. In fact, during this and previous work, the 
routine microscopic analysis of Giemsa stained blood smears to control the parasitemia 
showed that Hz started to appear in small dispersed fine granules in P. berghei and only 
clumped together by the end of schizogony, as previously observed by Warhurst et al. [36], 
while in P. falciparum, Hz crystals aggregate as they start to appear (data not shown). It 
also appears possible that the depolarization signal can still be improved as a result of 
CHAPTER III - DEVELOPMENT OF THE HEMOZOIN DRUG ASSAY USING P. FALCIPARUM 
LABORATORY-ADAPTED STRAINS	
	 105	
technical modifications to the instrument. The Cyflow® flow cytometer uses a blue laser 
(488 nm). However, longer wavelengths may increase the depolarization signal as has been 
described for a red HeNe (633 nm) or Kr+ laser (647 nm) [18]. Furthermore, the 
polarization ratio of most solid-state lasers is usually given as >1:100. If the laser had a 
higher polarization ratio, as do HeNe and Kr+ lasers, positive depolarization signals might 
be better distinguished from background noise.  
To assess parasite maturation and drug effects we chose to use the simple ratio of all 
identifiable depolarizing events as a percentage of all events analyzed (Figure III.1C and 
D). Other measurements, like depolarizing intensity, showed no clear advantage (data not 
shown). A parasitemia of 1% proved to be the optimal parasitemia to detect parasite 
maturation and growth over 48 hours. Thus, it was used in the Hz detection assay to obtain 
time-curves when investigating the drug effects in P. falciparum in vitro cultures. 
However, an initial 1% parasitemia is higher than the ones used in other assays, such as the 
HRP2 or the WHO schizont maturation test, which can use parasitemias as low as 0.02% 
[8], [37], [38]. However, when investigating the lower detection limit of the Hz assay, 
parasite maturation and drug effects of chloroquine, artesunate and pyrimethamine could 
still be clearly detected at parasitemias as low as 0.3%. Nevertheless, this remains higher 
than the ones used for the HRP2 assay and the WHO schizont maturation test. Still, it is 
comparable to the parasitemias used in other assays, such as the [3H]-hypoxanthine assay 
(0.25 – 0.5%) [6] or the SYBR green I assay (0.5 - 1%) [9], [39], [40] (Table SIII.1). 
Of note, in all Hz assay experiments, only around 30% of all parasites were typically 
detected by depolarization measurements (Figure III.1D) as compared to microscopy or 
SYBR green I fluorescence. The reasons for this are unclear and could be a consequence of 
the culture not being highly synchronized. At the 30 hour peak of maturation, schizonts as 
well as some second generation ring forms are present, as confirmed by microscopy; the 
immature ring forms have insufficient Hz to be reliably detected [28]. Another possible 
explanation is the already mentioned Hz aggregation that occurs in the mature parasites, 
which may reduce side scatter intensity.  
Certainly, the initial parasitemia of 0.3% required is still a major limitation of this assay if 
used directly with patient blood samples, some of which may have lower parasitemias [41]. 
However, further optimization of the assay may lead to an improvement of the detection 
limit. Nevertheless, future studies conducted in the field will allow us to evaluate the 
performance of the novel Hz detection assay using ex vivo patient samples. 
 




Aspects of parasite maturation 
Using a red blood cell surface marker (CD235) (Figure III.1G) and a DNA stain (SYBR 
green I) we showed that the depolarizing events (Figure III.1F) were indeed infected red 
blood cells. SYBR green I fluorescent intensity reflects DNA content [42], [43]. Most of 
the depolarizing events showed high SYBR green I fluorescence (80%), indicating that 
they were mature parasites (Figure III.1H). Comparing depolarization and fluorescence 
intensity in a P. berghei ANKA infected sample stained with SYBR green I showed, 
similarly, that the level of depolarization appears to reflect parasite maturation [27].  
Usually, the described P. falciparum life cycle lasts 42 – 48 hours in vitro [44]. Contrary to 
this, we observed a peak of parasite maturation earlier, at around 30 hours, as reflected by 
the peak in depolarization (Figure III.2A) followed by a steady increase in SYBR green I 
positive events indicating replication (Figure III.2B). Corresponding parasite forms were 
also observed during microscopic observation of Giemsa stained blood smears. This can be 
explained by the fact that because the assay did not start immediately after re-invasion, the 
indicated time points correspond to the time post-drug-treatment and not the time post-
invasion. Moreover, the fact that cultures were not highly synchronized seem to have 
contributed to this apparent shorter life cycle. It is known that to obtain highly 
synchronized cultures, at least one other sorbitol treatment would be needed [45].  
After a single synchronization approximately 90% of the parasites are ring forms. 
However, individual parasites can present differences of several hours in their 
development. Thus, at the beginning of the experiments, some parasites may have already 
developed for 12 hours within the ring form population while others are only 6 hours into 
their development. The microscopic observation of Giemsa stained blood smears at 36 
hours gives weight to this reasoning, because both schizonts and second generation ring 
forms could be observed at this time point.   
 
Drug effects and potential use of the Hz assay 
One of the major advantages of the Hz detection assay is the fact that samples can be easily 
analyzed without further preparation or additional reagents allowing a rapid and easy real-
time assessment of parasite maturation and drug effects. For instance other assays, such as 
the [3H]-hypoxanthine assay, cultures have to be incubated for additional 24 hours with 
the isotope before measurements are possible [6], [15], [46], [47], [48]. Another advantage 
is the very early detection of inhibitory drug effects after only 18 hours (Table III.1 and 
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Figures III.3, III.4 and III.5), in contrast to several other assays, such as the [3H]-
hypoxanthine [6], [44] assay, which measures drug effects at 48 hours, and the SYBR 
green I [15], [40], [49], [50] and the HRP2 [8], [15], [51], [50] assays, which require at 
least 72 hours.  
Although, for example, chloroquine sensitive and resistant strains are easily 
distinguishable after only 18 hours (Figure III.3) using the Hz assay, the inhibitory effect 
of the slow acting drug pyrimethamine could only be detected after 72 hours (Figure III.6). 
This drug has no effect on asexual parasites in the first half of the parasite life cycle (24 
hours) [41], [52] and effects can only be detected later in the second parasite generation. 
For this reason the Hz assay detects slow acting drugs effects, such as pyrimethamine, only 
after 72 hours of incubation. Interestingly, at concentrations of 200 nM, higher 
depolarization values were observed after 30 hours (Figure III.6A), which appear to reflect 
the observed schizont arrest observed by microscopy.  
As shown in Table III.1, the Hz detection assay allows determination of a drug’s inhibitory 
concentrations at different time-points during the first and second life cycle, thus extending 
its potential usefulness. 
 
Artemisinins in the Hz assay 
Artemisinin and artesunate growth curves were different from the other tested drugs. At 
concentrations of 32 nM and 4 nM, respectively, a delayed maturation was observed, 
starting at 18 hours (Figures III.4C and III.5). However, the SYBR green measurements 
performed simultaneously indicated that the parasites replicate, reaching approximately the 
same parasitemia as the drug free control after 48 hours of incubation (data not shown). 
The reason for this observation remains unclear. Furthermore, samples treated with 8 nM 
of artesunate showed an initial inhibition with a delayed rise after 30 hours (Figures III.5A 
and B). SYBR green I measurements, however, did not change over the 48 hour incubation 
period, indicating that the parasites were somehow able to mature but unable to replicate 
(Figure III.5C). These parasites, treated a single time with 8 nM of artesunate, were re-
cultured in CMCM and no growth could be observed during the following four days. 
Interestingly, similar behavior has been previously described for artemisinin [53] and was 
interpreted as a consequence of its rapid degradation [54]. The drug level had to be kept 
constant by replacing the media with the drug every 24 hours, otherwise the number of 
viable parasites increased at 96 and 120 hours after drug addition [53]. In fact, renewing 
the artesunate every 12 hours in the culture medium showed that the inhibition was 




maintained throughout the 48 hours of incubation and the delayed rise was lost (Figure 
III.5B).  
Dormancy has been described after treatment with artemisinins, where early stage parasites 
enter a dormant stage under drug pressure but later regrow  [55]. It has been reported that 
parasites treated with dihydroartemisinin arrested their development shortly after drug 
exposure, but after 9 days 50% of the parasites managed to resume their growth [58]. Thus, 
to detect recrudescence of these dormant parasites cultures would have to be monitored for 
at least 4 life cycles (9 days = 216 hours). Our findings showed a delayed increase during 
the first life cycle (after 30 hours of incubation), in samples treated with artesunate at 8 nM 
Although this might represent the detection dormancy and parasite recrudescence, the data 
we have obtained so far are not sufficient to confirm or exclude this hypothesis, because 
these parasites were not monitored for longer than four days. Further investigation is 
needed to clarify this issue.  
 
Comparison of IC50 values 
The IC50 determined by the Hz detection assay were comparable with the ones reported 
for other, already validated assays (Tables III.1, III.2 and SIII.2). However, slightly higher 
values were observed for some of the drugs, especially for artesunate, where most 
publications report values below 2.5 nM [15], [37], [47]. One explanation could be the 
inoculum effect, i.e., an increase in the inhibitory drug concentration when greater 
numbers of parasites are inoculated. This is thought to be the consequence of some drug 
accumulating inside the parasitized RBC [56] and has been described for drugs like 
artemisinin and artesunate, as well as for chloroquine and mefloquine [57]. In fact, in the 
Hz assay parasitemias of around 1% were used as compared to other assays, which used 
parasitemias range from 0.05 to 0.5 % [37], [58]. This might explain the increased IC50 
values observed in the Hz detection assay and interestingly, a decrease in the parasitemia 
from 1.4% to 0.7% led to a decrease in the artemisinin IC50 value from 32 to 13.2 nM. 
However, no such decrease was observed with artesunate. 
It is important to note, that the comparison of IC50 values between assays can be 
misleading. The IC50 values in the literature vary substantially between assays, even for 
the same strain. For instances, the standard [3H]-hypoxanthine incorporation assay shows 
differences of 2 to 23 fold for artesunate (Table SIII.2). Not too surprisingly, one study 
reported that the reliability of the assays may be influenced by the mechanism of action of 
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individual drugs [15]. Moreover, variations in parasite density and hematocrit as well as 
the stage-dependent action of antimalarial drugs, may have a significant impact on the 
outcome of these sensitivity assays [14], [57]. 
 
 Assay – prospects, future possibilities 
Because the Hz detection assay allows parasite maturation to be monitored in real time, it 
could possibly be used to investigate drug effects on different parasite developmental 
stages (stage specificity of drugs). It might also be interesting to assess the performance of 
the assay with parasite strains that have been reported to show clinical signs of resistance 
to artemisinins. Since modeling of parasite-clearance curves suggests that artemisinin 
resistance affects ring-stage parasites more than the more mature parasite stages, thus in 
vitro tests focusing on the inhibition of ring stage parasites could become valuable 
surveillance tools  [58].  
The fact that a flow cytometer is required may pose an obstacle to the widespread use of 
the Hz assay in the field. Furthermore, flow cytometers that use fiber optic cables for light 
collection, such as the BD LSRFortessa or FACSaria, require relatively elaborate optical 
modification to detect depolarization. However, detection of depolarization as we have 
described can be implemented simply on many existing flow cytometers, for example the 
flow sorter Influx   (http://www.bdbiosciences.com/instruments/influx/features/index.jsp, 
accessed 14/08/2012), the Cyflow Cube (Danny Koehler, Partec, Münster, Germany, 
personal communication), the Life Technologies Attune (Grace Chojnowski, Queensland 
Institute of Medical Research, Brisbane, Australia, personal communication), and can even 
be retrofitted to the venerable BD FACSCalibur (Lisa Nichols, Cytek Development, 
Fremont, CA, USA, personal communication). More importantly, some low-cost flow 
cytometers for CD4 counts in resource-poor countries could be modified rather easily to 
detect depolarization, and are already available on site in several African countries 
(http://www.partecnorthamerica.com/Press-Release-01Dec2012-_b_2.html accessed 
22/12/12). 
Furthermore, it is now evident [59] that optical measurements of both DNA and Hz can be 
made in small, robust, simple, widefield multiparameter optical imaging apparatus an order 
of magnitude less expensive than a typical flow cytometer, using LEDs costing only a few 
dollars for illumination and employing camera chips only slightly higher in quality than 
those used in mobile phones as detectors. Signals from all cells in an entire well of an 
assay microplate can be analyzed in seconds, without the need for precise stage motion or 




focus adjustment.  Somewhat more elaborate and expensive versions of such devices are 
already commercially available; minimalist instruments optimized for field use in the 
resource-poor areas in which malaria is prevalent should arrive within a few years. 
In conclusion, the novel Hz detection assay allows parasite maturation to be monitored in 
real time without the need of further reagents or sample preparation. The assay detects 
inhibitory drug effects of major antimalarial drug classes after only 18 hours of incubation 
and permits determination of IC50 values at 24 hours. Future work will have to address the 
utility of this assay in the field. Issues such as the use of less expensive alternatives to flow 
cytometry and the application of the assay to such tasks as the determination of stage 
specific effects of antimalarial drugs will have to be investigated further.  
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Table SIII.1: Comparative descriptions of available in vitro sensitivity assays for Plasmodium 
falciparum 
 












































25 - 100 μL 
 
10 – 200 μL 
 
100 μL 
Hematocrit 1.5 – 20% 1 – 2.5% 2.5% 1.5 – 2.5% 1.5% 
Parasitemias:      
Laboratory 
strains 
1% 0.5% 0.25 – 1% 0.5 -1% 0.05% 

























- Accurate and 
sensitive. 





- Simple, does not 
require specialized  
personnel. 
- Low detection 
limit (0.05% 
parasitemias). 
Limitations - Subjective and 
labor-intensive. 






















with reagents.  









Table SIII.2: Antimalarial activities of several antimalarial drugs determined by different in 






SYBR green plate 
assay HRP2 assay 
Quinine 63 nM [1] 35 nM [1] 6.9 nM [13] 5.9 nM [13] 
 
102.3 nM [2] 
   
 
47.1 nM [3] 
   
 
59.9 nM [4] 
   Mefloquine 42.6 nM [5] 12.1 nM [11] 9.4 nM [13] 8.4 nM [13] 
 
6.1 nM [2] 
 
9.5 nM  [14] 
 
 
18.2 nM [3] 
 
40.7 nM [12] 
 
 
34.5 nM [4] 
   Chloroquine 15.7 nM [5] 14.79 nM [7] 8.1 nM [13] 7.5 nM [13] 
 
6 nM [6] 
 
22.2 nM [15] 9.7 nM [7] 
 
9.7 nM [2] 
 
16 nM [16] 
 
 
11.3 nM [3] 
 




   
 
9.6 nM [7] 
   
 
29.6 nM [8] 
   Amodiaquine 20.3 nM [9] 7.8 nM [1] 
  Artemisinin 22 nM [5] 
 
9 nM [14] 
 
 
10.1 nM [10] 
   Dihydroartemisinin 5.3 nM [5] 
 
3.78 nM [15] 2.3 nM [17] 
 
4.2 nM [8] 
 
22.1 nM [12] 
 Artesunate 1.1 nM [7] 3.7 nM [7] 1.9 nM [7] 1.5 nM (48h) [7] 
 
9.4 nM [9] 5.4 nM [12] 3.6 nM [15] 2.5 nM (72h) [7] 
 
0.4 nM [3] 
  
2.4 nM [17] 
 
0.9 nM [4] 
   Atovaquone 1.3 nM [5] 0.11 nM [7] 0.06 nM [7] 0.8 nM [7] 
 
1.1 nM [9] 
   
 
0.06 nM [7] 
   Pyrimethamine 78.4 nM [2] 32.2 nM (48h) [7] 7.2 nM  [14] 26.6 nM (48 h) [7] 
 
5 nM [6] 26.3 nM (72h) [7] > 100 nM (48h) [7] 53.9 nM (72h) [7] 
 
19.3 nM (48h) [7] 
 
23.9 nM (72h) [7] 
   19.4 nM (72h) [7] 
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Figure SIII.1: Cyflow® flow cytometer and optical bench layout 
Images in the top row show the components (A) and the optical bench layout (B) of the Cyflow® 
flow cytometer. The 488 nm laser light is vertically polarized. A horizontally polarized filter is 
placed in front of a second side scatter detector to allow detection of depolarized light (depol SSC). 
Images C, D and E show a Cyflow® in the laboratory and being easily packed for transport at the 
Medical Research Unit of the Albert Schweitzer Hospital in Lambaréné, Gabon. 
(The subject of the photograph has given written informed consent, as outlined in the PLOS 
consent form, to publication of the photograph). 
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In vitro sensitivity assays are crucial to detect and monitor drug resistance. Plasmodium 
falciparum has developed resistance to almost all anti-malarial drugs. Although different in 
vitro drug assays are available, some of their inherent characteristics limit their application, 
especially in the field. A recently developed approach based on the flow cytometric 
detection of hemozoin (Hz) allowed reagent-free monitoring of parasite maturation and 
detection of drug effects in culture-adapted parasites. In this study, the set-up, performance 
and usefulness of this novel assay were investigated under field conditions in Gabon.  
An existing flow cytometer (Cyflow Blue) was modified on site to detect light 
depolarization caused by Hz. Blood from malaria patients was incubated for 72 hours with 
increasing concentrations of chloroquine, artesunate and artemisinin. The percentage of 
depolarizing red blood cells (RBC) was used as maturation indicator and measured at 24, 
48 and 72 hours of incubation to determine parasite growth and drug effects. 
The flow cytometer was easily adapted on site to detect light depolarization caused by Hz. 
Analysis of ex vivo cultures of parasites, obtained from blood samples of malaria patients, 
showed four different growth profiles. In 39/46 samples, 50% inhibitory concentrations 
(IC50) were successfully determined. IC50 values for chloroquine were higher than 200 
nM in 70% of the samples, indicating the presence of chloroquine-resistant parasites. For 
artesunate and artemisinin, IC50 values ranged from 0.9 to 60 nM and from 2.2 nM to 124 
nM, respectively, indicating fully sensitive parasites.  
Flow cytometric detection of Hz allowed the detection of drug effects in blood samples 
from malaria patients, without using additional reagents or complex protocols. Adjustment 
of the initial parasitaemia was not required, which greatly simplifies the protocol. 
Although, it may lead to different IC50 values. Further investigation of set-up conditions 
of the Hz assay, as well as future studies in various settings should be performed to further 
determine the usefulness of this assay as a tool for rapid resistance testing in malaria-
endemic countries.  
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2. Background 
In the last decade the number of malaria deaths has decreased in large part due to the 
availability of effective treatments, in particular artemisinin combination therapy (ACT) 
[1]. However, these achievements are in danger and might even be reversed because 
parasites with prolonged parasite clearance times (PCT), observed in patients treated with 
ACT, have emerged in Southeast Asia [2, 3]. Indeed, this is considered an early sign of the 
development of parasite resistance [2, 3] and a major concern in the fight against malaria, 
as illustrated by the WHO Global Plan for Artemisinin Resistance Containment issued in 
2011 [4]. Artemisinin resistance, currently defined as prolonged PCT, has spread across 
Southeast Asia [5]. Recently, a Vietnamese patient who apparently acquired malaria in 
Angola failed to respond to intravenous artesunate/clindamycin and an oral ACT after 
returning to Vietnam [6]. It is not unlikely that it will emerge in sub-Saharan Africa, and 
drug sensitivities should be monitored pro-actively. In this scenario, in vitro sensitivity 
assays may play a crucial role in future. In vitro assays allow reducing host-related factors 
and thus, provide an objective insight into the intrinsic sensitivity of malaria parasites.  
Several phenotypic and genotypic methods have been developed and tried for drug testing 
in the field [7]. Genetic resistance markers are known for some anti-malarial drugs, but are 
not yet able to predict sensitivity to all commonly used anti-malarial drugs [8]. Only 
recently, alterations in the kelch13 gene were linked to delayed parasite clearance in 
artemisinin-treated patients [9]. Thus, phenotypic assays continue to be important for 
detection of resistance and validation of genetic markers. The main phenotypic assays 
successfully used to detect drug resistance in the field include: (i) the microscopic schizont 
maturation test [10]; (ii) the incorporation of radioactive hypoxanthine [11]; (iii) ELISA 
assays for detection of pLDH [12] and HRP2 [13] antigens; and, (iv) fluorescent-based 
techniques using either fluorometry [14] or flow cytometry [15] to detect parasite 
DNA/RNA. However, inherent limitations are common, especially during field 
applications. The supply, handling and disposal of radioactive isotopes are major obstacles. 
Microscopy is labor-intensive and subjective, although it has a rather quick turn-around 
time (24-30 hours) when compared to other techniques, especially ELISA-based methods, 
which can take up to 72 or even 96 hours [16, 17]. Moreover, assays may require the use 
of, often, expensive antibodies or DNA/RNA stains, highlighting the issues of adequate 
storage and cold chain as well as limited shelf life.  
Regarding flow cytometry, the majority of cytometric methods apply combinations of dyes 
to reliably detect infected red blood cells (iRBC), which implies a complex multiparameter 
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analysis [15,18]. Ideally, if parasite maturation was detectable using a direct and simple 
measurement of a product from the parasite, the need for additional reagents would be 
avoided. 
Hemozoin (Hz) is produced in increasing amounts by the parasite as it matures inside the 
iRBC, constituting an optimal maturation indicator [10]. Measuring Hz with a simple flow 
cytometry method allows detection of parasite maturation and drug effects as early as 18 
hours after incubation in culture-adapted laboratory strains [19]. 
The objectives of this study were to evaluate if the Hz detection assay could be easily set 
up in a remote malaria-endemic area, and to assess whether anti-malarial drug effects 
could be detected in wild-type strains obtained from malaria patients, using a simple 
protocol. 
 
3. Material and Methods 
The study was carried out at the Centre de Recherches Médicales de Lambaréné 
(CERMEL) in Gabon, a malaria-endemic region in Africa. Ethical approval was obtained 
from the Institutional Review Board of the Medical Research Unit (CERMEL) of the 
International Foundation of the Albert Schweitzer Hospital. 
 
Samples 
EDTA anti-coagulated blood samples from malaria patients were obtained from the 
Clinical Analysis Laboratory of the Albert Schweitzer Hospital after the samples had been 
processed for full blood count (FBC). Malaria diagnosis and parasite loads (number of 
parasites/μl of blood) were determined by standard microscopic observation of Giemsa-
stained thick blood films. Briefly, parasitemia was quantified 
by counting the number of parasites per microscopic field from a defined volume of blood 
(10 μl) spread on a defined area (1.8 cm2), as described elsewhere [20]. RBCs from these 
blood samples were washed twice in culture medium before further use. 
 
Flow cytometric detection of depolarized side-scattered light 
Flow cytometric analysis was performed using a CyFlow® Blue (Partec, Münster, 
Germany) available on site. The existing configuration, which was modified on site for this 
study and is shown in Figure IV.1, consisted of forward scatter (FSC), side scatter (SSC) 
and three fluorescent detectors (FL1, FL2 and FL3). A set of four optical filters was 
necessary, as shown in Figure IV.1B: (1) a 500-nm dichroic mirror; (2) a 50:50 beam-
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splitter; (3) a 488-nm vertical polarizer; and, (4) a 488-nm horizontal polarizer. Briefly, a 
500-nm dichroic mirror (DM) (B1) was placed on the site of the original 540-nm DM and 
the other original 500-nm DM was replaced by a 50:50 beam-splitter (B2), which allowed 
the creation of two SSC detectors (Figure IV.1). A 488-nm filter coupled with a polarizer 
in the same orientation as the incident laser beam (vertical) was placed in front of one of 
the SSC detectors. Another 488-nm filter coupled with a polarizer perpendicularly 
orientated in relation to the laser beam (horizontal) was placed in front of the other SSC 
detector, allowing the detection of light depolarization (Figure IV.1C). The optical 
components required to modify the optical bench of flow cytometers can be obtained 
directly from the instruments’ manufacturer.  
 
 
Figure IV.1: Flow cytometry modifications to detect light depolarization. 
The optical set-up of the Cyflow (Partec, Münster, Germany) (A) was easily modified to allow the 
detection of light depolarization. Four optical components from the original set-up (blue boxes in 
A) had to be replaced by the optical components shown in B, as described in the Methods section. 
Filters were simply replaced by unscrewing the original ones from the filter holder, or by removing 
the metallic ring (second row in B). This was accomplished using simple tools (bottom row in B). 
Note that in this case, polarization filters were glued inside the holder (arrows in B) so that they 
would not move, since to attain the best depolarization signal polarizers should be perpendicular to 
each other. The final optical layout to detect light depolarization is presented in C.  
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Anti-malarial drugs  
Samples were tested against different concentrations of chloroquine, artesunate and 
artemisinin (Sigma Aldrich, St Louis, MO, USA). Stock solutions of chloroquine were 
prepared in sterile water, and artemisinin and artesunate were prepared in pure methanol. 
Doubling concentrations, ranging from 25 to 200 nM for chloroquine and from 0.12 to 128 
nM for artemisinin and artesunate, were prepared from the stock solutions in in complete 
malaria culture medium (CMCM), which consists of RPMI 1640 supplemented with 25 
mM HEPES, 2.4 mM L-glutamine, 50 μg/mL gentamicin, 0.5% w/v Albumax , 11 mM 
glucose, 1.47 mM hypoxanthine and 37.3 mM NaHCO3. 
CMCM. Each drug concentration was tested in triplicate. 
 
Hemozoin detection assay 
RBCs obtained from malaria patients were diluted at a hematocrit of 5% in CMCM. To 
simplify the assay, the parasitaemia was not adjusted so that, eventually, the use of 
uninfected blood could be avoided. A volume of 100 μL was distributed into the wells of a 
96-well plate, previously loaded with 100 μL of anti-malarial drugs at different 
concentrations, or 100 μL of CMCM for the drug-free controls, respectively. Plates were 
incubated for 72 hours at 37°C in 5% CO2 atmosphere. Flow cytometric measurements 
were performed at 24, 48 and 72 hours of incubation. Parasite maturation from ring-stage 
to schizonts was assessed based on the increase in the percentage of Hz-containing cells 
overtime, as described before [19]. To assess parasite replication (re-invasion), the same 
samples were stained with SYBR green I at 1x (Invitrogen, Carlsbad, CA, USA), as 
described elsewhere [19]. 
 
Histidine-rich protein-2 (HRP2) enzyme-linked immunosorbent assay (ELISA)  
For the HRP2-ELISA, RBCs were diluted in CMCM at a hematocrit of 3%. Parasitemia 
was adjusted to 0.05% using RBCs obtained from healthy volunteer donors. A volume of 
100 μL was distributed into the wells of a 96-well plate, previously loaded with 100 μL of 
anti-malarial drugs at different concentrations or 100 μL of CMCM for the drug-free 
controls. Plates were incubated for 72 hours at 37°C in 5% CO2, after which they were 
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Data analysis 
Flow cytometry results were analysed using FlowJo software (version 9.0.2, Tree Star Inc., 
Oregon, USA). Depolarizing events were defined in plots of SSC versus depolarized-SSC, 
as those with a signal above the background observed in the uninfected control (gate in 
Figure IV.2A and B). To determine SYBR green I-positive cells, green fluorescence (FL1) 
versus red fluorescence (FL3) plots were used. The FL1 detector had a 527/30 band-pass 
filter and FL2 had a 620-nm long-pass filter. SYBR green I-positive events were 
established based on a stained uninfected control and had to be adjusted at each time point, 
always using the uninfected SYBR green I-stained sample from the corresponding time 
point. A non-linear regression model (sigmoidal dose-response/variable slope) was used to 
calculate the individual 50% inhibitory concentrations, with SigmaPlot-Systat Software 
(Chicago, IL, USA). Only those samples with a ≥2 ratio of drug-free control to highest 
drug concentration were included. 
 
4. Results and Discussion 
Growth and maturation of wild-type Plasmodium falciparum strains 
Forty-six samples from malaria patients were analysed during this study. Parasite loads 
ranged from 50 to 452,000 parasites/μL of blood (median of 15,000 parasites/μL). Ex vivo 
cultures of infected RBCs showed that parasites had four different growth profiles (Table 
IV.1): (i) seven samples showed no maturation, as defined by an increase in depolarization; 
(ii) another eight samples showed maturation at 24 hours and replication at 48 hours; (iii) 
17 samples showed maturation at 24 hours but no re-invasion occurred; and, (iv) 14 
samples had a delay in parasite growth, with maturation being observed at 48 hours and 
replication at 72 hours.  
One crucial step in the in vitro sensitivity assays is the culture of parasites [22]. Maturation 
of Plasmodium falciparum from early rings to late schizonts takes 42-48 hours in vitro [23] 
and consequently, an increase in parasitemia can only be observed every 42-48 hours, after 
re-invasion of RBCs occurs. Differences in ex vivo parasite maturation and replication 
have already been observed in strains obtained directly from different patients [24,25]. 
Indeed many factors related to the protocol, the host and the parasite itself might greatly 
influence the in vitro growth of parasites.  
Regarding the protocol factors such as the type of anticoagulant used to collect the blood 
from the patients to the atmosphere where the parasites will be incubated have to be taken 
into account [7]. During this study EDTA-collected blood was used. Although the use of 
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EDTA is discouraged by the reference protocol from MR4 [26] it has been shown by 
different studies that EDTA-collected blood can be successfully used for ex vivo drug 
testing [27-31]. In one of these reports even long-term cultures of parasites present in 
patients’ blood were accomplished [31]. Moreover, the use of specific anticoagulants 
requires drawing more blood just for the purpose of sensitivity testing. This can be avoided 
by using EDTA-anticoagulated blood which was obtained as part of the routine FBC 
analysis, preventing all inherent problems associated with an extra blood drawing.  
The incubation atmosphere recommended for P. falciparum growth in culture include the 
use of a low O2 atmosphere [26]. However, such mixed gas atmospheres may not be 
available in the resource-limited settings found in malaria endemic countries. Because of 
this, it has been investigated whether a simple 5% CO2 atmosphere could be used instead 
without compromising parasite survival after drug treatment [32]. Results showed no 
differences in parasite survival using between trigas (5% CO2, 5% O2, 90% N2), candle jar 
or 5% CO2  atmospheres [32]. 
Undoubtedly, host-specific factors, often difficult to control, ranging from the immune 
response to the presence of pharmacologically active substances might influence the 
growth of the parasite in vitro. Indeed, the fact that some of the patients might already have 
been treated at the time of blood collection during this study cannot be discarded, possibly 
explaining some of the differences observer in the parasites’ growth profiles. Yet, it is very 
difficult to control for all these factors and this might not only imply detailed histories, but 
eventually laboratory test to confirm immune status or presence of drug-metabolites. 
Perhaps explaining why very few studies on this filed are including such detailed 
information. 
Conversely, parasite-related factors may even be more important. The delay between 
sample collection and processing influences the viability of freshly collected clinical 
isolates, because it is considerably decreased after a sample has been kept for several hours 
at room temperature [7]. However, in one study where all 43 samples were cultured within 
30 minutes of collection [25], 50% developed into schizonts within 27 hours, while the 
other half reached schizont stage only between 28 and 63 hours. In this study no 
correlation between the delay until culture and any of the four parasite growth patterns was 
observed, supporting the idea that possible host factors may have been more relevant. 
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Table IV.1: Summarized data of isolates exhibiting different ex vivo growth profiles analysed 
by the hemozoin assay 
 Group 1 Group 2 Group 3 Group 4 
Growth profile No maturation 
Maturation at 24 hours 
and replication at 48 
hours 
Maturation at 24 

















(mean) nd 10.5 nM 15.2 nM 5.6 nM 
IC50 Artemisinin 
(mean) nd 46 nM 47.3 nM 14.4 nM 
 nd – not determined 
IC50 – 50% inhibitory concentration 
Note: Results from chloroquine were not presented in this Table because the majority of the 
samples (32 out of 46) had IC50 values higher than 200 nM. Chloroquine had an inhibitory effect 
in only four samples from group 3 (IC50 mean = 76.8 nM). In ten samples, chloroquine activity 
could not be determined.  
 
Detection of anti-malarial drug effects by the hemozoin assay 
In P. falciparum-infected patients the majority of circulating iRBC are ring forms that 
contain little or no detectable Hz, as observed in a previous report whereby flow 
cytometric assessment of Hz these forms could not be detected [33]. This study confirms 
this observation, as at 0 hours, no difference in depolarizing events was observed between 
the infected and the uninfected samples (Figure IV.2A and B). Only after incubation the 
percentage of depolarizing cells increased, indicating higher Hz content and, thus 
maturation (Figure IV.2B), seen in drug-free controls or drug-resistant parasites. This 
contrasts with diminished or absent depolarizing events when anti-malarial drugs are 
effective (Figure IV.2C). Drug inhibitory effects were determined in 39/46 (85%) of 
samples, in which parasite maturation was observed (groups 2, 3 and 4). In 25 samples 
(groups 2 and 3), drug effects were measurable at 24 hours, as expected from culture-
adapted strains [19]. In the remaining 14 samples (group 4) parasite maturation was 
delayed; however, it was still possible to detect drug effects at 48 hours of incubation.  
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Figure IV.2: Representative analysis of drug effects assessed after ex vivo culture of blood 
samples from malaria patients. 
Representative plots of flow cytometric analysis of an uninfected blood sample (A) and a sample 
from a malaria patient with 1.5% parasitemia (B). At time point 0 of incubation, no difference in 
depolarizing events is observed between the infected samples and the uninfected control (A and B). 
However, Hz is produced as the parasite matures, and after 24 hours of incubation an increase in 
the percentage of depolarizing cells is detected (B) from 0.02 to 0.36. In this example, drug effects 
could be determined after only 24 hours of incubation (C). Contrary to chloroquine, where 
resistance was observed, artesunate and artemisinin are still effective drugs (C).  
 
IC50 values of chloroquine and artemisinins 
The IC50 values are shown in the Table IV.1. There was a poor correlation between the 
IC50 values of individual samples and the different assays. In fact, this is commonly 
observed even when using the same laboratory-adapted strain [19]. Indeed, several factors, 
such as the initial parasitemia, the hematocrit and the end point for measuring parasite 
growth can influence IC50 values [7,34]. Samples with higher initial parasitemia (group 3), 
showed increased IC50 values for artesunate and artemisinin (Table IV.1). Apparently, a 
higher initial parasitemia may be associated with an increase in inhibitory drug 
concentration of artemisinin, artesunate, chloroquine, and mefloquine [11], which could 
explain some of the increase observed in the IC50 values. Interestingly, mean IC50 values 
for artesunate and artemisinin in isolates that had a delayed growth (group 4) were 
somewhat lower than in groups 2 and 3, where maturation was detected at 24 hours. This 
could be due to the different growth profile of drug exposed and non-exposed parasites in 
group 4. Overall, IC50 values ranged from 0.9 to 60 nM and from 2.2 nM to 124 nM for 
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artesunate and artemisinin, respectively (Figure IV.3). These values are higher than 
previously described in the same region, using the HRP-2 assay [35]. Because several 
assay-related factors can influence IC50 values they may not be directly comparable 
between different assays [7,34]. In the previous study, the final hematocrit was 1.5% [35], 
while in the Hz detection assay it was 2.5%. It has been observed that higher hematocrits 
may cause an increase in IC50 values [34]. Preliminary data using the same culture-
adapted strain showed that the IC50 value for dihydroartemisinin increases from 1.7 nM to 
7.5 nM when the hematocrit of the sample is raised from 1 to 2.5% (unpublished data).  
 
 Figure IV.3: Inhibitory 50% concentrations 
obtained for artesunate and artemisinin.  
Using the Hz detection assay, IC50 values for 
artesunate and artemisinin differed between 
samples ranging from 0.9 to 60 nM and from 
2.2 nM to 124 nM, respectively. IC50 values 
obtained by the HRP-2 ELISA ranged from 0.6 
to 31 nM for artesunate and from 0.6 to 94.8 





For chloroquine, 70% of the samples had IC50 values higher than 200 nM, indicating 
resistance, which is in line with an earlier reports and which is explained through the high 
usage of amodiaquine, many years after the use of chloroquine had been curbed and finally 
abandoned [36,37]. In Malawi [38, 39], Kenya [40] and Tanzania [41], chloroquine 
resistance decreased after its withdrawal, contrary to the study site, even though 
chloroquine treatment was discontinued 11 years ago, as observed by others [37,42]. One 
explanation brought forward is the use of artesunate/amodiaquine, because amodiaquine 
appears to select mutant pfcrt allele, which is responsible for chloroquine resistance [43].  
Interestingly, the Hz-detection assay showed in some of the chloroquine-resistant strains 
that the percentage of Hz-containing cells increased as chloroquine concentration increased 
as well (Figure IV.2C). It is known that several drugs, especially quinoline-type drugs, 
directly interact with Hz, as discussed elsewhere [44]. This interaction may lead to 
alterations in the crystals distribution within the parasite that may affect the depolarized 
light signal. Recently it has been shown that parasites containing several small but 
distributed Hz crystals can have a higher depolarized signal than a parasite containing a 
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single large clump of Hz [45]. In this context it is not unlikely that at higher concentrations 
of chloroquine some of the drug may interact with Hz avoiding its coalescence. Thus, 
explaining why at higher concentrations of this drug the signal seems to be increased. 
Certainly, the mechanism of this observation is not known, and further investigation is 
required to understand the exact cause of this phenomenon. 
During this study the HRP2-ELISA was performed alongside. However, drug effects could 
only be detected in 17 samples (37%), with IC50 values ranging from 0.6 to 31 nM for 
artesunate and 0.6 to 94.8 nM for artemisinin (Figure IV.3). This success rate appears to be 
at the lower end of reported studies with 45% [14], while others had success rates of 75% 
[46] and 87% [13]. Of note, these samples were collected on purpose to be used 
exclusively in the scope of these studies. Contrary to this, here, samples were collected for 
other purposes, which might have contributed to a lower success rate. Furthermore, 
samples were preselected based on their parasitemias of 0.01% or higher [13], while in this 
study all samples were included. Apparently, re-invasion of uninfected RBCs (replication) 
is considered the main criterion for the success of the HRP2 assay [21]. However, even 
when no schizont maturation is observed after 24 hours of incubation, samples can still be 
successfully tested by the HRP2 assay [21]. During this study, most results (14 out of 17) 
were obtained in samples that exhibited delayed-growing parasites (group 4), whereas drug 
effects were only detected in two samples from groups 1 and 2, and in five samples from 
group 3.  
Indeed, the low detection limit is a major advantage of the HRP2 assay. For instance, the 
Hz assay failed to determine drug effects in samples from group 1, possibly due to the low 
parasitaemias present in this group, which were below the previously reported 0.3% 
detection limit of the Hz assay [19]. On the other hand, when parasitemias are higher than 
0.1% [21], samples have to be diluted with uninfected RBCs from healthy donors, which 
can be a limiting step. Results from group 3, where the parasitemia ranged from 0.2 to 
12%, indicate that the Hz detection assay does not seem to require adjustment of the 
parasitemia to allow the detection of drug effects.  
 
Field applications of flow cytometry 
The optical bench of the CyFlow® flow cytometer available on site had a typical 
configuration common in most small instruments, consisting of one blue-laser (488 nm) 
and detectors for FSC, SSC and three fluorescences FL1 (green), FL2 (orange) and FL3 
(red) (Figure IV.1A). For the detection of light depolarization the original set-up was easily 
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modified by simply changing the respective filters and mirrors, even taking advantage of 
the existing filter holders (Figure IV.1B). The optical bench layout required for the 
detection of light depolarization is simple (Figure IV.1C) and therefore, other instruments 
should also be easily modifiable, unless they use fiber-optic cables for light collection.  
Few studies describe the use of flow cytometry for drug testing in the field [15,47], 
possibly because of the perceived expense and complexity in setting up and running such 
instruments. Nowadays the number of simple, robust and portable flow cytometers has 
increased, including instruments such as the Attune® (Life Technologies, Carlsbad, USA), 
the Accuri™C6  (BD Biosciences, La Jolla, USA), the Cyflow Cube 6 (Partec, Münster, 
Germany), among others. It has been shown that theses instruments can be easily modified 
to detect Hz-caused light depolarization [45] and most of them can be used with an 
autosampler for higher throughput [48]. Moreover, the initial purchase costs of these 
instruments have dropped substantially from those practiced before for larger instruments, 
allowing them to be used and available in the field. Indeed, recent field studies take 
advantage of this, by using for example the Accuri C6 [15,47]. Even smaller and simpler 
instruments used for CD4+ T cell counting in HIV-infected patients exist, such as the 
CyFlow®miniPOC from Partec, which are used in low-resource settings [49]. Although 
the way was often difficult, cytometry is no longer the very expensive, high-end 
technology based on bulky instruments. In the future, simple image cytometers might 
replace flow cytometers, as they seem to perform a broad range of measurements, and 
eventually parameters such as light depolarization could be detected as well [50,51]. 
 
Opening new avenues for anti-malarial drug testing in the field 
This study showed that drug effects of clinically relevant anti-malarial drugs as well as 
resistance to chloroquine could be assessed by simply detecting Hz. This method measures 
parasite maturation and does not require re-invasion to occur; consequently, results can be 
obtained earlier than with other currently available methods, except for microscopy. 
However, microscopy relies on trained observers’ ability to detect morphological changes 
of iRBC [52], which sometimes can be rare. Flow cytometric measurements can provide 
more objective, reliable and effective results than microscopy, as it has been previously 
observed in a different context [53]. Moreover, it allows the assessment of additional 
parameters, such as DNA and RNA content, which can improve parasite detection [51]. 
Finally, drug effects could be detected without having to decrease the sample’s 
parasitemia. This may greatly simplify the protocol as it avoids the need to obtain blood 
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from healthy donors. Yet, this seems to lead to increased IC50 values. Thus, whether 
parasitemia ought to be adjusted or not should be further investigated.  
These findings open new avenues for other Hz-detection methods. Interestingly, several Hz 
detection methods exist [54-58] and they could possibly be used to detect drug effects as 
early, or even earlier, than the flow cytometric Hz detection.  
 
5. Conclusion 
This study conducted in the field showed flow cytometry could be easily implemented and 
performed in field conditions. Flow cytometric detection of Hz could be used as an 
alternative tool to assess drug effects on parasites obtained directly from patients’ blood 
samples, without the need for additional reagents or complex protocols. However, further 
optimization of the Hz assay regarding its set-up conditions, for example, changing the 
hematocrit, may contribute to obtain IC50 values more comparable to the ones that have 
been previously reported [13, 59].  
 
Future studies should be performed in various settings, to further investigate the Hz assay 
and its usefulness as a tool for rapid resistance testing in malaria-endemic countries. 
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1.1. Artemisinin-combination therapies 
The current first-line treatment for malaria is based on artemisinin-combination therapies 
(ACTs) [1]. Since the introduction of ACTs the burden of malaria has significantly 
decreased. In fact, in the last 15 years, the number of deaths and the incidence of malaria 
have been reduced by 48% and 18%, respectively [2].  
Artemisinin drugs kill all asexual stages of parasite development in the blood and it is able 
to reduce the parasite load by up to 10.000-fold per cycle [3]. Moreover, it also affects 
gametocytes, the forms that are responsible for transmission [4]. Importantly, in addition to 
its benefits in the treatment of uncomplicated malaria, artesunate is also more effective 
than quinine in reducing the deaths associated with severe P. falciparum malaria (Figure 
V.1) [5, 6]. 
 
 
Figure V.1: Antimalarial activity of artemisinin in comparison to quinine.  
Representative pictures of blood-stage P. falciparum parasites in Giemsa-stained blood smears (A). 
Parasitized erythrocytes circulate for the first third of the 48-hour cycle and then sequester in 
capillaries. Artemisinins inhibit development of a broader age range of the parasites than do 
quinine and other antimalarial drugs. The effect on the young rings prevents their development to 
the more pathological mature parasites that sequester (A) [4]. Kaplan-Meier curves comparing 
survival in African children with severe P. falciparum malaria treated with either parenteral 
artesunate or quinine. The numbers in parentheses are the deaths during the indicated time (B) [6]. 
 
Despite their potency, if artemisinins are given alone as monotherapy for 3 days, 
recrudescence rates are high [3, 7, 8]. Extending the treatment for 7 days reduces the 
recrudescence events but does not eliminate them completely. This is thought to be a 
consequence of their inherently short in vivo half-life (approximately 1 hour) [4]. 
Combination of artemisinins with a longer-acting partner drug that has a different mode of 
action (such as lumefantrine, amodiaquine, piperaquine, mefloquine, sulfadoxine–
pyrimethamine, and pyronaridine) prevents recrudescence and may also delay the 
A.	 B.	




emergence of drug resistant parasites. The rationale for ACTs is that the highly potent 
artemisinins will have a rapid onset of action, however they have a very short half-life. 
Thus, combination with a longer-acting, but less potent, partner drug will allow to kill any 
remaining parasites over the following 1–2 weeks.  
In 2001, the WHO recommended treating uncomplicated malaria with combinations of two 
unrelated drugs in the form of ACTs. By 2009, 77 of 81 P. falciparum malaria-endemic 
countries had implemented the use of ACTs in their national drug policy program [9]. 
 
 
Figure V.2: Current global distribution of artemisinin-based combination therapies as the 
first-line treatment of uncomplicated falciparum malaria. 
This distribution was collated from maps of country-wide artemisinin-based combination therapy 
use, as published in [1].  , artemether–lumefantrine;  , dihydroartemisinin–piperaquine;  , 
artesunate–amodiaquine;    , artesunate–mefloquine;   , artesunate–sulphadoxine/pyrimethamine 
[10]. 
 
1.2. Artemisinin-induced dormancy  
Artemisinin-induced dormancy has been suggested as the main cause of recrudescence 
observed in patients treated with artemisinin monotherapies [11]. 
Artemisinin induced dormancy was reported for the first time in 1996, where 
dihydroartemisinin (DHA) treated parasites arrested their development at early ring-stage 
and survived in a dormant form from 3 to 8 weeks, after which they resumed their growth 
[12]. This led to the hypothesis that artemisinin treated parasites enter a state of dormancy 
where they are protected from the drug effect and at a later stage, when the drug is no 
longer present, they recover and resume their growth. More recently, five P. falciparum 
strains with different genetic backgrounds were tested and all became dormant following 
exposure with high-dose of DHA [13]. However, the recovery rates varied from 0.04% to 




1.3% between strains [13]. It was reported that the great majority of dormant parasites die 
in this state but some recover and become growing parasites with a normal morphology 
between 3 and 20 days post-treatment [11, 13]. Dormant parasites have been described to 
exhibit distinct morphological features: “the vacuole is not present, the cytoplasm is 
condensed and tightened towards the nucleus and the nucleus is condensed” [14]. 
Nevertheless, microscopic assessment of whether a parasite is dead or dormant can be 
difficult, as depicted in Figure V.3.  
 
 
Figure V.3: Comparison of dormant and dead parasites after a typical exposure to 
artemisinin drugs.  
After ring-stage parasites were treated with artemisinin drugs, they became dormant, developed a 
rounded morphology, and retained blue cytoplasm and red chromatin on a Giemsa smear (A). Dead 
parasites lacked distinct chromatin and cytoplasm, appearing globular, and they appeared 
red/purple on a Giemsa smear (B) [14].  
 
Later, dormancy has also been associated with artemisinin resistance [14–16]. Laboratory 
selected resistant parasites [15] were investigated and it was observed that when dormancy 
is induced resistant parasites recover faster, leading to an earlier recrudescence [15]. 
However, artemisinin-induced dormancy occurs in both sensitive and resistant parasites in 
vitro [14, 17] and thus, this phenomenon appear to be independent of drug resistance. 
Moreover, there have been no reports to date that dormant parasites exist in human 
infections [11]. Yet, this might be due to the fact that these “abnormal” parasites may be 
difficult to be distinguished in blood smears from patients. Or it may be that these forms 
are removed from circulation and the number of dormant parasites found in the blood is 












1.3. Artemisinin resistance 
The first reports of artemisinin resistance came from two separate efficacy trials conducted 
in Cambodia, where patients treated with ACTs showed a delay in parasite clearance times  
[18, 19]. In the first trial, two out of 60 patients had prolonged parasite-clearance times 
after monotheprapy with artesunate. Ex vivo IC50 values of these two patients were four-
times higher than the ones present in cured patients [18]. The second trial was conducted in 
Cambodia and Thailand, where both treatment regimens of artesunate monotherapy or 
artesunate in combination with mefloquine were used. Results showed delayed parasite 
clearance times in Cambodian patients, suggesting P. falciparum parasites isolated from 
these patients had reduced susceptibility to artesunate. Unlike the first trial, the isolates 
collected in this trial showed no significant differences in their in vitro susceptibility (IC50 
values) to DHA or artesunate, when measured using conventional in vitro drug assays. 
Moreover, no correlation between the delayed parasite clearance and putative molecular 
markers were found [19].  
The phenotypic profile or artemisinin resistant parasites differ from what has been 
observed for other antimalarial drugs, where an increase in IC50 values is usually observed 
in resistant parasites [20]. Indeed, no correlation between what is observed in the patients 
can be made with results obtained by the commonly used in vitro tests [19]. Moreover, the 
majority of patients who have delayed parasite clearance following treatment with an ACT 
still manage to clear their infections [19].  Therefore, artemisinin resistance has been 
exclusively defined as delayed parasite clearance (e.g. parasite clearance half-life ≥ 5 
hours) following treatment with an artesunate monotherapy or with an ACT [20, 21]. This 
is officially named by the WHO as partial resistance [22]. More recently, a molecular 
marker associated with artemisinin resistance has been described [23]. Mutations in the 
kelch 13-propeller domain were associated with delayed parasite clearance [24–26]. Even 
though further validation is still required, this led the WHO to update and divide the 
definition of artemisinin resistance into: “suspected artemisinin resistance (defined as a 
high prevalence of the delayed parasite clearance phenotype or high prevalence of K13 
mutants) and confirmed artemisinin resistance (defined as a combination of both delayed 
parasite clearance and K13 resistance-validated mutations for the same patient)” [22]. 
Recent reports indicate that artemisinin resistance has now spread across Southeast Asia 
[24], but it did not reach the African continent yet [24, 27].  




Even though ACTs still cure malaria patients, provided that the partner drug is effective, 
one must recognize the threat that artemisinin resistance possess in the fight against 
malaria. It was predicted that	 artemisinin resistance would cause an excess of 116.000 
deaths annually, with medical costs and productivity losses evaluated as 146 million USD 
and 385 million USD per year, respectively [28]. Moreover, artemisinin resistance may 
lead to the development of resistance to the partner drugs by allowing higher numbers of 
parasites to be exposed to the partner drug alone. Consequently, this larger parasite 
biomass is more likely to develop resistance to the partner drug [20], as it is currently 
being witnessed in Cambodia for DHA-piperaquine [29–31].  
 
1.4. In vitro detection of artemisinin resistance 
Standard in vitro drug assays fail to detect artemisinin resistance [19]. This may be 
explained by the fact that only young ring-form parasites exhibit reduced susceptibility to 
artemisinins [17, 32]. Currently used in vitro assays determine drug effects over 48 hours 
of incubation, reflecting the activity of the drug on all stages of parasite development from 
rings to mature schizonts. Therefore, results would be relatively unaffected if only a short 
part of the cycle was affected by the underlying mechanism of resistance. For this reason 
several modified protocols of currently available drug assays were investigated for their 
potential to detect artemisinin resistance in vitro [33–35].  
The first one to be reported was the Ring-Stage-Assay (RSA). This assay format mimics 
what occurs in treated patients, where parasites are exposed to high concentrations of drug 
for short periods of 1-2 hours. Thus, in this assay early ring-stage parasites (0-3h of 
development) are incubated with a 6-hour pulse of DHA at 700 nM [33]. Survival rates of 
parasites exposed and non-exposed to treatment are calculated based on microscopy. 
Inherently, this assay is extremely time-consuming, labor-intensive and it requires more 
than one trained microscopist for the read-out of results.  
Another approach based on the RSA was developed. In this case, a DNA and a viability 
stains were used in combination to detect viable parasites by flow cytometry [34]. The use 
of such combination allowed to differentiate the population of infected cells into cells 
containing viable parasites or cells containing non-viable parasites. It was shown that this 
method performs as well as microscopy and can be used more easily to standardize the 
collection of RSA data between research groups [34]. 
A modified 24-hour throphozoite maturation test was developed and compared to the 
traditional 48-hour schizont maturation test (WHO microtest) [35]. This adaptation was 




based on the fact that only ring-forms are less susceptible to artemisinin and thus, it is 
more likely to be able to detect drug effects at an earlier time-point during parasite 
development. Indeed, this modified assay showed that IC50 values obtained for the 
resistant strains were higher than the ones obtained with the standard 48h-schizont 
maturation test, and that they correlated with parasite clearance half-life, whereas the 
standard 48-hour test values did not [35]. Even though this adapted version could be used 
to detect artemisinin resistance, it is also based on microscopic read-out which makes it 
laborious, slow and requires experienced personnel.  
In summary, different approaches have been successful in detecting artemisinin resistance 
in vitro, however the fact that they require either expensive stains or are laborious and 
time-consuming limits their application. 
 
1.5. Hemozoin as an alternative assay to detect artemisinin resistance in vitro 
The hemozoin detection assay relies on the detection of hemozoin by flow cytometry to 
monitor real-time parasite maturation. Therefore, no additional reagents are needed [36]. It 
has been shown that this method allows to detect drug effects in vitro earlier than other 
available drug assays [36]. It was further validated ex vivo in the field using samples from 
malaria patients [37]. Thus, the hemozoin detection assay me be an alternative assay for 
artemisinin testing in vitro or ex vivo.  
The main objective of the work presented in this chapter was to investigate the potential 
and the usefulness of the hemozoin assay in the detection and study of artemisinin 
resistance in vitro.  
 
2. Material and Methods 
All reagents were obtained from Sigma Aldrich (St Louis, Mo, USA), unless stated 
otherwise.  
 
Flow cytometer modification (depolarized side scatter detection) 
The Cyflow® Blue (Partec, Münster, Germany) was modified as described elsewhere [38]. 
Briefly, two side-scatter (SSC) detectors were created, with a 50%/50% beam splitter 
between them. A polarizer was placed orthogonally (horizontal) to the polarization plane 
of the laser light (vertical), in front of one of the SSC detectors, allowing the detection of 
depolarized side scatter.  





Parasitemia, parasite maturation and the synchronicity of parasites in culture were assessed 
by light microscopic examination of Giemsa-stained blood smears. Air-dried blood smears 
were fixed in absolute methanol and stained with Giemsa (Merck, Darsmstadt, Germany) 
in a 1:10 dilution in 0.4% PBS, for 20 minutes.  
 
Flow cytometric analysis  
Parasite maturation was assessed by analyzing the percentage of hemozoin-containing cells 
(depolarizing events), or by the intensity of SYBR green positive events at different time-
points. The parasitemia was determined by assessing by the percentage of SYBR green 
positive cells.  
Flow cytometry results were analyzed using FlowJo software (version 9.0.2, Tree Star Inc., 
Oregon, USA).  Hemozoin-containing cells (depolarizing events) were defined in plots of 
side scatter (SSC) versus depolarized-SSC as those with a signal above the background 
observed in the uninfected control (Figure V.4A).  To determine SYBR green I positive 
cells, green fluorescence (FL1) versus red fluorescence (FL3) plots were used (Figure 
V.4B).  SYBR green I positive events were established based on a stained uninfected 
control and had to be adjusted at each time point, always using the uninfected SYBR green 
stained sample from the corresponding time point.  
 
 
Figure V.4: Gating strategy used to detect infected erythrocytes based on depolarization or 
SYBR green staining. 
Depolarizing events were gated in plots of side scatter versus depolarized-side scatter (A). SYBR 
green positive cells were gated in plots of green fluorescence (FL1) versus red fluorescence (FL3) 
(B). In both cases positive events were gated based on the uninfected samples.  
 
Plasmodium falciparum strains  
All Plasmodium falciparum strains were provided by the Malaria Research and Reference 
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MRA-1239/IPC5188 (artemisinin-sensitive strain) and MRA-1240/IPC5202 (artemisinin-
resistant strain) were contributed by Didier Ménard, while the 3D7 (laboratory-adapted 
strain sensitive to artemisinin) was contributed by Daniel J. Carucci.  
 
Plasmodium falciparum continuous cultures 
All Plasmodium falciparum strains were grown in recently collected donor erythrocytes in 
RPMI based complete malaria culture medium (CMCM) according to the 
recommendations of the Malaria Research and Reference Reagent Resource Center (MR4) 
[39].Cultures were maintained at 5% hematocrit, at 37ºC in an atmosphere of 5% O2 and 




Culture-adapted parasites were synchronized two to three times with 5% sorbitol at 
approximately 40-hours intervals, as described elsewhere [40]. Then, synchronous 
segmenting schizonts were incubated for 15 minutes at 37ºC in RPMI-1640 supplemented 
with 15 U/mL of sodium heparin (Roche, Basel, Switzerland) and then purified on a 
35%/75% Percoll gradient, washed in RPMI-1640, and cultured for 3 hours with 
uninfected erythrocytes. Cultures were treated with 5% sorbitol to eliminate remaining 
schizonts, adjusted to 2% hematocrit and approximately 1% parasitemia by adding 
uninfected erythrocytes, and dispensed into 96 well plates. The Ring-Stage-Assay was 
performed immediately (Figure V.5A).   
 
Mild sorbitol synchronization  
When continuous cultures of P. falciparum reached a parasitemia of > 2%, with a 
minimum of 50% rings, the first sorbitol treatment was performed, as described elsewhere 
[40]. Briefly, the culture medium was discarded after centrifugation of the culture, at 1800 
rpm, for 5 minutes. Then, a volume of sorbitol at 5% (corresponding to 10x the volume of 
the pellet) was added to the pellet and incubated for 10 minutes, at 37ºC. Cultures were 
washed once in RPMI-1640 by centrifugation at 1800 rpm, for 5 minutes. Finally, CMCM 
was added to the pelleted cells, and the synchronized culture was incubated at 37ºC in an 
atmosphere of 5% O2 and 5% CO2 .  
In this mild synchronization protocol, culture-adapted parasites were synchronized four 




times with 5% sorbitol. In the first three times, synchronization was done in approximately 
50 hours intervals (to select for younger ring-forms, assuming that the parasite life cycle 
would be of approximately 48 hours). The last sorbitol was performed after approximately 
38h (Figure V.5B). 
 
Figure V.5: Comparison of the two synchronization protocols.  
Ring-stage assay require the use of tightly synchronized cultures (A). A simple, less laborious 
synchronization protocol was further investigated (B).  
 
Pulse Assay – based on the Ring-Stage-Assay 
Dihydroartemisinin (DHA) in powder was dissolved in DMSO, stored up to 6 months in 
individual aliquots, at -20ºC. In the day of the experiments working solutions of DHA were 
prepared by diluting the stock solution in CMCM.  
Tightly and mildly synchronized ring-form parasites were incubated with 700 nM of DHA. 
After 6 hours the drug was washed away and infected RBCs were put back in culture with 
CMCM, as described elsewhere [33]. Parasite maturation and growth was assessed by flow 
cytometry at 30, 48 and 72 hours. Microscopy determination of parasitemia was performed 
after 72 hours of incubation. Parasite survival was determined by counting the proportion 
of viable parasites (in approximately 2000 erythrocytes) that developed into parasites with 
normal morphology at 72 hours after drug removal. The survival rate was expressed by the 
ratio of viable parasites in DHA treated samples in comparison to the parasites viable in 


















































Standard Drug Assay  
Mildly synchronized ring-form parasites at 2.5% hematocrit and at approximately 1% 
parasitemia were incubated with increasing concentrations of DHA (0.12, 0.5, 2, 8 and 32 
nM), in 96 well-plates, for 72 hours, at 37ºC, in a 5% CO2 and 5% O2 atmosphere. 
For each flow cytometric measurement approximately 100.000 events were analyzed. A 
volume of 5 µL of the blood suspension present in the wells was stained with SYBR green 
1x, as described below. All samples were analyzed in triplicate.  
A nonlinear regression model (sigmoidal dose-response/variable slope) was used to 
calculate the 50% inhibitory concentrations (IC50), with SigmaPlot - Systat Software 
(Chicago, IL, USA) at specific time-points. 
 
SYBR green I staining 
For each measurement 5 µl of the culture (approximately 800.000 cells) was stained with 
the DNA-specific dye SYBR green I (Invitrogen, Carlsbad, USA) at 1x. After 20 minutes 
of incubation, in the dark, the stained sample was immediately analyzed by flow cytometry 
using a 535/45 nm bandpass filter in front of the detector. 
  




3. Results and Discussion 
3.1. Artemisinin Resistant parasites show increased IC50 values when using the Hz 
detection assay  
The 50% inhibitory concentrations (IC50) for DHA were calculated for the artemisinin-
resistant (1240) and sensitive (1239, 3D7) strains. Two different approaches were used to 
measure parasite maturation and growth: 1) the percentage of hemozoin-containing cells 
that depolarize light was assessed after 24 hours of incubation and 2) the percentage of 
SYBR green positive cells, which reflects the parasitemia, was determined after 48 hours 
of incubation. Hemozoin depolarizes light and thus can be detect by flow cytometry. As 
the content of hemozoin increases as parasites matures, assessment of the percentage of 
depolarizing cells overtime allows to monitor parasite maturation in real-time [36].   
Quantification of depolarizing events at 24 hours allowed the detection of increased IC50 
values for the ART-resistant strain (average 15 nM) in comparison to the ART-sensitive 
strains (average 8 nM) (Figure V.6). However, when IC50 values were calculated based on 
the percentage of SYBR green positive cells (parasitemia) at 48 hours of incubation no 




Figure V.6: Inhibitory 50% concentrations of dihydroartemisinin.  
Using the hemozoin detection assay (A), IC50 values for the artemisinin-resistant strain (red dots) 
were higher than the ones obtained for the artemisinin-sensitive strains (3D7 – white dots; 1239 – 
black dots) at 24 hours of incubation.  When parasitemia (% SYBR green positive cells) is assessed 
after 48 hours incubation, no difference in the IC50s was observed between the different strains.  
 
In fact, one of the hallmarks of artemisinin resistance is precisely the fact that the delayed 














assays, including the reference method based on the incorporation of [3H]Hypoxanthine 
[19, 33]. This can be explained by the fact that only the young ring-forms show reduced 
susceptibility to DHA [17]. Thus, as currently used in vitro assays determine drug effects 
after 48 hours of incubation, they reflect the activity of the drug on all stages of parasite 
development. Based on this idea a modified 24-hour throphozoite maturation test was 
developed and compared to the traditional 48h-schizont maturation test (WHO microtest) 
[35]. As the name indicates in this assay drug effects were measured earlier at 24 hours of 
incubation, instead of the conventional 48 hours. IC50 values obtained by the 24-hours 
throphozoite maturation assay for the resistant strains correlated with parasite clearance 
half-life, whereas the standard 48-h test values did not [35]. 
A modified version of the [3H]Hypoxanthine radioactive assay was also developed [14]. In 
this case, if [3H]Hypoxanthine is added at the same time as the drug, instead of the 
common addition at 24 or 48 hours after incubation with the drug, any differences in 
growth of resistant rings would be observed. Results using an in vitro derived ART-
resistant line of P. falciparum showed that these parasite lines had increased IC50 values in 








3.2. Artemisinin-resistant parasites show increased survival rates in comparison to 
artemisinins-sensitive strains  
Due to the inability of standard in vitro drug assays to detect artemisinin resistance, a 
modified protocol based on a high-dose pulse of DHA for 6 hours, named as the ring-stage 
assay (RSA) was developed [33]. Here, IC50 values are not calculated (a single drug 
concentration is tested) and survival rates are determined instead. Results showed that 
survival rates were associated with parasite clearance times. Fast-clearing (sensitive) 
parasites had a median 0.23% survival in comparison to 11% in slow-clearing (resistant) 
parasites [33].  
Survival rates were assessed using the previously described RSA protocol [33] and the 
final read-out was made using four different approaches: 1) the recommended microscopy 
assessment of parasitemia; 2) the quantification of depolarizing events (Figure V.7A); 3) 
the determination of SYBR green positive cells (Figure V.7B); and 4) the assessment of 
SYBR green intensity (Figure V.7C).  
 
 
Figure V.7: Comparison of artemisinin resistant and sensitive P. falciparum strains using 
different approaches to assess parasite growth and maturation.  
Solid lines represent the drug-free control (df) and dashed lines represent the samples exposed to a 
6-hour pulse of dihydroartemisinin at 700nM (6h). Artemisinin (ART)-sensitive samples are 
presented in black and the ART-resistant strain is represented in red. Parasite maturation assessed 
by the percentage of depolarizing cells showed a decrease in depolarization after 24h in the ART-
sensitive strains (black), while in the ART-resistant parasites (red) the percentage of depolarizing 
cells is similar to the drug-free control overtime (A). ART-resistant parasites showed an increase in 
parasitemia after 48h of incubation, whilst the parasitemia of sensitive parasites remains the same 
overtime (B). No difference between ART-sensitive and ART-resistant strains was detected when 







































































































































All tested approaches, with the exception of the determination of SYBR green intensity, 
allowed to distinguish between ART-resistant and ART-sensitive strains (Figure V.7 and 
V.8). No further investigation was done based on the SYBR green intensity because it was 
observed that this approach does not seem to allow to distinguish artemisinin-resistant 
from sensitive strains.  
 
 
Figure V.8: Survival rates of tightly synchronized parasites exposed to a 6-hour pulse of 
dihydroartemisinin (DHA).  
Survival rates were expressed as ratios of viable parasitemias in DHA-exposed and drug-free 
samples. Different approaches were used to assess the survival rates of artemisinin-resistant (red) 
and artemisinin-sensitive (black) strains. In all of them artemisinin-resistant parasites had higher 
survival rated in comparison to artemisinin-sensitive strains.  
 
Survival rates obtained by the recommended microscopic read-out were of approximately 
4% and 44% for the ART-sensitive and ART-resistant strain, respectively (Figure V.8A). 
These values differed from the ones that were previously described for these same strains 
(0.1% and 80%). Because artemisinin resistance phenotype appears unstable [35], it was 
thought that the phenotype could have been partially lost during in vitro cultivation. 
Therefore, two samples with different times in culture (3 and 8 months) were analysed 
using molecular methods. Results showed that the recently described K13 polymorphism 
R539T, which is associated with artemisinin resistance [23], was present in both samples, 
indicating that the tested strain should be resistant to artemisinin (Table V.1). The reason 
for the observed difference in survival rates is indeed intriguing. However, it should be 
noted that in several studies survival rates for ART-resistant parasites ranged between 4% - 
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Table V.1: Kelch 13 gene locus polymorphism associated with delayed parasite clearance 
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(cultured for 3 months) G T C T G 
1240B 
(cultured for 8 months) G T C T G 
 
Assessment of depolarizing events at 30 hours showed increased survival rates for both 
ART-resistant (53%) and ART-sensitive (30%) strains, in comparison to microscopy 
(Table V.2). The same was observed in the ART-senitive strains when parasitemia was 
determined by assessing the percentage of SYBR green positive cells at 48 and 72 hours 
(17% and 12% respectively). The culture-adapted 3D7 strain (ART-sensitive) was also 
tested alongside and survival rates were comparable to the ones obtained for the ART-
sensitive 1239 strain (Figure V.8 and Table V.2). 
The increased survival rates observed in the ART-sensitive strains determined by 
assessment of the percentage of SYBR green positive cells may be simply explained by the 
fact that dead parasites may still be accountable in such a measurement, whereas in 
microscopy they are not. Microscopy assessment accounts only for parasites with a normal 
morphology. SYBR green is a DNA stain that binds to DNA independently of whether the 
DNA belongs to viable or a dead parasite. Precisely because of this, another flow 
cytometric approach was investigated recently, where a viability stain (Mitotracker) was 
used in combination with SYBR green to allow the quantification of only viable parasites 
[34]. In this study, results obtained with the flow cytometric read-out were comparable to 
the ones obtained by microscopy.   
Regarding the increased survival rates obtained when assessing the percentage of 
depolarizing cells no clear explanation has been found yet. However, what certainly may 
contribute for this is the fact that the detection of depolarizing cells only allows the 
quantification of parasites that contain a considerably high amount of hemozoin, therefore 
parasite that are also mature but contain less hemozoin might no be included in this 
analysis. Moreover, it was observed that at 30 hours of incubation, as an example, only 
around 30% of the cells that are SYBR green positive do depolarize. This may explain the 
increased values of survival rates in both sensitive and resistant strains, since the real 
increase in drug free control samples may be masked by the inability of this method to 
detect the whole population of infected erythrocytes.  




3.3. Assessment of parasite survival using a simpler protocol for parasite 
synchronization 
The synchronization protocol described for the RSA is time-consuming and laborious. It 
requires complex steps of synchronization, including several sorbitol treatments and one 
percoll-enrichment to obtain 0-3 hour ring-form parasites (Figure V.5). It has been 
reported that when older parasites are used instead (9-12 hours or 18-21 hours) the 
difference in survival rates between resistant and sensitive strains is lost. During this study 
a simpler synchronization protocol using only the sorbitol synchronization was 
investigated. In this case, parasites should have around 12 – 20 hours of development. In 
general, the difference in survival rates between ART-resistant and ART-sensitive strains 
was more discrete than what was observed when using tightly synchronized cultures. 
Moreover, in the case of microscopy and flow cytometric assessment of depolarization, 
results varied considerably between experiments (Figure V.9 and Table V.2). Thus, it 
seems that discrimination between strains is better when younger and tighter synchronized 




Figure V.9: Survival rates of mildly synchronized parasites exposed to a 6-hour pulse of 
dihydroartemisinin.  
Survival rates were expressed as ratios of viable parasitemias in dihydroartemisinin-exposed and 
drug-free samples. Different approaches were used to assess the survival rates of artemisinin-
resistant (red) and artemisinin-sensitive (black) strains. Artemisinin-resistant parasites had higher 
survival rated in comparison to artemisinin-sensitive strains in all approaches, yet results differed 
considerably between experiments.  
 
Interestingly, two other different synchronization protocols have been recently described 
for the RSA [41]. One is based on the use of three 5% sorbitol treatments, the first two are 
performed at exactly 46-hour intervals to tighten synchronicity and the last one is done 
when parasites are between very late schizonts and very early rings to remove the 
remaining mature forms. The other approach consists on the combination of two sorbitol 

























A.	 B.	 C.	 D.	




treatments followed by a filtration step, where mature schizonts will burst mechanically 
and free merozoites are obtained and put in culture for 2 hours before drug is added, thus 
parasites with two hours of development are obtained. In both protocols results were 
comparable to the RSA standard synchronization protocol [41]. However, the 
synchronization by filtration leads to low parasitemias of 0.07% and thus, assessment of 
parasitemia even after 72 hours may be difficult [41]. Nevertheless, the synchronization 
using only sorbitol treatments seems promising and would certainly be less laborious than 
the current RSA synchronization protocol.  
 
Table V.2: Summarizing table of mean survival rates for artemisinin-sensitive (3D7 and 
1239) and artemisinin-resistant strains (1240). 
  






microscopy (72h) 5.5 (± 2.1) 4 (± 3.2) 44 (± 0.6) 11 
depolarization (30h) 25 (± 14) 30 (± 2) 53 (± 2) 1.8 
%SYBR green (48h) 13 17 (± 1.4) 40.5 (± 0.7) 2.4 
%SYBR green (72h) 11 12 (± 1.4) 42 (± 2.1) 3.5 
Mild 
Synchronization 
microscopy (72h) nd 6 (± 0.9) 35.1 (± 29.4) 5.9 
depolarization (30h) nd 19 (± 8) 52 (± 37) 2.7 
%SYBR green (48h) nd 22 (± 2.8) 38.5 (±9.2) 1.8 
%SYBR green (72h) nd 21 (± 6) 31.3 (±7.7) 1.5 
nd: not determined; average values from two or more experiments ± one standard deviation 
 
  




3.4. Artemisinin-resistant parasites do not seem to enter dormancy 
The growth of parasites exposed to a 6-hour pulse of DHA at 700 nM was monitored and 
compared to drug-free control samples after 72 hours of incubation (Figure V.10 and 
V.11). Microscopic observation of blood smears showed that indeed the majority of 
parasites in the ART-sensitive sample arrest their development after drug treatment (Figure 
V.10 – left panel). In the ART-resistant strain some parasites were also found to be 
dead/dormant but others managed to survive to drug treatment (Figure V.10 – right panel 
and V.11B).  
 
Figure V.10: Representative microscopic pictures of untreated and dihydroartemisinin 
treated samples at 72 hours of incubation.  
Artemisinin (ART)-resistant and ART-sensitive parasites developed as expected in the drug-free 
control samples (top panels). When treated with 6-hour pulse of dihydroartemisinin (DHA) at 700 
nM, most parasites in the ART-sensitive strain were dead/dormant (left – bottom panel). Viable 
parasites could be detected in the ART-resistant strain (right bottom panel).  
 
 
Figure V.11: Representative microscopic pictures of untreated and dihydroartemisinin 
treated samples at 72 hour of incubation.   
Three representative pictures of Giemsa stained blood smears from drug-free control samples and 
samples exposed for 6-hour to dihydroartemisinin (DHA) at 700 nM. In the artemisinin-sensitive 
strain most parasites were found dead or dormant at 72 hours of incubation in the treated sample 
(A). Some parasites managed to survive in the artemisinin-resistant culture that was exposed to 
DHA (B) and some dead or dormant parasites were also found. The development of parasites that 





















































Interestingly, in the ART-resistant strain not only some parasites were able to survive 
treatment but they also managed to replicate overtime, leading to an increase of 
parasitemia (Figure V.12). This was corroborated by the fact that parasites at 
approximately the same stage of development of the ones present in the drug-free control 
were found in drug treated samples (Figure V.11B). The number of parasites that survived 
drug treatment was considerably higher in the ART-resistant strain (44%), in comparison 
to the ART-sensitive strain (3%)  (Figure V.12B).   
 
 
Figure V.12: Progression of parasitemia in artemisinin-sensitive and artemisinin-resistant 
parasites after a 6-hour pulse of dihydroartemisinin.   
The parasitemia of artemisinin-sensitive (1239 - black) and artemisinin-resistant (1240 - red) 
parasites was monitored after 72 hours of incubation in drug-free samples (solid lines) and in 
samples treated with 6-hour pulse of dihydroartemisinin (DHA) at 700 nM (dashed line). 
Artemisinin-resistant parasites showed a 4-fold increase in parasitemia, whereas no increase was 
detected in artemisinin-sensitive parasites (A). The survival rate was determined by dividing the 
parasitemia of the drug-free control by the parasitemia of drug exposed samples measured at 72 
hours of incubation (B). Artemisinin-resistant parasites had a higher survival rate (44%) than the 
artemisinin-sensitive strain (2.9%) (B).  
 
These results seem to indicate that upon an effective concentration of DHA most parasites 
are killed, but not all. This small percentage of parasites that survive treatment will 
develop and replicate at approximately the same rate as non-treated parasites. However, 
the percentage of survivor parasites is likely to be below the detection limit of most assays. 
Thus, depending of depending on the number of parasites that survived treatment, it may 
take longer for these parasites to grow above the detection limit of the assays. It was 
observed that the number of viable parasites in the ART-resistant strain is higher than in 
the ART-sensitive strain. Consequently, ART-resistant parasites show increased levels of 
parasitemia earlier than the ART-sensitive parasites (Figure V.13), as it was observed in 
other studies [15, 42]. Based on this, it was hypothesized that ART-resistant parasites 
manage to survive a 6-hour exposure to a high-dose of DHA by a mechanism that is not 


















































Figure V.13: Representative model of parasite replication after exposure to 6-hour pulse of 
dihydroartemisinin.  
The parasitemia of untreated ring-stage synchronized parasites increase approximately 5-fold after 
48 hours of incubation. After a 6-hour pulse with dihydroartemisinin (DHA) at 700 nM most 
parasites are killed but some manage to survive. The number of parasites that survives drug 
treatment in the artemisinin-resistance sample is higher than the ones in the artemisinin-sensitive 
sample (A). Survivor parasites will developed approximately at the same rate as untreated 
parasites, however due to the reduced numbers of parasites parasitemia will greatly differ between 
the sensitive and resistant strains (B). For example, resistant parasites manage to reach a 10% 
parasitemia at day 4 (red line), whereas sensitive parasites will only reach such parasitemia later 
around day 6 (black line).  
 
Dormancy has been suggested as the underlying mechanism of artemisinin resistance, 
where ART-resistant parasites manage to survive to DHA exposure by entering state of 
dormancy or quiescence during which parasites are protected from the drug [11, 16]. 
The classical definition of quiescence is “a reversible absence of proliferation”, i.e., a non-
dividing cell which eventually restarts its cell cycle when conditions become appropriate 
[43]. In fact, the ability of microorganisms to persist in metabolically inactive states 
enables survival in unfavorable conditions and it has been described for several human 
pathogens [44]. For example Mycobacterium tuberculosis can enter a dormant state during 
which they are resistant to drug effects and sometimes to the host immune defenses [45]. 
In the case of Plasmodium spp., parasites arrest their development at the sporozoite stage 
in the mosquito salivary glands and at the gametocyte stage in the blood. In the case of P. 
vivax and P. ovale sporozoites are able to stop their cell cycle in the liver, originating 
dormant forms known as hypnozoites, which cause relapses weeks to months after the 



































































Initially, artemisinin-induced dormancy was proposed as the main cause for the high 
recrudescence rates observed after artemisinin monotherapy [3, 8, 12]. It is widely known 
that, because of their short half-life, when artemisinins are used alone they fail to eliminate 
all parasites and recrudescence occurs [3, 7, 8]. Thus, it was hypothesized that artemisinin-
treated parasites enter a state of dormancy where they are protected from the drug. After 
drug effect is no longer present, parasites recover and resume normal growth, causing 
recrudescence [13]. In vitro studies showed that when parasites are exposed to a high-dose 
of artemisinin (200 ng/mL) the ring-forms arrest their development and enter a dormant 
state that can last up to 20 days [13]. A computer simulation model that incorporates the 
ring-stage dormancy, recovery rates, and dose dependency of ART-induced dormancy 
predicts clinical and parasitological failures at rates comparable to those reported in the 
field with ART monotherapy [47]. Moreover, dormant parasites morphologically similar to 
those observed in vitro [14] were found in vivo in a rodent malaria model following ART 
treatment [48]. These parasites were shown to be viable because then managed to cause 
infection after they were transferred into new hosts [48]. All the results presented in these 
studies suggest that dormancy may be the cause of the high recrudescence associated with 
artemisinin monotherapy. However, whether dormancy is directly induced by artemisinins 
is still unclear. Interestingly, dormancy has also been associated with exposure to other 
drugs such as mefloquine, pyrimethamine and atovaquone [49–51]. This could indicate 
that dormancy may be an inherent phenomenon that occurs within a parasite population, 
where “naturally” some parasites will have the ability to persist in the presence of the drug 
and resume their growth later, instead of being induced by a specific drug. Indeed, this 
concept is not new and it has been described for bacteria. Bacterial cells escape the effects 
of antibiotics without undergoing genetic change, these cells are know as persisters [44, 
52]. They represent a small fraction of the bacterial population and, unlike resistant cells, 
these cells do not grow in the presence of antibiotics. Persister cells arise due to a state of 
dormancy, defined as a state in which cells are metabolically inactive [52]. Exit from this 
state seems to be unaffected by any external stimuli [44]. However, the mechanism of 
persister cell formation is not well understood and the metabolic state of these cells is still 
debated.  
The association between dormancy and artemisinin resistance was made for the first time 
by Witkwoski et al [16]. In this study, ART-tolerant strains obtained after in vitro drug 
pressure were exposed to high-doses (9 – 70 μM) of artemisinin for 48 or 96 hours. Even 




though, the majority of parasites died after drug treatment, the ART-resistant strains 
recovered faster (8 days) than the ART-sensitive strains (16 days). Observations made at 
48 hours of incubation indicated that in the ART-resistant parasite culture only rare ring-
forms (0.1%) were detected and no mature forms were observed. Later, after 24 and 30 
hours of drug removal mature forms are detected, indicating that parasites managed to 
replicate after drug exposure. These observations led the authors to state that: “drug 
tolerance is mediated by cell cycle arrest at the ring stage, as they were the only viable 
forms observed during the 48 hours ART pressure period.” Here, it is assumed that the 
ring-form parasites observed at 48 hours are parasites that persisted since the beginning of 
the experiment rather than second-generation ring-forms. To confirm this scheduled 
sorbitol treatments, that selectively kill all late-parasite stages except ring-forms, were 
performed five times during the 48 hours of drug exposure and it was observed that 
parasite survival was not affected by these sorbitol treatments. Yet, it should be noted that 
parasites used in these experiments were not tightly synchronized. Moreover, sorbitol 
synchronization selects for parasites with 0-20 hours of development [53]. Thus, even 
though sorbitol treatments were made five different times during the 48 hours period it 
may be that some parasites were indeed not affected because they are not in the 0-20 hours 
developmental period, where the sorbitol is effective, rather than being dormant or 
arrested. In fact, at this time-point (48 hours of incubation) it would be expected that the 
majority of parasites would be ring-form parasites. This could be easily concluded by the 
observation of parasite forms present in the drug-free control sample. Unfortunately, data 
regarding the drug-free control was not presented nor discussed. Thus, besides considering 
that parasites arrested their development and were dormant, the hypothesis that some 
parasites managed to survive to drug exposure and replicated as well as parasites that were 
not in the presence of the drug should not be discarded. 
Later, two other studies reported the same association between artemisinin resistance and 
dormancy [14, 15]. ART-resistant parasite lines created in vitro were used and it was 
observed that ART-resistant parasites recovered from dormancy faster than ART-sensitive 
ones [14, 15]. Interestingly, it was found that sensitive parasites enter dormancy as well 
[14]. Nevertheless, it may be hypothesized that drug-induced dormancy confers a survival 
advantage which will ultimately select for artemisinin-resistant parasites. Yet, it should be 
noted that the ART-resistant laboratory parasite lines used in these studies differ from the 
ART-resistant parasites isolated from patients that have prolonged clearance times. For 




example, these strains exhibit increased IC50 values [14, 15], whereas the ones isolated 
from the patients do not [19].  
The correlation of these different findings with the reduced susceptibility of field isolates 
observed in Cambodia was investigated [54]. Parasites obtained from patients in Pailin (a 
province of Cambodia where artemisinin resistance has been reported) had higher survival 
rates in comparison to isolates from Ratanakiri after exposure to 700 nM of DHA [54]. 
Interestingly, intact arrested ring-form parasites, referred as quiescent parasites, were 
observed after the ART-resistant strain was exposed with 700 nM DHA for 24 hours. The 
morphology of these dormant/quiescent parasites differs from what has been previously 
described, where dormant parasites have been reported to have a smaller cytoplasm and 
more-condensed chromatin that indeed resemble pyknotic forms rather than ring-forms 
(Figure V.3) [14, 15]. 
Moreover, initial in vitro studies of dormancy and recovery rates reported that the 
dormancy observed in parasites after exposure to DHA seems to be rather short (less than 3 
days) and that parasites are active enough to be inhibited by a second drug treatment [13]. 
In this study, synchronous ring-stage parasites were exposed to a 6-hour pulse of DHA at 
700 nM, after which a passage through a magnetic column for three consecutives days was 
performed to eliminate mature forms. It was observed that samples that were exposed to 
DHA and passed through the magnetic column took longer to recover than the ones that 
were only exposed to DHA. This delay in recovery indicates that either a small number of 
parasites are unaffected by the drug or that dormant parasites recover during the first three 
days and are removed by the magnetic columns. Furthermore, when a combination 
treatment with artemisinin and mefloquine was investigated, it was observed that the 
proportion of parasites recovering from treatment with both drugs was decreased by 10-
fold as compared to the single treatment with artemisinin, implying that dormant parasites 












Table V.3: Studies that have investigated artemisinin-induced dormancy. 
Study Strains  Drug treatment Findings 




after in vitro 
drug pressure. 
High-dose (9 – 70 
μM) of 
artemisinin for 
48h to 96h.  
• No differences in IC50 values were 
observed between the ART-sensitive and 
ART-resistant strains. 
• ART-resistant strains recovered faster than 
ART sensitive when exposed for 48h with 
the drug, taking 8 and 16 days to reach a 
parasitemia of 5%, respectively. 
• The majority of parasites died after drug 
treatment. 
ART-resistant strain: 
• At 48h of incubation with the drug only 
rare ring-forms (0.1%) were observed in 
the ART-strain.  
• 24h and 30h after drug removal mature 
forms were observed.  
ART-sensitive strain: 
• no mature forms could be observed at 24h 
and 30h after ART removal. 




strains W2, D6 
and HB3.  
6h DHA (700 
nM) pulse and 
passage through a 
magnetic column 
for 3 consecutives 
days to eliminate 
mature forms.  
 
• Higher DHA doses yielded a lower 
recovery rate. 
Drug exposure but no passage through 
magnetic column:  
• only morphologically abnormal rings and 
no mature parasite forms were observed in 
culture for 3 days. 
• Parasitemia >10% was reached at day 11.  
Drug exposure and passage through 
magnetic column:  
• Parasitemia >10% was reached between 
day 14 – 19.  
Codd et al 2011 
[47] 
Computer simulation model to assess 
different regimens of artemisinins in 
single-dose, 3-day and 7-days 
treatments.  
 
• Dormancy could explain the recrudescence 
observed after monotheprapy with 
artemisinin. 
• Repeated treatment reduced dormancy 
recovery rate and the rate of recrudescence, 
but a small proportion of treatment failures 
are still predicted 




laboratory strains  
6h high-dose AL 
pulse 
• AL-resistant parasite strains showed 
increased IC50 values. 
• AL-resistant strains recover faster (4 days) 
than AL-sensitive strains (8 days).  
• Dormancy occurs in resistant parasites but 
higher concentrations of drug are needed to 
induce it. 






6h DHA (700 
nM) pulse 
• ART-resistant strains recover faster (3 
days) than ART-sensitive strains (4 days).  
• ART-resistant parasite strains showed 
increased IC50 values. 







DHA (700 nM) 
pulses of 6h and 
24h. 
• ART-resistant strains recover faster (3 
days) than ART-sensitive strains (more 
than 6 days).  
• Quiescent parasites exhibit a different 
morphology (intact ring-form) than the 
dormant parasites described by others [14]  
ART – artemisinins; AL – Artelienic acid; DHA - Dihydroartemisinin 
 




Contrary to what has been described for other microorganisms, such as Mycobacterium 
tuberculosis, it seems that dormancy observed in parasites exposed to artemisinins is rather 
short and does not cause a full arrest of parasite metabolical activity [13]. Recently it was 
reported that most metabolic pathways are down regulated in DHA-induced dormant 
parasites [55]. However, continued transcription of genes encoding apicoplast and 
mitochondrial proteins was detected, indicating that these dormant parasites are not 
metabolically quiescent but, even though their growth and replication is arrested [55]. 
Others have also observed that parasites do not enter dormancy once they are exposed to 
artemisinins. Indeed, what was shown is that both ART-resistant and ART-sensitive 
parasites seem to have a dose-dependent growth retardation after being exposed to 
artemisinin in comparison to the drug-free controls [56, 57].  
It is evident that ART-resistant parasites manage to survive to a greater extent to DHA 
exposure than ART-sensitive parasites. However, it is still unknown why only some of 
these parasites survive and not all. Dormancy has been widely mentioned as the 
mechanism behind artemisinin resistance, yet discrepancies between studies and the 
findings described above seem to indicate that the mechanism associated with artemisinin 
resistance might not be related to dormancy, at least as it is defined for other organisms. 
Dormancy implies that organisms are metabolically inactive for long periods of time. This 
seems no to be the case in the dormancy phenotype observed in P. falciparum. Therefore, 
along with further investigation an update of this definition or the use of a different 
nomenclature should be considered in the future.  
 
  




3.5. Artemisinin resistant parasites exhibit altered developmental patterns  
It has been described that in the absence of the drug, ART-resistant parasites exhibit an 
inherent delayed growth in vitro in comparison to ART-sensitive parasites [58]. The 
parasite developmental patterns of the three different strains used in this study were 
investigated in 6-hour intervals during the whole 48-hour life cycle, in the absence of drug 
treatment. It was observed that ART-resistant parasites had a delay in parasite development 
of approximately 6 hours (Figure V.14). This delay was detected both when using tightly 
(0-3 hours of development)  (Figure V.14A) or mildly synchronized (Figure V.14B) (12-20 




Figure V.14: Parasite developmental patterns in the absence of drug.  
The development of parasite in culture was monitored in tightly (A) and mildly synchronized  (B) 
parasites. In both cases, artemisinin-resistant parasites (40) showed a longer cycle of development 
in comparison to artemisinin-sensitive strains. It seems that this pronlogued cycle is associated with 
a prolongued ring-stage development of 18 hours, instead of the 12 hours observed for the sensitive 
strains. The duration of the throphozoite stage and the schizont stage seems to be the same between 
parasite strains.  
 
In fact, it has been described that ART-resistant parasites exhibit a prolonged ring-stage of 
development and a shorten trophozoite stage, but that the overall duration of the parasite 






















































































that ART-resistant parasites seem to have a prolonged life cycle of 48 hours in comparison 
to the 42-hour life cycle observed in ART-sensitive strains (Figure V.14A). The delay in 
parasite development occurs during the ring stage of development, where ART-resistant 
parasites have a ring phase of approximately 18 hours, instead of the 12-hour ring-stage 
duration observed for the ART-sensitive strains. However, no reduction in the duration of 
the trophozoite stage was observed between strains (Figure V.14).  
The potential of the flow cytometric detection of hemozoin to detect delayed parasite 
growth was investigated. Alongside quantification of parasitemia by flow cytometry was 
performed as well. The hemozoin detection allowed to distinguish between ART-resistant 
parasites and ART-sensitive strains only at 72 hours of incubation, when an increase in the 
percentage of hemozoin-containing cells was observed in the sensitive parasites but not in 
the resistant ones (Figure V.15A). This reflects what is observed by microscopy, where at 
72 hours sensitive parasites are late throphozoites/young schizonts whilst resistant ones are 
younger ring-forms (Figure V.15A). Assessment of parasitemia by flow cytometry, using 
SYBR green stained samples, allowed to detect delayed growth at 42 hours of incubation 
in tightly synchronized parasites, or at 36 hours in mildly synchronized ones (Figure 
V.15B). In this case, second generation ring-forms are already present at 42 hours in the 
ART-sensitive strain, whereas in the ART-resistant strain parasites from the second 
generation  only appear later at 48 hours. This explains why the increase in parasitemia 
(percentage of SYBR green positive cells) is detected at the abovementioned time-points.  
The prolonged ring-stage has been suggested as defense mechanism that the parasite 
develops to cope better once it is in the presence of artemisinins parasites [58]. It is known 
that young ring-form parasites are the forms that have reduced sensitivity to artemisinins 
[54] and that these drugs have a short half-life of (~1 hour) [4]. Thus, if parasites could 
extend this stage until the activity of the drug is lost, it would allow them to resume their 
growth later. However, not all ART-resistant clones have a prolonged ring phase of 
development. In fact, it was reported that one resistant clone had an accelerated 36-hour 
life cycle instead parasites [58]. Thus, further research is needed to elucidate the role of 
altered parasite growth patterns in the context of artemisinin resistance.  
 
 





Figure V.15: Parasite development monitored by flow cytometry. The percentage of 
depolarizing events (hemozoin-containing cells) and SYBR green positive cells (parasitemia) 
was assessed overtime.  
Detection of depolarizing events allowed to distinguish between the slow-growing resistant strain 
(red line) and the sensitive strain (black line) at 72 hours of incubation (A). At this time sensitive 
parasites start to mature and produce hemozoin, whilst the resistant parasites did not matured as 
much. An increase in parasitemia on the sensitive strains but not on the resistant one was detected 































































































































Novel and more practical in vitro assays are needed to further investigate artemisinin 
resistance. Flow cytometry detection of hemozoin may be a useful tool for the in vitro 
investigation of artemisinin resistance. Unlike other available drug assays for P. 
falciparum, the hemozoin assay allows real-time monitoring of parasite maturation and, 
consequently, drug effects can be detected earlier (at 24 hours of incubation) than most 
assays. This feature is especially relevant in the case of artemisinin resistance because only 
the young ring forms seem to be resistant to artemisinin. Therefore, the earlier the assay is 
able to detected drug effects the better.  
Results showed that the hemozoin detection assay allowed to detect increased IC50 values 
already at 24 hours of incubation. This can possibly allow to distinguish between ART-
resistant and ART-sensitive strains based on their respective IC50 values. Moreover, when 
pulse assays (based on the previously described Ring-Stage-Assay) were performed the 
flow cytometric readout of parasite maturation (detection of depolarization caused by 
hemozoin) and parasitemia (percentage of SYBR green positive cells) allowed to detect 
increased survival rates associated with artemisinin resistance after 30 and 48 hours of 
incubation, respectively. Yet, obtained survival rates, especially in the ART-sensitive 
strains, were higher than the ones observed by microscopy at 72 hours. This may be an 
inherent limitation of the flow cytometric approaches. While microscopy only assesses 
parasites with a normal morphology and thus, likely to be viable, the quantification of 
SYBR green positive cells by flow cytometry will also include dead parasites which did 
not degenerate yet and are still stained by SYBR green. On the other hand, flow cytometric 
detection of hemozoin only allows the quantification of parasites that have a hemozoin 
content above a certain threshold and therefore, it is unlikely that all parasites would be 
detected at a specific time-point. In fact, it was observed that the peak of schizogony 
(which corresponds to the peak of depolarization) in untreated samples occurred at around 
42 hours of incubation. Future experiments should include measurements of parasite 
maturation at 42 hours of incubation, rather than the 30 hours previously used. This may 
lead to decreased survival rates, which would be closer to the ones obtained by microscopy 
at 72 hours.  
A simpler synchronization protocol for the pulse assay was also investigated. Although, it 
was still possible to distinguish between ART-resistant and ART-sensitive parasites, 
results differed considerably between experiments. Moreover, discrimination between 




ART-resistant and ART-sensitive strains was better when younger and tighter 
synchronized parasites are used.  
Interestingly and contrary to some reports, artemisinin resistance does not seem to be 
related with dormancy. In fact, parasites that survived to drug treatment developed and 
replicated at approximately the same rate as parasites that were not treated. Yet, these 
results are preliminary and further demonstration of this observation is required. Future 
experiments should include the monitoring of parasite maturation in tighter intervals of 
time (for example 2 to 4 hour intervals). Comparison of parasite development in drug free 
control samples and in samples exposed for 6-hours to DHA would be more precise and 
would allow to determine if treated parasites arrest their growth and, if so, when it occurs 
and for how long.   
An additional aspect is that ART-resistant parasites used in this study showed a delayed 
development in the absence of drug pressure, as it has been previously described. This 
delay was determined by flow cytometric detection of hemozoin at 72 hours of incubation. 
Whether this altered growth pattern could allow to distinguish ART-resistant strains from 
ART-sensitive ones remains unclear and further validation is required. Importantly, 
previous results from the field-study conducted in Gabon showed that parasites that have 
similar susceptibility/resistant profiles to the same drug may exhibit differences in ex vivo 
growth. This seems to indicate that the altered parasite growth observed in ART-resistant 
strains in vitro may not be enough to reliably distinguish between ART-sensitive and ART-
resistant strains ex vivo. Perhaps, one could speculate that the delayed parasite growth is 
associated to drug resistance in a more general way. 
Flow cytometry could be a useful tool to study artemisinin resistance in vitro. However, 
the data set presented here is limited and all observations were made using a single ART-
resistant strain (MRA-1240). Indeed, results should be further confirmed using other 
culture-adapted ART-resistant strains available on the Malaria Research and Reference 
Reagent Resource Center (MR4). Then, after establishing an optimal in vitro protocol the 
hemozoin detection assay should be tested on site, obviously somewhere in Southeast Asia 
where artemisinin resistance has been reported. Both ART-sensitive and ART-resistant 
strains obtained directly from patients with fast and slow-clearing infections should be 
included. This field-study may allow to clarify some of the remaining doubts and, 
ultimately, would determine the usefulness of the hemozoin detection assay for the study 
and detection of artemisinin resistance.		
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Antimalarial drug resistance is a major obstacle in the fight against malaria. In the past the 
development of resistance to chloroquine led to an increase in the number of cases and 
deaths from malaria [1, 2]. Substantial gains in malaria control were lost and the 
reemergence of the disease in many countries occurred due to antimalarial drug resistance 
[3]. Recently resistance to artemisinin, the basis of the current first-line treatment of 
malaria, seems to be emerging and is spreading in Southeast Asia [4–6]. However, 
artemisinin resistance is considered by the WHO as partial resistance and artemisinin-
combination therapies (ACTs) are still the mainstay for malaria treatment [7].  
In vitro tools to monitor the emergence and spread of resistant malaria parasites are of 
utmost importance for malaria control. Several different antimalarial drug assays are 
currently available [8, 9]. However, an optimal approach has not been developed yet. 
Microscopic assessment of parasite maturation was the first method that allowed the 
assessment of drug effects on parasites [10]. Even though it is an affordable method and 
simple to perform, it is subjective and requires experienced personal or special training. 
Currently, the reference method for antimalarial drug testing is based on the incorporation 
of radioactive [3H]-hypoxanthine [11]. The use of a radioactive reagent to assess parasite 
growth is the main limitation of this assay, especially in malaria-endemic countries. 
Another limitation is the relatively high parasite densities of approximately 0.5% required 
for this assay [8]. More recently, an ELISA method based on the detection of an antigen 
from the malaria parasite (the HRP2 antigen) developed in 2002 has been successfully 
used to assess drug effects [12]. It overcomes some of the limitations of previously 
mentioned assays as it is easy to perform, it allows the analysis of a large number of 
samples and it has a low detection limit of 0.05% parasitemia. Yet, it requires the use of 
expensive reagents (e.g. antibodies), the availability of a cold chain to store samples and/or 
reagents and it has a long-turn-around time of at least 72 hours. More importantly, lately 
concerns regarding the fact that some parasites lack the HRP2 gene have emerged and this 
would certainly limit the application of this assay [13]. 
In this scenario, it would be ideal if a parasite product could be used to readily assess 
parasite growth or maturation, avoiding the main limitations of current assays. Hemozoin, 
a crystal produced by the parasite during its maturation inside the erythrocyte seems to be 
an optimal candidate. The content of hemozoin increases as parasite matures from ring-
forms to trophozoites and, finally, to schizonts. Moreover, hemozoin is a birefringent 
crystal, and thus it is able to depolarize light. The resulting light depolarization can be 
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detected by optical methods such as microscopy [14] or flow cytometry [15]. Interestingly, 
detection of light depolarization by flow cytometry is not new and was developed back in 
1986 [15]. However, Abbott Diagnostics patented this feature, and thus it was only 
available in Abbot’s Cell Dyn hematology analyzers. Other manufacturers were not 
allowed to implement this feature in their machines. In 1999, it was reported for the first 
time that leukocytes that contain hemozoin could be detected by the Cell-Dyn 3500 
hematology analyser [16]. Since then other reports have shown the same [17–20] and the 
use of hematology analyzers to diagnose malaria has been further investigated, as it is 
extensively reviewed elsewhere [21]. Importantly, some of these studies reported the 
possibility of detecting infected erythrocytes that contain hemozoin [20, 22]. This 
observation led to the hypothesis that if infected erythrocytes that contain hemozoin could 
be detected, maybe the quantification of these cells overtime would allow to detect parasite 
maturation and, consequently, drug effects could be determined as well.  
Indeed, this idea was already investigated in the past and it was the basis of a drug assay 
developed by Rieckmann in 1982 [23]. However, the visual read-out of hemozoin 
formation performed at the time was not accurate enough due to the leukocyte interference.  
 
2. Detection of intra-erythrocytic hemozoin as an alternative drug assay for 
Plasmodium spp. 
2.1. Detection of light depolarization by flow cytometry 
Hematology analyzers are far from being ideal and practical instruments to be used to 
further investigate the potential of the flow cytometric detection of hemozoin for 
antimalarial drug testing. Besides being expensive and bulky, these instruments are closed 
systems where no modifications can be done. Ideally an affordable, accessible and easy to 
transport instrument would be a better option. The Cyflow SL (Partec) is a portable 
benchtop flow cytometer with an accessible optical bench. Modifications of the optical 
layout can de done easily and it is always possible to switch back to the original optical 
set-up. This instrument was easily modified to allow the detection of light depolarization 
caused by hemozoin [24, 25]. In fact, the modification of the optical bench to allow the 
detection of this additional parameter of light depolarization was also accomplished in 
other flow cytometers, such as the: MoFlo (Beckman Coulter), Accuri C6 (BD 
Biosciences) and the Attune (Life Technologies) [25].  
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2.2. Preliminary proof-of-principle using a rodent malaria model  
Rodent malaria parasites, that have high amounts of scattered hemozoin and that were 
readily available at the institute, were used to determine if the resulting light depolarization 
caused by hemozoin could be detected by flow cytometry. The main goal was to assess if 
flow cytometric detection of hemozoin allows to detect drug effects using a rodent malaria 
model. Indeed, light depolarization caused by hemozoin was detected and it allowed to 
easily distinguish between infected and uninfected samples. Moreover, measurements of 
depolarizing events overtime allowed to detect parasite maturation and drug effects [26]. 
This work was not part of this PhD project but it paved the way for the work that was later 
developed in the context of this thesis.   
 
2.3. Further development of the flow cytometric detection of hemozoin using the 
human parasite P. falciparum 
The aim of this PhD project was to further investigate the flow cytometric detection of 
hemozoin as a novel antimalarial drug assay. For that in vitro cultures of P. falciparum 
were established for the first time at the institute. Investigation of the newly developed 
drug assay based on the flow cytometric detection of hemozoin using in vitro cultures of P. 
falciparum showed that drug effects and drug resistance could be detected earlier than any 
other available assay, already at 18 hours of incubation [24]. However, limitations of in 
vitro studies using culture-adapted strains included: 1) the fact that hemozoin released 
during schizont rupture accumulates in the culture and can not be eliminated; and 2) that 
these parasites have adapted to successfully grow in culture, contrary to parasites that are 
isolated directly from of malaria patients.  
Ex vivo culturing of parasites obtained from malaria patients would overcome these 
limitations and would allow to further elucidate the usefulness of this method as a drug 
sensitivity assay for P. falciparum. Preliminary experiments were done using blood 
samples from malaria patients returning from endemic countries that were admitted at the 
Hospital Santa Maria [27]. Yet, the number of samples was limited. Moreover, most 
samples were collected and stored for several days before they were finally analysed by 
flow cytometry. Thus, they were not in the best conditions to allow further parasite growth 
in vitro.  
To overcome this a preliminary field trial in Gabon, a malaria endemic country, was 
planned. The 6-month field study was conducted at the Centre de Recherches Médicales de 
Lambaréné (CERMEL) which is linked to the Abert Schweitzer Hospital. The Cyflow SL 
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available on site was successfully modified to detect light depolarization caused by 
hemozoin. A total of fourty-six samples from malaria patients admitted at the Albert 
Schweitzer Hospital were analysed. Drug inhibitory effects and drug resistance could be 
detected by the flow cytometric detection of hemozoin, as it was previously observed using 
in vitro cultures of P. falciparum. However, IC50 values were higher that the ones 
obtained when samples were tested using the HRP2-ELISA [25]. Indeed, the same was 
also detected when culture-adapted strains were tested in vitro [24]. Surely the fact that 
these assays measure parasite growth at different times (24 hours versus 72 hours) and 
using different growth indicators (hemozoin versus HRP2-antigen) may explain these 
differences. Nevertheless, it should be noted that the hemozoin detection assay inherently 
tends to lead to increased IC50 values. Indeed, comparison of IC50 between different drug 
assays is difficult since these values can vary considerably between assays [9, 24]. Yet, this 
is becomes less relevant when comparisons are done between results obtained by the same 
drug assay. Furthermore, not all parasites obtained from malaria patients successfully 
grew/replicated ex vivo. In fact, different growth profiles were observed. It is important to 
note that tested samples were not specifically collected for the purpose of this study. Thus, 
information regarding the patients was scarce and might explain some of the differences 
observed in parasite growth ex vivo. 
Results obtained during this study served as proof-of-principal of the original idea of using 
hemozoin detection as a mean to determine drug effects on P. falciparum. However, 
ultimate clinical validation would only be possible by conducting a controlled clinical trial, 
where a higher number of samples would be tested and detailed information of the patients 
would be made available.  
 
3. Limitations of flow cytometric detection of hemozoin for antimalarial drug testing 
Studies performed in the context of this PhD project showed that the hemozoin detection 
by flow cytometry allows to monitor parasite maturation and to detect drug effects and 
drug resistance more rapidly (24 hours) that other available drug assays (48 – 96 hours). 
Moreover, because it is based on the detection of a parasite product it does not require the 
use of additional reagents. However, some limitations exist, mainly associated with: 1) a 
high detection limit of 0.3% parasitemia and 2) the fact that it does not allow the analysis 
of a high number of samples per day.  
Improved detection limits can be obtained by further optimizing the protocol of sample 
preparation. Preliminary results, which were not presented in this thesis, seem to suggest 
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that by lysing the erythrocytes, a higher volume of blood sample can be analysed by flow 
cytometry, and thus depolarizing signals above the background can be detected in samples 
with parasitemias as low as 0.05% (the same detection limit of the HRP2-ELISA assay).  
Flow cytometry is inherently a single-channel instrument, meaning that only a single 
sample can be analyzed at a time. This implies that a limited and rather reduced number of 
samples can be analysed in a specific period of time. This is certainly a limitation, 
specially in validation, epidemiological or drug screening studies where a high number of 
samples is ought to be tested. Ideally, processing of several samples at the same time 
would be the best option. High-throughput systems have been developed for flow 
cytometry [28] and the use of such a system would make the hemozoin assay much more 
time-efficient. However, these additional systems are expensive and may often require 
maintenance.  
These limitations should be considered and addressed in the future to establish the 
hemozoin detection assay as a tool for rapid antimalarial resistance testing. In this context 
and with the aim of investigating better cytometric tools for malaria investigation in 
resource-limited settings a working group led by Dr. Howard Shapiro was formed at 
CYTO 2012 Meeting of the International Society for the Advancement of Cytometry 
(ISAC), held in Leipzig, Germany. Since then, several workshops on Malaria and 
Cytometry have been held at different meetings to document the current state of malaria 
cytometry and its applications so further development could be efficiently achieved in the 
future.  
 
4. Further implementation of hemozoin detection in different contexts 
4.1. Image cytometry 
Image cytometry may be an alternative to flow cytometric methods. The main difference 
between these two methods is that one requires a fluidic system (flow cytometry) and the 
other does not (image cytometry) [29]. Indeed, wide-field image cytometry is now capable 
of measuring the same parameters that would be measured by flow cytometry, such as 
DNA, RNA and possibly hemozoin [29]. Wide-field imaging cytometry requires small 
volumes of blood, short exposure times (no longer than a few seconds) and analysis of data 
from thousands of cells in one field can be done in few minutes [30]. Overall, an image 
cytometer is more robust and portable and less complex and costly than a flow cytometer. 
Furthermore, affordable image cytometers can now be built using cheap materials such as: 
LED light sources (< 10-100 USD), CMOS or CCD camera chips (~ 25 USD), and 
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microprocessors similar to those used in smartphones (~ 25 USD) [30]. This would allow 
to keep the production costs of such devices at low cost, making them affordable for 
resource-limited settings found in most malaria endemic countries.   
Image cytometry could be an alternative method to detect hemozoin and thus, allow to 
determine drug effects and drug resistance. Currently, a prototype of such an instrument 
exists; however it has not yet been tested for its potential to detect hemozoin.  
  
4.2. Other novel hemozoin detection technologies  
It is important to note that in recent years hemozoin has played a central role in the 
development of alternative and novel methods to diagnose malaria [31–36]. Indeed, in the 
2016’s Malaria Diagnostics Technology and Market Landscape report it is mentioned that 
six independent groups have been developing hemozoin-detecting technologies [37]. Even 
though these methods differ in their technological approach they are based on two unique 
physical properties of hemozoin: 1) its optical properties - hemozoin crystals scatter and 
depolarize light in a unique way; and 2) its magnetic properties. Importantly, most of the 
hemozoin-based technologies are designed to be hand-held devices that use finger-prick 
collected blood samples [37]. Moreover, no reagents are needed and results are rapidly 
available (in less than five minutes).  
It is known that hemozoin is only detectable in more mature parasite forms and in most P. 
falciparum infections these parasite forms are not found in circulation. We have previously 
observed that flow cytometric detection of hemozoin does not allow to reliably detect 
young immature parasite forms found in blood samples form malaria patients [27]. 
Therefore, hemozoin may not be the ideal marker for diagnosis of P. falciparum malaria. 
Yet, results presented in the context of this thesis show that it may be a useful maker of 
parasite maturation and, consequently, may allow the detection of drug effects. Definitely 
novel devices that are able to detect hemozoin should be further explored and investigated 
for their potential and usefulness as alternative antimalarial drug assays.  
A preliminary study using one such device, the Magneto-optical method (MOT) developed 
by University of Budapest [32, 33], was performed at our laboratory. It was shown that the 
MOT was able to monitor infection in a rodent model of malaria [34], thus indicating that 
it might allow the detection of parasite maturation and drug effects as well. Indeed, 
unpublished data showed that the antimalarial activity of several antimalarial drugs could 
be detected in in vitro cultures of P. falciparum after 20 hours of incubation, 
approximately at the same time as drug effects are detected by flow cytometric detection of 
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hemozoin. The great advantage of this method in comparison to flow cytometry is its low 
detection limit of 0.0008% parasitemia [33]. Like in flow cytometry, the MOT device is a 
single-channel instrument and only a single sample can be measured at a time. However, 
while by flow cytometry sample acquisition is done in less than a minute, in the MOT 
method at least five minutes are required. Further optimization of the device should be 
performed to allow a more rapid sample analysis.  
Nevertheless, results obtained with the MOT method reinforces the idea that hemozoin 
detection, independently of the method or technology used to detect it, is a relevant 
biomarker for the detection of antimalarial drug effects.  
 
5. Hemozoin detection and artemisinin resistance 
The usefulness of the flow cytometric detection of hemozoin was further investigated in 
the context of artemisinin resistance. One of the hallmarks of artemisinin resistance is that 
the delayed parasite clearance times observed in patients does not correlate with IC50 
values obtained in vitro, when conventional drug assays are used [5, 38]. This is thought to 
be consequence of the fact that artemisinin resistance seems to exist only in young ring-
form parasites [39, 40]. All other parasites forms seem to remain susceptible to the drug. 
Thus, as most in vitro drug assays determine drug effects after a whole 48-hour parasite 
life cycle, results would be relatively unaffected if only a short part of the cycle was 
affected by the underlying mechanism of resistance [41].  
As the flow cytometric detection of hemozoin allows to detect drug effects earlier than any 
other drug assays, it might be particularly useful for the in vitro detection of artemisinins 
resistance. It was shown that, contrary to other assays, when parasite maturation was 
assessed by the hemozoin detection assay at 24 hours of incubation, artemisinin-resistant 
parasites had increased IC50 values in comparison to the ones obtained for the artemisinin-
sensitive strains. Moreover, increased survival rates associated with artemisinin resistance 
were observed after only 30 hours of incubation, instead of the 72 hours described the for 
previously validated ring-stage assay [38].  
Since it was first reported artemisinin resistance has been considered “as a clear and 
present danger” [42]. For now observed resistance of Plasmodium falciparum is 
considered to be partial by the WHO and artemisinin-combination therapies are still the 
mainstay of antimalarial treatment [43]. However if the current phenotype spreads to areas 
with high malaria endemicity, such as the ones found in Sub-Saharan Africa, ACTs may 
also start failing there. Development of full resistance to the artemisinins may lead to 
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increased numbers of deaths and morbidity associated with malaria and will certainly 
jeopardize all efforts and progress made in the last decades in the context of malaria 
control. As it has been witnessed with the spread of chloroquine resistance in Africa [2], 
emergence of full resistance to artemisinin would put the life of millions of people at risk 
again. Better and effective tools to detect artemisinin resistance in vitro are needed. 
Detection of hemozoin may offer a great opportunity to investigate artemisinin resistance. 
Preliminary results are promising but further optimization using more artemisinin-
resistance strains is required. Moreover, validation studies including field trials in 
Southeast Asia need to be performed to determine the actual usefulness of the flow 
cytometric detection of hemozoin in the study and detection of artemisinin resistance. 
 
6. Final remarks 
Hemozoin has played an important role in the study of malaria since the very beginning. In 
fact, malaria was discovered by associating the observation of hemozoin in the organs of 
sick patients and the parasite that caused the disease. For centuries it was thought that 
hemozoin was a waste product of the parasite, however its importance have increased in 
the last decades. It is now acknowledged that hemozoin plays an important as an 
antimalarial drug target [44–46] and as an immune system modulator [47–50]. The work 
presented in this thesis further shows that hemozoin can also be used for antimalarial drug 
testing [24–26]. Indeed, detection of hemozoin may offer a great opportunity to further 
investigate and unravel antimalarial drug resistance.  
Flow cytometry is one of the possible approaches to be used in the future. Indeed, simple 
and affordable instruments are now available and flow cytometric measurements of other 
parameters, such as DNA content and base composition and RNA content, in addition to 
hemozoin may provide improved accuracy and sensitivity of parasite detection and 
characterization [29]. However, an inherent limitation of flow cytometric methods is the 
fact that only a single sample can be analyzed at a time. This may be overcome by novel 
technologies or methods that are also able to detect hemozoin [31–36]. In fact, some of 
such methods are currently available and should definitely be further explored for their 
potential to detect antimalarial drug effects. Ideally, joint efforts should be made by 
combining technical knowledge with biological and clinical expertise to allow the efficient 
development of better in vitro tools for antimalarial drug testing that will, ultimately, play 
a central role in the successful fight against malaria. 
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Abstract
Background: Malaria pigment (haemozoin, Hz) has been the focus of diverse research efforts. However,
identification of Hz-containing leukocytes or parasitized erythrocytes is usually based on microscopy, with inherent
limitations. Flow cytometric detection of depolarized Side-Scatter is more accurate and its adaptation to common
bench top flow cytometers might allow several applications. These can range from the ex-vivo and in-vitro
detection and functional analysis of Hz-containing leukocytes to the detection of parasitized Red-Blood-Cells
(pRBCs) to assess antimalarial activity.
Methods: A standard benchtop flow cytometer was adapted to detect depolarized Side-Scatter. Synthetic and
Plasmodium falciparum Hz were incubated with whole blood and PBMCs to detect Hz-containing leukocytes and
CD16 expression on monocytes. C5BL/6 mice were infected with Plasmodium berghei ANKA or P. berghei NK65 and
Hz-containing leukocytes were analysed using CD11b and Gr1 expression. Parasitized RBC from infected mice were
identified using anti-Ter119 and SYBR green I and were analysed for depolarized Side Scatter. A highly depolarizing
RBC population was monitored in an in-vitro culture incubated with chloroquine or quinine.
Results: A flow cytometer can be easily adapted to detect depolarized Side-Scatter and thus, intracellular Hz. The
detection and counting of Hz containing leukocytes in fresh human or mouse blood, as well as in leukocytes from
in-vitro experiments was rapid and easy. Analysis of CD14/CD16 and CD11b/Gr1 monocyte expression in human or
mouse blood, in a mixed populations of Hz-containing and non-containing monocytes, appears to show distinct
patterns in both types of cells. Hz-containing pRBC and different maturation stages could be detected in blood
from infected mice. The analysis of a highly depolarizing population that contained mature pRBC allowed to assess
the effect of chloroquine and quinine after only 2 and 4 hours, respectively.
Conclusions: A simple modification of a flow cytometer allows for rapid and reliable detection and quantification
of Hz-containing leukocytes and the analysis of differential surface marker expression in the same sample of
Hz-containing versus non-Hz-containing leukocytes. Importantly, it distinguishes different maturation stages of
parasitized RBC and may be the basis of a rapid no-added-reagent drug sensitivity assay.
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Background
The malaria pigment, or haemozoin (Hz), is gaining
increasing attention, as has been reviewed recently [1,2]:
(i) Hz production is an important drug target, (ii) Hz
appears to have immunomodulatory properties, (iii) detec-
tion of Hz-containing leukocytes allows diagnosis of
malaria, and (iv) Hz-containing leukocytes appear to be
associated with disease severity. However, one important
drawback in this area of research is the fact that counting
of Hz-containing leukocytes or the detection of Hz-
containing parasitized red-blood cells (pRBCs) is based on
microscopy [3,4]. This is not only cumbersome, but intro-
duces a significant statistical error if the number of
Hz-containing leukocytes is low [5]. An alternative to this
is based on the detection of depolarized Side-Scatter by
flow cytometry [6]. Hz is birefringent and as a conse-
quence rotates the plane of polarized light, a process called
depolarization. LASER light, commonly used in flow cyt-
ometers, produces polarized light. Thus, by placing a
polarization filter orthogonally (90° rotated) to the plane
of the LASER light in front of a second SSC detector
allows to detect depolarized light and consequently Hz.
Depolarized SSC detection is incorporated into the
Cell-Dyn® haematology analysers (Abbott, Santa Clara,
CA, USA) to differentiate eosinophils from granulocytes.
As a result of this, these instruments detect Hz-contain-
ing leukocytes as well as Hz in parasitized red blood
cells (pRBC) without need for modifications, [7,8].
Unfortunately, the software analysis and analysis algo-
rithms of the analysers cannot be accessed without the
intervention of the manufacturer and thus, studies
depended on counting the events (cells) on the instru-
ment’s screen or the printout, with consequent data loss
and no option for further analysis of the raw data [9].
However, if a simple modification of common flow cyt-
ometers created a reliable method for detection and
analysis of Hz in leukocytes or pRBC it might open
novel approaches for diagnostic applications and
research.
For example, flow cytometric counting of Hz-contain-
ing leukocytes may be a better marker for disease sever-
ity than microscopy based counts [5,10]. Detection and
functional analysis of Hz-containing leukocytes may also
help to elucidate further aspects on the immunomodula-
tory properties of Hz. In fact, most in-vitro studies use
concentrations of Hz that maximize uptake by the
majority of monocytes in a given cell population and
compare them with a control population that was not
exposed to Hz [11]. However, the situation may be dif-
ferent in vivo, where both populations coexist. For
example, a recent large study, based on microscopy,
reported that the median percentage of circulating
Hz-containing monocytes was only 2-5% [3].
Interestingly, monocytes are a heterogeneous cell
population, even in peripheral blood [12,13], mainly
based on the CD14 and CD16 expression: classical
“inflammatory” monocytes (CD14+/CD16-), “intermedi-
ate” monocytes (CD14+/CD16+) and “resident, pro-
inflammatory” monocytes (CD14dim/CD16+). They also
seem to differ functionally [14]. Recent research showed
differences in the ratio of these populations in malarious
children with different types of malaria [15], as well as
differences in surface marker expression and parasite
inhibitory action in acute uncomplicated malaria [16].
However, little is known whether Hz phagocytosis con-
tributes to these findings in vivo. In fact, the interplay of
Hz-containing and non-Hz-containing subpopulations
might produce different biological results in vivo, when
compared to those in vitro models, where nearly all
monocytes contain Hz.
Another important area for flow cytometric detection
of Hz could be the reliable detection of pRBC harbour-
ing different Hz content. This may be useful for sensi-
tivity testing and drug development, because the
Hz-content increases proportional to the maturation of
the parasite [17].
This paper describes a simple way to modify a stan-
dard bench-top flow cytometer to allow depolarized
Side-Scatter measurements. The method was then tested
for its usefulness to detect Hz-containing leukocytes and
erythrocytes and examples for potential applications are
presented.
Methods
Flow cytometer modification (depolarized Side Scatter
detection)
The CyFlow® Blue (Partec, Münster, Germany) is a
small, five parameter flow cytometer (Figure 1a) with
blue laser (488 nm) excitation, and detectors for For-
ward Scatter (FSC), Side Scatter (SSC), green fluores-
cence (FL1), orange fluorescence (FL2) and red
fluorescence (FL3) (Figure 1b). For this study the set-up
was changed, mainly by creating two SSC detectors,
using a 50%/50% beam splitter. Then a polarization filter
was placed orthogonally to the polarization plane of the
laser light, in front of one of these SSC detectors which
allowed the detection of depolarized Side-Scatter. This
and other necessary changes are indicated in Figure 1c.
Reagents
All reagents were obtained from Sigma Aldrich (St
Louis, Mo, USA), unless stated otherwise. Fluorescein
isothiocyanate (FITC) or phycoerythrin (PE) labelled
antibodies against surface antigens as well as isotype
antibodies (CD14-FITC, CD16-PE, CD11b-FITC,
Gr1-PE, TER119-PE, Fc-block) were purchased from
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A
B Common layout:




C depol. SSC detection:
(FSC, SSC, depol. SSC, FL-1, FL-3)
Figure 1 Alterations to the optical bench of a common bench-top flow cytometer which allows detection of depolarized side-scatter.
a) The lid of the CyFLow® Blue flow cytometer can be easily removed and filters can be swapped by the operator. b) Light path in
conventional filter set-up for detection of Forward Scatter (FSC), Side-Scatter (SSC), green (FL-1), orange (FL-2) and red (FL-3) fluorescence. c)
Filter set-up that allows detection of depolarized Side-Scatter instead of FL-2 detection. Squares with broken line indicate dichroic mirrors that
need to be changed. Red error shows 50%/50% beam splitter. Other beam splitters which divert more light to the depolarized SSC are possible,
such as 90%/10% or even 95%/5%. DM = Dichroic Mirror; BP = Bandpass filter, LP = Longpass filter, numbers indicate wavelength in nm.
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eBioscience (San Diego, USA). DNAse/RNAse free ultra-
pure water, Phosphate buffer saline (PBS), Fetal Bovine
Serum (FBS), HEPES and RPMI 1640 were purchased
from Gibco (Grand Island, NY). Ultrapure water was
obtained with a Milli-Q purification system (Millipore,
Madrid, Spain).
Haemozoin preparation and quantification
Synthetic haemozoin (sHz) was prepared by dissolving
1.1 gr of hemin chloride in 70 ml of 0.4 M NaOH and
62 ml of ultrapure water. The heme was then precipi-
tated by the addition of 68 ml of glacial acetic acid. The
mixture was heated at 37°C over night to promote the
formation of b-haematin. The following day, the formed
crystalline synthetic haemozoin (sHz) was washed 5
times in 5% pyridine (in 0.02 M HEPES at pH 7.5) and
five times in ultrapure water. Finally, sHz was resus-
pended in PBS, quantified and stored at 4°C.
Plasmodium. falciparum (strain 3D7) haemozoin
(Pf-Hz) was purified from a synchronized culture at a
parasitaemia of around 3-5%. Infected erythrocytes were
spun at 2000 rpm for 10 min and resuspended for 10
min in a mixture of 40 ml ultrapure water with 2 ml of
a 1% saponin in water. Cell lysates were then centri-
fuged at 13,200 rpm for 15 min. The Hz pellets were
washed 4x with PBS, resuspended in 1 ml PBS, quanti-
fied and stored at 4°C. Both types of Hz showed no
DNA contamination and were negative for Mycoplasma.
The concentration of Hz was determined as haem
content (haem-equivalent) after solubilization in 20 mM
NaOH for 1 hour at room temperature. The haem con-
centration was then determined by luminescence at
400 nm using the QuantiChrom Heme Assay Kit from
BioAssay Systems (Hayward CA, USA).
In vitro incubation of human whole blood with synthetic
haemozoin
Heparin-anticoagulated blood from healthy human
donors was diluted 1:1 in RPMI 1640; and distributed
into a 24 well plate. Then sHz was added at 0.01; 0.06
and 0.12 μmol haem-equivalent/ml. The plate was incu-
bated for 7 hours at 37°C in 5% CO2. Leucocytes were
analysed in triplicates at time 0, 4 and 7 hours.
In vitro incubation of human PBMCs with synthetic and P.
falciparum haemozoin
Human PBMC were isolated from 40 ml heparin-antic-
oagulated blood collected from healthy volunteers and
after dilution 1:1 in RPMI 1640 and placed in a Ficoll
gradient (Ficoll-Paque Plus, GE Healthcare, Uppsala,
Sweden). Cells were centrifuged at 700 g for 20 min and
the interface containing the PBMCs was collected. The
PBMCs were washed, counted and resuspended at a
concentration of 1 × 106 PBMC/ml in RPMI 1640
supplemented with 2 mM L-glutamine, 0.05 mg/ml gen-
tamicin and 10% foetal calf serum and distributed into a
24 well plate. Then sHz was added at 0.004 and 0.007
μmoles heme-equivalent/ml and P.f.-Hz was added at
0.002 and 0.004 μmol haem-equivalent/ml in triplicates.
Polystyrene latex beads (0,1 μm) were diluted from the
stock at 10% (vol/vol) to a final concentration of 0.001%
and used as control. The plate was incubated for
6 hours at 37°C in 5% CO2.
Flow cytometric analysis of human leukocytes
EDTA anticoagulated blood was obtained from volun-
teers and patients for immediate analysis. One hundred
μl of EDTA-anticoagulated blood was incubated for
20 minutes with anti-CD14 and anti-CD16. RBC were then
lysed prior to analysis with Whole Blood Lysis Reagent
(Partec, Münster, Germany) without further washing.
For the in vitro whole blood assay 50 μl were incu-
bated with anti-CD14 and anti-CD16 antibodies. RBC
were lysed with BD FACS lysing solution (BD Bios-
ciences, San Jose) for 5 minutes and washed before ana-
lysis. PBMCs were labelled as described for the whole
blood assay, without erythrocyte lysis. All in-vitro sam-
ples were performed in triplicate. The gating strategy for
monocytes and granulocytes and identification of
Hz-containing leukocytes is shown in Figure 2.
Flow cytometric analysis of murine leukocytes
Groups of five C57BL/6 mice (Charles River, Spain)
were infected intraperitoneally with Plasmodium berghei
ANKA (PbA) as model for experimental cerebral
malaria or P. berghei NK65 (PbNK) as model for hyper-
parasitaemia. Uninfected and P. berghei NK65 infected
mice were followed for 18 days. PbA-infected mice were
sacrificed on day 5 when showing obvious signs of mor-
bidity. Parasitaemia and flow cytometric analysis of
blood was performed on days 3, 5, 12 and 18 post infec-
tion. At each time point approximately 25 μl of blood
was collected from a tail vein, incubated with Fc-block
and then labelled with anti-CD11b and anti-Gr1. After
washing the cells, RBC were lysed with 125 μl of BD
FACS lysing solution (BD Biosciences, San Jose) for
5 min. The cells were washed again, resuspended in
FACS buffer and analysed by flow cytometry. Granulo-
cytes and monocytes were analysed as described pre-
viously [18], in particular following a protocol that uses
Side Scatter, CD11b and Gr1 expression [19] (see: addi-
tional file 1 - mouse blood gating strategy.pdf).
Analysis of murine Hz-containing RBC
Mice (C57BL/6) (Charles River, Spain) were infected
with P. berghei ANKA. Blood samples were collected
when mice had a parasitaemia of approximately 5%.
RBC were incubated with Fc-block and then labelled
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Figure 2 Detection of Hz-containing monocytes and granulocytes in human whole blood. Top rows: Gating strategy for detection of
haemozoin (Hz) containing monocytes (CD14+) and granulocytes (CD16+). Top row: blood from healthy donor without Hz, second row:
incubated for 7 hours with synthetic haemozoin (0.06 μmol/ml heme-equivalent). Using plots from healthy volunteers (top row) gates were
created to identify depolarizing monocytes and granulocytes. Bottom two rows: Colour backgating for samples shown in row one and two, as
well as for a patient with P. falciparum malaria (0.2% parasitaemia). Blue = non-depolarizing monocytes, red = depolarizing monocytes, green =
non-depolarizing granulocytes, orange = depolarizing granulocytes.
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with anti-TER119. After washing the cells, SYBR green I
(Invitrogen, Carlsbad, USA) was used to stain the DNA
of intraerythrocytic parasites. Briefly, 2.5 μl of the SYBR
Green I solution at 10x was added to a blood suspen-
sion of approximately 400,000 cells/mL and incubated
for 20 minutes, in the dark.
Anti-malarial drug effect on P. berghei infected RBC in-
vitro
Blood from infected mice was diluted 1:50 in RPMI
medium supplemented with 10% foetal calf serum, 1%
non essential amino acids, 1% penicillin/streptomycin,
1% glutamine and 10 mM Hepes, pH 7. The blood sus-
pension was diluted 1:1 in complete RPMI medium and
incubated with either chloroquine or quinine for
12 hours in a 24 well plate at 37°C in a 5% CO2 atmo-
sphere. Chloroquine diphosphate salt or quinine hydro-
chloride were dissolved in ultrapure water to prepare
the stock solution. Final concentrations of 25 nM,
50 nM and 100 nM of chloroquine or 400 nM and 800
nM of quinine were used. Flow cytometric measure-
ments were done during every two hours by diluting 5
μl of the suspension present in the wells in 1 mL of
FACS buffer. The effect of the anti-malarial drugs on
the parasites was assessed by quantifying the percentage
of highly depolarizing events (hdRBC).
All flow cytometry results were analysed using FlowJo
software (version 9.0.2, Tree Star Inc., Oregon, USA).
The study was approved by the Ethical Committee of
the Faculty of Medicine, University of Lisbon. All
experiments involving animals were performed in
compliance with the relevant laws and institutional
guidelines.
Results
The Cyflow® instrument can be easily adapted to detect
depolarized Side-Scatter (depol-SSC) by the operator,
without any sophisticated tools or special knowledge. It
is only necessary to open the instrument’s cover, after
releasing four screws, and change the respective filters
and dichroic mirrors (Figure 1). This is a very simple
procedure that lasts approximately 5 minutes. No spe-
cial software is necessary and the same set-up (linear) as
used for conventional SSC detection is sufficient,
although the gain (voltage) of the detectors had to be
adjusted.
Detection of Hz-containing leukocytes in human blood
Using anti-CD14 and anti-CD16 it was possible to iden-
tify Hz-containing monocytes and granulocytes in whole
blood from healthy human volunteers incubated with
Hz (Figure 2 and 3) as well as in a sample from a
patient with malaria (Figure 2). Importantly, Hz-contain-
ing monocytes show much higher Side-Scatter than
normal monocytes, which overlap with the granulocyte
population (Figure 2, bottom rows).
Incubation of whole blood from healthy volunteers
with sHz shows that the percentage of Hz-containing
monocytes and granulocytes depends on the initial
Hz-dose and time of incubation (Figure 3).
In addition, different types of Hz cause distinct
expression of CD16 on Hz-containing monocytes, as
compared with non-haemozoin containing monocytes in
mixed populations (Figure 4, 5). Contrary to the syn-
thetic Hz used in this study, P. falciparum derived Hz
increases significantly CD16 expression on Hz-contain-
ing monocytes from healthy volunteers (P < 0.01);
Figure 4 and 5). Interestingly, in a single case of P. falci-
parum malaria with 5.4% Hz-containing monocytes, a
substantial increase of CD16 expression was noticed and
the majority of HZ-containing monocytes were clustered
in the CD14+/CD16+ subpopulation (Figure 4, bottom
row, right).
Altogether, the data clearly show that a simple altera-
tion in a bench-top flow cytometer for detection of
depolarized side-scatter allows quantification of Hz-con-
taining monocytes, which could be easily detected in a
case of P. falciparum malaria.
Hz-containing murine leukocytes
Using anti-CD11b and anti-Gr1 it was possible to iden-
tify Hz-containing monocytes and granulocytes in
mouse blood (Figure 6). Mice with PbA infection were
sacrificed on day 5 because they developed symptoms
compatible with experimental cerebral malaria. Overall,
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Figure 3 Phagocytosis of haemozoin in-vitro depends on dose
and incubation time. Whole Blood from a healthy human
volunteer was incubated with synthetic haemozoin (sHz) at 0.01,
0.06 and 0.12 μmol/ml of heme equivalent and with no sHz
(control). The percentage of Hz-containing granulocytes (open bars)
and monocytes (grey bars) was determined at time zero, and after
four and seven hours of incubation. Identification of leukocytes and
depolarization as described in the text and shown in figure 2.
Results are the mean values of triplicates (± one SD).
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leukocytes increased when parasitaemia was higher
(Figure 6). However, when mice infected with the two
different parasite strains were compared when they had
a similar parasitaemia, i.e. day 5 for PbA (5.7 ± 3.1%)
and day 12 for PbNK (7.7 ± 1,3%), PbA infected mice
had higher percentages of Hz-containing monocytes
than PbNK infected mice (Figure 6, top graph). Also,
while the levels of parasitaemia of PbNK at day 18 of
infection were significantly higher than the levels of
parasitaemia of PbA at day 5 of infection (28.5 ± 12%
and 5.7 ± 3.1%, respectively, P < 0,001) the percentages
of Hz-containing monocytes were almost the same
(13,3% and 13,0%, respectively). Furthermore, a compar-
ison of the degree of Gr1 expression (low, medium,
high) on the Hz-containing monocytes, appeared to
show differences in these two groups of mice at similar
parasitaemia (Figure 6, bottom graph).
Interestingly, using CD11b and F4/80 showed that it
appears possible to identify Hz-containing tissue macro-
phages as shown in additional file 2 (Additional file 2 -
mouse spleen macrophages.pdf).
Altogether, using two distinct rodent models of infection,
Hz-containing monocytes and granulocytes can also be
detected in this flow cytometer. Most importantly, the data
suggest that the percentage and type of Hz-containing
monocytes may also be a associated with disease severity.
Detection of Hz in murine pRBCs
Plasmodium accumulates Hz throughout its develop-
ment stage inside RBCs. The detection of depolarization
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Figure 4 Different expression of CD16 on Hz-containing monocytes. PBMCs were isolated from blood of a healthy human volunteer and
were incubated with synthetic Hz (0.007 μmol/ml heme-equivalent) and with Plasmodium falciparum Hz (P.f.Hz) at 0.004 μmol/ml heme-
equivalent. PBMCs incubated with latex beads and with no Hz were used as controls. CD14+ monocytes were gated, analysed for depolarization
and then analysed for CD16 expression. Patient with P. falciparum malaria (0.2% parasitaemia) 2 days into treatment (bottom right panel). Blue
shaded area: non-depolarizing monocytes, red line depolarizing monocytes.
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was evaluated to determine whether this measurement
could be used to detect pRBCs and most importantly to
distinguish different pRBC stages. In whole blood from
mice infected with P. berghei a population of depolariz-
ing events is observed (Figure 7). More than 97% of
these events were positive for the RBC marker TER119
(red population, Figure 7E). SYBR green I staining was
positive in this population, indicating that the depolariz-
ing erythrocytes contained DNA, and thus were parasi-
tized RBC (pRBC) (Figure 8). Further analysis revealed
that events with a higher degree of depolarization also
showed a higher degree of SYBR green fluorescence
(Figure 8), with several distinct peaks, likely representing
different maturation stages of the parasite (ring-forms,
early and late trophozoites and schizonts).
Detection of Hz in parasitized murine RBC to assess drug
effects
Based on the above findings (Figure 8, gate A), which
contained the pRBC with the highest degree of depolari-
zation (hdRBC) and as such contains the most mature
parasites, the flow cytometric method was investigated
to see if it could be used to rapidly assess drug effects.
Thus, the percentage of this hdRBC population was
determined over a 12-hour period in an in-vitro culture
of P. berghei pRBC. The results clearly show that the
inhibitory effect of chloroquine and quinine is detected
in a dose dependent manner throughout time (Figure 9).
Importantly, inhibitory effects were discernable after
only two hours for chloroquine and four hours for
quinine.
Discussion
Modification of flow cytometers
This study shows that a simple modification of a com-
mon flow cytometer for the detection of depolarized
Side-Scatter, allows the detection of Hz-containing leu-
kocytes and erythrocytes. In fact, a study using a
MoFlo® high speed cell sorter (Beckman Coulter, Inc,
Fullerton, CA), showed that depolarizing leukocytes did
contain Hz [20]. However, MoFlo® sorters are expensive
and sophisticated instruments, and by far not as com-
monly available as flow cytometers, which are even stan-
dard equipment in most research centres in malaria
endemic regions nowadays. Nonetheless, the widespread
incorporation of this method in common flow cyt-
ometers of major manufacturers has somehow been
hampered by the fact that the company of the Cell-
Dyn® instruments held the patent of this method (US
patent 5017497) [21]. However, this patent was filed in
1989 and published in 1991, and as such, according to
US legislation [22], it expired in March 2009. The neces-
sary filters and dichroic mirrors (Figure 1c) used to
change the CyFlow® cytometer were obtained for less
than €2.000. No special software is necessary and the
settings resemble those of the conventional SSC detec-
tion, albeit with an increased gain (voltage) of the detec-
tor. For the set-up in this study a 50%/50% beam
splitter used to divert the respective light to the depolar-
ized SSC and SSC detector (Figure 1, red error). Using a
90%/10% or even 95%/5% beam splitter may increase
the signal of the depolarized SCC, without decreasing
the quality of the SSC signal.
Any flow cytometer can be modified as described here.
However, it should be noted that to modify some flow
cytometers, which use fibre optic cables for light collec-
tion, for example, the newer Becton Dickinson instru-
ments (Franklin Lakes, NJ, USA), it is necessary to
confirm that these cables maintain polarization of the
light.
Detection and counting of Hz-containing leukocytes
Hz-containing monocytes and granulocytes could be
rapidly determined in fresh human or mouse blood as
well as in in-vitro phagocytosis experiments involving
whole blood or PBMCs. As has been pointed out before,
previous studies on the immunological effects of Hz in-
vitro used diverse quantities of Hz, different incubation
times, as well as different types of phagocytic cells [1,2].
Few studies quantified the uptake of Hz by monocytes,
although some used a luminescence assay after lysing













































Figure 5 CD16 expression on monocytes fed with different
types of haemozoin in-vitro. PBMCs were isolated from blood of a
healthy human volunteer and were incubated with synthetic Hz
(sHz) at 0.004 and 0.007 μmoles/ml heme equivalent and with
Plasmodium falciparum Hz (P.f.Hz) at 0.002 and 0.004 μmol/ml heme
equivalent. PBMCs incubated with latex beads and with no Hz were
used as controls. Cells were incubated for 6 hours and then labelled
with anti-CD14 and anti-CD16. The Geometric mean values for
expression of CD16 were calculated for non-Hz containing
monocytes (open bars) and Hz-containing monocytes (grey bars).
Differences between sHZ and P.f. were significant (P < 0.01). Shown
are values of triplicates (± one SD). Controls and beads had no
depolarizing populations.
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P. berghei ANKA P. berghei NK65 
Figure 6 Haemozoin containing leukocytes in two different mouse models of malaria. Groups with five C57BL/6 mice where infected with
P. berghei ANKA (PbA) or with P. berghei NK65 (PbNK). Blood was drawn on day 3, 5 12 and 18 and analysed after labelling with with anti-CD11b
and Gr1. Analyses and gating strategy is described in the text (additional file 1). Percentage of Hz-containing monocytes and granulocytes (top
graph) as well as parasitaemia are mean values per group (± one SD). Open bars = Hz-containing granulocytes; grey bars = Hz-containing
monocytes. Uninfected controls had no Hz-containing leukocytes and are not shown. Bottom graph shows proportion of different Gr1
expression (high = black, medium = grey; and low = light grey) of Hz-containing monocytes, shown in top figure. Percentages on x-axis
represent mean parasitemia. Mice with PbANKA infection were sacrificed on day 5.
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equivalents found in around 8-10 trophozoites per
monocyte [23]. However, even less studies mention the
percentage of Hz-containing monocytes. In one of these
studies confocal microscopy was used and showed that
75% (± 31%) of human PBMCs contained Hz after only
180 min, albeit only based on counting a total of ≥ 400
cells [11]. Contrary to this, the presented method allows
the analysis of ten-thousands of cells to determine
rapidly adequate doses of Hz and required incubation
times to get the desired percentage of Hz containing
leukocytes (Figure 3).
Furthermore, it allows to investigate Hz-containing
monocytes from malarious patients who usually have
only a few percent of these cells in circulation [3]. For
example, considering that in common protocols for the
analysis of whole blood, 100 μl are labelled, and further
assuming 1,000 monocytes/μl with only 5% of these
containing Hz, a total of 5000 Hz-containing cells could
be easily analysed using the flow cytometric method
proposed here. As previously reported [5,10], this
method also allows to re-address the question if the
number of Hz-containing leukocytes is associated with
disease severity or certain types of malaria.
In some studies, however, the identification of mono-
cytes was based on the typical monocyte gate in the For-
ward Scatter (FSC)/SideScatter (SSC) plot [16,20]. One
problem with this is that monocytes containing several
or larger Hz crystals might thus be excluded from analy-
sis as they have higher SSC and appear superimposed on
the granulocyte population (Figure 2), with a possible
impact on final results.
Single cell analysis for studies of Hz-containing
leukocytes
This may open the possibility to investigate functional
differences of Hz-containing and non-containing leuko-
cytes, especially in monocyte subsets found in fresh
human blood from malarious patients or in mouse mod-
els of malaria. For example, recent papers reported dif-































































Figure 7 Detection of haemozoin in P. berghei ANKA infected mouse RBC. Uninfected control (upper panel). Whole blood from a C57BL/6
mouse with a parasitaemia of 8.1% (lower panel). Gate to indentify the depolarizing events in the control (0.2% events) (B) and in the infected
mouse RBC (4.7% events) (D). Depolarizing events in this gate (D) were indentified as erythrocytes by anti-TER119 staining (> 97% positive) and
are shown as red dots in E. Colours in plots A-D represent frequency of events. In plot E colour backgating; with blue = TER119 positive events
without depolarization, red = TER119 positive events which depolarize; and green = any other event
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subsets in malarious patients [15,16], or in peripheral
blood dendritic cells in children [24]. Measurement of
depolarized Side-Scatter and, thus, identification of Hz-
containing cells might allow to establish if these cells
may have an imported role in the reported results. It
would also allow the possibility to study functionally
leukocytes on single cell level in-vitro, including surface
expression or intracellular cytokines, comparing Hz with
non-Hz containing leukocytes in the same cell popula-
tion. In fact, differences in CD16 expression in a mixed
population of Hz-containing and non-containing cells
were observed (Figures 4 and 5), a finding that differs
from a previous report that found no difference in
CD16 expression in an in-vitro model [25]. Despite
recent reports of differences between human and mouse
monocytes [26], the current method may also allow to
investigate the effects of Hz on phagocytic cells in fresh
blood using different mouse models (Figure 6).
First results (additional file 2) indicate that it appears
possible to detect tissue macrophages. This may allow
to compare Hz-containing and non-Hz-containing cells
from tissues such as spleen, liver or bone marrow which
may help to elucidate recent findings, for example, the
association of Hz with severe anaemia [27,28]. However,
the reliable identification of tissue macrophages may
require more than the two antibodies used in this study.
In this case, instruments that have several light sources
are necessary.
Detection of pRBC and sensitivity testing of antimalarious
drugs
Flow cytometric analysis of depolarized Side-Scatter
allows to easily detect pRBCs (Figure 7) and distinguish
different maturation stages of the parasite (Figure 8).
Both findings might serve as the basis for a novel drug
sensitivity assay. In fact, the idea to use Hz as a matura-
tion indicator is not new and was tried in a simple visual
agglutination test in the 1980s [17]. Apparently, this
method did not produce very reliable results, mainly due
to leukocyte interference [29]. However, these limitations
could be overcome by single-cell flow cytometric analysis.
Currently several drug sensitivity assays for P. falci-
parum exist and have been reviewed elsewhere [29,30].
Nonetheless, all of these assays have some disadvan-
tages, including long turn-around times or the need for
additional and often expensive reagents. Interestingly, a
recent report concluded that the reliability of some of
these assays may depend on the mode of action of the
tested drugs [31]. Flow cytometry appears to be a reli-
able technique to assess parasite maturation and sensi-
tivity to antimalarial drugs. However, protocols reported
so far require additional reagents, usually to stain DNA
and/or RNA and may even require flow cytometers with
more than one light source [32,33].
The presented method is based on the detection of
Hz, without the need of any further reagents. Determin-






































Figure 8 Degree of depolarization corresponds to different developmental stages of P. berghei ANKA. Blood from a C57BL/6 mouse with
a parasitaemia of 9.7% as determined by microscopy. Top plot shows several populations with decreasing degree of depolarization (A, B, C). Gate
D shows low or non-depolarizing events. The four histograms show the number of events (n) and their fluorescence intensity (x-axis) of SYBR
Green I, representing the DNA content. Gate D contains a population of 7.24% (arrow), likely including ring-forms with little Hz and thus very
low or no depolarization.
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present in blood samples from infected mice, it was pos-
sible to detect the inhibitory effect of chloroquine (CQ)
and quinine (Q) after only a few hours of in-vitro cul-
ture (Figure 9). In this study an experimental model
using C57BL/6 mice infected with P. berghei was chosen
to assure that only maturation of parasites was
measured, because P. berghei does not replicate in in-
vitro cultures [34]. However, although the preliminary
results seem promising, further work with different
drugs and, most importantly, P. falciparum cultures are
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Figure 9 Inhibitory effect of chloroquine and quinine on Hz containing parasites within unlysed RBC. Blood from PbA infected C57BL/6
mice with parasitaemias around 5% were incubated with different concentrations of chloroquine (upper graph) or quinine (lower graph). The
percentage of highly depolarizing events is shown (gate A in Figure 8). Each point represents the mean of triplicate measurements (± one SD).
CQ = chloroquine, Q = quinine.
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Conclusions
A simple modification of a flow cytometer allows the
reliable detection of Hz containing leukocytes and
pRBCs. This method facilitates the rapid and reliable
detection and counting of Hz-containing leukocytes in
human or animal blood. It also allows single cell analysis
of Hz-containing versus non-Hz-containing leukocytes
in the same sample, including functional analysis, both
in-vitro experiments or using fresh blood. Finally, it
detects different maturation stages of parasitized RBC
and may be the basis of a rapid no-added-reagent drug
sensitivity assay.
Additional material
Additional file 1: Description of flow cytometric gating strategy to
indentify Hz-containing mouse granulocytes and monocytes.
Additional file 2: Detection of Hz-containing mouse spleen
macrophages.
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a  b  s  t  r  a  c  t
Several  methods  based  on  the  detection  of  the  parasite-specific  pigment  haemozoin  (Hz)  in blood  are
currently  being  investigated  as  alternative  diagnostic  methods  for  malaria.  Although  this  approach  may
appear  attractive,  the fact  that  in Plasmodium  falciparum  (P.  f.)  malaria,  the  severity  of which  should  give  it
the  highest  diagnostic  priority,  the  fact  that  most  circulating  intra-erythrocytic  P. f. parasites  contain  little
or no  Hz  raises  some  concern.  We  used  flow cytometry  to  investigate  the  possibilities  and  limitations
of  the  detection  of  intra-erythrocytic  Hz in  malaria  infected  patient  blood  samples  and  in  vitro  cultures.
However,  reliable  detection  of  ring-forms  or  young  trophozoites  of  P.  f. parasites  could  not  be  achieved,
although  one-quarter  of  mature  parasites  could  be detected  after  24–48  h in  culture.  Our  results  strongly
suggest  that,  although  it may  be  useful  for  monitoring  maturation,  detection  of  intra-erythrocytic  Hz by
flow  cytometry  will  not  provide  an optimal  method  for diagnosis  of  P. falciparum  malaria.
© 2012 Elsevier B.V. All rights reserved.
1. Introduction
Haemozoin (Hz), an optically birefringent, paramagnetic pig-
ment (Hänscheid et al., 2007), is produced from haem by
intra-erythrocytic malaria parasites and is detectable at develop-
mental stages beyond the ring form. It can be visualized more
easily using polarization and/or darkfield microscopy, in some
instances using either minimally and inexpensively modified stan-
dard microscopes or other inexpensive optics (Jamjoom, 1983,
1988; Maude et al., 2009; Wilson et al., 2011). In recent years,
automation of this technology, sometimes combined with exploita-
tion of the magnetic properties of Hz (Mens et al., 2010), has
been advocated and supported as an approach to rapid and afford-
able malaria diagnosis, with the potential advantage of providing
reagent-free detection of a parasite-specific material.
Flow-cytometry of depolarized side scatter, employed in some
automated full-blood-count analysers (Cell-Dyn series; Abbott
Diagnostics, Santa Clara, CA) to count eosinophils, which have
birefringent granules, also detects Hz in monocytes and neu-
trophils that have phagocytosed parasitized erythrocytes or Hz.
Although the presence of such cells could diagnose malaria with
reported sensitivities from 49% to 100% in 13 reviewed studies
∗ Corresponding author at: Instituto de Medicina Molecular, Faculdade de
Medicina de Lisboa, Av. Prof. Egas Moniz, P-1649-028 Lisboa, Portugal.
Tel.: +351 217999458; fax: +351 217999459.
E-mail address: t.hanscheid@fm.ul.pt (T. Hänscheid).
(Campuzano-Zuluaga et al., 2010), it is known that Hz-containing
phagocytes may  be found in blood for days after an acute infection
is cured.
The sensitivity of Hz detection for malaria diagnosis, especially
in infected erythrocytes, depends on two main factors: (i) the total
parasitemia and (ii) the amount of Hz present inside the individ-
ual parasites. The latter is strongly dependent on the distribution
of developmental stages; immature forms, i.e., rings and young
trophozoites, contain little if any detectable Hz. That this could be
a limitation for Hz microscopy was noted by Jamjoom (1988);  it
is of particular concern with respect to Plasmodium falciparum (P.
f.) malaria, in which trophozoites and schizonts are removed from
blood by binding to endothelial cells.
Since P. f. causes the vast majority of malaria deaths, its rapid
diagnosis is critical, and it would be desirable to establish how well
a method based on Hz-detection might work in typical clinical sam-
ples, which contain few if any mature parasites. For this, a flow
cytometry Hz detection method was  used (Frita et al., 2011).
2. Material and methods
Reagents were obtained from Sigma–Aldrich (St. Louis, MO,
USA), unless stated otherwise.
The P. falciparum 3D7 strain was  used. Although, this strain has
a slow growing nature no difference in haemozoin morphology
is observed between different P. falciparum clones (Noland et al.,
2003). Briefly, the P. f. 3D7 strain was  grown in recently collected
0001-706X/$ – see front matter ©  2012 Elsevier B.V. All rights reserved.
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Fig. 1. Growth curve of P. falciparum (3D7) in culture. The primary Y-axis (left-hand) corresponds to the percentage of depolarizing events and the secondary Y-axis (right-
hand)  corresponds to the percentage of SYBR green positive cells. The percentage of depolarizing (red lines) and SYBR green positive events (green lines) were followed for
48  h in non-infected (dotted lines) and Plasmodium falciparum infected RBC cultures (solid lines). The initial parasitemia was  1.3% (secondary Y-axis), while the corresponding
depolarizing events were only 0.07% (primary Y-axis), at 0 h of incubation. Each time point represents the mean value of triplicate samples ± one SD. Red blood cell lysis
was  excluded by total cell counts. The pictures are representative of the parasite stages found at each time point. Within the first 6 h the amount of haemozoin inside intra-
erythrocytic parasites, which are the ring forms predominant in the peripheral circulation of patients, is very low (dotted rectangle). (For interpretation of the references to
color  in this figure legend, the reader is referred to the web  version of the article.)
donor erythrocytes in RPMI based complete malaria culture
medium (CMCM) according to the recommendations of Malaria
Research and Reference Reagent Resource Center (MR4) (Mphande
et al., 2008).
As uninfected controls, erythrocytes from healthy donors were
cultured as described above. Cultures were maintained at 5% hema-
tocrit at 37 ◦C in an atmosphere of 5% CO2. The culture was
synchronized to ring stages by incubating the red blood cell cul-
ture with 5% sorbitol for 10 min, at room temperature (Lambros
and Vanderberg, 1979).
After one further life cycle (48 h) parasitemia and hematocrit
were adjusted to approximately 1% and 2.5%, respectively and the
culture incubated as described above. Measurements were done at
6-h intervals during 48 h. For each measurement 5 !l of the cul-
ture was stained with the highly DNA-specific dye SYBR green I
(Invitrogen, Carlsbad, USA) at 1×. After 20 min  of incubation, the
stained sample was immediately analysed using a CyFlow flow
cytometer with 488 nm excitation and detectors for Forward Scat-
ter, Side-Scatter (SSC), depolarized SSC and green fluorescence
(FL1), as described elsewhere (Frita et al., 2011). Parasitemia was
also assessed by microscopic observation of Giemsa-stained thin
blood smears.
EDTA anticoagulated blood was obtained from patients with
microscopy confirmed P. f. malaria from the adjacent hospital,
stained with SYBR green I at 1× and analysed. The study was
approved by the local Ethics Committee.
3. Results
Growth curves for SYBR green I and Hz detection are shown
in Fig. 1, representative of six separate experiments performed in
triplicate. The percentage of parasites, as determined with SYBR
green, remained stable during the first 30 h and increased only
after RBC invasion by the second generation of parasites. Contrary
to this, the percentage of parasites as determined by Hz-detection
remained very low, at around 0.07% during the first 6 h of incuba-
tion. The maxima of Hz-containing parasites were detected at 24 h
and 30 h, although they only represented 20% and 9% of all parasites,
respectively, as determined by SYBR-green.
Fig. 2 shows samples from a healthy donor, a P. f. malaria-
infected patient, and a ring form-synchronized P. f. culture. It is
noteworthy that only 2.2% of SYBR green positive events in the cul-
ture showed depolarization indicating the presence of Hz. In ten
blood samples from patients with P. f. malaria only immature forms
were found as confirmed by microscopic observation of Giemsa-
stained blood smears. In all the cases with young trophozoites being
the most mature forms seen. Parasitemias in these samples ranged
from 0.5% to 7.0% and no depolarizing events which were also SYBR
green positive could be detected above the background (Fig. 2).
However, incubating three patient samples for 48 h allowed the
detection of a maximum of 2.72% depolarizing events, representing
38% of the SYBR green positive population.
4. Discussion
Although depolarized SSC may  be able to detect around one-
quarter of mature P. f. parasites in culture after 24–48 h of
incubation, using the 3D7 laboratory strain or patient blood, it
appears difficult if not impossible to reliably detect young imma-
ture P. f. either in culture or in patient blood using flow cytometric
detection of Hz alone on a single cell level (Fig. 2). Thus, optical
methods such as the investigated flow cytometric one or those
based on Hz microscopy will almost certainly suffer from low sen-
sitivity in the detection of P. falciparum malaria, unless additional
characteristics of parasites (e.g., DNA content, as in our study) as
well as Hz are examined.
The relatively complex magneto-optical (MOT) method (Mens
et al., 2010) is said to be capable of detecting haemozoin levels cor-
responding to 50–100 parasites/!L.  When applied to 86 known P.
f. – positive patient samples with parasitemias ranging from 600 to
85,000/!L, found 65 (77.4%) as positive, but failed to detect Hz in
the remaining 19, with parasitemias between 5680 and 78,000/!L.
These levels are at least ten times higher than the lowest para-
sitemias (200–500/!L) reported detectable by thin film Giemsa
(Ohrt et al., 2008) and fluorescence microscopy (Lenz et al., 2011).
It is not clear that more complex and expensive Hz detec-
tion methodology (Scholl et al., 2004; Nyunt et al., 2005; Bélisle
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Fig. 2. Detection of immature P. falciparum forms. Flow cytometric analysis of uninfected RBC from healthy donor (a), ring-stage synchronized Plasmodium falciparum (P. f.)
culture (b), and a patient blood sample with 7% P. f. parasitemia before (c) and after 48 h of incubation (d). The parasite developmental stages present in the patient blood
sample were confirmed by microscopy as being ring-form parasites (c). The gate was  optimized to select for depolarizing cells above background. SYBR green was  used to
stain  parasites (green dots), which are absent in the uninfected sample and could only be found below the gate in the patient blood sample. In the ring-stage synchronized
P.  f. culture only a small percentage (2.2%) of SYBR green positive cells showed depolarized SSC. In the patient blood sample this percentage was the same as the uninfected
control.  Only after 48 h of incubation this percentage increased to 38%. *Percentage in brackets represents SYBR green positive events (parasites) which depolarize. (For
interpretation of the references to color in this figure legend, the reader is referred to the web version of the article.)
et al., 2008; Karl et al., 2011), more difficult to adapt to field
conditions, could improve sensitivity. Of course, all the Hz-based
methods may  work for the detection of non-falciparum strains,
where mature forms with abundant Hz are present in circulation,
as do flow cytometry based haematology analysers (Campuzano-
Zuluaga et al., 2010).
An ideal novel method ought to detect all clinically relevant
malaria cases and thus, likely detect parasitemias below the thick
blood film. Furthermore it should be rapid, robust and easy, allow
parasite quantification and, ideally, speciation. The cost ought to be
in the range or below low-cost Rapid-Diagnostic-Tests.
With respect to P. falciparum malaria, Hz-detection methods,
used alone or combined with other cytometric parameters, may
provide a sensitive means of monitoring the maturation of these
parasites (and those) of other species, which may  be useful in non-
diagnostic applications such as monitoring of antimalarial drug
effects, as we recently reported (Frita et al., 2011).
In conclusion, Hz detection methods may  not be the ideal
approach for a novel test to diagnose P. falciparum malaria due to
the low content of Hz in circulating immature forms. Neverthe-
less, the multiparameter cytometric methodology used to date with
flow cytometers is also now readily transferable to simpler, less
expensive widefield imaging cytometers (Shapiro and Perlmutter,
2006; Shapiro and Ulrich, 2010). Thus, we suggest that further
investigation along these lines is at least as likely to yield useful
and affordable diagnostics, especially for P. f., as is continued work
focused solely on Hz detection, particularly in parasitizes erythro-
cytes.
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Abstract
Resistance of Plasmodium falciparum to almost all antimalarial drugs, including the first-line treatment with artemisinins, has
been described, representing an obvious threat to malaria control. In vitro antimalarial sensitivity testing is crucial to detect
and monitor drug resistance. Current assays have been successfully used to detect drug effects on parasites. However, they
have some limitations, such as the use of radioactive or expensive reagents or long incubation times. Here we describe a
novel assay to detect antimalarial drug effects, based on flow cytometric detection of hemozoin (Hz), which is rapid and
does not require any additional reagents. Hz is an optimal parasite maturation indicator since its amount increases as the
parasite matures. Due to its physical property of birefringence, Hz depolarizes light, hence it can be detected using optical
methods such as flow cytometry. A common flow cytometer was adapted to detect light depolarization caused by Hz.
Synchronized in vitro cultures of P. falciparum were incubated for 48 hours with several antimalarial drugs. Analysis of
depolarizing events, corresponding to parasitized red blood cells containing Hz, allowed the detection of parasite
maturation. Moreover, chloroquine resistance and the inhibitory effect of all antimalarial drugs tested, except for
pyrimethamine, could be determined as early as 18 to 24 hours of incubation. At 24 hours incubation, 50% inhibitory
concentrations (IC50) were comparable to previously reported values. These results indicate that the reagent-free, real-time
Hz detection assay could become a novel assay for the detection of drug effects on Plasmodium falciparum.
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Introduction
Resistance of Plasmodium falciparum to almost all antimalarial
drugs has been observed [1]. In fact, resistance to commonly
effective and useful drugs such as chloroquine or sulfadoxine/
pyrimethamine has severely compromised their use for malaria
control [2]. Alarmingly, resistance to the currently used first-line
treatment compounds, the artemisinins, characterized by a
prolonged parasite clearance time [3], has already been reported
from South-East-Asia. Consequently, detection and monitoring of
drug resistance is of paramount importance.
Traditionally, therapeutic efficacy trials are the gold standard
for assessing parasite response to antimalarial drugs. The obvious
complexity of these trials led to the development of in vitro assays
[4]. The major in vitro phenotypic assays include the WHO
schizont maturation microtest [5], the isotope ([3H]-hypoxan-
thine) incorporation assay [6], the detection of the parasite
antigens pLDH [7] or HRP2 [8] by ELISA, and assays using
fluorescent DNA dyes, such as SYBR green I [9], YOYO [10],
PicoGreen [11] and DAPI [12] with either spectrophotometric or
cytometric readout (Table S1).
The development of novel antimalarial compounds hinges on
assays to determine the inhibitory effects of drugs on the parasite
[13]. Although all these assays have been successfully applied to
detect drug effects on the parasite, they all have relevant
limitations. For example, the WHO microtest is based on the
tedious and subjective microscopic observation of parasite
maturation [14]. The [3H]-hypoxanthine assay requires expensive
equipment as well as complex isotope handling precautions and
radioactive waste management [6]. All these assays require
reagents for parasite detection that are often rather expensive
and frequently require a cold chain. Importantly, they also need
incubation times of 48 up to 96 hours to reliably detect drug
effects [15].
Molecular methods are highly desirable, because they do not
depend on viable parasites and have the capacity to provide rapid
results. Their major drawback is the limited number of known and
validated resistance markers [4]. It is important to note that there
is currently no specific in vitro test to identify artemisinin resistance,
as stated by an expert panel in the WHO Global Plan for
Artemisinin Resistance Containment (GPARC) [16].
In this scenario, alternative assays that may overcome the
limitations previously mentioned are highly desirable. An assay
that would not only allow real-time determination of drug effects
during a single parasite cycle but could also detect drug effects in a
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second or even third cycle would certainly be a useful tool,
permitting the assessment of inhibitory effects of drugs with
different times of action.
Malaria pigment, i.e., hemozoin (Hz), is produced in increasing
amounts by the parasite during the erythrocytic cycle and,
therefore, constitutes an ideal maturation indicator. Hz, the end
product of plasmodial hemoglobin metabolism, has been identified
as an important modulator of the host’s immune response to
Plasmodium spp., as a marker for disease severity and prognostic
factor for disease outcome, and also as an adjuvant diagnostic tool,
of particular use regarding the non-immune traveler [17–19]. Hz
depolarizes light and can be easily detected thereby without
reagents by optical methods including dark-field microscopy [20],
polarization microscopy [21] and flow cytometry [22].
In 1999, a study reported that the flow cytometry based full-
blood-count analyser, Cell-DynH (Abbott, Santa Clara, CA), could
detect Hz within leucocytes [23]. More importantly, studies
reported that the Cell-DynH seemed to detect Hz inside
parasitized red blood cells (RBC) [24], [25]. Based on the flow
cytometric detection of depolarized side scatter [26], as used in the
Cell-DynH, we showed that Hz could be detected inside
parasitized RBC in P. berghei infected rodents [27]. Moreover, in
vitro parasite maturation, as well as the inhibitory effect of
chloroquine and quinine, could be detected after only 6 hours of
incubation [27]. Later, we showed that maturation of P. falciparum
in culture could also be determined [28].
Our present data show how flow cytometric detection of Hz can
be used as a novel, reagent-free, real time assay to assess
antimalarial drug effects on P. falciparum.
Methods
All reagents were obtained from Sigma Aldrich (St Louis, Mo,
USA), unless stated otherwise.
Flow cytometer modification (depolarized side scatter
detection)
The CyflowH Blue (Partec, Münster, Germany) is a portable
(Figure S1), five parameter flow cytometer with blue laser (488 nm)
excitation, and detectors for forward scatter (FSC), side scatter
(SSC), green fluorescence (FL1), orange fluorescence (FL2) and red
fluorescence (FL3). For this study the set-up was modified as
described elsewhere [27]. Briefly, two SSC detectors were created,
with a 50%/50% beam splitter between them. Then a polarization
filter was placed orthogonally (horizontal) to the polarization plane
of the laser light (vertical), in front of one of the SSC detectors,
allowing the detection of depolarized side scatter (Figure S1). The
CyflowH is equipped with an absolute cell count method (http://
www.partec.com/instrumentation/flow-cytometry.html, accessed
3/8/2012), which allows determination of the number of particles
in 200 ml of sample. Absolute counts were performed for all
experiments to control for possible red blood cell lysis.
Microscopy
Parasitemia, parasite maturation and the synchronicity of
parasites in culture were assessed by light microscopic examination
of Giemsa-stained blood smears. Air-dried blood smears were
fixed in absolute methanol and stained with Giemsa (Merck,
Darsmstadt, Germany) in a 1:10 dilution in PBS 16, for
20 minutes.
Plasmodium falciparum continuous cultures
The Plasmodium falciparum resistant (Dd2) and susceptible (3D7)
strains were grown in recently collected donor erythrocytes in
RPMI based complete malaria culture medium (CMCM) accord-
ing to the recommendations of the Malaria Research and
Reference Reagent Resource Center (MR4) [29]. Cultures were
maintained at 5% hematocrit, at 37uC in an atmosphere of 5%
CO2. As uninfected controls, erythrocytes from healthy donors
were cultured as described above.
Synchronizing Plasmodium falciparum continuous
cultures
Continuous cultures of P. falciparum were cultivated until they
reached a parasitemia of .2% with a minimum of 50% rings.
They were synchronized by adding 5% sorbitol for 10 minutes at
room temperature as described elsewhere [30]. Briefly, the culture
medium was washed away by centrifuging the culture at
1800 rpm, for 5 minutes. Next, 10 mL of 5% sorbitol was added
to the pelleted red blood cells and incubated for 10 minutes, at
room temperature. Cultures were washed twice in PBS 16 by
centrifugation at 1800 rpm, for 5 minutes. Finally, CMCM was
added to the pelleted cells, and the synchronized culture was
incubated for another 48 hours, at 37uC in a 5% CO2
atmosphere.
Hemozoin detection sensitivity assay
Ring-stage synchronized cultures (at least 90% of ring forms) at
2.5% hematocrit and at approximately 1% parasitemia were
incubated with antimalarial drugs or with CMCM (used for the
drug free and uninfected controls) in 24 or 96 well-plates, for
48 hours, at 37uC in a 5% CO2 atmosphere.
Quinine, chloroquine, mefloquine, artemisinin, artesunate, and
pyrimethamine were purchased from Sigma Aldrich (St Louis,
Mo, USA). NITD246 was kindly provided by Dr. Bryan Yeung
from the Novartis Institute for Tropical Diseases, Singapore. Stock
solutions of chloroquine and quinine were prepared in distilled
water, artemisinin and mefloquine in pure methanol (Merck,
Darmstadt, Germany), pyrimethamine in absolute ethanol (Merck,
Darmstadt, Germany), artesunate in 70% ethanol and NITD246
in pure DMSO.
Doubling concentrations ranging from 6 to 200 nM for
chloroquine, 10 to 160 nM for mefloquine, 12 to 200 nM for
pyrimethamine and 4 to 64 nM for artesunate and artemisinin
were tested. For NITD246 concentrations of 0.1, 0.2, 1 and 2 nM
were used, while for quinine concentrations of 3, 12, 50, 200 and
800 nM were tested.
For each flow cytometric measurement approximately 100,000
events were analyzed. A volume of 5 mL of the blood suspension
present in the wells was stained with SYBR green 16, as described
below. To determine the best time point for IC50 calculation,
measurements were done at 6 hour intervals over 48 hours for the
majority of the drugs tested, except for pyrimethamine which was
measured again at 72 hours. All samples were analyzed in
triplicate and, for each drug, at least three different experiments
were performed. In order to investigate possible inoculation
effects, artesunate and artemisinin were also investigated at a lower
parasitemia of 0.4 and 0.7%, respectively.
To assess if renewing artesunate would influence its effect on
parasite growth, cultures were washed and fresh artesunate, at a
concentration of 8 nM, was added every 12 hours, during
48 hours of incubation.
To investigate the detection limit of the novel Hz assay, ring-
stage synchronized cultures with parasitemias of 0.05%, 0.1%,
0.3%, 0.5%, 0.6% and 1% were incubated for 48 hours.
Finally, to assess the performance of the Hz assay with low
parasitemias, ring-stage synchronized cultures at 0.3% parasitemia
were incubated for 72 hours with increasing concentrations of
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chloroquine, artesunate and pyrimethamine (as mentioned above).
Flow cytometric analysis was performed in 24 hours intervals.
SYBR green I staining
For each measurement 5 ml of the culture (approximately
800 000 cells) was stained with the DNA-specific dye SYBR green
I (Invitrogen, Carlsbad, USA) at 16. After 20 minutes of
incubation, in the dark, the stained sample was immediately
analyzed by flow cytometry using a 535/45 nm bandpass filter in
front of the detector.
CD235 (glycophorin A) staining
A volume of 10 mL of a continuous P. falciparum culture, at 5%
hematocrit, was transferred into a well of a 96 well plate, washed
in cold FACS buffer (PBS 16and 2% bovine albumin serum) and
then centrifuged at 1400 rpm, for 3 minutes at 4uC. A volume of
50 mL of a 1:500 dilution of CD235-Phycoerythrin antibody
(eBioscience, San Diego, US) was added to the cells and incubated
for 20 minutes on ice in the dark. After a final wash, the cells were
re-suspended in PBS 16 and analyzed by flow cytometry using a
610 nm long-pass filter.
Flow cytometric analysis
Flow cytometry results were analyzed using FlowJo software
(version 9.0.2, Tree Star Inc., Oregon, USA). The gating scheme
used is shown in Figure 1. The red blood cells in uninfected and
infected samples were detected by their characteristic forward
(FSC) and side scatter (SSC) properties (Figure 1A and 1B).
Staining with the anti-glycophorin A CD235 antibody was used
to establish that all events detected represented red blood cells.
The antibody was not used for routine analyses.
Depolarizing events were defined in plots of SSC versus
depolarized-SSC as those with a signal above the background
observed in the uninfected control (Figure 1C and 1D).
To determine SYBR green I positive cells, green fluorescence
(FL1) versus red fluorescence (FL3) plots were used; these provide
better separation between weakly stained and autofluorescent cells
than can be obtained from one-dimensional histograms. SYBR
green I positive events (Figure 1F) were established based on a
stained uninfected control (Figure 1E) and had to be adjusted at
each time point, always using the uninfected SYBR green stained
sample from the corresponding time point.
Histidine-rich protein-2 (HRP2) sensitivity assay
A histidine-rich protein-2 (HRP2) enzyme-linked immunosor-
bent assay (ELISA) was established and performed according to
standard procedures [8], also available on the internet website:
malaria.farch.net. (http://www.meduniwien.ac.at/user/harald.
noedl/malaria/ assessed 3/8/2012)
Ring-stage synchronized P. falciparum cultures, at an initial
parasitemia of 0.05% and at 1.5% hematocrit, were incubated
with the antimalarial drugs for 72 hours, at 37uC in a 5% CO2
atmosphere. At the end, samples were frozen at 220uC until the
HRP2 ELISA assay was performed.
Briefly, after two freezing and thawing cycles, 100 mL of the
lysed sample was transferred to a 96 well-plate pre-coated with
MPFM-55A antibody (Immunology Consultants Laboratories,
Portland, USA) and incubated for one hour. The cells were
washed three times and then incubated for another hour with the
secondary antibody, MPFG-55P (Immunology Consultants Lab-
oratories, Portland, USA). Cells were washed again and incubated
for 5–10 minutes with the chromogen, TMB One (Biotrend, Köln,
Germany). The reaction was stopped by adding sulphuric acid at
1 M (Merck, Darmstadt, Germany) and the absorbance was
immediately determined using the Infinite M200 plate reader
(Tecan, Männedorf, Switzerland), at a wavelength of 450 nm.
To assess a possible inoculum effect of artemisinin, the HRP2
assay was also performed using a parasitemia of 1%.
Data analysis
A nonlinear regression model (sigmoidal dose-response/variable
slope) was used to calculate the IC50s, with SigmaPlot - Systat
Software (Chicago, IL, USA).
Results
Depolarized side scatter detects parasitized red blood
cells
Staining with the red blood cell surface marker (CD235)
antibody was used to establish that the events detected represented
red blood cells. Figure 1G shows that 99.5% of events detected are
red blood cells. Representative dot plots of side scatter versus
depolarized side scatter are shown in Figure 1C and 1D. At
24 hours of incubation, depolarizing events were very low in the
uninfected control (0.027%) (Figure 1C), but could easily be
detected (0.46%) in the infected blood sample (Figure 1D). The
depolarizing events present in the infected sample were also
positive for SYBR green I. Analysis of SYBR green I fluorescence
intensity showed that the majority of these depolarizing events
(79.4%) had high fluorescence (pink line in Figure 1H) indicating
high DNA content and thus, represented parasitized red blood
cells with mature parasites.
All subsequent results reported in this paper are based on the
depolarizing events expressed as a percentage of all events
analyzed.
Depolarized side scatter detects parasite maturation
We next sought to establish whether this type of analysis
would discriminate among different Plasmodium falciparum stages.
To that end, samples of 100,000 events were analyzed.
Determination of the absolute number of cells at each time
point showed no evidence for red blood cell lysis. Following the
percentage of depolarizing events during 48 hours of incuba-
tion, in a ring-stage synchronized culture (1.4% parasitemia),
showed an increase at 18 hours, with a peak at 30 hours and a
subsequent decrease (Figure 2A). The same sample stained with
the DNA stain, SYBR green I, showed no change in the
percentage of fluorescent events until 30 hours, followed by a
steady increase until 48 hours (Figure 2B). Observation of
Giemsa stained blood smears at all time points showed parasite
maturation until 30 hours, which coincided with the peak of
depolarizing events. Thereafter, from 36 to 48 hours, immature
forms were observed, coinciding with a decrease of depolarizing
events and an increase of fluorescent events (Figure 2). These
changes reflect parasite growth with the 30 hour peak of
depolarization corresponding with the peak of maturation, after
which erythrocytes rupture and daughter-merozoites are
released along with Hz, explaining the decrease in depolarizing
events and the increase in SYBR green I fluorescent events,
observed after 30 hours.
The increase in the percentage of depolarizing events over time
and the inhibitory effect of chloroquine, artesunate and pyrimeth-
amine could be detected at parasitemias down to 0.3%. At lower
parasitemias (0.05 and 0.1%) no clear increase above the
background could be detected during the first 48 hours of
incubation.
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Detection of inhibitory effects of chloroquine on
sensitive (3D7) and resistant (Dd2) P. falciparum strains
Using a chloroquine sensitive strain (3D7), the difference
between inhibiting and non-inhibiting concentrations was clearly
visible after 18 hours, with the largest difference observed at
30 hours (Figure 3A). The first sign of drug effect could be
consistently detected at 18 hours, where at concentrations of 6 and
12 nM a percentage of 0.1% depolarizing events were observed,
while at 25, 50 and 100 nM only 0.004% were detected
(Figure 3A).
In the resistant P. falciparum strain (Dd2), chloroquine resistance
could clearly be detected at 18 hours after drug exposure, with
growth curves of all concentrations following the drug free control
(Figure 3B). At this time point (18 hours), in all drug concentra-
tions around 0.1% depolarizing events were observed, compared
to the 0.01% seen at the beginning of the incubation (Figure 3B).
Detection of inhibitory effects of other antimalarial drugs
Representative growth curves in the presence of different
concentrations of quinine, mefloquine, artemisinin and the
spiroindolone NITD246 are shown in Figure 4. The curves for
artesunate are shown in Figure 5 and those for the slow acting
drug, pyrimethamine, are shown in Figure 6. As was the case with
chloroquine, inhibitory concentrations showed a clear effect from
18 hours onwards in three different compound classes: quinolones
(quinine and mefloquine), endoperoxides (artemisinin and artesu-
nate) and a spiroindolone (NITD246).
Interestingly, artemisinin showed a delayed growth curve at
the 32 nM concentration in comparison to the drug free control
(Figure 4C). The same was observed for artesunate at a lower
concentration of 4 nM (Figure 5A). Of note, the artesunate
growth curve at an intermediate concentration of 8 nM showed
an initial inhibition with a delayed rise starting after 30 hours
and an absence of the typical peak at 24–30 hours (Figure 5A
and B). By renewing the artesunate every 12 hours in the culture
medium, this delayed rise was lost and the initial inhibition was
maintained throughout the 48 hours of incubation (Figure 5B).
In both cases, however, the percentage of SYBR green I positive
events remained largely unchanged over the 48 hours of
incubation, indicating absence of parasite replication
(Figure 5C). The parasites, previously treated only once with
artesunate at 8 nM, were also re-cultured and observed for
growth during four days. No growth was detected during these
four days, as confirmed by flow cytometry, nor was an increase
in either depolarization or SYBR green percentage and intensity
observed.
Figure 1. Gating for detection of depolarizing parasitized red blood cells in a Plasmodium falciparum culture. Flow cytometric analysis of
an uninfected and a synchronized P. falciparum (3D7) infected culture (1.5% parasitemia) after 24 hours of incubation, stained with SYBR green I. Plots
of forward vs. side scatter for the uninfected and infected cultures appear in Figures A and B; corresponding plots of side scatter vs. depolarized side
scatter appear in Figures C and D. The gates in Figures C and D identify the depolarizing events. Figures E and F (see text) illustrate gates defining
SYBR green-positive parasitized cells. The blue dots on Figure F represent the depolarizing events. Staining with the red blood cell surface marker
(CD235) shows that 99.5% of events in a stained sample (red line) exhibit fluorescence above the highest level measured in an unstained control
(black line), indicating that the detected events are red blood cells (G). In the SYBR green I histogram (H) of the infected culture, the overall
population (black line) shows a distinct peak with a high fluorescent intensity in the third decade. This peak corresponds mainly to the gated
population of depolarizing events (pink line). Because SYBR green I intensity correlates with DNA content and thus with parasite level of maturation,
the depolarizing population (pink line) consists mainly (79.4%) of mature parasites. The highly red- and green-fluorescent events visible outside the
SYBR green gate just to the right of its apex represent contaminating white blood cells among the donor red cells.
doi:10.1371/journal.pone.0061606.g001
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Inhibitory effect of slow-acting drugs (pyrimethamine)
Pyrimethamine (Figure 6A and B) required an incubation time
of 72 hours to reliably detect drug effects (Figure 6B). Interestingly,
while concentrations of 12 to 50 nM followed the drug free
control, the curve of 100 nM showed slightly higher values from
30–48 hours, while the highest concentration of 200 nM showed a
marked increase of depolarizing events and a delayed peak at
36 hours, with twice as many events (Figure 6A).
Figure 2. Growth curves of Plasmodium falciparum (3D7) in culture. Flow cytometric analysis of a synchronized P. falciparum (3D7) culture
(1.4% parasitemia). The percentages of depolarizing events (A) and SYBR green I positive events (B) were followed for 48 hours in uninfected (black
lines in A and B) and infected red blood cells (red line in A and green line in B). Analysis of depolarizing events (Hz-containing parasitized
erythrocytes) shows an increase at 18 hours, peaking at 30 hours (A). SYBR green I positive events (parasitized RBC) remain unchanged at 1.4% until
30 hours, after which a steady increase can be noted (B). Hz detection reflects parasite maturation with increasing amounts of Hz until 30 hours,
while the parasitemia remains unchanged (SYBR green I positive events). After 30 hours, increasing SYBR green I positive events indicate replication
and presence of immature forms, which explains the decrease observed in the depolarizing population. Each time point represents the mean value of
triplicate samples 6 one SD. Red blood cell lysis was excluded by absolute cell counts, which remained stable.
doi:10.1371/journal.pone.0061606.g002
Figure 3. Effect of chloroquine on the growth curve of P. falciparum sensitive and resistant strains. Synchronous cultures of sensitive
(3D7, parasitemia of 1.3%) and resistant (Dd2, parasitemia of 1.4%) P. falciparum strains were incubated for 48 hours with doubling concentrations of
chloroquine and analyzed at 6 hourly intervals. The inhibitory effect of chloroquine at higher concentrations (.25 nM) is clearly visible (arrow) after
18 hours of incubation (A). The resistant strain can easily be distinguished from the sensitive strain with growth curves of all drug concentrations
being identical to the drug free control (B). Each time point represents the mean value of triplicate samples 6 one SD.
doi:10.1371/journal.pone.0061606.g003
Hemozoin Detection for Malaria Sensitivity Testing
PLOS ONE | www.plosone.org 5 April 2013 | Volume 8 | Issue 4 | e61606
IC50 values obtained by the Hemozoin detection assay
are comparable with other available assays
To determine the earliest time-point that would allow us to
reliably calculate IC50 values, results obtained from the Hz
detection assay at different time-points (18, 24, 30 and 36 hours)
(Table 1) were compared with those reported in the literature
(Table S2), as well as with results from the already validated HRP2
ELISA assay (Table 2). This analysis led us to use the 24 hour time
point for all subsequent IC50 calculations. The IC50 results for
our Hz assay and the HRP2 assay are shown in Table 2.
Concerning the inoculum effect, no reliable results could be
obtained with the HRP2 assay at a parasitemia of 1%, because no
differences were observed between the drug treated samples and
the drug free control. Using a lower parasitemia in the Hz assay,
discrepant results were observed for artemisinin and artesunate:
while the IC50 of artesunate remained the same (4 nM) at a
Figure 4. Effect of quinine, mefloquine, artemisinin and a spiroindolone (NITD246) on the growth curve of P. falciparum (3D7).
Synchronous cultures of a P. falciparum 3D7 strain were incubated for 48 hours with increasing concentrations of quinine (A), mefloquine (B),
artemisinin (C) and NITD246 (D). In all cases the dose-dependent inhibitory effect of the drugs could already be detected at 18 hours by comparing
the treated samples (solid lines) with the drug free control (dotted red line). The curves allowed the determination of IC50 values at 24 hours. Of note,
artemisinin at 32 nM showed a 6 hour delayed growth curve, from 18 to 42 hours, with the peak of maturation occurring at 36 hours. Each time
point represents the mean value of triplicate samples 6 one SD. DF ctrl – drug free control; UI ctrl – uninfected control.
doi:10.1371/journal.pone.0061606.g004
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parasitemia of 1.3% and 0.4%, the IC50 value for artemisinin
decreased from 32 nM at 1.0% parasitemia to 13.2 nM at a
parasitemia of 0.7%.
Discussion
This study confirms that the optical detection of Hz can be
easily achieved by a simple adaptation of a common flow
cytometer to allow detection of light depolarization (Figure S1).
This study also extends observations [27] that maturation of P.
falciparum and inhibitory antimalarial drug effects can be assessed
by the detection of Hz inside intra-erythrocytic parasites. Although
this novel approach is based on previous observations that Hz in
parasitized RBC could be detected by flow cytometric methods
[24], [27] it should be noted that the idea of using Hz for a
sensitivity assay is not new and was described in the 1980s [31].
Figure 5. Effect of artesunate on the growth curve of P. falciparum (3D7) and the effect of 12 hourly renewing of artesunate during
incubation. Synchronous cultures of a P. falciparum 3D7 strain were incubated for 48 hours with doubling concentrations of artesunate (A) or with a
single concentration of 8 nM of artesunate for the whole time or renewed at 12 hour intervals (B and C). Figures A and B show detection of Hz
(depolarizing events) while Figure C shows detection of SYBR green I fluorescence (DNA in parasites). The inhibitory effect of artesunate was already
detectable after 18 hours of incubation (A). Similar to artemisinin (Figure 4C), the growth curve of artesunate at 4 nM showed a 6 hourly delayed
growth curve from 18 to 42 hours, including a 6 hour delay in the peak, occurring at 36 hours. Interestingly, the growth curve at 8 nM seemed to
show inhibition until 30 hours, when a slight increase was observed (A and B). However, renewing artesunate at 12 hourly intervals eliminates this
effect (green line in B). The percentage of SYBR green I positive events remained approximately the same during the 48 hours of incubation (C). This
indicates that parasites at the non-renewed 8 nM concentration showed some maturation as indicated by Hz detection but were unable to replicate.
Each time point represents the mean value of triplicate samples 6 one SD.
doi:10.1371/journal.pone.0061606.g005
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However, the assay format used a visual readout and appears to have been rather inaccurate because of nonspecific agglutination
[32]. Recently, an improvement of this approach has been
reported where the Hz produced is measured by a colorimetric
method [33]. To do this, the Hz produced by the parasites after
72 hours of incubation is liberated and transformed back into
heme before reading the absorbance at 405/750 nm. However,
the assay involves multiple manipulation steps, including lysis and
several washing steps, which are cumbersome and may introduce
variability. In fact, in our hands, the isolation of Hz and
quantification of heme requires meticulous attention to accurate
pipetting to guarantee reproducible results [34].
Depolarization signal strength and detection limit
The comparison of an uninfected RBC sample with a
synchronized P. falciparum infected RBC sample at 24 hours of
incubation showed a depolarizing population that could be easily
identified and gated (Figure 1D). However, the degree of
depolarization of the whole population was much lower than
previously described for P. berghei infected blood samples [27]. A
possible explanation for this may be different side scatter signals,
which are a measure of cell granularity [35], that could be caused
by the different shape and distribution of the Hz crystals within
these parasites. A parasite containing several small but distributed
Hz crystals will have a higher depolarized side scatter signal than a
parasite containing a single big Hz crystal. In fact, during this and
previous work, the routine microscopic analysis of Giemsa stained
blood smears to control the parasitemia showed that Hz started to
appear in small dispersed fine granules in P. berghei and only
clumped together by the end of schizogony, as previously observed
by Warhurst et al. [36], while in P. falciparum, Hz crystals aggregate
as they start to appear (data not shown). It also appears possible
that the depolarization signal can still be improved as a result of
Figure 6. Growth curve of Plasmodium falciparum (3D7) after treatment with pyrimethamine. Synchronous cultures of a P. falciparum 3D7
strain were incubated for 72 hours with doubling concentrations of pyrimethamine. No inhibitory effect could be observed during the first 48 hours
at any concentration (A). However, an inhibition was clearly visible at 72 hours (B). This could be explained by the fact that pyrimethamine is a slow
acting drug and its effect can only be detected on the second generation, after 48 hours. Interestingly, the growth curves at all concentrations follow
the drug free control after the 30 hour peak, while the curve for 200 nM shows a later peak at 36 hours with a higher number of depolarizing events,
compared to the drug free control (A). See discussion for possible explanation. Each time point represents the mean value of triplicate samples 6 one
SD. DF ctrl – drug free control; UI ctrl – uninfected control.
doi:10.1371/journal.pone.0061606.g006
Table 1. Inhibitory concentrations (50%) of several
antimalarial drugs against P. falciparum 3D7 strain determined
by the Hemozoin detection assay at different times of
incubation.
Time of incubation
18 h* 24 h 30 h* 36 h* 72 h*
Chloroquine 41.9 nM 34.2 nM 33.6 nM 35.9 nM 29.6 nM
(619.3) (68.1) (610.1) (610.1) (67.4)
Quinine 98.5 nM 54.6 nM 92.2 nM 142.7 nM 45 nM
(69)
Mefloquine 17.2 nM 21.3 nM 33.5 nM 64.9 nM 19.5 nM
(67) (66.4) (620.2)
Artemisinin 28.2 nM 25.6 nM 34.5 nM 43.7 nM n.d.
(63.5) (65.9) (65.8) (616)
Artesunate , 4 nM 6.4 nM 10.8 nM 12.4 nM n.d.
(62.3) (63.6) (66.3)
PyrimethamineXXXX25.4 nM(610.3)
Mean inhibitory concentration values (50%) 6 one standard deviation are
presented.
Standard deviation values are not shown for results that were not supported by
at least three independent experiments. Time-points identified with (*) were
not systematically analyzed, since the 24 hour time-point was used as the
preferential time-point to reliably calculate IC50 values (as discussed in the
manuscript).
(X) values could not be determined; (n.d.) no data available.
doi:10.1371/journal.pone.0061606.t001
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technical modifications to the instrument. The CyflowH flow
cytometer uses a blue laser (488 nm). However, longer
wavelengths may increase the depolarization signal as has
been described for a red HeNe (633 nm) or Kr+ laser (647 nm)
[18]. Furthermore, the polarization ratio of most solid-state
lasers is usually given as .1:100. If the laser had a higher
polarization ratio, as do HeNe and Kr+ lasers, positive
depolarization signals might be better distinguished from
background noise.
To assess parasite maturation and drug effects we chose to use
the simple ratio of all identifiable depolarizing events as a
percentage of all events analyzed (Figure 1C and D). Other
measurements, like depolarizing intensity, showed no clear
advantage (data not shown). A parasitemia of 1% proved to be
the optimal parasitemia to detect parasite maturation and growth
over 48 hours. Thus, it was used in the Hz detection assay to
obtain time-curves when investigating the drug effects in P.
falciparum in vitro cultures. Still, an initial 1% parasitemia is higher
than the ones used in other assays, such as the HRP2 or the WHO
schizont maturation test, which can use parasitemias as low as
0.02% [8], [37], [38]. However, when investigating the lower
detection limit of the Hz assay, parasite maturation and drug
effects of chloroquine, artesunate and pyrimethamine could still be
clearly detected at parasitemias as low as 0.3%. Nevertheless, this
remains higher than the ones used for the HRP2 assay and the
WHO schizont maturation test. Yet, it is comparable to the
parasitemias used in other assays, such as the [3H]-hypoxanthine
assay (0.25–0.5%) [6] or the SYBR green I assay (0.5–1%) [9],
[39], [40] (Table S1).
Of note, in all Hz assay experiments, only around 30% of all
parasites were typically detected by depolarization measurements
(Figure 1D) as compared to microscopy or SYBR green I
fluorescence. The reasons for this are unclear and could be a
consequence of the culture not being highly synchronized. At the
30 hour peak of maturation, schizonts as well as some second
generation ring forms are present, as confirmed by microscopy;
the immature ring forms have insufficient Hz to be reliably
detected [28]. Another possible explanation is the already
mentioned Hz aggregation that occurs in the mature parasites,
which may reduce side scatter intensity.
Certainly, the initial parasitemia of 0.3% required is still a major
limitation of this assay if used directly with patient blood samples,
some of which may have lower parasitemias [41]. However,
further optimization of the assay may lead to an improvement of
the detection limit. Nevertheless, future studies conducted in the
field will allow us to evaluate the performance of the novel Hz
detection assay using ex vivo patient samples.
Aspects of parasite maturation
Using a red blood cell surface marker (CD235) (Figure 1G) and
a DNA stain (SYBR green I) we showed that the depolarizing
events were indeed infected red blood cells (Figure 1F). SYBR
green I fluorescent intensity reflects DNA content [42], [43]. Most
of the depolarizing events showed high SYBR green I fluorescence
(80%), indicating that they were mature parasites (Figure 1H).
Comparing depolarization and fluorescence intensity in a P. berghei
ANKA infected sample stained with SYBR green I showed,
similarly, that the level of depolarization appears to reflect parasite
maturation [27].
Usually, the described P. falciparum life cycle lasts 42–48 hours in
vitro [44]. Contrary to this, we observed a peak of parasite
maturation earlier, at around 30 hours, as reflected by the peak in
depolarization (Figure 2A) followed by a steady increase in SYBR
green I positive events indicating replication (Figure 2B). Corre-
sponding parasite forms were also observed during microscopic
observation of Giemsa stained blood smears. This can be
explained by the fact that because the assay did not start
immediately after re-invasion thus, the indicated time points
correspond to the time post-drug-treatment and not the time post-
invasion. Moreover, the fact that cultures were not highly
synchronized seem to have contributed to this apparent shorter
life cycle. It is known that to obtain highly synchronized cultures,
at least one other sorbitol treatment would be needed [45].
After a single synchronization approximately 90% of the
parasites are ring forms. However, individual parasites can present
differences of several hours in their development. Thus, at the
beginning of the experiments, some parasites may have already
developed for 12 hours within the ring form population while
others are only 6 hours into their development. The microscopic
observation of Giemsa stained blood smears at 36 hours gives
weight to this reasoning, because both schizonts and second
generation ring forms could be observed at this time point.
Drug effects and potential use of the Hz assay
One of the major advantages of the Hz detection assay is the
fact that samples can be easily analyzed without further
preparation or additional reagents allowing a rapid and easy
real-time assessment of parasite maturation and drug effects. For
instance other assays, such as the [3H]-hypoxanthine assay,
cultures have to be incubated for additional 24 hours with the
Table 2. Antimalarial activities of several antimalarial drugs determined by the Hemozoin detection assay and the HRP2 assay.
Hemozoin detection* 24 hours of incubation HRP2 72 hours of incubation
Chloroquine 34.2 nM (68.1) 22 nM
Quinine 54.6 nM (69) 52 nM
Mefloquine 21.3 nM (67) 21 nM
Artesunate 6.4 nM (62.3) 1.1 nM
Artemisinin 25.6 nM (65.9) 11.5 nM
Pyrimethamine 25.4 nM (610.3)1) 30.5 nM
NITD 246 0.8 nM 0.4 nM
The averages of 50% inhibitory concentration values 6 one standard deviation are presented above.
*For the Hemozoin detection assay each drug was tested at least three times (except for the novel compound NITD246).
HRP2 – Histidine-rich protein 2;
1)after 72 hours of incubation.
doi:10.1371/journal.pone.0061606.t002
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isotope before measurements are possible [6], [15], [46–48].
Another advantage is the early detection of inhibitory drug effects
after only 18 hours (Table 1 and Figures 3, 4 and 5), in contrast to
several other assays, such as the [3H]-hypoxanthine assay [6],
[48], which measures drug effects at 48 hours, the SYBR green I
[15], [40], [49], [50] and the HRP2 [8], [15], [37] assays, which
require at least 72 hours.
Although, for example, in the Hz assay chloroquine sensitive
and resistant strains are easily distinguishable after only 18 hours
(Figure 3), the inhibitory effect of the slow acting drug
pyrimethamine could only be detected after 72 hours (Figure 6).
This drug has no effect on asexual parasites in the first half of the
parasite life cycle (24 hours) [41], [51] and effects can only be
detected later in the second parasite generation. For this reason
the Hz assay detects slow acting drugs effects, such as pyrimeth-
amine, only after 72 hours of incubation. Interestingly, at
concentrations of 200 nM, higher depolarization values were
observed after 30 hours (Figure 6A), which appear to reflect
schizont arrest, which was observed by microscopy.
As shown in Table 1, the Hz detection assay allows
determination of a drug’s inhibitory concentrations at different
time-points during the first and second life cycle, thus extending its
potential usefulness.
Artemisinins in the Hz assay
Artemisinin and artesunate growth curves were different from
the other tested drugs. At concentrations of 32 nM and 4 nM,
respectively, a delayed maturation was observed, starting at
18 hours (Figures 4C and 5A). However, the SYBR green I
measurements performed simultaneously indicated that the
parasites replicate, reaching approximately the same parasitemia
as the drug free control after 48 hours of incubation (data not
shown). The reason for this observation remains unclear.
Furthermore, samples treated with 8 nM of artesunate showed
an initial inhibition with a delayed rise after 30 hours (Figures 5A
and 5B). SYBR green I measurements, however, did not change
over the 48 hour incubation period, indicating that the parasites
were somehow able to mature but unable to replicate (Figure 5C).
These parasites, treated a single time with 8 nM of artesunate,
were re-cultured in CMCM and no growth could be observed
during the following four days. Interestingly, similar behavior has
been previously described for artemisinin [52] and was interpreted
as a consequence of its rapid degradation [53]. The drug level had
to be kept constant by replacing the media with the drug every
24 hours, otherwise the number of viable parasites increased at 96
and 120 hours after drug addition [52]. In fact, renewing the
artesunate every 12 hours in the culture medium showed that the
inhibition was maintained throughout the 48 hours of incubation
and the delayed rise was lost (Figure 5B).
Dormancy has been described after treatment with artemisinins,
where early stage parasites enter a dormant stage under drug
pressure but later regrow [54]. It has been reported that parasites
treated with dihydroartemisinin arrested their development shortly
after drug exposure, but after 9 days 50% of the parasites managed
to resume their growth [54]. Thus, to detect recrudescence of these
dormant parasites cultures would have to be monitored for at least
four life cycles (9 days = 216 hours). Our findings showed a
delayed increase during the first life cycle (after 30 hours of
incubation), in samples treated with artesunate at 8 nM. Although
this might represent the detection of dormancy and parasite
recrudescence, the data we have obtained so far are not sufficient
to confirm or exclude this hypothesis, because these parasites were
not monitored for longer than four days. Further investigation is
needed to clarify this issue.
Comparison of IC50 values
The IC50 determined by the Hz detection assay were comparable
with the ones reported for other, already validated assays (Tables 1, 2
and S2). However, slightly higher values were observed for some of
the drugs, especially for artesunate, where most publications report
values below 2.5 nM [15], [37], [47]. One explanation could be the
inoculum effect, i.e., an increase in the inhibitory drug concentration
when greater numbers of parasites are inoculated. This is thought to
be the consequence of some drug accumulating inside the parasitized
RBC [55] and has been described for drugs like artemisinin and
artesunate, as well as for chloroquine and mefloquine [56]. In fact, in
the Hz assay parasitemias of around 1% were used as compared to
other assays, which used parasitemias ranging from 0.05 to 0.5% [6–
9], [37–40]. This might explain the increased IC50 values observed
in the Hz detection assay and interestingly, a decrease in the
parasitemia from 1.4% to 0.7% led to a decrease in the artemisinin
IC50 value from 32 to 13.2 nM. However, no such decrease was
observed with artesunate.
It is important to note, that the comparison of IC50 values
between assays can be misleading. The IC50 values in the
literature vary substantially between assays, even for the same
strain. For instances, the standard [3H]-hypoxanthine incorpora-
tion assay shows differences of 2 to 23 fold for artesunate (Table
S2). Not too surprisingly, one study reported that the reliability of
the assays may be influenced by the mechanism of action of
individual drugs [15]. Moreover, variations in parasite density and
hematocrit as well as the stage-dependent action of antimalarial
drugs, may have a significant impact on the outcome of these
sensitivity assays [14], [56].
Assay – prospects, future possibilities
Because the Hz detection assay allows parasite maturation to be
monitored in real time, it could possibly be used to investigate drug
effects on different parasite developmental stages (stage specificity
of drugs). It might also be interesting to assess the performance of
the assay with parasite strains that have been reported to show
clinical signs of resistance to artemisinins. Since modeling of
parasite-clearance curves suggests that artemisinin resistance
affects ring-stage parasites more than the more mature parasite
stages, thus in vitro tests focusing on the inhibition of ring-stage
parasites could become valuable surveillance tools [57].
The fact that a flow cytometer is required may pose an obstacle
to the widespread use of the Hz assay in the field. Furthermore,
flow cytometers that use fiber optic cables for light collection, such
as the BD LSRFortessa or FACSaria, require relatively elaborate
optical modification to detect depolarization. However, detection
of depolarization as we have described can be implemented simply
on many existing flow cytometers, for example the flow sorter
Influx (http://www.bdbiosciences.com/instruments/influx/features/
index.jsp, accessed 14/08/2012), the Cyflow Cube (Danny Koehler,
Partec, Münster, Germany, personal communication), the Life
Technologies Attune (Grace Chojnowski, Queensland Institute of
Medical Research, Brisbane, Australia, personal communica-
tion), and can even be retrofitted to the venerable BD
FACSCalibur (Lisa Nichols, Cytek Development, Fremont,
CA, USA, personal communication). More importantly, some
low-cost flow cytometers for CD4 counts in resource-poor
countries could be modified rather easily to detect depolariza-
tion, and are already available on site in several African
countries (http://www.partecnorthamerica.com/Press-Release-
01Dec2012-_b_2.html assessed 22/12/12).
Furthermore, it is now evident [58] that optical measurements
of both DNA and Hz can be made in small, robust, simple,
widefield multiparameter optical imaging apparatus an order of
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magnitude less expensive than a typical flow cytometer, using
LEDs costing only a few dollars for illumination and employing
camera chips only slightly higher in quality than those used in
mobile phones as detectors. Signals from all cells in an entire well
of an assay microplate can be analyzed in seconds, without the
need for precise stage motion or focus adjustment. Somewhat
more elaborate and expensive versions of such devices are already
commercially available; minimalist instruments optimized for field
use in the resource-poor areas in which malaria is prevalent should
arrive within a few years.
In conclusion, the novel Hz detection assay allows parasite
maturation to be monitored in real time without the need of
further reagents or sample preparation. The assay detects
inhibitory drug effects of major antimalarial drug classes after
only 18 hours of incubation and permits determination of IC50
values at 24 hours. Future work will have to address the utility of
this assay in the field. Issues such as the use of less expensive
alternatives to flow cytometry and the application of the assay to
such tasks as the determination of stage specific effects of
antimalarial drugs will have to be investigated further.
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CERMEL, Lambaréné, Gabon. (The subject of the photograph
has given written informed consent, as outlined in the PLOS
consent form, to publication of the photograph).
(DOCX)
Author Contributions
Evaluated and provided advice on different aspects of the novel assay and
its development, and contributed to writing and revising the final
manuscript: MPG HMS MMM. Conceived and designed the experiments:
MR HMS MMM MPG TH. Performed the experiments: MR CS.
Analyzed the data: MR CS HMS TH. Contributed reagents/materials/
analysis tools: MMM TH. Wrote the paper: MR MPG HMS TH.
References
1. Hyde JE (2007) Drug-resistant malaria - an insight. FEBS J. 27:4688–4698.
2. White NJ (2004) Antimalarial drug resistance. J Clin Invest 113:1084–1092.
3. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, et al. (2009) Artemisinin
resistance in Plasmodium falciparum malaria. N Engl J Med 361: 455–467.
4. Bloland PB (2001) Drug resistance in malaria. WHO Press, Geneva,
Switzerland.
5. Rieckmann KH, Campbell GH, Sax LJ, Mrema JE (1978) Drug sensitivity of
Plasmodium falciparum. An in-vitro microtechnique. Lancet 1:22–23.
6. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD (1979) Quantitative
assessment of antimalarial activity in vitro by a semiautomated microdilution
technique. Antimicrobial Agents and Chemotherapy 16: 710–718.
7. Makler MT, Hinrichs DJ (1993) Measurement of the lactate dehydrogenase
activity of Plasmodium falciparum as an assessment of parasitemia. Am J Trop Med
Hyg 48: 205–210.
8. Noedl H, Wernsdorfer WH, Miller RS, Wongsrichanalai C (2002) Histidine-rich
protein II: a novel approach to malaria drug sensitivity testing. Antimicrobial
Agents and Chemotherapy 46: 1658–1664.
9. Smilkstein M, Sriwilaijaroen N, Kelly JX, Wilairat P, Riscoe M (2004). Simple
and inexpensive fluorescence-based technique for high-throughput antimalarial
drug screening. Antimicrobial Agents and Chemotherapy 48: 1803–1806.
10. Li Q, Gerena L, Xie L, Zhang J, Kyle D, et al. (2007) Development and
validation of flow cytometric measurement for parasitemia in cultures of P.
falciparum vitally stained with YOYO-1. Cytom A 71: 297.
11. Corbett Y, Herrera L, Gonzalez J, Cubilla L, Capson TL (2004) A novel DNA-
based microfluorimetric method to evaluate antimalarial drug activity. Am J Trop
Med Hyg 70:119–24.
12. Baniecki ML, Wirth DF, Clardy J (2007). High-throughput Plasmodium falciparum
growth assay for malaria drug discovery. Antimicrob Agents Chemother 51: 716.
13. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR (2002)
Epidemiology of drug resistant malaria. Lancet Infect Dis 2:209–218.
14. Noedl H, Wongsrichanalai C, Wernsdorfer WH (2003) Malaria drug-sensitivity
testing: new assays, new perspectives. Trends in Parasitology 19: 175–181.
15. Wein S, Maynadier M, Tran Van Ba C, Cerdan R, Peyrottes S, et al. (2010)
Reliability of antimalarial sensitivity tests depends on drug mechanisms of action.
J Clin Microbiol 48: 1651–1660.
16. World Health Organization (2011) Global paln for artemisinin resistance
containement (GPARC). WHO Press, Geneva.
17. Hanscheid T, Egan TJ, Grobusch MP (2007) Haemozoin: From melatonin
pigment to drug target, diagnostic tool and immune-modulator. The Lancet
Infectious Diseases 7: 675–685.
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Assessing anti-malarial drug effects ex vivo using
the haemozoin detection assay
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Abstract
Background: In vitro sensitivity assays are crucial to detect and monitor drug resistance. Plasmodium falciparum has
developed resistance to almost all anti-malarial drugs. Although different in vitro drug assays are available, some of
their inherent characteristics limit their application, especially in the field. A recently developed approach based on the
flow cytometric detection of haemozoin (Hz) allowed reagent-free monitoring of parasite maturation and detection of
drug effects in culture-adapted parasites. In this study, the set-up, performance and usefulness of this novel assay were
investigated under field conditions in Gabon.
Methods: An existing flow cytometer (Cyflow Blue) was modified on site to detect light depolarization caused by Hz.
Blood from malaria patients was incubated for 72 hrs with increasing concentrations of chloroquine, artesunate and
artemisinin. The percentage of depolarizing red blood cells (RBC) was used as maturation indicator and measured at
24, 48 and 72 hrs of incubation to determine parasite growth and drug effects.
Results: The flow cytometer was easily adapted on site to detect light depolarization caused by Hz. Analysis of ex vivo
cultures of parasites, obtained from blood samples of malaria patients, showed four different growth profiles. In 39/46
samples, 50% inhibitory concentrations (IC50) were successfully determined. IC50 values for chloroquine were higher
than 200 nM in 70% of the samples, indicating the presence of chloroquine-resistant parasites. For artesunate and
artemisinin, IC50 values ranged from 0.9 to 60 nM and from 2.2 nM to 124 nM, respectively, indicating fully sensitive
parasites.
Conclusion: Flow cytometric detection of Hz allowed the detection of drug effects in blood samples from malaria patients,
without using additional reagents or complex protocols. Adjustment of the initial parasitaemia was not required, which
greatly simplifies the protocol, although it may lead to different IC50 values. Further investigation of set-up conditions
of the Hz assay, as well as future studies in various settings should be performed to further determine the usefulness of
this assay as a tool for rapid resistance testing in malaria-endemic countries.
Keywords: Malaria, field trial, Anti-malarial sensitivity testing, Resistance, Flow cytometry, Haemozoin
Background
In the last decade, the number of malaria deaths has de-
creased in large part due to the availability of effective
treatments, in particular artemisinin combination ther-
apy (ACT) [1]. However, these achievements are in dan-
ger and might even be reversed because parasites with
prolonged parasite clearance times (PCT), observed in
patients treated with ACT, have emerged in Southeast
Asia [2,3]. Indeed, this is considered an early sign of the
development of parasite resistance [2,3] and a major
concern in the fight against malaria, as illustrated by the
WHO Global Plan for Artemisinin Resistance Contain-
ment issued in 2011 [4]. Artemisinin resistance, cur-
rently defined as prolonged PCT, has spread across
Southeast Asia [5]. Recently, a Vietnamese patient who
apparently acquired malaria in Angola failed to respond
to intravenous artesunate/clindamycin and an oral ACT
after returning to Vietnam [6]. It is not unlikely that it
will emerge in sub-Saharan Africa, and drug sensitivities
should be monitored pro-actively. In this scenario,
in vitro sensitivity assays may play a crucial role in the
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future. In vitro assays allow reducing host-related factors
and thus, provide an objective insight into the intrinsic
sensitivity of malaria parasites.
Several phenotypic and genotypic methods have been
developed and tried for drug testing in the field [7].
Genetic resistance markers are known for some anti-
malarial drugs, but are not yet able to predict sensitivity
to all commonly used anti-malarial drugs [8]. Only re-
cently, alterations in the kelch13 gene were linked to de-
layed parasite clearance in artemisinin-treated patients
[9]. Thus, phenotypic assays continue to be important
for detection of resistance and validation of genetic
markers. The main phenotypic assays successfully used
to detect drug resistance in the field include: (i) the
microscopic schizont maturation test [10]; (ii) the in-
corporation of radioactive hypoxanthine [11]; (iii) ELISA
assays for detection of pLDH [12] and HRP2 [13] anti-
gens; and, (iv) fluorescent-based techniques using either
fluorometry [14] or flow cytometry [15] to detect parasite
DNA/RNA. However, inherent limitations are common, es-
pecially during field applications. The supply, handling and
disposal of radioactive isotopes are major obstacles. Micros-
copy is labour-intensive and subjective, although it has a ra-
ther quick turn-around time (24–30 hrs) when compared
to other techniques, especially ELISA-based methods,
which can take up to 72 or even 96 hrs [16,17]. Moreover,
assays may require the use of, often, expensive antibodies
or DNA/RNA stains, highlighting the issues of adequate
storage and cold chain as well as limited shelf life.
Regarding flow cytometry, the majority of cytometric
methods apply combinations of dyes to reliably detect
infected red blood cells (iRBC), which implies a complex
multiparameter analysis [15,18]. Ideally, if parasite mat-
uration was detectable using a direct and simple meas-
urement of a product from the parasite, the need for
additional reagents would be avoided.
Haemozoin (Hz) is produced in increasing amounts by
the parasite as it matures inside the iRBC, constituting an
optimal maturation indicator [10]. Measuring Hz with a
simple flow cytometry method allows detection of parasite
maturation and drug effects as early as 18 hrs after incu-
bation in culture-adapted laboratory strains [19].
The objectives of this study were to evaluate if the Hz
detection assay could be easily set up in a remote malaria-
endemic area, and to assess whether anti-malarial drug ef-
fects could be detected in wild-type strains obtained from
malaria patients, using a simple protocol.
Methods
The study was carried out at the Centre de Recherches
Médicales de Lambaréné (CERMEL) in Gabon, a
malaria-endemic region in Africa. Ethical approval was
obtained from the Institutional Review Board of the
Medical Research Unit (CERMEL) of the International
Foundation of the Albert Schweitzer Hospital.
Samples
EDTA anti-coagulated blood samples from malaria pa-
tients were obtained from the Clinical Analysis Laboratory
of the Albert Schweitzer Hospital after the samples had
been processed for full blood count (FBC). Malaria diag-
nosis and parasite loads (number of parasites/μl of blood)
were determined by standard microscopic observation of
Giemsa-stained thick blood films. Briefly, parasitaemia
was quantified by counting the number of parasites per
microscopic field from a defined volume of blood (10 μl)
spread on a defined area (1.8 cm2), as described elsewhere
[20]. RBCs from these blood samples were washed twice
in culture medium before further use.
Flow cytometric detection of depolarized side-scattered
light
Flow cytometric analysis was performed using a CyFlow®
Blue (Partec, Münster, Germany) available on site. The
existing configuration, which was modified on site for
this study and is shown in Figure 1, consisted of forward
scatter (FSC), side scatter (SSC) and three fluorescent
detectors (FL1, FL2 and FL3). A set of four optical filters
was necessary, as shown in Figure 1B: (1) a 500-nm di-
chroic mirror; (2) a 50:50 beam-splitter; (3) a 488-nm
vertical polarizer; and, (4) a 488-nm horizontal polarizer.
Briefly, a 500-nm dichroic mirror (DM) (B1) was placed
on the site of the original 540-nm DM and the other ori-
ginal 500-nm DM was replaced by a 50:50 beam-splitter
(B2), which allowed the creation of two SSC detectors
(Figure 1). A 488-nm filter coupled with a polarizer in
the same orientation as the incident laser beam (vertical)
was placed in front of one of the SSC detectors. Another
488-nm filter coupled with a polarizer perpendicularly
orientated in relation to the laser beam (horizontal) was
placed in front of the other SSC detector, allowing the
detection of light depolarization (Figure 1C). The optical
components required to modify the optical bench of
flow cytometers can be obtained directly from the in-
struments’ manufacturer.
Anti-malarial drugs
Samples were tested against different concentrations of
chloroquine, artesunate and artemisinin (Sigma Aldrich,
St Louis, MO, USA). Stock solutions of chloroquine
were prepared in sterile water, and artemisinin and arte-
sunate were prepared in pure methanol. Doubling con-
centrations, ranging from 25 to 200 nM for chloroquine
and from 0.12 to 128 nM for artemisinin and artesunate,
were prepared from the stock solutions in in complete
malaria culture medium (CMCM), which consists of
RPMI 1640 supplemented with 25 mM HEPES,
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2.4 mM L-glutamine, 50 μg/mL gentamicin, 0.5% w/v
Albumax, 11 mM glucose, 1.47 mM hypoxanthine and
37.3 mM NaHCO3.
Each drug concentration was tested in triplicate.
Haemozoin detection assay
RBCs obtained from malaria patients were diluted at a
haematocrit of 5% in CMCM. To simplify the assay, the
parasitaemia was not adjusted so that, eventually, the use
of uninfected blood could be avoided. A volume of 100 μL
was distributed into the wells of a 96-well plate, previously
loaded with 100 μL of anti-malarial drugs at different con-
centrations, or 100 μL of CMCM for the drug-free con-
trols, respectively. Plates were incubated for 72 hrs at 37°C
in 5% CO2 atmosphere. Flow cytometric measurements
were performed at 24, 48 and 72 hrs of incubation.
Parasite maturation from ring-stage to schizonts was
assessed based on the increase in the percentage of Hz-
containing cells overtime, as described before [19]. To
assess parasite replication (re-invasion), the same sam-
ples were stained with SYBR green I at 1x (Invitrogen,
Carlsbad, CA, USA), as described elsewhere [19].
Histidine-rich protein-2 (HRP2) enzyme-linked immunosorbent
assay (ELISA)
For the HRP2-ELISA, RBCs were diluted in CMCM at a
haematocrit of 3%. Parasitaemia was adjusted to 0.05%
using RBCs obtained from healthy volunteer donors. A
volume of 100 μL was distributed into the wells of a 96-
well plate, previously loaded with 100 μL of anti-malarial
drugs at different concentrations or 100 μL of CMCM
for the drug-free controls. Plates were incubated for
Figure 1 Flow cytometry modifications to detect light depolarization. The optical set-up of the Cyflow (Partec, Münster, Germany) (A) was
easily modified to allow the detection of light depolarization. Four optical components from the original set-up (blue boxes in A) had to be replaced
by the optical components shown in B, as described in the Methods section. Filters were simply replaced by unscrewing the original ones from
the filter holder, or by removing the metallic ring (second row in B). This was accomplished using simple tools (bottom row in B). Note that in
this case, polarization filters were glued inside the holder (arrows in B) so that they would not move, since to attain the best depolarization signal polarizers
should be perpendicular to each other. The final optical layout to detect light depolarization is presented in C.
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72 hrs at 37°C in 5% CO2, after which they were frozen
at −20°C until the HRP2-ELISA was performed accord-
ing to standard procedures [21].
Data analysis
Flow cytometry results were analysed using FlowJo software
(version 9.0.2, Tree Star Inc., Oregon, USA). Depolarizing
events were defined in plots of SSC versus depolarized-SSC,
as those with a signal above the background observed in
the uninfected control (gate in Figure 2A and B). To deter-
mine SYBR green I-positive cells, green fluorescence (FL1)
versus red fluorescence (FL3) plots were used. The FL1 de-
tector had a 527/30 band-pass filter and FL2 had a 620-nm
long-pass filter. SYBR green I-positive events were estab-
lished based on a stained uninfected control and had to be
adjusted at each time point, always using the uninfected
SYBR green I-stained sample from the corresponding time
point. A non-linear regression model (sigmoidal dose–re-
sponse/variable slope) was used to calculate the individual
50% inhibitory concentrations, with SigmaPlot-Systat
Software (Chicago, IL, USA). Only those samples with
a ≥2 ratio of drug-free control to highest drug concentra-
tion were included.
Results and discussion
Growth and maturation of wild-type Plasmodium falcip-
arum strains
Forty-six samples from malaria patients were analysed
during this study. Parasite loads ranged from 50 to
452,000 parasites/μL of blood (median of 15,000 para-
sites/μL). Ex vivo cultures of infected RBCs showed that
parasites had four different growth profiles (Table): (i)
seven samples showed no maturation, as defined by an
increase in depolarization; (ii) another eight samples
Figure 2 Representative analysis of drug effects assessed after ex vivo culture of blood samples from malaria patients. Representative
plots of flow cytometric analysis of an uninfected blood sample (A) and a sample from a malaria patient with 1.5% parasitaemia (B). At time
point 0 of incubation, no difference in depolarizing events is observed between the infected samples and the uninfected control (A and B).
However, Hz is produced as the parasite matures, and after 24 hrs of incubation an increase in the percentage of depolarizing cells is detected (B)
from 0.02 to 0.36. In this example, drug effects could be determined after only 24 hrs of incubation (C). Contrary to chloroquine, where resistance was
observed, artesunate and artemisinin are still effective drugs (C).
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showed maturation at 24 hrs and replication at 48 hrs;
(iii) 17 samples showed maturation at 24 hrs but no re-
invasion occurred; and, (iv) 14 samples had a delay in
parasite growth, with maturation being observed at
48 hrs and replication at 72 hrs.
One crucial step in the in vitro sensitivity assays is the
culture of parasites [22]. Maturation of Plasmodium falcip-
arum from early rings to late schizonts takes 42–48 hrs
in vitro [23] and consequently, an increase in parasitaemia
can only be observed every 42–48 hrs, after re-invasion of
RBCs occurs. Differences in ex vivo parasite maturation
and replication have already been observed in strains ob-
tained directly from different patients [24,25]. Indeed many
factors related to the protocol, the host and the parasite it-
self might greatly influence the in vitro growth of parasites.
Regarding the protocol factors, such as the type of
anticoagulant used to collect the blood from the patients
to the atmosphere where the parasites will be incubated,
have to be taken into account [7]. During this study
EDTA-collected blood was used. Although the use of
EDTA is discouraged by the reference protocol from
MR4 [26] it has been shown by different studies that
EDTA-collected blood can be successfully used for
ex vivo drug testing [27-31]. In one of these reports even
long-term cultures of parasites present in patients’ blood
were accomplished [31]. Moreover, the use of specific
anticoagulants requires drawing more blood just for the
purpose of sensitivity testing. This can be avoided by
using EDTA-anticoagulated blood, which was obtained
as part of the routine FBC analysis, preventing all inher-
ent problems associated with an extra blood drawing.
The incubation atmosphere recommended for P. fal-
ciparum growth in culture include the use of a low O2
atmosphere [26]. However, such mixed gas atmospheres
may not be available in the resource-limited settings found
in malaria endemic countries. Because of this, it has been
investigated whether a simple 5% CO2 atmosphere could
be used instead without compromising parasite survival
after drug treatment [32]. Results showed no differences
in parasite survival between trigas (5% CO2, 5% O2, 90%
N2), candle jar or a 5% CO2 atmosphere [32].
Undoubtedly, host-specific factors, often difficult to
control, ranging from the immune response to the pres-
ence of pharmacologically active substances might influ-
ence the growth of the parasite in vitro. Indeed, the fact
that some of the patients might already have been
treated at the time of blood collection during this study
cannot be discarded, possibly explaining some of the dif-
ferences observer in the parasites’ growth profiles. Yet, it
is very difficult to control for all these factors and this
might not only imply detailed histories, but eventually
laboratory test to confirm immune status or presence of
drug-metabolites. Perhaps explaining why very few stud-
ies on this filed are including such detailed information.
Conversely, parasite-related factors may even be more
important. The delay between sample collection and
processing influences the viability of freshly collected
clinical isolates, because it is considerably decreased
after a sample has been kept for several hours at room
temperature [7]. However, in one study where all 43
samples were cultured within 30 minutes of collection
[25], 50% developed into schizonts within 27 hrs, while
the other half reached schizont stage only between 28
and 63 hrs. In this study no correlation between the
delay until culture and any of the four parasite growth
patterns was observed, supporting the idea that possible
host factors may have been more relevant.
Detection of anti-malarial drug effects by the haemozoin
assay
In P. falciparum-infected patients the majority of circu-
lating iRBC are ring forms that contain little or no de-
tectable Hz, as observed in a previous report whereby
flow cytometric assessment of Hz these forms could not
be detected [33]. This study confirms this observation,
as at 0 hrs, no difference in depolarizing events was ob-
served between the infected and the uninfected samples
(Figure 2A and B). Only after incubation the percentage
of depolarizing cells increased, indicating higher Hz con-
tent and, thus maturation (Figure 2B), seen in drug-free
controls or drug-resistant parasites. This contrasts with
diminished or absent depolarizing events when anti-
malarial drugs are effective (Figure 2C). Drug inhibitory
effects were determined in 39/46 (85%) of samples, in
which parasite maturation was observed (groups 2, 3
and 4). In 25 samples (groups 2 and 3), drug effects were
measurable at 24 hrs, as expected from culture-adapted
strains [19]. In the remaining 14 samples (group 4) para-
site maturation was delayed; however, it was still possible
to detect drug effects at 48 hrs of incubation.
IC50 values of chloroquine and artemisinins
The IC50 values are shown in the Table 1. There was a
poor correlation between the IC50 values of individual
samples and the different assays. In fact, this is com-
monly observed even when using the same laboratory-
adapted strain [19]. Indeed, several factors, such as the
initial parasitaemia, the haematocrit and the end point
for measuring parasite growth can influence IC50 values
[7,34]. Samples with higher initial parasitaemia (group
3), showed increased IC50 values for artesunate and ar-
temisinin (Table). Apparently, a higher initial parasit-
aemia may be associated with an increase in inhibitory
drug concentration of artemisinin, artesunate, chloro-
quine, and mefloquine [11], which could explain some of
the increase observed in the IC50 values. Interestingly,
mean IC50 values for artesunate and artemisinin in iso-
lates that had a delayed growth (group 4) were somewhat
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lower than in groups 2 and 3, where maturation was de-
tected at 24 hrs. This could be due to the different growth
profile of drug exposed and non-exposed parasites in
group 4. Overall, IC50 values ranged from 0.9 to 60 nM
and from 2.2 nM to 124 nM for artesunate and artemisi-
nin, respectively (Figure 3). These values are higher than
previously described in the same region, using the HRP-2
assay [35]. Because several assay-related factors can influ-
ence IC50 values they may not be directly comparable be-
tween different assays [7,34]. In the previous study, the
final haematocrit was 1.5% [35], while in the Hz detection
assay it was 2.5%. It has been observed that higher haema-
tocrits may cause an increase in IC50 values [34]. Prelim-
inary data using the same culture-adapted strain showed
that the IC50 value for dihydroartemisinin increases from
1.7 nM to 7.5 nM when the haematocrit of the sample is
raised from 1 to 2.5% (unpublished data).
For chloroquine, 70% of the samples had IC50 values
higher than 200 nM, indicating resistance, which is in
line with an earlier reports and which is explained
through the high usage of amodiaquine, many years after
the use of chloroquine had been curbed and finally
abandoned [36,37]. In Malawi [38,39], Kenya [40] and
Tanzania [41], chloroquine resistance decreased after its
withdrawal, contrary to the study site, even though
chloroquine treatment was discontinued 11 years ago, as
observed by others [37,42]. One explanation brought
forward is the use of artesunate/amodiaquine, because
amodiaquine appears to select mutant pfcrt allele, which
is responsible for chloroquine resistance [43].
Interestingly, the Hz-detection assay showed in some
of the chloroquine-resistant strains that the percentage
of Hz-containing cells increased as chloroquine concen-
tration increased as well (Figure 2C). It is known that
several drugs, specially quinoline-type drugs, directly
interact with Hz, as discussed elsewhere [44]. This inter-
action may lead to alterations in the crystals distribution
within the parasite that may affect the depolarized light
signal. Recently it has been shown that parasites con-
taining several small but distributed Hz crystals can have
a higher depolarized signal than a parasite containing a
single large clump of Hz [45]. In this context it is not
unlikely that at higher concentrations of chloroquine
some of the drug may interact with Hz avoiding its co-
alescence. Thus, explaining why at higher concentrations
of this drug the signal seems to be increased. Certainly,
the mechanism of this observation is not known, and
further investigation is required to understand the exact
cause of this phenomenon.
During this study the HRP2-ELISA was performed
alongside. However, drug effects could only be detected
in 17 samples (37%), with IC50 values ranging from 0.6
to 31 nM for artesunate and 0.6 to 94.8 nM for artemisi-
nin (Figure 3). This success rate appears to be at the
lower end of reported studies with 45% [14], while
others had success rates of 75% [46] and 87% [13]. Of
note, these samples were collected on purpose to be
used exclusively in the scope of these studies. Contrary
Table 1 Summarized data of isolates exhibiting different ex vivo growth profiles analysed by the haemozoin assay
Group 1 Group 2 Group 3 Group 4
Growth profile No maturation Maturation at 24 hrs and replication at 48 hrs Maturation at 24 hrs but no replication Delayed maturation
Number of samples 7 8 17 14
Parasitaemia 0.01%; 0.3%; 3.5%; 0.3%;
(median; range) 0.001-0.1% 0.2-2.2% 0.2-12% 0.1-1.9%
IC50 Artesunate (mean) nd 10.5 nM 15.2 nM 5.6 nM
IC50 Artemisinin (mean) nd 46 nM 47.3 nM 14.4 nM
nd – not determined.
IC50 – 50% inhibitory concentration.
Note: Results from chloroquine were not presented in this Table because the majority of the samples (32 out of 46) had IC50 values higher than 200 nM.
Chloroquine had an inhibitory effect in only four samples from group 3 (IC50 mean = 76.8 nM). In ten samples, chloroquine activity could not be determined.
Figure 3 Inhibitory 50% concentrations obtained for artesunate
and artemisinin. Using the Hz detection assay, IC50 values for
artesunate and artemisinin differed between samples ranging from
0.9 to 60 nM and from 2.2 nM to 124 nM, respectively. IC50 values
obtained by the HRP-2 ELISA ranged from 0.6 to 31 nM for artesunate
and from 0.6 to 94.8 nM for artemisinin.
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to this, here, samples were collected for other purposes,
which might have contributed to a lower success rate.
Furthermore, samples were preselected based on their
parasitaemias of 0.01% or higher [13], while in this study
all samples were included. Apparently, re-invasion of un-
infected RBCs (replication) is considered the main cri-
terion for the success of the HRP2 assay [21]. However,
even when no schizont maturation is observed after
24 hrs of incubation, samples can still be successfully
tested by the HRP2 assay [21]. During this study, most
results (14 out of 17) were obtained in samples that ex-
hibited delayed-growing parasites (group 4), whereas
drug effects were only detected in two samples from
groups 1 and 2, and in five samples from group 3.
Indeed, the low detection limit is a major advantage of
the HRP2 assay. For instance, the Hz assay failed to de-
termine drug effects in samples from group 1, possibly
due to the low parasitaemias present in this group,
which were below the previously reported 0.3% detection
limit of the Hz assay [19]. On the other hand, when
parasitaemias are higher than 0.1% [21], samples have to
be diluted with uninfected RBCs from healthy donors,
which can be a limiting step. Results from group 3,
where the parasitaemia ranged from 0.2 to 12%, indicate
that the Hz detection assay does not seem to require ad-
justment of the parasitaemia to allow the detection of
drug effects.
Field applications of flow cytometry
The optical bench of the CyFlow® flow cytometer available
on site had a typical configuration common in most small
instruments, consisting of one blue-laser (488 nm) and de-
tectors for FSC, SSC and three fluorescences FL1 (green),
FL2 (orange) and FL3 (red) (Figure 1A). For the detection of
light depolarization the original set-up was easily modified
by simply changing the respective filters and mirrors, even
taking advantage of the existing filter holders (Figure 1B).
The optical bench layout required for the detection of light
depolarization is simple (Figure 1C) and therefore, other
instruments should also be easily modifiable, unless they
use fiber-optic cables for light collection.
Few studies describe the use of flow cytometry for drug
testing in the field [15,47], possibly because of the perceived
expense and complexity in setting up and running such in-
struments. Nowadays the number of simple, robust and
portable flow cytometers has increased, including instru-
ments such as the Attune® (Life Technologies, Carlsbad,
USA), the Accuri™C6 (BD Biosciences, La Jolla, USA), the
Cyflow Cube 6 (Partec, Münster, Germany), among others.
It has been shown that theses instruments can be easily
modified to detect Hz-caused light depolarization [45] and
most of them can be used with an autosampler for higher
throughput [48]. Moreover, the initial purchase costs of
these instruments have dropped substantially from those
practiced before for larger instruments, allowing them to
be used and available in the field. Indeed, recent field stud-
ies take advantage of this, by using for example the Accuri
C6 [15,47]. Even smaller and simpler instruments used for
CD4+ T cell counting in HIV-infected patients exist, such
as the CyFlow®miniPOC from Partec, which are used in
low-resource settings [49]. Although the way was often dif-
ficult, cytometry is no longer the very expensive, high-end
technology based on bulky instruments. In the future, sim-
ple image cytometers might replace flow cytometers, as
they seem to perform a broad range of measurements, and
eventually parameters such as light depolarization could be
detected as well [50,51].
Opening new avenues for anti-malarial drug testing in
the field
This study showed that drug effects of clinically relevant
anti-malarial drugs as well as resistance to chloroquine
could be assessed by simply detecting Hz. This method
measures parasite maturation and does not require re-
invasion to occur; consequently, results can be obtained
earlier than with other currently available methods, ex-
cept for microscopy. However, microscopy relies on
trained observers’ ability to detect morphological
changes of iRBC [52], which sometimes can be rare.
Flow cytometric measurements can provide more object-
ive, reliable and effective results than microscopy, as it
has been previously observed in a different context [53].
Moreover, it allows the assessment of additional parame-
ters, such as DNA and RNA content, which can improve
parasite detection [51]. Finally, drug effects could be de-
tected without having to decrease the sample’s parasit-
aemia. This may greatly simplify the protocol as it avoids
the need to obtain blood from healthy donors. Yet, this
seems to lead to increased IC50 values. Thus, whether
parasitaemia ought to be adjusted or not should be fur-
ther investigated.
These findings open new avenues for other Hz-
detection methods. Interestingly, several Hz detection
methods exist [54-58] and they could possibly be used to
detect drug effects as early, or even earlier, than the flow
cytometric Hz detection.
Conclusion
This study conducted in the field showed flow cytometry
could be easily implemented and performed in field con-
ditions. Flow cytometric detection of Hz could be used
as an alternative tool to assess drug effects on parasites
obtained directly from patients’ blood samples, without
the need for additional reagents or complex protocols.
However, further optimization of the Hz assay regarding
its set-up conditions, for example, changing the haem-
atocrit, may contribute to obtain IC50 values more
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comparable to the ones that have been previously re-
ported [13,59].
Future studies should be performed in various settings,
to further investigate the Hz assay and its usefulness as a
tool for rapid resistance testing in malaria-endemic
countries.
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Light Depolarization Measurements in
Malaria: A New Job for an Old Friend
Maria Rebelo,1* Carolina Tempera,1 Claudia Bispo,2 Claudia Andrade,2
Rui Gardner,2 Howard M. Shapiro,3 Thomas H€anscheid1
! Abstract
The use of flow cytometry in malaria research has increased over the last decade. Most
approaches use nucleic acid stains to detect parasite DNA and RNA and require complex
multi-color, multi-parameter analysis to reliably detect infected red blood cells (iRBCs).
We recently described a novel and simpler approach to parasite detection based on flow
cytometric measurement of scattered light depolarization caused by hemozoin (Hz), a
pigment formed by parasite digestion of hemoglobin in iRBCs. Depolarization measure-
ment by flow cytometry was described in 1987; however, patent issues restricted its use
to a single manufacturer’s hematology analyzers until 2009. Although we recently dem-
onstrated that depolarization measurement of Hz, easily implemented on a bench top
flow cytometer (Cyflow), provided useful information for malaria work, doubts regard-
ing its application and utility remain in both the flow cytometry and malaria commun-
ities, at least in part because instrument manufacturers do not offer the option of
measuring depolarized scatter. Under such circumstances, providing other researchers
with guidance as to how to do this seemed to offer the most expeditious way to resolve
the issue. We accordingly examined how several commercially available flow cytometers
(CyFlow SL, MoFLo, Attune and Accuri C6) could be modified to detect depolarization
due to the presence of free Hz on solution, or of Hz in leukocytes or erythrocytes from
rodent or human blood. All were readily adapted, with substantially equivalent results
obtained with lasers emitting over a wide wavelength range. Other instruments now
available may also be modifiable for Hz measurement. Cytometric detection of Hz using
depolarization is useful to study different aspects of malaria. Adding additional parame-
ters, such as DNA content and base composition and RNA content, can demonstrably
provide improved accuracy and sensitivity of parasite detection and characterization,
allowing malaria researchers and eventually clinicians to benefit from cytometric tech-
nology. VC 2015 International Society for Advancement of Cytometry
! Key terms
Key terms: polarization; depolarized side scatter; hemozoin; flow cytometry; malaria;
light depolarization
MALARIA remains one of the most important parasitic diseases, killing around
700,000 people each year (1). Reliable detection of parasites and identification of the
species are crucial for clinical diagnosis, as well as for many research applications.
Both may require differentiation of asexual and sexual forms, determination of dif-
ferent maturation stages, and reliable quantification of parasite density (numbers per
unit volume of blood or percentage of infected red blood cells). Antimalarial drug
development and assessment of resistance to drugs may additionally require evalua-
tion of parasite metabolic state and viability. Cytometry could potentially provide an
alternative to microscopy of Giemsa stained smears (2), the accepted method for
diagnosis for over a century.
Malaria parasites growing inside infected erythrocytes (iRBCs) catabolize hemo-
globin, producing the strongly absorbing and birefringent pigment hemozoin (Hz).
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Once the parasite completes its growth cycle in the iRBC, Hz
is released and, subsequently ingested by peripheral blood
phagocytes (3). The presence and form of Hz in iRBCs are
useful characteristics for distinguishing various species and
developmental stages; observation of Hz, known to be associ-
ated with malaria, in cells in unstained blood led Alphonse
Laveran to the initial discovery of malaria parasites in 1880
(3). Staining came later.
In addition to strongly absorbing light at wavelengths
between 300 and 700 nm, Hz is able to depolarize light and
can, as has long been known, be detected by optical methods
such as dark-field microscopy (4–7) or depolarization micros-
copy (8,9). In the latter, crossed polarizing filters are inserted
in the illumination and observation paths of a microscope
and bright spots indicate the presence of Hz.
By 1987, it had been shown that flow cytometry of DNA
and RNA content of iRBCs could differentiate stages and, in
some cases, species (10,11). Flow cytometry has since been
used to study parasite physiology and response to antimalarial
drugs (12–17). This is most often done using fluorescent DNA
and RNA stains and complex multi-color, multi-parameter
analysis (2,18); additional maturation/viability markers may
also be measured (17,19).
Also in 1987, it was reported that depolarized light scatter
could also be detected by flow cytometry; this was initially
recognized as providing a simple, reagent-free means to dis-
tinguish eosinophil from neutrophil leukocytes based on the
birefringence of eosinophil granules (20). A patent (US, Pat-
ent: 5017497: http://www.google.com/patents/US5017497
accessed on 01/08/2014) on the procedure was licensed by
Abbott Diagnostics (Santa Clara, CA) and used in their Cell-
Dyn hematology analyzers; the patent also prevented manu-
facturers of research flow cytometers from offering the mea-
surement in their apparatus.
In 1999, it was found that Hz-containing monocytes in
the blood of malaria patients could be detected by the Cell-
Dyn analyzers (21). Since then, several other studies have
reported the detection of Hz inside monocytes and neutro-
phils with both those instruments and user-modified research
flow cytometers (22–25), and the use of hematology analyzers
to diagnose malaria in non-endemic and endemic countries
has been extensively reviewed elsewhere (26). Of note, some
of these studies reported the possibility of detecting Hz in
iRBCs as well (22,27).
With the patent no longer in force, we recently imple-
mented depolarized scatter measurement on a bench top flow
cytometer (Cyflow SL, Partec/Sysmex). This permitted compar-
ing cytometric detection of Hz-containing leukocytes using this
cytometer and the Cell-Dyn instrument with microscopy
(28,29). More importantly, it confirmed that Hz inside iRBCs
could be detected, leading to further studies (30,31).
Although this work attracted some interest in both the
malaria and the flow cytometry communities, questions
remained as to whether and how readily depolarized scatter
measurements could be easily installed and measured on other
common instruments, what kind of Hz can be detected (e.g.,
free Hz, intraleukocytic Hz, intraerythrocytic Hz from rodent
or human parasites), and to what extent aspects of instrument
setup, e.g., the laser wavelengths, might interfere with meas-
urements. Addressing these issues, we have now shown that
light depolarization caused by Hz from different sources can
be easily detected in a variety of flow cytometers. We hope
that this will encourage malaria researchers and clinicians to
make productive use of the technique.
Table 1. Samples and protocols used for preparation of samples
SAMPLES PROTOCOL REFERENCES
Plasmodium berghei
infected red blood cells
BALB/c mice (Charles River, Spain) were infected with the transgenic P. berghei
ANKA (259 cl2) that constitutively expresses GFP during the whole life cycle.
Blood samples were collected by cardiac puncture into a heparinized collection
tube, as described elsewhere.
(30)
Plasmodium falciparum
infected red blood cells
P. falciparum 3D7 strain was obtained from MR4 (ATCC, Manassas, VA) and kept
in continuous culture according to the recommendations of the Malaria
Research and Reference Reagent Resource Center (MR4) and as previously
described elsewhere (32). Cultures were maintained at 5% hematocrit, at 37 #C
in an atmosphere of 5% CO2.
(32)
Intraleukocytic hemozoin Human peripheral blood mononucleated cells (PBMCs) were incubated with syn-
thethic Hz, as described elsewhere (30). Briefly, PBMCs were isolated from blood
collected from healthy volunteers and placed in a Ficoll gradient (Ficoll-Paque
Plus, GE Healthcare, Uppsala, Sweden), where the interface containing the
PBMCs was collected after centrifugation. PBMCs were washed, counted and
ressuspended at a concentration of 5 x 10^5 PBMC/ml. Synthetic Hz (obtained
as explained below) was added at 50 uM (hme equivalent) and the plate was
incubated for 6 h at 37 #C in 5% CO2 (33).
(30,33)
Synthetic hemozoin Synthetic hemozoin was obtained by the method described by Slater et al. (1991),
with some modifications previously reported.
(64,65)
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MATERIAL AND METHODS
Samples
Free synthetic Hz, Plasmodium berghei (rodent) and Plas-
modium falciparum (human) infected RBC, as well as Hz con-
taining human peripheral blood mononucleated cells
(PBMCs) were analyzed (Table 1).
P. falciparum infected red blood cells were fixed with 2%
paraformaldehyde (PFA) and stained with SYBR green I at 1x
(Invitrogen, Carlsbad, CA, USA).
Flow Cytometric Detection of Depolarized Side
Scattered Light
Depolarized side scatter detection was implemented
using the following flow cytometers (Figs. 1 and 2):
The CyFlow Blue (Sysmex/Partec, Munster, Germany), has a
488 nm excitation laser, and detectors for Forward Scatter
(FSC), Side Scatter (SSC), green fluorescence—FL1 (BP 535/
35 nm), orange fluorescence—FL2 (BP 590/50 nm) and red
fluorescence—FL3 (LP 630 nm). For this study the instru-
ment was modified as described elsewhere (30). Briefly, two
SSC detectors were created, with a 50/50 beam splitter
between them. A polarizing filter coupled with a 488 nm fil-
ter was placed in front of one of the SSC detectors with the
filter’s axis of polarization horizontal and therefore orthogo-
nal to the vertical polarization plane of the laser light, allow-
ing the detection of depolarized side scatter.
The MoFlo high speed cell sorter (Beckman Coulter, Fort Col-
lins, CO, USA) optical set-up was modified as described in
Kr€amer 2001 and Frita 2011 (23,30). Briefly, scattered light
from a 488 nm laser (200 mW air-cooled Sapphire, Coher-
ent) was split in two using a 95/5 beam splitter to measure
normal SSC (5% of the light) and depolarized SSC (95% of
the light) by placing a polarization filter with its axis of
polarization orthogonally to the polarization plane of the
laser illumination. Both detectors had 488/10 nm bandpass
filters; O.D. 1.0 and 2.0 neutral density (ND) filters were,
respectively, fitted to the normal and depolarized SSC
detectors. SYBR-Green fluorescence, diverted by a
505DCRX dichroic filter ahead of the polarizer, was
detected through a 540/30 nm bandpass filter.
The Attune Acoustic Focusing Cytometer (Life Technologies,
Carlsbad, CA, USA) is equipped with 488 nm and 405 nm
lasers with detectors for: FSC, SSC, and six fluorescence
regions (BP 530/30, BP 574/26, LP 640, BP 603/48, BP522/
31 and BP 450/40). Two SSC detectors were created, with a
50/50 beam splitter between them, and polarizing filters
were placed orthogonally to the polarization plane of each
laser light, one in front of a detector in the violet laser opti-
cal path (VL2) and the other in front of the fluorescence
detector of the blue laser path (BL2).
The Accuri C6 (BDBiosciences, La Jolla, USA) is equipped
with a 488 nm solid state laser and a 640 nm diode laser,
detectors for FSC, SSC and four fluorescence detectors with
the following optical filters: BP 533/30 (FL1), BP 585/40
(FL2), LP 670 (FL3), and BP 675/25 (FL4). The BP 585/
40A fluorescence filter in the FL2 detector was replaced by
a 488 nm bandpass filter coupled with a plastic polarizing
filter oriented orthogonally to the polarization plane of the
laser light, allowing detection of depolarized side scatter.
Figure 1. Optical layout of three different bench top flow cytometers modified to detect light depolarization. Three bench top flow cytom-
eters were adapted to detect light depolarization caused by hemozoin. The Cyflow (Partec) and the Attune (Life Technologies) were modi-
fied similarly, briefly: two sides-scatter detectors (SSC) (red boxes) were created by placing a 50/50 beam splitter between them, and a
horizontally polarized filter (H polar) was placed in front of one of the SSC detectors. In the Attune this was done twice: for the blue and
violet lasers optical paths. The Accuri C6 (BD Biosciences) was easily modified by replacing the emission filter in front of the second detec-
tor of fluorescence with a 488 nm filter coupled with a polarizer filter with its axis in the horizontal plane; no further alterations were
required. Boxes with the blue background represent the optical components that were modified in comparison to the original set up.
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Measuring Depolarized Scatter with Different
Wavelengths Using a MoFlo
Depolarized side scatter was measured at different wave-
lengths on a MoFlo using a Coherent Innova I90C Argon laser
tuned to multiline UV at 1.10 W, 457 nm at 80 mW, 488 nm
at 80 mW, or 514 nm at 80 mW. Each laser line was used sepa-
rately, but always simultaneously with the main 488 nm Sap-
phire laser as a control. A mounted Glan–Thompson calcite
polarizer with an extinction ratio >100,000:1 (GTH10M,
Thorlabs) was placed in front of each secondary laser line.
Scattered light from the secondary laser was transmitted
through the third instrument pinhole. Normal and depolar-
ized SSC were measured using the corresponding bandpass fil-
ters (multiline UV: 350/50 nm; 457 nm: 455/30 nm; 488 nm:
488/10 nm; 514 nm: 510/20 nm; and 640 nm: 630/20 nm)
after a 70/30 beam splitter and with an orthogonally posi-
tioned polarizer filter in the 70% end of the beam splitter.
The separation index (SI) (Median Positive 2 Median
Negative)/(2 3 StdDev Negative) between the Hz-containing
cell population and the uninfected cells was calculated in
order to evaluate the capacity of each laser wavelength to
resolve these two populations, and compared with the SI
measured with the main 488 nm laser. A ratio of 1 indicates
there are no differences in the capacity of the respective wave-
length to resolve the Hz-containing cells compared to the
main 488 nm laser. One-way ANOVA with n 5 4 for each
wavelength was performed to assess whether there were statis-
tical differences between each ratio.
Microscopy
In the P. berghei infected sample, sorted cells were centri-
fuged and transferred to a glass slide, which was then fixed in
methanol and Giemsa-stained.
In the case of P. falciparum, sorted cells were left to sedi-
ment overnight. Supernatant was discarded and a 10 ll drop of
pelleted cells was placed into a glass slide which was immedi-
ately covered using a square coverslip. Leica DM5000B (Leica,
Solms, Germany) and Leica DM2500 microscopes were used
for fluorescence and depolarized microscopy, respectively.
Cell Sorting Using the MoFlo
Populations with different levels of depolarization were
sorted. The instrument was run at a pressure of 483 kPa (70
psi) with a 70 mm nozzle and a drop formation frequency of
$96 kHz. Sorting rates were typically about 3.5 3 107 cells
per hour. Cells were collected into $1 mL of PBS maintained
at 4 #C.
Flow Cytometry Data Analysis
Flow cytometry results were analyzed using FlowJo soft-
ware (version 9.0.2, Tree Star, Oregon, USA). Depolarizing
events were defined in plots of SSC versus depolarized-SSC as
those with a signal above the background observed in the
uninfected control.
To assess if the depolarization level would reflect parasite
development, parasites tagged with a green fluorescent protein
(GFP) in the case of P. berghei ANKA or stained with a fluo-
rescent DNA dye (SYBR green I) in the case of P. falciparum,
were analyzed. To determine SYBR green I or GFP positive
cells, green fluorescence (FL1) versus red fluorescence (FL3)
plots were used. SYBR green I positive events were established
based on a stained uninfected control.
The study involving human samples was approved by the
Ethical Committee of the Faculty of Medicine, University of
Figure 2. Detection of depolarizing side-scattered light by four dif-
ferent flow cytometers. Representative plots (side scatter versus
depolarized side-scatter) of mouse uninfected red blood cells
(RBCs) (left row) and RBCs infected with Plasmodium berghei
(right row). Light depolarization caused by hemozoin was detected
in four different cytometers: the Cyflow (A), the Attune (B), the
Accuri C6 (C), and the MoFlo (D). Depolarizing cells were selected
after establishing a gate using the uninfected controls (left row).
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Lisbon. All experiments involving animals were performed in
compliance with the relevant laws and institutional guidelines.
RESULTS
Detection of Light Depolarization Using Different
Instruments
The Attune, Accuri C6, CyFlow, and MoFlo could all be
set up for depolarized side scatter by making a few simple
changes to the optics, allowing restoration of the original con-
figuration within a few minutes (Fig. 1). Hz from P. berghei
iRBC could be successfully detected (Figs. 2, 3A, and Support-
ing Information Fig. S1). In fact, a CyFlow instrument located
in the rather remote location of Lambar"en"e, Gabon, was also
easily converted and used to investigate indigenous malaria
parasites from local patients.
Detection of Light Depolarization Caused by Different
Types of Hemozoin
All forms of Hz could be easily detected by measuring
depolarized side-scattered light. Intraerythrocytic Hz from
both the rodent malaria parasite P. berghei and the human
malaria parasite P. falciparum were detected, although Hz-
containing cells of these two species exhibited different levels
of depolarized side scatter (Fig. 3B and Supporting Informa-
tion Fig. S2). Hz in P. berghei iRBC showed higher levels and a
wider distribution of depolarization than Hz in P. falciparum
iRBC. PBMCs containing synthetic Hz also showed a high
level of depolarization (Fig. 3C). Free crystals of synthetic Hz
could be detected as well and showed a wide range of depolar-
ized side-scatter (Fig. 3D).
Hemozoin Induced Depolarization at Different
Wavelengths
When depolarized side scatter was measured at several
different wavelengths commonly used in flow cytometers, the
separation index (SI) ratio obtained with each wavelength in
comparison to the SI measured with the main 488 nm was
close to one (Fig. 4), indicating that there appears to be little
difference in the detection of depolarizing events, statistically
confirmed with one-way ANOVA test (n 5 4 for each
wavelength).
Identification of P. berghei and P. falciparum Infected
RBCs with Different Degrees of Depolarization
In the P. berghei-GFP infected RBCs four different pop-
ulations were selected, designated as non, low, medium and
high depolarizing (Supporting Information Fig. S1). As the
depolarization degree increases an increase in the GFP was
observed, which indicates that more mature parasites have a
higher level of depolarization (Supporting Information Fig.
S1A). Although some overlap in the GFP intensity signal
could be observed, there was a clear difference between the
highly-depolarizing and non-depolarizing populations, with
median values of GFP fluorescence of 1063 and 129, respec-
tively. Microscopic analysis of the sorted populations corro-
borated this observation, where infected RBCs with
immature parasites with no observable Hz were only present
in the non-depolarizing population. While, in the high-
depolarizing population, only parasites with large amounts
of dispersed Hz were present. Interestingly, mature parasites
with a single but large clump of Hz could be found in the
low and medium-depolarizing populations (Supporting
Information Fig. S1B).
In the case of P. falciparum infected RBCs, only two gates
were created, designated as SG1/Hz1 (depolarizing) and
SG1/Hz2 (non-depolarizing) (Supporting Information Fig.
S2). Results showed that the depolarizing population (SG1/
Hz1) had a much higher intensity of SYBR green I fluores-
cence with a median value of 3735 compared to 514 median
of the non-depolarizing population (SG1/Hz2), indicating
more DNA and thus, reflecting their more advanced stage of
development (Supporting Information Fig. S2A). Bright-field
and fluorescence microscopy of SYBR green I showed that
mature, multinucleated schizonts were only detected in the
depolarizing population, whereas single-nucleated young par-
asites were only found in the non-depolarizing population
(Supporting Information Fig. S2B).
Figure 3. Detection of intraerythrocytic, intraleukocytic and free hemozoin (Hz). Representative plots (side scatter against depolarized
side-scatter) of mouse red blood cells (RBCs) infected with Plasmodium berghei (A), human RBCS infected with Plasmodium falciparum
(B), Hz-containing phagocytes (C), and free synthetic Hz (D), analyzed using a Cyflow. The resulting depolarization of light caused by Hz
could be detected in these four different samples, however different degrees of depolarization were observed, possibly indicating a differ-
ent distribution of Hz crystals within the cells. Note: Gain values had to be adjusted for the various samples, since they had inherently dif-
ferent characteristics. However, for the depolarized side-scatter parameter the gain values did not differ considerably, ranging from 230 to
280. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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DISCUSSION
Malaria and Flow Cytometry
Cytometry of malaria-infected RBC has been used for (i)
monitoring of infected RBC, mainly in mouse models
(34–39), (ii) characterization of infected RBC (15), (iii)
assessment of maturation and/or viability of parasites in
infected RBC (10,13,14,16,17,40,41), and (iv) to detect and
count P. falciparum infected RBC in culture (14,42–44) or
from patient blood (45–47), with the possibility to distinguish
species based on base composition (2,10,11).
Reliable discrimination of parasitized RBC from
micro-nucleated RBC and/or reticulocytes can, however,
be difficult (47). Usually, this requires elaborate/laborious
manipulation steps, such as removal of RNA (12,34) or
the use of a combination of different nucleic acid stains
(13,36), frequently requiring instruments with more than
one light source, e.g., UV in the case of the frequently
used Hoechst 33342 stain. More complex protocols can be
more error-prone.
Hemozoin is a Useful and Simple Parameter to
Measure
Hz measurement is attractive as an addition and/or an
alternative to the range of cytometric measurements now
made on malaria parasites. Detection by microscopy using
simple polarizing filters (8,9) or by cytometric depolarized
scatter measurement is reagent-free and does not require
extensive sample preparation, and thus can easily be done on
native samples (31,32). Because it is produced throughout
schizogony by growing parasites, Hz is an ideal maturation
marker (48). Hz distribution and amount also vary between
species and parasite forms. For example, Hz is higher in game-
tocytes than in most asexual forms of P. falciparum, providing
aid in identification (6). Although Hz levels in early P. falcipa-
rum ring-forms are below the detection thresholds of both
dark-field microscopy (49) and flow cytometry (31) when
analyzing native samples, it may be detected in bulk in blood
after rigorous lysis of the sample (50). Even though we have
shown that free synthetic Hz can be easily detected by flow
cytometry (Fig. 3D), we have not investigated detection of
free Hz obtained after blood sample lysis. The utility and pos-
sible applications of the cytometric Hz detection in phago-
cytes (Fig. 3C) have been reviewed elsewhere (33).
Detection of Light Depolarization Caused by
Hemozoin Using Different Flow Cytometers
Compact bench top instruments, such as CyFlow SL
(Partec), the Attune (Life Technologies) or the Accuri C6
(BDBiosciences), which we show are easily modifiable for Hz
(Figs. 1 and 2), are relatively easy to run in resource-limited
environments, making it feasible for cytometric Hz measure-
ment to be more widely used.
The benchtop systems and a MoFlo sorter were all easily
modified without any special training and it was easy to
return them to their original configurations.
Although patent issues no longer impede modification of
flow cytometers for depolarized scatter, a major obstacle has
arisen with the common use of fiber optic cables, which do
not preserve the polarization of light, in the light collection
path(s) for fluorescence and side scatter. It should be noted
that, unlike the model we used, the new Attune NxT is
equipped with such fiber optics and is therefore not usable to
detect depolarized scatter.
The depolarized population detected with the Accuri C6
was not as clearly separated from the non-depolarized popula-
tion, as was the case with the other instruments (Fig. 2E). The
Accuri differs in design from the other systems in several
respects; the light that is detected in the depolarized side scat-
ter detector is not at 90# from its original path (Fig. 1), and
the detector gains are not easily adjustable by the user. More-
over, the Accuri filters and filter holders are much smaller
than those in the Attune, CyFlow, and MoFlo, limiting the
choice of optical components initially available to us. We are
awaiting arrival of parts for a new filter design that we expect
will improve performance.
The use of different beam splitters between the SSC and
depolarized SSC seemed to have little, if any influence on the
detected population (data not shown). It is noteworthy that
placing a 1:100;000 Glan polarizer into the laser illumination
path ahead of the cuvette also appeared to have little effect
(data not shown). We also found that depolarization was
adequately detectable at different wavelengths (Fig. 4), corrob-
orating the report from Kr€amer et al. (23) that side scatter
light polarization could be detected in a modified MoFlo at
wavelengths of 488, 633, and 647 nm. They noted that longer
wavelengths produced marginally stronger signals. Results
obtained from additional excitation wavelengths (UV multi-
line, 457 and 514 nm) did not differ significantly from those
obtained using a 488 nm laser (Fig. 4). Indeed, although cer-
tain longer wavelengths and perhaps a 95/5 beam splitter or
better polarization ratios might be expected to provide better
results, the light sources and wavelengths commonly used in
Figure 4. Assessing hemozoin depolarization with different
wavelengths. Bars represent ratios of Separation Index (SI; see
Methods) obtained with each wavelength in comparison to the SI
measured with the main 488 nm Sapphire laser. A ratio close to
one indicates there is no difference, confirmed statistically with
one-way ANOVA test (n 5 4 for each wavelength). Increasing laser
power did not improve separation (data not shown). Each mea-
surement represents the median value of four samples 6 Stan-
dard Error of the Mean. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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flow cytometers, 50/50 beam-splitters, and simple polarizing
filters appear sufficient for the measurement of Hz in suspen-
sion, inside infected RBCs or inside leukocytes (Fig. 3).
Flow Cytometric Detection of Intraleukocytic and
Intraerythrocytic Hemozoin
At the end of the maturation cycle, schizonts rupture,
releasing Hz which is phagocytized by circulating neutrophils
and monocytes (51). After detection of Hz leukocytes using
the Cell-Dyn hematology analyzer was reported (21), several
studies, reviewed elsewhere (26), addressed the performance
and utility of this approach.
Although finding Hz in leukocytes as part of an auto-
mated blood count might allow the detection of malaria even
in the absence of clinical suspicion, this is still only possible
using the Cell-Dyn instruments (52). These “closed” plat-
forms, which use proprietary reagents, fixed detection and
analysis algorithms and provide no ready access to list-mode
data are limited in adaptability (23,26,29). However, their
detection of intraleukocytic Hz has been correlated with
malaria severity (53–55), and flow cytometric counts of Hz-
containing leukocytes have been shown to be a better marker
of disease severity than microscopic counting (28). Intraleu-
kocytic Hz detection is also potentially applicable to the diag-
nosis of malaria during pregnancy (9).
Importantly, since Hz has immune modulating effects, as
reviewed elsewhere (33), flow cytometric detection/sorting of
Hz-containing leukocytes and non-containing leukocytes
from the same host might help elucidate further details
(30,33,56).
Hz detection by microscopy provides the foundation for
the slide-based schizont maturation assay, still a mainstay
in detecting antimalarial drug resistance in clinical settings.
Several flow cytometric procedures analogous to the
schizont maturation assay have been described by others
(13,16,17,40,57); since depolarized scatter measurements were
not available on their apparatus, they could not use Hz con-
tent as a maturation indicator for stage determination. Instead
a combination of DNA and RNA content was employed, pro-
viding more precise stage identifications than would be
obtained by cytometric detection of DNA content alone but
requiring two dyes and two fluorescence measurements.
In a classic schizont maturation assay of P. falciparum,
initial clinical samples contain little Hz because stages later
than early trophozoites are removed from circulation. Para-
sites in drug-free medium and drug-resistant parasites form
Hz as they continue to grow and mature, whereas Hz forma-
tion is diminished or absent in parasites cultured in effective
concentrations of antimalarial agents. We have shown that
schizonts in these contexts are easily distinguished from
younger parasites solely based on their level of depolarization
(Supporting Information Fig. S2), measurable without addi-
tion of reagents.
We have demonstrated a field-suitable novel flow cyto-
metric assay for antimalarial susceptibility based on this
rationale (30,32). This assay has also been shown to detect
drug effects on parasite maturation much earlier than any
other available technique (32).
Unpublished preliminary experiments with flow cytome-
ters equipped to measure DNA, RNA, and Hz simultaneously
in parasitized RBC indicate that although both RNA content
and Hz signals increase during maturation, these two parame-
ters are not highly correlated and that measuring both may
therefore provide more information about parasite physiology
than would measuring only one or the other.
P. berghei- and P. falciparum-infected RBC showed differ-
ent populations with depolarized side scatter signals. It has
long been known that the amount, appearance and location of
pigment in different species of malaria parasites show wide
variations (58). In P. berghei Hz crystals are fine and dispersed
granules which only clump together by the end of schizogony
(Supporting Information Fig. S1B, second and third panel
from top), while in P. falciparum the Hz crystals aggregate as
they start to appear (Supporting Information Fig. S2B, lower
panels). Thus, in P. falciparum forms with highly dispersed Hz
and, consequently, high degree of depolarization are absent.
This explanation also fits with the obtained depolarized side
scatter signals because side scatter is also a measure of cell
granularity (59). Therefore, it is likely that a parasite contain-
ing several small but distributed Hz crystals will have a higher
depolarized side scatter signal than a parasite containing a sin-
gle large clump of Hz.
Microscopy has shown that Hz is also more abundant
and dispersed in gametocytes (6) and our analyses of P. ber-
ghei-infected blood samples showed higher levels of depolar-
ized side scatter in gametocytes (Supporting Information Fig.
S2B). Thus, this approach can eventually be applied to aid in
the detection of these sexual forms, which are responsible for
transmission. Currently, in vitro assays to screen dugs for
gametocytes are either based on labor-intensive microscopy or
on the analysis of transgenic fluorescent gametocytes by flow
cytometry (60–62). Hz detection may be useful to help and
develop novel assays for the detection and quantification of
gametocytes, with different applications such as, the develop-
ment and investigation of novel transmission blocking drugs.
Gametocytes differ from sexual forms in that, although
their Hz signals are high and may even be higher than those of
schizonts, their RNA content is relatively low; our preliminary
experiments indicate that cytometry can resolve two gameto-
cyte populations with higher and lower modal RNA content,
presumably representing macrogametocytes (female) and
microgametocytes (male), the former known to exhibit cyto-
plasmic basophilia in Giemsa-stained smears, characteristic of
RNA staining.
Future Prospects: Malaria Cytometry in Simple
Imaging Systems
During the past few years, fluorescence imaging cytome-
ters usable for some multiparameter analyses formerly only
possible using flow cytometry, including CD41 T cell count-
ing in HIV patients and multiplexed bead PCR assays for
malaria species identification, have come into use. The DNA
and RNA dye measurements typically done in malaria
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cytometry require less sensitivity, and could be implemented
in similar apparatus. A recent report on spectral imaging of
malaria-infected cells in a microscope illuminated by multiple
LEDs suggests that Hz may be detected efficiently by transmis-
sion measurements in the 630–700 nm range (63) without a
need to use polarized light; we have also found evidence for
this. In addition to its substantially lower cost and complexity,
a multiparameter imager for malaria cytometry would offer
the considerable advantage of being able to analyze slides. We
have just begun work with a prototype of such an instrument.
CONCLUSION
The old parameter of light depolarization measurements
has found a new job in malaria. It allows to detect Hz, free in
blood or inside iRBCs erythrocytes leukocytes all of which can
be used in several applications, such as: (i) detection of Hz-
containing leukocytes for diagnostic applications and to
unravel malaria-associated immunopathology; (ii) detection
of parasitized RBC and determination of species and stages
for diagnosis and drug susceptibility determination; and (iii)
discrimination of gametocytes and other low-abundance para-
site subpopulations. Depolarized light scatter measurements
are easily implemented on common benchtop flow cytometers
and work across a wide range of illumination wavelengths;
equivalent optical measurements for Hz detection can also be
made in imaging cytometers. Adding Hz detection to other
parameters, such as DNA or RNA content, will provide
improved accuracy and sensitivity of parasite detection and
allow researchers to expand the use of cytometry in the field
of malaria.
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Transdermal Diagnosis  
of Malaria Using 
Vapor Nanobubbles








To the Editor: Establishing reliable noninvasive 
methods for diagnosis of malaria has been a challenge. 
Lukianova-Helb et al. should be applauded for developing 
such a method on the basis of hemozoin (Hz) detection (1). 
The authors reported a proof of principle and are preparing 
for “large-scale studies in humans” (2). Such large endeav-
RUVVKRXOGEHEDVHGRQ¿UPHYLGHQFHVRLWLVVXUSULVLQJWKDW
the results presented were from a single patient, remarkable 
for the unusual quadruple drug treatment (2). In such a sce-
nario, to compensate for the limited data, the results should 
EHRIFRQYLQFLQJVFLHQWL¿FTXDOLW\
However, the case described raises several doubts that 
could have been addressed, such as the reliability of the di-
DJQRVLVLIRQO\DWKLQ¿OPDQGDUDSLGWHVWZHUHXVHGFRLQ-
fection excluded) and why parasitemia was not determined 
at the time of the device test (instead of 4 hours before 
and 9 hours after). What developmental stages were the 
parasites in at the time of the evaluation (for example, al-
ready early trophozoites containing Hz or Hz-rich gameto-
F\WHV":K\ZDVWKHSDWLHQWQRWUHHYDOXDWHGWR¿QGRXWLI
repeated measurements would become appropriately nega-
tive (test-of-cure)?
The methods and results used in the study contrast 
with the extraordinary numbers for the limit of detection 
(LOD): 0.0001% in human blood and 0.00034% in a rodent 
model (1,2). However, the LOD is a virtual, inferred para-
sitemia rate based on the detection of free Hz added to un-
infected blood (1). An LOD can be obtained from serially 
diluted cultures or samples (3). In rodent models, detection 
of Hz tends to be much easier (4). Moreover, in Plasmodi-
um falciparum infections, only immature forms have been 
observed, with little or no detectable Hz (5).
The prospects of a noninvasive test for malaria are excit-
ing. However, in times of cost restraints, any diagnostic test 
RULQWHUYHQWLRQVKRXOGSURYLGHVXI¿FLHQWO\FRQYLQFLQJUHVXOWV
before consideration of resource-intensive large-scale trials.
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From the Greek haima (“blood”) + zoon (“animal”), hemozoin is a pigment produced by PDODULDSDUDVLWHVIURPKHPRJORELQLQWKHKRVW¶VUHGEORRGFHOOV7KLVSLJPHQWZDV¿UVW
observed by Johann Heinrich Meckel in 1847 in the blood and spleen of a mentally impaired 
SHUVRQ,Q5XGROI9LUFKRZPDGHWKHFRQQHFWLRQWRPDODULDEXWLWZDVLQLWLDOO\EHOLHYHG
WKDW LWZDV SURGXFHG LQ WKH SDWLHQW¶V VSOHHQ DV D SDUW RI WKH LPPXQH UHVSRQVH WRPDODULD 
In 1880, Charles Louis Alphonse Laveran observed pigmented parasites in the blood of an 
Algerian soldier and realized that the parasites, not the patient, produce “malaria pigment.” 
The term “hemozoin” was coined by Louis Westenra Sambon.
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In Response: The letter by Rebelo et al. (1) that ques-
tions our previously described noninvasive malaria diag-
nostics (2,3) misinterprets both articles. The main objec-
tion comes to our alleged call for “large-scale studies in 
humans”; no such statement appeared in our 2014 article 
(2), and in the 2015 article (3), we clearly stated that large-




Concerning the quality of the standard clinical diagno-
VLVERWKWKLQEORRG¿OPDQDO\VLVDQGUDSLGGLDJQRVWLFWHVW
UHVXOWVZHUHREWDLQHGLQDFHUWL¿HG86FOLQLFDOODERUDWRU\
and returned consistent data. The lack of re-evaluation of 
the patient and the diagnostic timing are indeed limitations 
but were caused by the clinical restrictions. Our goal in the 
2015 article (3ZDV WR GHPRQVWUDWH WKH¿UVW QRQLQYDVLYH
diagnosis of malaria in a human, which was achieved. The 
additional parameters discussed in the letter were not the 
subject of this study. Their letter further misinterprets our 
2014 study, stating that parasitemia was virtual in that ar-
ticle; in fact, we studied actual infections among mice (2).
The criticism of Rebelo et al. might have been fueled 
E\WKHLURZQOLPLWHGGHWHFWLRQRIKHPR]RLQZLWKÀRZF\-
tometry and microscopy (4), in which they used parasite 
FXOWXUHV DQG DQ XQVSHFL¿HG QXPEHU RI PDODULD SDWLHQWV
That the methods they used might not have performed well 
does not mean that the novel technology we described, 
based upon a different mechanism, would have the same 
limitations in detecting hemozoin.
In conclusion, we agree with the need for optimization 
of the technology and additional testing. We are currently 
developing and testing our technology in a malaria-endem-
ic country. Nevertheless, the letter by Rebelo et al. does not 
alter the fact that our novel noninvasive malaria diagnostic 
technology worked in a human.
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Flow Cytometry for Antimalarial Drug Testing: More than Meets
the Eye
Maria Rebelo, Thomas Hänscheid
Instituto de Medicina Molecular, Faculdade de Medicina, Lisbon, Portugal
Resistance to antimalarial drugs has been increasing, with resis-tance to artemisinins in Southeast Asia being of particular
concern. Monitoring resistance requires useful and feasible in
vitro tests, and Woodrow et al. should be applauded for their re-
port on a two-color flow cytometry assay (1), a right step in the
direction of establishing a practical, objective, alternative testing
strategy which addresses the shortcomings of other existing assays.
Despite the impressive performance of the assay, it should be
noted that this assay requires two nucleic acid stains (dihydro-
ethidium and SYBR green), whereas another recent report using
this assay format to assess drug sensitivity used only a single stain,
which is certainly a desirable improvement (2). Importantly, the
authors mention incorrectly that all flow cytometry assays are
based on nucleic acid stains (1). A review by Grimberg on this
issue already showed that viability stains are a useful alternative
(3). Furthermore, our group has shown that the flow cytometric
detection of hemozoin (Hz) is a possible reagent-free assay alter-
native, both in vitro for laboratory strains and ex vivo in the field
(4, 5).
Notably, the use of nucleic acid stains is prone to interference
by other cells. The method described requires the removal of white
blood cells, since staining DNA/RNA may interfere with measure-
ments. Although this may not require expensive materials, it cer-
tainly makes the assay much more complex and labor-intensive.
However, the most relevant question is whether the de-
scribed flow cytometric assay has the potential to detect arte-
misinin resistance. In fact, only recently, a very time-consum-
ing and complex assay was described as being able to achieve
this, the ring-stage assay (RSA). This method requires a com-
plicated and meticulous synchronization protocol and is based
on microscopic readouts (6).
In contrast, flow cytometric detection of Hz allows tracking of
parasite maturation in real time and detection of drug effects
much earlier than other phenotypic assays. This is very relevant in
the case of artemisinin resistance, as the very young parasite forms
are responsible for the observed resistance to this drug. Therefore,
this approach may be an attractive alternative to consider and
investigate in the context of artemisinin resistance testing.
In conclusion, more flow cytometric assays are available than
the one described by Woodrow et al. Some need fewer or no de-
tection reagents, such as the Hz assay, which may have the addi-
tional advantage of detecting artemisinin resistance. A prudent
approach would be considering all novel approaches, including
cytometric detection of Hz, rather than contemplating only flow
cytometry solutions with multicolor staining of nucleic acids.
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The study of human malaria, one of the most widespread infectious diseases of the globe, is an important agenda 
of today’s scientific research. It involves various methods ranging from epidemiological analysis and clinical stud-
ies to laboratory model systems such as in vitro parasite cultures in human red blood cells (RBCs) and in vivo 
rodent models. Rodent models of malaria have been widely used to study the biology and pathology of malaria 
(reviewed in ref. 1) as well as for in vivo evaluation of novel vaccine and drug candidates2,3. Rodent models were 
also applied to successfully investigate the host immune response (reviewed in ref. 1) despite their limitations to 
replicate certain aspects of the human disease4,5.
Under natural conditions the Plasmodium life cycle in the mammalian host starts with the inoculation of 
sporozoites into the skin by parasite-infected mosquitos. After inoculation the parasites rapidly reach the liver 
where they infect hepatocytes and develop into thousands of exoerythrocytic merozoites. Once released from the 
hepatocyte, the merozoites infect red blood cells, leading to the blood stage of the infection that is characterized 
by cyclic asexual replication. The duration of the liver development and the length of the asexual cycle varies 
between species. In the case of the P. berghei rodent parasites investigated here, the asymptomatic liver stage lasts 
47–52 hours and the length of one erythrocytic cycle is approx. 24 hours6,7. Experimental challenges can be car-
ried out either via the bites of infected mosquitos, or through the artificial injection of liver-infecting sporozoites 
or infected erythrocytes. The progression of the blood stage is quantitatively characterized by the percentage of 
infected RBCs, i.e. the parasitemia.
The reference method of diagnostics, light microscopy of Giemsa-stained thin blood smears, is a 
labour-intensive procedure relying on the expertise of the investigator. On the other hand, more sensitive molec-
ular methods based on polymerase chain reaction (PCR) are still not used for either the continuous monitoring 
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of laboratory experiments or for the primary diagnosis of patient samples due to their high running cost8,9. In 
laboratory studies automated approaches, such as flow cytometry are preferred and extensively used. However, 
to achieve sufficient sensitivity they often require special dyes combined with complex protocols10–12 or trans-
genic fluorescent protein-expressing parasites13–15. The use of transgenic luciferase expressing parasites has 
also been shown to accurately evaluate the pre-patent period, i.e. the time between sporozoite inoculation and 
the appearance of parasites in the peripheral circulation, and the early blood stages in a novel bioluminescent 
assay16. However, methods exploiting the chemiluminescent properties, besides being costly, are limited to animal 
models.
The need for a universally applicable and automated method for diagnostics has motivated extensive research 
on malaria pigment (hemozoin), a natural biomarker of the infection. In particular, various magnetic and/or 
optical detection schemes targeting hemozoin have been proposed17–21.
Hemozoin is a micro-crystalline heme compound produced by all Plasmodium spp. during the intraerythro-
cytic stage as they detoxify free heme derived from hemoglobin digestion22–24. The steadily increasing hemozoin 
content of the parasites acts as an optimal indicator of their maturation during the erythrocytic cycle. Indeed, the 
hemozoin-based flow cytometric detection of parasite maturation has been utilized in a novel reagent-free drug 
sensitivity assay as well25,26.
The rotating-crystal magneto-optical (MO) technique determines the concentration of hemozoin crystals via 
their linear dichroism and magnetic anisotropy27. In our recent study the sensitivity of the method has been eval-
uated using ring and schizont stages from P. falciparum in vitro cultures where detection thresholds of 0.0008% 
and 0.0002% parasitemia have been found, respectively28. These results implied that the MO method is suitable 
for the high-sensitivity detection of the infection as a laboratory tool or, eventually, as an in-field diagnostic 
technique.
Here we test the MO method in vivo by monitoring the onset of the blood-stage after sporozoite challenge in 
a malaria mouse model using P. berghei parasites. To evaluate the sensitivity of the MO technique light micros-
copy, PCR and flow cytometry were used as control methods. The clearance of hemozoin during the treatment of 




ǡƪǤ The onset of the blood-stage following P. berghei sporozoite challenges 
was monitored in three independent experiment series (A, B and C). Mice in series A and B were infected intra-
venously, while mice in series C were subjected to mosquito bites (for details see Methods). In order to evaluate 
the sensitivity of the MO method in comparison with standard techniques and to determine the time scale of 
the first positive detections, blood was drawn from mice starting at the end of the liver stage in approx. 5-hour 
intervals until the fourth day of blood-stage infection. The blood samples were examined to assess the appearance 
of the first parasites by thin smear microscopy, flow cytometry and MO measurements i) from 48 h to 132 h post 
infection (pi) in series A, ii) from 70 h to 132 h pi in series B and iii) from 56 h to 166 h in series C. For the last two 
methods the detection limit was determined as the average value plus three times the standard deviation of the 
data measured for the uninfected references (for details see Methods). Additionally, q-PCR measurements were 
performed in the early time points of the intraerythrocytic parasite development for series A and B.
The Giemsa-stained thin blood films showed the first parasites in the circulation of mice in series A and B 
between 66–75 h pi with one exception, when parasites were observed only at 85 h pi (Fig. 1a). The first occur-
rences of positive microscopy results show small variation in these controlled infections and coincide well with 
the estimated end of the first erythrocytic cycle (approx. 70–75 h). In series C the first parasites were observed in 
the same time interval (61–71 h pi), however in these cases only single parasites were found in the smears until 
76 h pi (Fig. 2a).
Real-time PCR analysis was performed on blood samples drawn from mice in series A between 48–66 h pi and 
from mice in series B at 70 h pi. Results in Fig. 1c show that the difference in the PCR signal between the infected 
and non-infected samples becomes significant at 56 h pi, and gradually increases for later samplings. These PCR 
data are in good agreement with previous findings described by Zuzarte-Luis et al.16 under similar experimental 
settings and they confirm the onset of the blood stage with the expected high sensitivity.
Flow cytometric analysis was also performed for measurement series A and C (Figs 3 and 4, respectively). 
In these experiments two different parameters were assessed simultaneously: i) fluorescence of GFP expressing 
parasites13 and ii) depolarized side scattering (DSS) properties of the hemozoin-containing red blood cells17,18. 
As an inherent advantage of flow cytometry, parasite counts can be determined in both cases directly. However, 
the number of GFP- and DSS-positive events may quantitatively differ as fluorescence detects all erythrocytic 
stages13, while DSS exposes only that fraction of parasitized RBCs that contain a sufficient amount of hemozoin17. 
Accordingly, the GFP positive events are used to assess parasitemia, while the DSS detection, similarly to MO and 
PCR yields indirect measure of the parasite burden.
The DSS and GFP values for series A, shown in Fig. 3, are scattered below the detection limit until 85–90 h 
pi, when both signals start to increase monotonically and the onset of the blood stage is confirmed with the first 
positive parasite counts of 0.04% and 0.12%, respectively. As expected the parasitemia counts determined by fluo-
rescence were higher at any time point than the corresponding DSS values. In summary, both cytometric methods 
confirmed the onset of the blood-stage in the middle of the second erythrocytic cycle.
The flow cytometric curves of mice in series C show larger individual variation than those in series A (Fig. 4). 
The GFP and DSS signals exceed the detection limit between 95–120 h pi. In average the first positive GFP and 
DSS detections can be placed in the beginning and the second half of the 3rd cycle, respectively. The average 
www.nature.com/scientificreports/
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Figure 1. Onset of the blood-stage in series A and B (intravenously infected mice) monitored by light 
microscopy, the magneto-optical method and q-PCR. (a) Microscopic examination of Giemsa-stained thin 
blood smears of mice in series A and B. + signals indicate that at least one parasite was found in the whole of 
the smears (approx. 20–40 fields), − signals mean that no parasites were detected in the smears. (b) The results 
of the MO measurements. Each circle (square) represents the MO signal of an infected mouse in series A (B) at 
a given time point after sporozoite injection. The continuous black line represents the average of the MO values 
of five uninfected control mice measured in all time points. The dashed black line is the detection limit defined 
as the average plus three times the standard deviation of the uninfected values (for details see Methods section). 
The MO signals of series A exceed the detection limit at 66 h pi. The MO signals of all mice in series B exceed 
the detection limit already at the first, 70 h sampling point. The background shading illustrates the estimated 
layout of the first three erythrocytic cycles of series A. (c) Results of the q-PCR measurements plotted by circles 
(squares) for series A (B). The error bars represent the standard deviation of technical duplicates. The ◽  
represent measurements on three uninfected controls and the real-time control mouse at 48 h and 61 h.
Figure 2. Onset of blood stage infection of series C (mosquito-infected mice) monitored by light 
microscopy and the magneto-optical method. (a) Microscopic examination of Giemsa-stained thin blood 
smears of mice in series C. + signals indicate that at least one parasite was found in the whole of the smears 
(approx. 20–40 fields), while − signals mean that no parasites were detected in the smears. (b) The results of 
the MO measurements. Each triangle represents the MO signal for a given mouse in series C at a given time 
point after the mosquito challenge. The continuous black line represents the average of the MO values of five 
uninfected control mice measured in all time points. The dashed black line is the detection limit defined as 
the average plus three times the standard deviation of the uninfected values (for details see Methods section). 
The MO signals of mouse C-1, C-2 and C-3 exceed the detection limit at 71 h, 76 h and 95 h, respectively. The 
background shading illustrates the estimated layout of the first three erythrocytic cycles.
www.nature.com/scientificreports/
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Figure 3. Monitoring parasitemia during the progression of the infection in series A and B via flow 
cytometry and light microscopy. (a) The results of the DSS measurements. The circles represent the 
percentages of DSS positive events in the total population of RBC counts for a given mouse in series A. The 
continuous black line represents the average signal of the uninfected reference, while the dashed black line is the 
detection limit defined as the average plus three times the standard deviation of the uninfected values (for 
details see Methods section). The DSS signals of all mice in series A unambiguously exceed the detection limit at 
90 h pi. (b) The results of the GFP measurements. The notation of the symbols is the same as in panel (a). The 
GFP percentages of mouse A-1, A-2 and A-3 exceed the detection limit (dashed line) at 85 h, 85 h and 109 h pi, 
respectively. The background shading illustrates the estimated layout of the first three erythrocytic cycles. Note 
the different vertical scales in graphs (a,b). (c) Averaged parasitemia values determined by light microscopy 
after 90 h pi at the inspected time points of series A ( ) and B ( ).
Figure 4. Monitoring parasitemia during the progression of the infection in series C via flow cytometry. (a) 
The results of the DSS measurements. The triangles represent the percentages of DSS positive events in the total 
population of RBC counts for a given mouse in series C. The continuous black line represents the average signal 
of the uninfected references, while the dashed black line is the detection limit defined as the average plus three 
times the standard deviation of the uninfected values (for details see Methods section). The DSS percentages 
of mouse C-1, C-2 and C-3 exceed the detection limit at 101 h, 120 h and 120 h pi, respectively. (b) The results 
of the GFP measurements. The notation of the symbols is the same as in graph (a). The GFP percentages of 
mouse C-1, C-2 and C-3 exceed the detection limit (dashed line) at 95 h, 100 h and 120 h pi, respectively. The 
background shading illustrates the estimated layout of the first three erythrocytic cycles. Note the different 
vertical scales in graphs (a,b).
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parasitemia measured by fluorescence at the time points of the first positive detection is approx. 0.04% and the 
average DSS percentage is 0.07%.
The MO values of the A and B series (Fig. 1b) clearly exceed the detection limit at 66 h pi and 70 h pi, respec-
tively. (Note that no measurements were performed on series B before 70 h pi). The MO measurements of the 
two series exhibit very similar tendencies and indicate that circulating parasites could be detected by the MO 
method as early as 66 h pi. The MO signals of the mosquito-infected mice in series C surpass the detection limit 
in the broad interval of 71–95 h pi. This large variation of the earliest detections is in agreement with the results 
of microscopy and flow cytometry, and is indeed expected due to the uncontrolled size of the inocula charac-
terizing the natural infections. The delayed detection as compared to the A and B series suggests a lower initial 
parasite load as seen in the flow cytometric measurements. Nevertheless, the onset of the blood stage still could 
be detected in the first erythrocytic cycle for two out of three mice.
ǦǤ After establishing 
the first time points of erythrocytic parasite detection by microscopy, PCR, flow cytometry and the MO method, 
the progression of the infection at later time points was monitored by microscopy, flow cytometry and the MO 
method until day 6 and 7 pi in series A and C, respectively.
In series A and B the parasitemia values, as measured both by flow cytometry and microscopy, reached the 
level of 0.1–0.5% on day 4 pi (90–100 h timeframe) similarly to the results of Ploemen et al.29, where experiments 
were performed with similar initial sporozoite loads. In the case of series C this parasitemia range was reached 
only at the end of the fifth day (120 h) as a result of the considerably lower initial sporozoite load.
In Fig. 1b the MO signals of all three infected mice from series A show the same profile after exceeding the 
detection limit: the MO signal increases rapidly, interrupted by a distinct drop at 76 h. Following another steadily 
increasing period a drop of the increase rate can be identified between 90–109 h pi. The same behavior is observed 
for series B with only slight variations in the positions of the drops, observable at 80 h, 100 h and 125 h. While the 
drops at the early time points (76 h and 80 h) are clearly visible with a 65% and 75% reduction of the MO signal 
for series A and B, respectively, at later time points they are less pronounced.
In conclusion, the overall time dependence of the MO signal is very similar in all intravenously initiated infec-
tions. These results, supported by similar observations in flow cytometry and microscopy (Fig. 3a–c), suggest that 
the early blood stages of these controlled infections followed quite similar courses and that this progression could 
be reliably monitored by the MO measurements.
The MO curves of series C (Fig. 2b) show similar features to that of series A and B, but the signals of the indi-
vidual animals reveal bigger variation as also found by the reference methods. It can be noted that the MO values 
of mice C-1 and C-2 exceed the detection limit already in the first erythrocytic cycle as found in series A and B, 
where mice were infected with considerably higher parasite loads.
The time evolution of the MO signal can be explained by considering that the total hemozoin concentration 
in the peripheral circulation is measured by this method. This includes crystals present within the parasites, free 
in circulation and/or inside phagocytic cells at the moment of blood sampling. Consequently, changes in the 
signal magnitude in the early phases of blood stage development are likely to result from two dynamic processes: 
i) the continuous production of hemozoin by the circulating parasites increases the MO signal and ii) the clear-
ance of free hemozoin or hemozoin-containing phagocytes decreases the MO signal. If these two processes have 
comparable rates in a synchronous infection at a given parasite density, the MO signal is expected to pursue the 
following course: (i) gradual increase from the beginning of the first cycle, (ii) reaching a maximum at the end of 
the cycle when mature schizonts have maximal hemozoin content, (iii) decrease due to the rupture of iRBCs and 
the subsequent hemozoin clearance and (iv) turnover and increase due to the hemozoin production of the new 
generation of parasites.
In P. berghei infections the egress of merozoites from hepatocytes is expected around 48–52 h after sporozoite 
injection6,7 and the length of the asexual life cycle is 22–24 h7. Accordingly, the first intraerythrocytic cycle is 
expected to end between 72–76 h pi. This timeframe coincides well with the peak of the MO signal at approx. 
72–75 h pi followed by the drop at 76–80 h pi observed both in series A and B. These observations indicate that 
the first parasites detected by the MO method around 66 h pi were approx. 14–16-hour-old parasites of the first 
synchronous life cycle. The additional drops observed with approx. 24-hour periodicity indicates that a partial 
synchronicity is preserved over a couple of cycles. The decreasing magnitude of subsequent drops indicates that 
synchronicity is eventually lost as known for P. berghei infections7,30.
In the first erythrocytic cycle the parasitemia levels were not quantifiable accurately by microscopy or by 
flow cytometry, but they can be estimated using the parasitemia values measured in the following cycles and the 
~10-fold multiplication rate characterizing the first few erythrocytic cycles of the P. berghei ANKA parasites31,32. 
This multiplication rate is also confirmed by the 10-fold increase of the MO values between the ends of consecu-
tive cycles. The average parasitemia for series A and B was in the range of 0.1–0.3% at the end of the second cycle. 
Accordingly, in these two series the parasitemia level of the first cycle was approx. 0.01–0.03%. For series C, the 
parasitemia values measured by GFP-detection at the end of the third intraerythrocytic cycle (Fig. 4b) were 0.6%, 
0.2% and 0.04% for mouse C-1, C-2 and C-3, respectively. Accordingly, the average parasite loads for the three 
mice at the time of the first positive MO detection was approx. 0.004%.
Ǥ In this study 5 mice (identified as T-1… 5) with 
severe P. berghei infections were treated by the daily administration of chloroquine for seven days. Their MO 
signal was measured during the treatment and for nine consecutive days in order to study the clearance of the 
parasites and to determine the time interval after which the MO signal is reduced to the detection level.
The first blood samples were collected from mice T-1, T-3 and T-4 on the first day of treatment (day 0 in Fig. 5). 
The corresponding parasitemia values, determined by microscopy, were 15%, 20% and 11% and the corresponding 
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MO values were 3.76, 5.20 and 2.78, respectively. Since mice were anemic on the first day of treatment, no 
further blood collection was performed until the administration of the fourth dose of chloroquine (day 3). 
Subsequent blood samplings were performed as indicated in Fig. 5.
The MO signals of all the studied mice follow very similar decreasing trends. The substantial decrease in para-
sitemia (0.16% ± 0.07% and 0.06% ± 0.04% on day 3 and 4, respectively) caused by the administration of the first 
three doses of chloroquine is reflected in the rapid (approximately two orders of magnitude) decrease of the MO 
signal observed between day 0 and day 3.
On day 5, no viable parasites were observable by light microscopy in any of the mice. Consequently, the MO 
signal measured between days 5–7 is attributed to hemozoin crystals released from ruptured schizonts remain-
ing in the circulation either freely or inside phagocytes33,34. The clearance rate with an approximate half-life of 
24 hours is in agreement with the observations of mid- and long-term hemozoin kinetics reported for in vivo 
P. berghei infections33. By day 10 the MO signals in all treated mice was reduced to the detection limit and 
remained at this level for the consecutive two days, confirming the absence of the infection and yielding true 
negative diagnostic results.

The rotating-crystal magneto-optical diagnostic method has demonstrated excellent sensitivity to detect low con-
centrations of synthetic hemozoin crystals27 and low parasite densities of P. falciparum in vitro cultures28. Besides 
its in vitro sensitivity the method fulfills the most important technical requirements for in-field applicability: 
the measurement is automated, it is label- and reagent-free, and the device can be designed into a commercially 
available format27,28. In the present study the in vivo efficiency of the method was investigated by comparing its 
performance to well-known techniques.
In the investigated P. berghei infections the first erythrocytic parasites were already detectable at the late ring 
stage 66 h pi when mice were injected with 50,0000 sporozoites. In experiments when mice were subjected to 
mosquito bites the course of infection showed larger individual variation: in two cases the infection was detected 
at the end of the first cycle and in one case in the second half of the second cycle. Based on these results we 
conclude that the performance of the MO method is similar that of light microscopy. This performance is only 
exceeded by the laboratory-grade q-PCR (with detection as early as 56 h pi). In later time points the quantitative 
monitoring of the progression of the infection was also feasible with the MO method.
The blood stage of P. berghei infections has three important aspects that influence the hemozoin levels observ-
able in the peripheral circulation: (i) the reticulocyte preference; (ii) the asynchronicity of later cycles and (iii) that 
the late schizonts tend to sequester in organs35. The first two properties are also typical features of the blood stage 
of P. vivax human infections. In this respect the current P. berghei experiments can be regarded as a simple model 
for the MO diagnostics of P. vivax infections.
The stage distribution of intraerythrocytic parasites in the case of P. falciparum infections, however, is differ-
ent. In the latter case parasites older than mid-stage trophozoites tend to cytoadhere to the endothelium, thus the 
young forms present in the circulation contain little or no hemozoin. Clearly, this scenario is different from the 
P. berghei infection model, where only the very late schizonts sequester. However, the present study yielded two 
results with important implications for the detection of P. falciparum infections: (i) the first generation of parasites 
in the late-ring stage were already detectable and (ii) the MO results obtained during treatment of mice show that 
there is a substantial amount of hemozoin crystals circulating in the blood stream for a few days after schizont 
rupture. These observations indicate that the MO method has potential to detect human P. falciparum infec-
tions as well, either via the lesser amounts of hemozoin present in the blood sample inside the freely circulating 
late-stage rings or by detecting the hemozoin that is released from the sequestered schizonts after the rupture of 
Figure 5. Monitoring parasite clearance during treatment by the MO method. The MO values of five mice 
were measured during and post treatment (T-series). Each colored triangle represents the MO value of a given 
mouse on a given day after the start of the treatment. The continuous black line represents the average of the 
MO values of five uninfected control mice measured in all time points. The dashed black line is the detection 
limit defined as the average plus three times the standard deviation of the uninfected values (for details see 




iRBCs. During the treatment of infected mice we found that the period of false positive outcomes after successful 
treatments is limited to four days implying a similar scenario in the case of human infections.
Though the extrapolation of the results of rodent malaria experiments to human infections is never straight-
forward, we believe that the present study provides a solid basis for the implementation of in-field tests, which will 
assess the real performance of the method for the diagnostics of human infections.

ǡǤ In experiment series A and B, four and three BALB/c mice (Charles 
River, Spain) were infected, respectively, with the transgenic P. berghei ANKA (259cl2) that constitutively 
expresses GFP during the whole life cycle. Sporozoites were obtained by the disruption of the salivary glands of 
freshly dissected, infected female Anopheles stephensi mosquitoes and collected in DMEM (Dulbecco’s Modified 
Eagle Medium from GIBCO). Mosquitoes were bred at the insect facility of the Instituto de Medicina Molecular. 
Each mouse was inoculated by the retroorbital injection of 50,000 sporozoites.
Blood was collected from the tail vein according to the following schedule: in series A sampling started at the 
time point of 48 h pi and it was carried out in 5-hour intervals until 80 h pi; in series B sampling started only at 
70 hours pi and two additional samples were taken at 75 h and 80 h pi. After 80 hours blood was collected daily 
in both series until the 5th day post infection. Blood samples were collected for microscopy, PCR, flow cytometry 
and the MO method at each time point.
In series C three mice were subjected to five P. berghei-infected mosquitos for 20 minutes, individually. The 
method of blood sampling and its schedule was the same as in series A.
In the treatment measurements (T-series), five mice with severe P. berghei ANKA infection were treated by the 
daily administration of 7 mg/ml of chloroquine for seven days. Mice exhibited anemia on the first days of treat-
ment and thus, no further blood was collected until the administration of the fourth dose of chloroquine (day 3). 
On this day blood samples from 4 mice were analyzed again by the MO method and by light microscopy. Further 
blood sampling and analysis was performed on days 4, 5, 7, 10, 12, and 13, as shown in Fig. 5.
Ǥ This study was approved by the Ethical Committee of the Faculty of Medicine, University 
of Lisbon. All experiments involving animals were performed in compliance with the relevant laws and institu-
tional guidelines. Animals were monitored daily and every effort was made to minimize their suffering. Upon 
completion of the experiments, mice were euthanized by administration of CO2 followed by cervical dislocation.
Ǥ Blood parasitemia was monitored by the microscopic analysis of Giemsa-stained 
thin blood smears at each measured time point. Smears were fixed in absolute methanol and stained with 10% 
Giemsa-solution prepared in PBS 1X.
The presence of parasites in the early time points, i.e., before 90 h post-infection was determined by light 
microscopic examination of whole smears (approx. 20–40 fields, i.e. approx. 7,000–14,000 scanned RBCs) with 
1000× magnification using a bright-field microscope (Leica, Solms, Germany) performed by two microscopists, 
independently. At later time points percentages of infected red blood cells and approximate age distribution of the 
parasites was assessed by light microscopic examination of 5–10 fields (approx. 1800–3600 RBCs).
ǦǤ All reagents were purchased from Sigma Aldrich (St Louis, Mo, USA) 
unless stated otherwise.
For the magneto-optical measurements 30 μl of blood was transferred from each mouse directly into 570 μl 
of lysis solution (0.066 V/V% Triton X-100 in 3 mM NaOH). The lysed sample was measured after 5 minutes, to 
enable the hemozoin crystals to be liberated from the RBC’s and from the parasites and become homogenously 
dispersed in the liquid27. MO measurements were performed using a volume of 450 μl from each lysed sample.
The scheme of the MO setup, as well as the underlying physical principles of the detection method, are 
described in detail in former studies27,28. Briefly, the lysed sample, filled into a cylindrical sample holder, is 
inserted into the center of a ring-shaped assembly of permanent magnets, which creates a strong uniform mag-
netic field (B = 1T) at the sample position. This magnetic field induces the co-alignment of the hemozoin crystals 
and when the magnetic ring is rotated, the co-aligned hemozoin crystals follow this rotation. During the meas-
urement polarized light from a laser diode is transmitted through the sample in the direction perpendicular to the 
plane of the rotating magnetic field. The rotation of the co-aligned dichroic crystals gives rise to a periodic change 
in the transmitted intensity (ΔT), which – divided by the time-averaged intensity (T) – corresponds to the meas-
ured MO signal (ΔT/T in %). The overall time required for the full MO measurement process is a few minutes.
The level of the detection limit was determined as the mean plus three times the standard deviation of the 
MO signals measured on the following samples: one control mouse in series A, which was measured at the same 
time points as the infected ones of the same series; and four controls in series C also measured together with the 
infected animals of the same series. For clarity we only plot the average of the uninfected values (black line) and 
the corresponding detection limits (dashed black line) in graphs Figs 1b, 2b and 5. The individual results of the 
control measurements are plotted in Fig. 3 of the Supplementary information.
Ǥ At the selected time points 5 μl of blood was collected from the tail 
vein into 200 μl of PBS 1X. DNA extraction was performed using the DNeasy Blood & Tissue Kit (Quiagen, USA), 
according to the manufacturer’s instructions. Real-time PCR analysis was performed in duplicates using 2 μl 
of DNA and the iTaq Universal SYBR Green Supermix from Bio-Rad according to the manufacturer’s instruc-
tions. Expression levels of 18 s rRNA were normalized against the housekeeping gene seryl-tRNA synthetase 
(PbANKA_061540). Gene expression values were calculated based on the ΔΔ Ct method. Primer pairs used were: 
PbA 18S rRNA: 5′ GGAGATTGGTTTTGACGTT TATGTG3′ and 5′ GGAGATTGGTTTTGACGTTTATGTG3′ ; 
PBANKA_061540: 5′ ATTGCTCAACCTTATCAAACTG3′ and 5′ AGCCACATCTGAACAACCG3′ .
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	Ǥ A volume of 5 μl of blood was collected and diluted in 1 ml of PBS 1X 
at each time point for each mouse. This blood suspension was analyzed in the CyFlow® Blue instrument (Partec, 
Munster, Germany), which is equipped with a 488 nm excitation laser, and has detectors for forward scatter 
(FSC), side scatter (SSC), green fluorescence – FL1 (BP 535/35 nm), orange fluorescence – FL2 (BP 590/50 nm) 
and red fluorescence – FL3 (LP 630 nm). For this study the setup was modified as described previously16,17. Flow 
cytometry data were analyzed using FlowJo software (version 9.0.2, Tree Star Inc., Oregon, USA). Depolarizing 
events were defined in plots of side-scatter (SSC) versus depolarized-SSC as those with a signal above the back-
ground observed in the uninfected control. GFP positive cells were determined in green fluorescence (FL1) versus 
red fluorescence (FL3) plots.
In measurement series A one uninfected control was used to define GFP positive cells, which consisted of the 
ones with green fluorescence levels above the uninfected control. The detection limit of the whole DSS (GFP) 
measurement series (dashed lines in Fig. 3a,b) was determined as the average plus three times the standard devi-
ation of the DSS (GFP) positive events measured on the uninfected control mouse in all of the investigated time 
points (not shown in the graphs).
In measurement series C the level of the detection limit (dashed lines in Fig. 4a,b) of the whole DSS (GFP) 
measurement series was determined as the mean plus three times the standard deviation of the DSS (GFP) pos-
itive events measured on the blood samples of four uninfected controls in the same time points as the infected 
mice (not shown in the graphs).
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Residence within a customized vacuole is a highly successful
strategy used by diverse intracellular microorganisms. The para-
sitophorous vacuole membrane (PVM) is the critical interface
between Plasmodium parasites and their possibly hostile, yet
ultimately sustaining, host cell environment. We show that tor-
ins, developed as ATP-competitive mammalian target of rapamy-
cin (mTOR) kinase inhibitors, are fast-acting antiplasmodial com-
pounds that unexpectedly target the parasite directly, blocking
the dynamic trafficking of the Plasmodium proteins exported
protein 1 (EXP1) and upregulated in sporozoites 4 (UIS4) to the
liver stage PVM and leading to efficient parasite elimination by
the hepatocyte. Torin2 has single-digit, or lower, nanomolar po-
tency in both liver and blood stages of infection in vitro and is
likewise effective against both stages in vivo, with a single oral
dose sufficient to clear liver stage infection. Parasite elimination
and perturbed trafficking of liver stage PVM-resident proteins are
both specific aspects of torin-mediated Plasmodium liver stage in-
hibition, indicating that torins have a distinct mode of action com-
pared with currently used antimalarials.
host-parasite interactions | malaria | protein trafficking | P. falciparum
The population at risk for developing malaria is vast, com-prising some 3.3 billion people particularly in sub-Saharan
Africa and Southeast Asia, with mortality estimates ranging from
655,000 to 1,200,000 (1). Widespread resistance has limited the
therapeutic utility of most existing antimalarial drugs, and artemisi-
nin, the highly efficacious cornerstone of artemisinin combination
therapies, appears to be at risk for the same fate (2). The need for
new antimalarial chemotherapeutic strategies is thus acute.
Plasmodium spp., the causative agents of malaria, have a complex
life cycle with alternating motile-nonreplicative and sessile-replica-
tive forms in both mammal and mosquito. In the mammalian host,
Plasmodium invades and replicates inside two very distinct cell
types: hepatocytes and red blood cells (RBCs). In mammals, the
Plasmodium life cycle is initiated by a motile sporozoite that invades
a hepatocyte, where it resides for 2–14 d, multiplying into >10,000
merozoites in a single cycle (3). Once released into the bloodstream,
each of these motile merozoites will infect an RBC and, within 1–3
d, generate 10–30 new merozoites, which will contribute to the
continuous cycle of blood stage infection that causes the symptoms,
morbidity, and mortality of malaria.
These two stages of mammalian infection, despite taking place
in distinct cell types and having an orders-of-magnitude difference
in parasite replication, do share common features. In both, the
motile “zoite” invades the host cell through formation of a para-
sitophorous vacuole (PV). Both stages grow and replicate exclu-
sively within the confines of the PV, and the parasitophorous
vacuole membrane (PVM), which is populated with parasite pro-
teins, constitutes the physical host–parasite interface throughout
development. Unlike the vacuoles of many intracellular pathogens
including Leishmania, Chlamydia, Mycobacteria, and Legionella
(4, 5), the Plasmodium vacuole, like that of Toxoplasma gondii,
does not fuse with host lysosomes and is not acidified (6). This is
not unsurprising in the context of Plasmodium development in an
RBC, which lacks endomembrane system trafficking and, indeed,
lysosomes. The highly polarized hepatocyte, however, has exten-
sive vesicular transport networks (7) and can target intracellular
pathogens residing in a vacuole (8), suggesting that the exo-
erythrocytic form (EEF) may need to resist host cell attack.
Although the PVM is thought to be critical for Plasmodium
growth in both the hepatocyte and the RBC contexts, its cellular
roles remain elusive. The importance of several Plasmodium
PVM-resident proteins, however, has been conclusively demon-
strated in both blood and liver stages. Attempts to generate
exported (exp)1 and Plasmodium translocon of exported protein
(ptex)150 knockout parasites in Plasmodium falciparum failed (9,
10), revealing that these are both essential proteins for the blood
stage, whereas Plasmodium berghei and Plasmodium yoelii
mutants lacking up-regulated in sporozoites (uis)3 or uis4 fail to
complete liver stage development (11, 12). These PVM-resident
proteins, and thus the PVM itself, are performing functions that
are crucial for Plasmodium growth, but delineating the functions
of individual PVM-resident proteins has proven as difficult as
identifying the cellular processes mediated by the PVM.
Significance
Plasmodium parasites have two distinct intracellular growth
stages inside the mammalian host—the first stage, which is
clinically silent, in liver hepatocytes, and the second, which
causes the symptoms of malaria, in red blood cells. This study
reports the discovery of a class of antimalarial compounds
called torins, which are extremely potent inhibitors of both
intracellular stages of Plasmodium. We show that torins block
trafficking of liver stage parasite proteins to the physical host–
parasite interface, called the parasitophorous vacuole mem-
brane (PVM), and that without continuous trafficking of PVM-
resident proteins, the parasite is subject to elimination by its
host hepatocyte.
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The one process in which both the centrality of the PVM is
known and evidence for the participation of specific PVM pro-
teins exists is the export of parasite proteins to the RBC. A cohort
of parasite proteins that are involved in extensive physiological
and structural modifications of the infected RBC (iRBC) is
exported into the iRBC cytoplasm and beyond (13). Five proteins
have been identified as components of PTEX, the proposed ex-
port machinery at the iRBC PVM (9). Although liver stage
protein export has been shown for the Circumsporozite (CS)
protein (14) and PTEX components are expressed in P. falcipa-
rum EEFs (15), a role for parasite protein export into the he-
patocyte remains speculative; the host hepatocyte may not
require the extensive structural remodeling that the iRBC does.
Conversely, however, the hepatocyte, with its extensive vesic-
ular transport network, intuitively constitutes a more hostile host
environment than the RBC, and there is evidence that the liver
stage PVM may play a crucial role in preventing host cell-
mediated parasite killing, as it does in Toxoplasma gondii (16).
Support for a protective role for the liver stage PVM comes from
knockout parasites that fail in the earliest steps of PVM for-
mation and remodeling. Sporozoites lacking the p52/p36 gene
pair invade hepatocytes successfully, but fail in PVM formation
(17, 18) and are severely reduced in abundance midway through
liver stage development. Parasites lacking slarp/sap (19, 20), a
regulator of early liver stage development, fail to express UIS4
and exported protein 1 (EXP-1), along with other parasite pro-
teins, and are also eliminated at the beginning of infection.
Acquisition of resources from the host-cell environment, an
unambiguous requirement for an obligate intracellular parasite
like Plasmodium, is a function ascribed to the PVM in both
mammalian stages. The PVM allows the free passage of molecules
(21, 22), presumably through proteinaceous pores, which may
contribute to acquisition of host nutrients and disposal of parasite
waste products. Members of the early transcribed membrane
protein (ETRAMP) family, single-pass transmembrane proteins
conserved among Plasmodium spp., which are highly expressed
and developmentally regulated in both blood and liver stage par-
asites (23, 24), could be candidates for mediating uptake of host
resources. Such a role in lipid uptake has indeed been proposed for
the P. berghei ETRAMP UIS3 on the basis of its interaction with
host-cell L-FABP (liver fatty acid binding protein) (25).
Although Plasmodium parasites must use host resources to
support their own growth in both mammalian stages, the single
cycle replicative output of the liver stage parasite is vastly greater
than that of the blood stage, which may reflect a similarly increased
need for host resources. In this respect, the hepatocyte constitutes
far superior “raw material” compared with the RBC; hepatocytes
are not onlymetabolically active, but also highly versatile cells, which
are capable of altering uptake, storage, production, and degradation
of a wide array of macromolecules in response to cellular and or-
ganismal requirements. The presence of a growing Plasmodium
parasite is sensed by the host hepatocyte, which responds with acti-
vation of cellular stress responses and altered metabolism (26, 27).
The mammalian target of rapamycin (mTOR) kinase integrates
signals from amino acids, stress, oxygen, energy, and growth factors
and responds by altering cellular protein and lipid synthesis, as well
as autophagy (28). As such, we sought to determine how inhibition
of host mTOR signaling would affect Plasmodium liver stage de-
velopment. Here we show that torins, a single structural class of
mTOR inhibitors, are highly potent antiplasmodial compounds
targeting both mammalian stages in vitro and in vivo. Independent
of host-cell mTOR, torins impair trafficking of Plasmodium liver
stage PVM-resident proteins, revealing the fast turnover of these
proteins at the liver stage PVM, and provoke elimination of liver
stage parasites.
Results
Torins Potently Inhibit Plasmodium Liver and Blood Stages. We first
tested whether Plasmodium infection could be modulated by
inhibition of host mTOR signaling using two unrelated mTOR
inhibitors (see Table S1 for structures, reviewed in ref. 29):
rapamycin, a naturally occurring macrolide that is an allosteric
mTOR inhibitor, and Torin1, a tricyclic benzonaphthyridinone
developed through medicinal chemistry efforts as an ATP-com-
petitive inhibitor (30). We plated two human hepatoma cell lines,
Huh7 and HepG2, and infected the cells with GFP-expressing
P. berghei sporozoites. Two hours after infection, by which time
sporozoite invasion is completed, cells were switched into me-
dium containing 250 nM of either rapamycin or Torin1. Control
cells were treated with DMSO alone (vehicle control). Infection
parameters were quantified by flow cytometry 48 h after sporo-
zoite addition. In both cell lines, the effects of the two mTOR
inhibitors were strikingly different. Treatment with rapamycin led
to a modest increase in the proportion of infected cells (number
of GFP+ cells) (Fig. 1A), or parasite development (Fig. 1B), as
indicated by the geometric mean of the GFP signal intensity,
which correlates with parasite development (31). Treatment with
Torin1, however, eliminated the vast majority of parasites in both
cells lines (Fig. 1A; HepG2 P < 0.0001) and blocked the develop-
ment of those few that remained (Fig. 1B; HepG2 P < 0.0001).
These results were confirmed by microscopy, and representative
examples of control, rapamycin-treated, and the rare remaining
Torin1-treated EEFs are shown in Fig. 1C.
A Torin1 analog with properties more amenable to large-scale
synthesis and in vivo use was recently reported (32). We next
synthesized and tested this analog, Torin2, for antiplasmodial ac-
tivity. Dose–response analysis revealed that Torin2 is an∼100-fold
more potent an inhibitor of Plasmodium liver stage growth than
Torin1; the calculated cellular EC50 of Torin1 and Torin2 for
parasite development was 106 nM 95% confidence interval (CI)
101–107 nMand 1.1 nM (95%CI 0.95–1.33 nM), respectively (Fig.
1D). Furthermore, a single dose of 10 mg/kg Torin2, administered
to mice 2 h after infection with 10,000 sporozoites, led to a highly
significant reduction inPlasmodium liver load (Fig. 1E,P< 0.0001)
40 h postinfection. In a controlled physiological infection model
with infection initiated by 500 P. berghei-GFP sporozites, the same
10 mg/kg dose of Torin2 was curative. Control mice became blood
stage positive by flow cytometry detection of GFP from day 4 to 6
postinfection, but none of the Torin2-treated animals ever de-
veloped blood parasitaemia by day 11 (Fig. 1F). Theflow cytometry
data were confirmed by microscopic examination of thin blood
smears for all of the Torin2-treated animals.
The discrepancy between the extremely potent inhibition of
P. berghei EEFs by the torins and the slight (and opposing) effects
of rapamycin led us to wonder whether the antiplasmodial activity
of the torins was really mediated by host mTOR. As a first step in
addressing this, we tested if the inhibitory effects of the torins
would extend to P. falciparum asexual blood stages, as the mature
enucleate RBCs in which P. falciparum replicates have no cata-
bolic capacity for mTOR to stimulate. Torin1 (200 nM) and
Torin2 (10 nM) were added to synchronized P. falciparum 3D7
ring stages, and parasite replication and reinvasion were assessed
by flow cytometry 48 h later. iRBCs were identified based on
SYBR green labeling of P. falciparumDNA. Strikingly, both Torin1
and Torin2 blocked parasite development and completely pre-
vented reinvasion, as evidenced by the static parasitemia, compared
with the DMSO-treated control (Fig. 2A, P < 0.0001 for both
Torin1 and Torin2 vs. control). Using a different cytometry-based
assay and the P2G12 clone of P. falciparum 3D7 (33), we performed
dose–response assays and determined the Torin2 EC50 for asexual
blood stages to be 1.4 nM (95% CI 1.31–1.59 nM) (Fig. 2B). Torin2
is also highly potent against early gametocytes, with a slightly lower
EC50 of 6.62 nM (95% CI 4.59–9.54 nM). (Table S1). We next














tested whether Torin2 would be capable of antimalarial activity
against the blood stage of P. berghei in vivo. C57BL/6 mice
infected with P. berghei-GFP iRBCs were treated with a single
oral dose of 10 mg/kg Torin2 on day 4 after infection when the
parasitaemia had reached 3%. All control mice succumbed to
experimental cerebral malaria by day 7, whereas the majority of
the Torin2-treated group did not (Fig. 2C), a highly significant
difference in survival (P < 0.0001). The single Torin2 dose also led
to a highly significant blunting of parasitaemia (Fig. 2D, P <
0.0001). Overall, our data demonstrate that torins are similarly
effective and potent against both blood and liver stage Plasmodium
parasites in vitro and in vivo. Thus, the mediator of the antimalarial
activity must be present in both of these host–parasite settings.
Inhibition of Host mTOR Signaling by Other Means Does Not
Phenocopy the Antiplasmodial Effects of Torins. The ability of torins
to potently target both liver and blood stages of Plasmodium in-
fection suggested a direct effect on the parasite and not on host
mTOR. We sought to further test this hypothesis using chemical
and genetic means to reduce host mTOR activity in hepatoma cells.
First, we evaluated the ability of PP242, another highly specific
ATP-competitive mTOR inhibitor that is structurally unrelated
to the torins (34), to inhibit Plasmodium liver stages. Treatment
with 2.5 μM PP242 [concentration showing complete inhibition
of mTORC1 and mTORC2 signaling in cellular assays (34)] did
not reduce either infected hepatocyte number or Plasmodium
liver stage growth (Fig. 3 A and B). Likewise, addition of PP242
to P. falciparum-synchronized 3D7 ring stages had no impact on
blood stage development and reinvasion (Fig. 3C).
We next turned to siRNA knockdown of mTORC1 components
in hepatoma cells. siRNA oligonucleotide pools targeting human
mTor or raptor transcripts were introduced by reverse transfection
and the knockdown cells infected with GFP-expressing P. berghei
sporozoites 48 h later. siRNA-mediated knockdown of neither
mTOR nor raptor could phenocopy the dramatic reduction of
infected cells or parasite development observed with Torin2
treatment (Fig. 3 D and E). EEF morphology 24 h after infection
was also comparable across the control, mTOR, and raptor knock-
down cells (Fig. 3F). Taken together, our data strongly suggest that
the target mediating the antiplasmodial effects of torins is not the
host cell mTOR kinase, but rather is parasite-encoded.
Torin2 Is Not Permissive to Generation of Drug-Resistant Parasite
Lines in Vitro. To identify the target of Torin2, we attempted
to generate drug-resistant mutants in P. falciparum blood stage
parasites. We first determined that the multidrug-resistant
Dd2 strain of P. falciparum retained Torin2 sensitivity, with an
EC50 of 0.7 nM (95% CI 0.48–1.02 nM) in asexual blood stage
growth assays (35). We then performed resistance selection with
clonal Dd2 ring stage parasites, exposing them to 10× EC50
(7 nM) Torin2 for 8 d. When parasites failed to recrudesce 60 d
after this treatment, we varied the length of selection to opti-
mize the mutation-selection window. We achieved parasite re-
crudescence in 4 of 32 independent selection attempts and only
with exposure times of 48 h or less (summarized in Table 1).
Remarkably, the four selected strains all failed to display any
resistance phenotype by SYBR dose–response or decrease in
time to recrudescence in subsequent repetitions of the selection
protocol (Table 1). We, and others, have used these selection
Fig. 1. Torins are antiplasmodial compounds with nano-
molar potency against Plasmodium liver stages and are
capable of curing infection. (A–C) Effect of mTOR inhib-
itors, rapamycin, and Torin1 on P. berghei liver stage in-
fection. HepG2 or Huh7 cells infected with P. berghei-GFP
sporozoites on the day after seeding. Torin1, rapamycin,
or DMSO (vehicle as control) were added 2 h after in-
fection and remained present until 48 h after sporozoite
addition, when samples were processed for flow cytom-
etry (A and B) or microscopy (C). Data from technical
triplicates of the DMSO control were averaged, and the
mean was set to 100%; all samples were then normalized
to this value. Mean ± SD from one representative experi-
ment is shown. (A) The number of GFP+ events detected
represents the number of infected cells. (B) The geometric
mean of the GFP signal, known to correlate with parasite
growth, represents EEF development. (C) Representive
confocal images. Huh7 cells were fixed and labeled with
anti-PbHSP70 (P. berghei heat shock protein 70) (EEF,
green) and DAPI (nuclei, blue). (D) Dose-dependent effects
of Torin1 and Torin2 on P. berghei liver stage infection.
HepG2 cell infection analyzed by flow cytometry 48 h later,
as in B. Each data point represents n = 3 biological tripli-
cates. Four-variable curve fitting was carried out using
GraphPad Prism. (E) Effect of a single Torin2 oral dose on
parasite liver load. C57BL/6 mice were infected i.v. with
10,000 Pb-GFP sporozoites and given 10 mg/kg Torin2 sus-
pended in sunflower oil or an equivalent dose of sunflower
oil alone 2 h after infection. Each point represents a single
animal (n = 3 independent experiments); mean ± SD is in-
dicated for each group. (F) Effect of a single Torin2 oral dose
on prepatency period. C57BL/6 mice were infected i.v. with
500 Pb-GFP sporozoites and given 10 mg/kg Torin2 sus-
pended in sunflower oil or an equivalent dose of sunflower
oil alone 2 h after infection. Animals were monitored daily
for appearance of parasitaemia in the blood by flow
cytometry. Data are from three independent experiments
with a total of 12 animals in each group.
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methodologies to raise resistance to antimalarials that act on
a variety of targets within the parasite’s cytosol and mitochon-
dria (36, 37). In contrast, Torin2 pressure has thus far failed to
induce a stable resistance phenotype after varied, repeated
attempts, suggesting that additional unbiased approaches will be
necessary to elucidate the drug target(s).
Plasmodium Growth Is Inhibited by Torin2 Throughout Liver Stage
Development. With the evidence leaning toward torins acting di-
rectly on Plasmodium spp., we sought to gain insight into the killing
mechanism by asking when the target(s) of Torin2 antiplasmodial
activity are present in liver stages. We first varied compound
treatment windows to target different stages of parasite invasion
and development during liver stage infection. Initially, we
checked whether Torin2 treatment of HepG2 cells 2 h before
sporozoite addition could impact either sporozoite invasion or
EEF development. Torin2 pretreatment did not alter either
parasite numbers or development, as assayed 24 h after infection
(Fig. S1A). We next tested if Torin2 treatment concomitant
with sporozoite addition would affect parasite invasion and again
found no effect; comparable amounts of cells were infected
(GFP+) after 2 h, demonstrating that sporozoite invasion occurs
normally in the presence of Torin2 (Fig. S1B). Next, sporozoites
were allowed to complete invasion of HepG2 cells, and then 10
nM Torin2 was added for varying time periods (as schematized in
Fig. 4A) corresponding roughly to “early PVM remodeling” (2 h),
trophozoite (6 h), and schizont (24 h) stages of intrahepatocyte
development. Infection was analyzed 50 h after sporozoite addi-
tion by flow cytometry, and none of the Torin2 treatment periods
was found to significantly increase HepG2 cell death (Fig. S1C).
As previously shown, continuous incubation of infected cells with
10 nM Torin2 after sporozoite invasion results in near-complete
parasite elimination (Fig. 4A). Remarkably, a mere 4-h in-
cubation with 10 nM Torin2 from 2 to 6 h after infection was also
capable of eliminating more than 90% of all parasites (Fig. 4A);
Torin2 treatment from 6 to 24 h postinfection was similarly ef-
fective (Fig. 4A). The very few developing EEFs under the 2- to 6-
or 6- to 24-h conditions showed slightly reduced development
compared with the control (Fig. 4B). Interestingly, when Torin2
treatment was initiated only after the start of schizogony (24–50 h),
fewer parasites were eliminated, with parasite numbers about
60% of the control (Fig. 4B). However, in this treatment group,
EEF development showed the strongest inhibition—to 30% of
control levels (Fig. 4B); on an individual level, these parasites
show aberrant development and fail to form merozoites (Fig.
S1D). Our data demonstrate that Torin2 is a potent inhibitor of
all phases of Plasmodium EEF development through late schi-
zogony. Torin2-treated parasite elimination, however, occurred
efficiently only when EEFs were exposed to Torin2 before the
onset of schizogony.
Torin2 Treatment Leaves the PVM Structurally Intact, but Lacking
PVM-Resident Proteins. A number of gene-knockout parasite
lines that successfully invade hepatocytes exist, but fail during
PVM establishment or remodeling and are rapidly eliminated
(11, 12, 17–20, 38). Given this phenotypic parallel to the effects
of Torin treatment, which also does not affect the invasion
Fig. 2. Torins potently inhibit Plasmodium blood stage infection. (A) Effect
of Torin1 and Torin2 in P. falciparum blood stage in vitro cultures. Syn-
chronized P. falciparum 3D7 ring stage parasites were treated with 200 nM
Torin1, 10 nM Torin2, or DMSO (vehicle control); reinvasion was analyzed
after SybrGreen labeling of parasite DNA 48 h later. Data represent mean ±
SD of three independent experiments. Starting parasitaemia are repre-
sented by dotted line. (B) Dose-dependent effect of Torin2 on P. falciparum
blood growth. Data represent mean ± SD of three independent experi-
ments. (C and D) Effect of a single 10-mg/kg oral dose of Torin2 administered
on day 4 after infection of C57BL/6 mice with 1 × 106 Pb-GFP–parasitized RBC
on survival (C) and parasitemia (D). Animals were monitored daily for
malaria-associated pathology (experimental cerebral malaria symptoms),
and parasitaemia was analyzed by flow cytometry. (C) Cumulative survival
curve for three independent experiments; n = 10 mice for control and
Torin2-treated groups. (D) Parasitaemia; each point represents the mean ±
SD from three independent experiments.
Fig. 3. mTOR inhibition by other means does not phenocopy the anti-
plasmodial effect of torins. (A and B) Effect of PP242 on inhibition of liver
stage infection. Infected HepG2 cells were treated with 2.5 uM PP242 2 h
after spozoroite addition, and the infection was analyzed by flow cytometry
48 h later, as in Fig. 1. Data represent mean ± SD three independent
experiments. (C) Effect of PP242 on blood stage infection. Synchronized P.
falciparum 3D7 rings were treated with 2.5 μM PP242 or DMSO (identical
control data set as in Fig. 2A), and reinvasion was analyzed after SybrGreen
labeling of parasite DNA 48 h later. Data represent mean ± SD of three in-
dependent experiments. (D–F) Effect of siRNA-mediated knockdown of
raptor or mTOR on liver stage infection. Validated siRNA pools were reverse-
transfected into HepG2 cells, which were infected with sporozoites 2 d later
and analyzed by flow cytometry as described above or with immunofluo-
rescence analysis (IFA) 24 h after sporozoite addition. (F) Representative
images with PbHSP7 (green), UIS4 (red), and DAPI (blue).














process itself, but leads to parasite elimination, we wondered if
Torin2 treatment might be altering the parasite PVM, or alter-
natively, if infected cells were selectively rendered nonviable by
a brief Torin2 treatment. To this end, we used a live imaging
setup to address two questions: (i) Are infected cells viable after
Torin2 treatment? and (ii) Is the PVM maintained intact after
Torin2 treatment? To that end, we infected HepG2 cells with
P. berghei-GFP sporozoites and used the vital dye tetrame-
thylrhodamine, ethyl ester (TMRE), which labels mitochon-
dria with an intact membrane potential, to assess host-cell
mitochondrial activity and unambiguously identify intracellular
EEFs. Additionally, we used the vital DNA dye Hoechst 33258,
which freely labels host-cell DNA or free sporozoites, which lack
a PVM, but is unable to label the DNA of developing EEFs until
maturation-induced PVM changes occur late in liver stage de-
velopment (39). Torin2 was added 2 h after infection, and the
cells were imaged 6 h later, after TMRE and Hoechst 33258 la-
beling. Based on our earlier data (Fig. 4B), the vast majority of
Torin2-treated EEFs are ultimately nonviable after such a treat-
ment. In both control and Torin2-treated cells, the 8-h EEFs
developed in host cells with normal nuclear morphology and
active mitochondria (Fig. S2A). Importantly, the EEF nuclei are
not labeled by Hoechst 33258 in either drug-treated or control
cells (Fig. S2A), although the nuclei of extracellular sporozoites
that have failed to invade clearly are an indication that Torin2-
treated EEFs reside in an intact PVM. To confirm this in-
terpretation, we used transmission electron microscopy (TEM) to
investigate PVM integrity in EEFs that were exposed to Torin2
from 2 to 8 h after infection. As expected, the 8-h control EEFs
were uniformly PVM-positive (Fig. 5A). Torin2-treated parasites
were also clearly surrounded by a PVM in all cases (Fig. 5A)
and tended to have more parasite PM waviness and intracellu-
lar complexity (e.g., membranous whorls) than the control
parasites observed.
Given that the PVM appeared intact in Torin2-treated infec-
ted cells, we next checked whether Plasmodium proteins known
to localize to the PVM were altered after exposure to Torin2.
UIS4, which is already transcribed in mature salivary gland
sporozoites (40), is localized to the PVM throughout develop-
ment inside the hepatocyte (11). Using UIS4-specific antiserum,
we confirmed that 2 h after infection UIS4 was already localized
to the PVM; the peak UIS4 signal is clearly outside of the par-
asite soma delineated by P. berghei heat shock protein 70
(HSP70) antibody staining (Fig. 5B). Torin2 treatment initiated 2
h after infection is thus acting upon developing parasites already
enclosed in UIS4-positive PVMs. Surprisingly, we found that 6 h
of Torin2 treatment completely abolished the PVM localization
of UIS4. In stark contrast to both the pretreated 2-h parasites
and the 8-h control parasites, UIS4 is found exclusively within
the parasite soma in Torin2-treated parasites (Fig. 5B).
Torins are potent antiplasmodials throughout liver stage de-
velopment, so we next investigated whether or not Torin2 treat-
ment could induce mislocalization of PVM-resident proteins in
more mature parasites. Infected HepG2 cells were treated with
10 nM Torin2 during a 12-h window starting 16 h after infection,
and localization of both UIS4 and EXP1, another known PVM-
resident protein [also called Hep17 (41)], was assessed in 28 h
EEFs. As expected, UIS4 and EXP1 were localized almost com-
pletely outside of the parasite soma in control 28-h EEFs (Fig.
5C). Again, Torin2 treatment led to a dramatic mislocalization of
UIS4, with signal largely found in the parasite soma in 28-h EEFs
(Fig. 5C), although some residual UIS4 could also be observed in
the host-cell cytoplasm. EXP1 localization was also completely
perturbed by Torin2 treatment, with a PVM (control) to soma
(Torin2-treated) shift paralleling that of UIS4 (Fig. 5C).
Additionally, Torin1 treatment also induces mislocalization of
UIS4 to the parasite soma (Fig. S2B). These data imply that
torins act against Plasmodium by altering the localization of
PVM-resident proteins.











10× EC50, 192 h 0/8 NA NA
10x EC50, 144 h 0/4 NA NA
20x EC50, 48 h
pulsed three times
0/4 NA NA
20x EC50, 48 h 1/7 26/24/30 1.04
20x EC50, 36 h 1/3 26/23/30 0.93
20x EC50, 24 h 2/4 22/24/31 1.14
20x EC50, 12 h 0/2 NA NA
Asexual Dd2 parasites were subjected to varied step-wise intermittent
selection protocol with10x EC50 Torin2.
*Number of days for each independent selection to return to 1% parasite-
mia. The time to recrudescence for subsequent rounds of selection is
expressed separately for the first/second/third round of selections and
expressed as the average of the number of days when multiple independent
selections were performed with identical protocols.
**Parental Dd2 strain EC50 is 0.7 nM (0.48,1.02). Values expressed as fold
change over Dd2 EC50.
Fig. 4. Plasmodium growth is inhibited by Torin2 through-
out liver stage development. (A and B) Effects of Torin2
throughout P. berghei liver stage development in vitro.
Infected HepG2 cells were treated with 10 nM Torin2 or
DMSO (vehicle control) as indicated in the schematic illus-
tration, and the infection analyzed by flow cytometry 50 h
after sporozoite addition, as in Fig. 1. Data represent mean ±
SD of quadruplicates from one representative experiment
with all conditions processed in parallel.
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EEF Elimination and PVM-Resident Protein Mislocalization Are Not
General Aspects of Liver Stage Inhibition by Antimalarials, Indicating
a Distinct Mechanism of Action for Torins. Although a comprehen-
sive study of the activity of currently used antimalarials against
rodent liver stage parasites has been carried out (42), we lack
such information on a phenotypic level, leading us to wonder
whether parasite clearance is the inevitable outcome for EEFs
that are rendered nonviable during the first hours of intra-
hepatocyte development. To address this, we first confirmed the
elimination of Torin2-treated parasites in HepG2 cells by mi-
croscopy; continuous exposure to Torin2 initiated after sporozo-
ite invasion results in a complete absence of developing EEFs
48 h later. We then compared Torin2 side by side with the re-
cently identified antiplasmodial decoquinate, which has the same
mechanism of action (MoA) as atovaquone (43, 44), the most
potent antimalarial in clinical use effective in the liver stage (42).
We chose to focus on decoquinate as its potency is more similar
to that of Torin2 than that of atovaquone. Treatment of infected
HepG2 cells 2 h after sporozoite invasion with either 10 nM
Torin2 or 26 nM decoquinate (10× EC50) resulted in complete
Plasmodium inhibition. Torin2 eliminated EEFs, as expected
(Fig. 6A, P < 0.0001), whereas decoquinate led to a modest re-
duction in the number of EEFs present 50 h after infection (Fig.
6A, P < 0.05). Furthermore, a 6-h treatment with decoquinate
from 2 to 8 h after infection was phenotypically equivalent to the
2- to 50-h treatment (Fig. S3). Despite the persistence of deco-
quinate-treated EEFs, they appear to be arrested very early in
development (Fig. 6A, P < 0.0001), a phenotype we have con-
firmed by microscopy in primary mouse hepatocytes (Fig. 6B).
EEF elimination is thus not a default outcome of parasite non-
viability early in development, but rather reflects a specific aspect
of the torin-treated EEF phenotype. This provides an intriguing
parallel to the phenotypes described for those mutant parasites
that successfully invade hepatocytes, but fail during PVM estab-
lishment or remodeling and are rapidly eliminated (17–20).
We next checked if the mislocalization of PVM-resident pro-
teins induced by the torins could be a previously unnoted feature
of pharmacological inhibition/killing of Plasmodium liver stages,
also provoked by known antimalarials active against the liver
stages. We tested this hypothesis by evaluating UIS4 and EXP1
localization in infected cells treated with representative members
of the classes, in terms of both chemical structure and MoA, of
currently known antimalarials (42). Primaquine, pyrimethamine,
and decoquinate were individually added to HepG2 cells 20 h after
infection at 10× EC50 concentrations. Ten hours later, coverslips
were fixed and processed for immunofluorescence. Compared with
the control and Torin2 conditions (Fig. 6C), decoquinate-treated
parasites retained robust anti-UIS4 labeling of the PVM but, no-
tably, EXP1 staining was nearly abolished (Fig. 6C), a feature we
also noted in mouse primary hepatocytes (Fig. 6B). In the pri-
maquine- and pyrimethamine-treated cells, both PVM-resident
proteins were properly localized (Fig. 6C). Additionally, PVM-
resident proteins remain properly localized in cells treated with the
known liver stage inhibitors genistein (45), lopinavir (46), and
cyclosporin A (47), as well as with the PI3K inhibitor LY294002
and rapamycin (Fig. S4). Furthermore, Torin2 treatment from 2 to
4 h postinfection is sufficient to mislocalize UIS4, but is reversible,
in terms of both parasite growth and UIS4 localization at 48 h
postinfection (Fig. 6D). Additionally, cycloheximide treatment (10
μg/mL), which blocks translation and is a potent antiplasmodial
compound (48), during the same 2 h window is uniformly lethal
for the developing EEFs, which do not grow after this time period;
this lethality is not accompanied by a penetrant defect in UIS4
localization as assayed at either 4 or 50 h after infection (Fig. 6D).
Thus, PVM-protein mislocalization is definitively not a conse-
quence of parasite death.
As such, we conclude that both parasite elimination and al-
tered localization of PVM resident proteins are specific pheno-
types of torin-mediated Plasmodium liver stage inhibition, which
strongly indicates that torins have a distinct MoA from currently
used antimalarials.
Plasmodium Liver Stage Parasites Require Replenishment of PVM-
Resident Proteins for Viability. As the alteration of PVM-resident
protein localization was not a general consequence of antimalarial
activity against EEFs, we sought to determine the mechanism by
which Torin2 provokes the mislocalization of these proteins.
Trafficking of blood stage P. falciparum proteins to specific
organelles, the vacuolar space, PVM, and beyond into the iRBC
itself has been a subject of intense study (49). Brefeldin A (BFA),
an inhibitor of eukaryotic ADP-ribosylation factor (ARF) GTPa-
ses and the retrograde Golgi-ER trafficking that they mediate in
many species, including Plasmodium (50), blocks export of knob-
Fig. 5. Torin2 treatment leaves the PVM structurally intact but lacking
PVM-resident proteins. (A and B) Effect of Torin2 treatment on the PVM and
UIS4 localization in young liver stage trophozoites. Schematic illustrates
experimental setup. (A) Representative images of TEM of 8-h EEFs after
Torin2 or DMSO (control) treatment. (B) IFA at 2 h (control, single confocal
slice) and at 8 h in control [maximum intensity projection (MIP)] and Torin2-
treated cells [single confocal slice (HSP70, green; DAPI, blue; UIS4, red)].
Fluorescence intensity graphs of the trajectory indicated by the white lines in
the preaddition and Torin2-treated images show the relative spatial in-
tensity peaks of the three fluorophores. (C) Effect of Torin2 treatment on
UIS4 and EXP1 during early liver stage schizogony. Schematic illustrates ex-
perimental setup. MIPs of the entire EEF are shown for A–C.














associated histidine-rich protein (KAHRP), P. falciparum eryth-
rocytemembrane protein 1 (PfEMP1) (51), and EXP1 (52) among
other proteins in blood stage parasites. Nothing is known about
the trafficking pathways used by the liver stage parasite, so we
tested whether UIS4 trafficking to the PVM proceeds through
a BFA-sensitive pathway. We added BFA to HepG2 cells 2 h
after infection, when UIS4 is already present in the PVM. After
BFA (5 μM) treatment for 6 h postsporozoite invasion, UIS4 is
found inside the parasite soma as in Torin2-treated parasites
(Fig. 7A). Compared with Torin2 treatment, which causes UIS4
to accumulate in discrete intracellular puncta (Fig. 7A) during
the samewindow, BFA causesUIS4 to accumulate in what appears
to be a more continuous distribution within the parasite soma. As
UIS4 colocalizes with the microneme marker thrombospondin-
related anonymous protein (TRAP) in mature salivary gland
sporozoites (40) and as TRAP is maintained in puncta throughout
the majority of liver stage development (53), we tested whether
UIS4 relocalized into TRAP-positive structures upon Torin2 or
BFA treatment. The data clearly show that UIS4 and TRAP do
not substantially colocalize in control, BFA-, or Torin2-treated
cells (Fig. S5A).
Most strikingly, BFA treatment, which blocks only protein
secretion, phenocopied the complete loss of PVM-localized
UIS4 seen in the Torin2-treated parasites (Fig. 7A). We quan-
tified the distribution of UIS4 and found that, on average, 62%
of the UIS4 signal is present outside of the parasite soma in 8-h
control EEFs, whereas BFA or Torin2 treatment resulted in
>95% overlap of UIS4 and HSP70 in the parasite soma (Fig.
7B). We extended these results to P. berghei EEFs developing
inside murine primary hepatocytes ex vivo (Fig. S5B); UIS4 and
EXP1 trafficking to the PVM is BFA- and Torin2-sensitive in
young liver stage schizonts (Fig. S5B), and both PVM-resident
proteins are also concomitantly depleted from the PVM.
Taken together, our data support a model (Fig. 7C) in which
Torin2 treatment prevents secretion of liver stage PVM-resident
proteins, leading to their accumulation inside the EEF soma.
This block in secretion causes the PVM to be left devoid of
PVM-resident proteins, particularly in trophozoites, which leads
to parasite elimination by the host hepatocyte.
Discussion
This study reports that torins, developed as ATP-competitive
mammalian mTOR kinase inhibitors, are extremely potent inhib-
Fig. 6. EEF elimination and PVM-resident protein-
trafficking defects are torin-specific phenotypes, not
general aspects of liver stage inhibition by anti-
malarials. (A and B) Effects of decoquinate and
Torin2 on EEF numbers and development. (A) Sche-
matic of treatment and analysis. Infected HepG2
cells analyzed by flow cytometry at 50 h after spo-
rozoite addition. Mean of n = 3 biological experi-
ments, each condition in triplicate. (B) Mouse
primary hepatocytes infected ex vivo with EXP1
(red), UIS4 (green), and HSP70 (blue) labeling. (C)
Effect of current antimalarial classes active against
the liver stage at the onset of schizogony. Schematic
illustrates experimental setup; representative con-
focal images shown with UIS4 (red), EXP1 (white),
PbHSP70 (green), and DAPI (blue) labeling. (D)
Effects of 2 h Torin2 or cycloheximide treatment on
UIS4 localization and EEF development. Schematic
illustrates experimental setup. Representative con-
focal images of control (DMSO), Torin2-, and cyclo-
heximide-treated EEFs labeled with anti-UIS4 (red),
anti-PbHSP70 (green), and DAPI (blue) 4 and 48 h
postinfection. Quantification of the proportion of
UIS4+ pixels not overlapping PbHSP70 in 20 EEFs
from each condition at 4 and 48 h postinfection;
quantification of EEF area 48 h postinfection.
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itors of both the liver and blood stages of Plasmodium parasites.
Although we first tested Torin1 (together with rapamycin) to in-
vestigate the role of host hepatocyte mTOR signaling in liver stage
Plasmodium infection, our data as a whole provide extremely
strong support for a parasite-encoded target mediating the anti-
plasmodial activity of the torins.We present three lines of evidence
that suggest that host-cell mTOR is not the mediator of the anti-
plasmodial activity of the torins. First, unrelated small-molecule
mTOR inhibitors (rapamycin and PP242) or siRNA-mediated
reduction of mTOR signaling both fail to inhibit Plasmodium liver
stage infection. Strong evidence that host mTOR is uninvolved
comes from the nonequivalence of PP242 and torins. Both cause
complete inhibition of mTORC1 and mTORC2 activity (30, 32,
34). The chemical structures of the two compounds are not at all
similar although, as we show here, neither are their effects on liver
or blood stage Plasmodium infection. Second, torins inhibit both
liver and blood stage parasites, with Torin2 maintaining a near
identical EC50 for the two stages and for different Plasmodium
species. Although it is easy to envisage mechanisms by which re-
duction of host hepatocyte mTOR signaling could alter liver stage
Plasmodium development, this is not the case for the iRBC. The
matureRBC lacks the capacity for both protein and lipid synthesis,
as well as gene expression, and although mTOR has been found in
the RBC “hidden proteome,” no evidence of functional protein
exists (54). Third, torins are able to alter the localization of Plas-
modium proteins during liver stage infection, an effect very un-
likely to be mediated by a host protein. As a whole, our data point
unequivocally to a Plasmodium-encoded molecule or molecules,
conserved across the genus and expressed in all mammalian stages,
as the target of the antiplasmodial activity of Torin1 and Torin2.
Sequence homology queries of current Plasmodium genome
assemblies show that no Plasmodium orthologs of mTOR exist,
and indeed the PI3K-like protein kinase family, of which mTOR is
amember, is not found (55, 56). The P. berghei proteins showing the
highest sequence similarity to human mTOR are the single pre-
dicted phosphatidylinositol-3-kinase (PI3K) (PBANKA_111490)
and the two predicted phosphatidylinositol-4 kinases (PI4Ks)
(PBANKA_110940 and PBANKA_072200), which show conser-
vation primarily in the kinase catalytic domain. Although little is
known about the activity of the two predicted Plasmodium PI4Ks,
PbPI3K is an essential gene (57), and treatment with the known
PI3K inhibitors wortmannin and LY294002 reduced PI3P pro-
duction by PfPI3K in vitro and inhibited blood stage parasite growth
(58). LY294002 does not phenocopy Torin2 inhibition of P. berghei
liver stages, however, and the inhibition of P. falciparum replication
by wortmannin and LY294002 (58) is muchmoremodest than what
we observed with either Torin1 or Torin2.
Our data clearly show that Torin2 is a potent antimalarial with in
vivo activity against both liver and blood stages, capable of curing
liver stage infection with a single, well-tolerated oral dose. Still,
given its demonstrated potent inhibition of human mTOR, we
cannot, and do not, see Torin2 itself as a lead compound; further
medicinal chemistry elaboration will be necessary to realize a torin
analog as a suitable antimalarial lead. Nevertheless, torins repre-
sent a new antimalarial chemotype that certainly warrants further
medicinal chemistry investigation due to the following highly de-
sirable properties: (i) versatility: Torin2 targets both liver and
blood stages, and is active against immature gametocytes; (ii)
speed of action: torins render P. falciparum parasites nonviable in
a single blood stage cycle and short treatment windows are suffi-
cient to kill liver stage parasites; (iii) distinct MoA from currently
utilized antimalarials: none of the compounds in current clinical
use which are active against Plasmodium liver stages provoke
PVM trafficking defects; and (iv) Torin2 retains potency against
the multidrug resistant Dd2 strain of P. falciparum, and is not
amenable to in vitro resistance generation, in contrast to most
antimalarials in current clinical use and leading candidates (36,
37, 59–63). Additionally, the mediator(s) of the antiplasmodial
activity of the torins is clearly druggable in vivo during both
mammalian stages.
Although the value of torin analogs for human antimalarial
use will rely on future medicinal chemistry elaboration, the
utility of torins for probing PVM function and protein-traf-
ficking pathways in the Plasmodium EEF is immediate. Plas-
modium parasites contain many unusual cellular compartments
and have evolved strategies to direct proteins not only to these
but also to destinations outside of the parasite soma—from the
PV to the host-cell membrane itself. The transport pathways
that the blood stage parasite uses to direct proteins to these
diverse locations has been a subject of intense study; whereas
specific trafficking pathways and molecular determinants ulti-
mately mediate protein movement to discrete locations—i.e.,
the vacuolar space, the Maurer’s clefts in the iRBC cytoplasm,
the digestive vacuole, or the PVM—most secreted proteins seem
to initially follow a common, canonical BFA-sensitive ER-Golgi
route in the blood stage parasites (49). As such, it is perhaps not
surprising that UIS4 and EXP1 trafficking to the liver stage PVM
requires the canonical BFA-sensitive ER-Golgi transport route, as
we have demonstrated. Still, it highlights the fact that the parasite
does use this, and undoubtedly other core pathways, throughout all
mammalian stages. It remains to be determined whether the EEF
uses the same parasite-encoded molecules for acquisition of host
hepatocyte resources that the blood stage parasite uses in remod-
Fig. 7. Plasmodium liver stage parasites require replenishment of PVM-
resident proteins for viability. (A and B) Comparative effects of Torin2 and
BFA on UIS4 trafficking to the PVM in young liver stage trophozoites.
Schematic illustrates experimental setup. (A) Representative confocal images
of control (methanol, BFA vehicle), Torin2-, and BFA-treated EEFs labeled
with anti-UIS4 (red), anti-PbHSP70 (green), and DAPI (blue). (B) Quantifica-
tion of the proportion of UIS4+ pixels not overlapping PbHSP70 in 20 EEFs
from each condition. DMSO and methanol, the vehicle controls for Torin2
and BFA, respectively, are grouped together as control. (C) Model of Torin2
liver stage MoA.














elling the “inert” RBC or whether components of the host hepa-
tocyte vesicular trafficking networks are co-opted by the parasite.
Comparing BFA- and Torin2-treated EEFs, we find clear
commonalities and subtle differences in phenotype. When either
drug is added after sporozoite invasion and intial UIS4-positive
PVM establishment, both treatments result in complete loss of
UIS4 at the PVM 6 h later, as well as intracellular accumulation
of UIS4. BFA blocks ER to Golgi trafficking by inhibiting the P.
falciparum orthologue of Arf1 (64). BFA-treated blood stage
parasites form a hybrid ER- Golgi compartment (65) that
accumulates proteins utilizing the canonical secretory pathway.
We interpret the similarity of BFA- and Torin2-treated EEF
phenotypes as highly suggestive that Torin2, like BFA, causes
a failure in anterograde protein trafficking. The compartment in
which UIS4 is retained appears qualitatively different, however,
with Torin2 treatment leading to the appearance of small puncta of
UIS4 and BFA treatment leading to a more continuous distribu-
tion of UIS4 inside the parasite soma. Future characterization of
the intracellular location in which PVM-resident proteins accu-
mulate after Torin2 treatment may help shed light on which traf-
ficking step is inhibited by Torin2.
Localization of a membrane protein to a specific compartment
can be achieved by either its retention at, or continuous transport
to, the compartment. Most intriguingly, our data illustrate that
UIS4 and EXP1 must be continuously transported to the PVM
throughout at least the first 30 h of liver stage development.
Several fascinating questions arise from this: Are UIS4 and EXP1
“lost” to the host cell during EEF development? Are UIS4 and
EXP1 subject to retrograde trafficking back into the PV or par-
asite soma? Are these dynamics generalizable to all liver stage
PVM-resident proteins, or do they reflect the specific functions of
EXP1 and UIS4? Whether or not torin treatment alters protein
trafficking in Plasmodium asexual and sexual blood stages also
remains to be established.
Proteins that are known to populate the nascent PVM of the
invading P. falciparum merozoite are synthesized during the pre-
ceding schizont stage and stored in the apical organelles of the
merozoite before release in the invasion process (66). The trans-
locon components HSP101, PTEX150, and EXP2 are examples of
this; they are found in the dense granules of merozoites, but will be
associated with the PVM throughout the subsequent cycle post-
invasion (67). The sporozoite invasion process is assumed to be
analogous to that of the merozoite. During the transit of the
Plasmodium sporozoite from the bite site to the hepatocytes, UIS4
is stored inside the sporozoite where it colocalizes with TRAP (40),
apparently in the micronemes, and is discharged only once the
sporozoite is in the process of hepatocyte invasion. We clearly
demonstrate that the pool of UIS4 that initially populates the
young EEF PVM is gone after 6 h of either Torin2 or BFA treat-
ment. As BFA is not thought to affect retrograde trafficking, it is
very unlikely that this indicates a block in UIS4 recycling from the
parasite soma to the PVM, suggesting that this pool of UIS4 has
been degraded either by the host cell or the parasite itself. How-
ever, this is not the case with the translocon components in the
iRBC, in which the initial pool of proteins released from the dense
granules appears to be stably retained at the PVM throughout
blood stage development, with further synthesis and trafficking
not required (67).
Although it is clear that the blood stage parasite is actively
secreting proteins, such as the stage-specific ETRAMPS (24), to
the PVM throughout development, more investigation will be
required to determine if some blood PVM proteins show dy-
namics like those of UIS4, and indeed whether EXP1 itself is
similarly dynamically localized to the blood stage PVM. The
hypothesis that PVM protein turnover would be related to pro-
tein function is attractive, but as the liver stage PVM also must
contend with extensive interactions with hepatocyte compo-
nents (22, 68), it remains possible that the host cell itself
dictates the turnover of the liver stage PVM-resident proteins
that we have examined.
Regardless of whether host or parasite ultimately drives the
turnover of the liver stage PVM-resident proteins that we have
studied, their replenishment at the PVM via continued expres-
sion and secretion through the early schizont stage, at the least,
is crucial for parasite viability. Clearly, the trafficking route to
the liver stage PVM and the molecular players that mediate it,
as well as the protective role of the PVM, constitute fascinating
avenues for future research into Plasmodium biology, as well as
antimalarial drug development.
Experimental Procedures
See detailed version in SI Experimental Procedures.
Plasmodium Liver Stage Assays. GFP-expressing P. berghei sporozoites were
added to HepG2 or Huh7 cells cultured in 24-well plates. Infected cells were
processed and analyzed by flow cytometry as described in ref. 31.
A total of 10,000 P. berghei-GFP sporozoites were injected i.v. into C57BL6
mice; 2 h later, a 10-mg/kg dose of Torin2 was given orally as a sunflower oil
slurry. Control animals received an equal dose of oil. Livers were harvested
44 h after infection, mRNA was extracted, and liver parasite load was de-
termined by quantitative RT-PCR of P. berghei 18s rRNA.
Plasmodium Blood Stage Assays. P. falciparum strains were cultured in vitro,
and parasite proliferation was determined by flow cytometry.
To test the antimalarial properties of Torin2 in vivo, 1 × 106 P. berghei-GFP
iRBCs were injected intraperitoneally into C57BL/6 mice, and parasitaemia
was monitored by flow cytometry. Torin2 (10 mM) in DMSO was diluted in
PBS, and 10 mg/kg was given orally on day 4 postinfection when parasitaemia
was above 3%. Control animals received equal doses of DMSO in PBS.
For resistance selection, ∼109 parasites were subject to a stepwise in-
termittent selection protocol beginning with 10× EC50 for various exposure-
time windows. Optimal resistance-selection conditions were obtained that
selected against the majority of parasites, but allowed recrudescence of
resistant parasites within 60 d. Upon recrudescence, additional selection
rounds were conducted to optimally obtain clones uninhibited by Torin2.
Immunofluorescence and Microscopy. Infected cells were fixed in 4% para-
formaldehyde (wt/vol) for 10 min at room temperature, permeabilized,
blocked in 2% BSA (wt/vol), and incubated with 1° antibodies. After wash-
ing, appropriate 2° antibodies were added, and coverslips were mounted in
Fluoromount. All images were acquired on Zeiss confocal microscopes.
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ABSTRACT
Malaria, caused by protozoan Plasmodium parasites, kills ∼800,000 people each year. Exact
figures are uncertain because presumptive diagnoses are often made without identifying parasites
in patients’ blood either by microscopy, using Giemsa’s century-old stain, or by simpler tests
that are ultimately dependent on microscopy for quality control. Microscopy itself relies on
trained observers’ ability to detect subtle morphological features of parasitized red blood cells,
only a few of which may be present on a slide. Quantitative and objective flow cytometric
measurements of cellular constituents such as DNA, RNA, and the malaria pigment hemozoin
are now useful in research in malaria biology and pharmacology, and can provide more reliable
identification of parasite species and developmental stages and better detection of low-density
parasitemia than could microscopy. The same measurements can now be implemented in much
smaller, simpler, cheaper imaging cytometers, potentially providing a more accurate and precise
diagnostic modality. Curr. Protoc. Cytom. 65:11.20.1-11.20.23. C⃝ 2013 by John Wiley & Sons,
Inc.
Keywords: flow cytometry ! fluorescence ! hemozoin ! image cytometry ! malaria !
microscopy ! polarized light
INTRODUCTION
Malaria has to date had far more influ-
ence on cytometry than cytometry has had on
malaria. Although cytometry—in the sense of
detecting, counting, measuring, and character-
izing cells—was initiated by van Leeuwen-
hoek, Hooke, and other early microscopists in
the late 1600s, the cellular culprits involved in
malaria and other diseases were not identified
for another 200 years. The clinical features
of malaria had been described millennia ear-
lier, however. Molecular biology recently con-
firmed (Hawass et al., 2010) that Tutankhamun
harbored the same protozoan malaria parasite,
Plasmodium falciparum, that has killed large
numbers of other young Africans annually
since his time. Even today, the precise num-
bers of malaria infections and deaths world-
wide remain uncertain because diagnoses are
often made without confirming the presence
of parasites in patients’ blood (World Health
Organization, 2011; Murray et al., 2012).
The current less-than-24-karat “gold stan-
dard” method for malaria parasite detection
uses high-magnification microscopy to exam-
ine blood smears stained with a dye mixture
developed by Gustav Giemsa in 1904. Quan-
tification of parasite density, i.e., the number
of parasites per unit volume of blood, provides
some measure of the severity of malaria in-
fection, and sequential density determinations
are recommended to assess treatment progress
in severe cases. Density measurements also
provide critical objective data to malaria
researchers studying the effects of drugs and
biologicals on parasite growth and develop-
ment in cultures and in animals, and to clini-
cians and epidemiologists analyzing data from
trials of vaccines and other preventive and ther-
apeutic interventions.
Quality assurance programs for diagnostic
malaria microscopy now aim at a lower limit
of detection of 100 to 200 parasites/µl (World
Health Organization, 2008, 2010). Although
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experienced microscopists can detect fewer
than 50 parasites/µl, they typically examine
no more than 0.1 µl of blood, making quantifi-
cation imprecise, even at the higher densities
(O’Meara et al., 2006, 2007). For some pur-
poses, e.g., the determination of whether or not
malaria has been eliminated from a geographic
region or population, investigators would need
to examine blood from asymptomatic individ-
uals. They would also need to be able to detect
densities no higher than 5 to 10/µl. The time
requirements alone make it impractical to con-
sider microscopy for this application; molec-
ular methods, although effective, have not yet
been made robust and affordable enough for
routine use in the field.
Until about 1950, cytometry was mi-
croscopy and microscopy was cytometry, pro-
viding the only means of detecting individual
cells—malaria parasites included—in blood or
any other material. By 1960, the first sim-
ple flow cytometers—electro-optical and elec-
tronic instruments capable of counting red
blood cells (erythrocytes, RBCs) and white
blood cells (leukocytes, WBCs)—had found
their way into both clinical and research lab-
oratories in places in which they were afford-
able and in which trained personnel and the
infrastructure needed to keep the apparatus
functioning were available. The identification
of different types of WBCs and other nucle-
ated cells and of malaria parasites in blood,
however, still required microscopy of stained
smears, in both rich and poor countries.
Since the 1970s, increasingly sophisticated
apparatus and techniques for flow and image
cytometry—using reagents far more specific
than any available in Giemsa’s time—have be-
come well established in other contexts, and
have been used for the detection and charac-
terization of many cell types found at low den-
sities in blood and other specimens. Malaria
microscopy remains unchanged; even in well-
equipped clinical and research laboratories in
affluent countries, malaria diagnosis, epidemi-
ology, and the development of new diagnos-
tics, drugs, and vaccines still critically rely
on a technique that is essentially neither in-
formed nor transformed by any scientific or
technological advances made during the past
108 years—including electric lighting!
Although cytometric apparatus has been
commercially available for over 50 years, and
more than 140,000 papers involving its use
have been published to date, fewer than 300
have described flow or image cytometry of
malaria parasites, and only a handful of inves-
tigators and laboratories worldwide combine
expertise in both malaria and cytometry. Dur-
ing the past decade, however, modern cytome-
try has come into increasing use in malaria re-
search for investigations of the physiology of
parasites and their responses to antimalarials.
It is also now feasible to take relatively com-
pact cytometers into the field for epidemio-
logic work, e.g., the detection of low-level par-
asitemia using either cell-based (Campo et al.,
2011) or molecular methods, in many places
in which malaria causes significant morbidity
and mortality.
A great deal is now known about which
cytologic characteristics, or parameters, of
malaria parasites can be best used to detect
them, identify different species and develop-
mental stages, and determine the effects of
pharmacologic and immunologic agents on
growth and development. Different groups of
investigators have developed increasingly so-
phisticated protocols for multiparameter cyto-
metric analysis of the parasites (Hare, 1986;
Hare and Bahler, 1986; Pattanapanyasat et al.,
1993; Jouin et al., 1995, 2004; Wongchotigul
et al., 2004; Grimberg et al., 2008, 2009;
Izumiyama et al., 2009; Karl et al., 2009;
Ch’ng et al., 2010; Apte et al., 2011; Campo
et al., 2011; Gerena et al., 2011; Malleret
et al., 2011; Boissière et al., 2012; Jogdand
et al., 2012; Jun et al., 2012; Kaushansky et al.,
2012; Philipp et al., 2012; Clark et al., 2013;
Sinnis et al., 2013). There have been no sys-
tematic multicenter collaborative studies to es-
tablish the relative merits of different proto-
cols, however, nor have serious attempts been
made to determine which of a variety of var-
ious reagents, or probes, and reagent combi-
nations would be optimal for use with a given
instrument.
It is important to note that, although con-
ventional cytometric technology has been
too costly and complex to be considered as
a replacement for malaria microscopy un-
til recently, now some newer field-capable
apparatus—primarily imaging instruments us-
ing light-emitting diodes (LEDs) for illumina-
tion and digital camera chips for detection—
can implement the same proven measurements
that are being done in flow cytometers. The
new systems are sufficiently small, simple, ro-
bust, energy efficient, and inexpensive to be
feasible for use in routine malaria diagnosis,
even in resource-limited settings.
Similar instruments are already in use in
such environments for CD4+ T cell count-




Current Protocols in Cytometry Supplement 65
implementation of CD4 counting on a world-
wide scale required decades of effort on the
part of hundreds of scientists and clinicians
in dozens of countries (Mandy et al., 2002).
Initially, it was necessary to know what cel-
lular characteristics to measure, what reagents
to use, and how to analyze the data. Equally
important, it was necessary to implement train-
ing and quality assurance programs. The same
processes will be required to make malaria cy-
tometry more widely usable and reliable as
a research tool and eventually enable it to
replace microscopy, yielding substantial im-
provements in sensitivity, accuracy, and preci-
sion of parasite density determination, whether
for diagnosis, epidemiology, or research.
As a first step in this direction, we convened
a brief Workshop on Malaria Cytometry at
the CYTO 2012 Meeting of the International
Society for the Advancement of Cytometry
(ISAC), held in Leipzig, Germany, in June
2012. At the workshop we agreed to cooperate
on further work and to document the current
state of malaria cytometry and its prospects
for further development and application. The
present work, in which we have tried to pro-
vide background information comprehensible
from the points of view of both malariologists
and cytometrists, represents our consensus.
Practical Flow Cytometry (Shapiro, 2003),
now available online in free downloadable
PDF format, provides details of cytometry
hardware, software, and the associated reagent
technology. Specific cytometry applications in
malaria are the subject of an extensive re-
cent review by Grimberg (Grimberg, 2011).
Malaria diagnosis and some relevant biology




Malaria had a profound influence on the
early development of modern medical science.
A number of authors have provided enjoy-
able narratives about this time (de Kruif, 1926;
Desowitz, 1991; Garfield, 2001). More schol-
arly accounts (Clark, 1983; Bosch and Rosich,
2008; Gaynes, 2011) supply additional detail.
Giemsa, Paul Ehrlich, and the others who
optimized mixtures of synthetic dyes to im-
prove the visualization of malaria parasites in
blood from the 1880s on had the disease to
thank for their palette of stains. The Americas,
free of malaria until the conquistadores and
their African slaves brought parasites there,
yielded an often-curative tree bark that made
its way across the Atlantic via native healers
and European priests. The “Jesuit powder” and
extracts containing its active ingredient, qui-
nine, remained the only effective agents for
the treatment and prophylaxis of malaria (or
any other serious disease) for centuries there-
after. Quinine, with or without gin added to
increase its palatability, sustained the British
Empire and others, but producing enough of
the drug was not a simple matter of growing
money on trees.
By the mid-1850s, William Perkin, a
teenaged chemistry student in London, had
attempted to synthesize quinine from aniline
and had failed. His reaction product was the
intensely colored purple dye, mauve. The dye
was the first of a long line of commercially
successful synthetic textile dyes, and the im-
petus for an international chemical industry
initially driven by the demands of fashion.
Within a few decades, some synthetic dyes
would be used to stain cells, including those
harboring malaria parasites, and, shortly there-
after, to treat malaria and other infectious dis-
eases. Many of the dye-manufacturing com-
panies would become more widely known as
producers of drugs, some of which even now
double as biological stains.
By the 1850s, improvements in micro-
scopes had facilitated the development and ac-
ceptance of the cell theory. In Germany, Rudolf
Virchow played a central role in moving the
study of disease to the cellular level. Virchow’s
assistant, Karl Weigert, Ehrlich’s older cousin,
was among the first to use synthetic dyes to im-
prove the visualization of cells and tissues by
microscopy, inspiring his younger relative to
explore differential staining of cells and their
components by dyes with differing chemical
properties and contrasting colors. By 1878,
Ehrlich had used combinations of acidic dyes
such as eosin and basic dyes such as methylene
blue to identify and classify different types of
WBCs in peripheral blood.
The identification of disease-specific cellu-
lar pathogens also began in the 1870s. Robert
Koch led the way, applying dyes to stain bac-
teria, and taking advantage of what would
now be called beta-tester status to obtain sub-
stage condensers, oil immersion objectives,
and other newly developed products from the
Zeiss works before they became commer-
cially available. He also introduced photog-
raphy to document results more objectively
than could be done with drawings. With the
help of Ehrlich’s methylene blue staining tech-
nique, Koch discovered the causes of an-
thrax and tuberculosis. By 1882, Ehrlich and
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Mycobacteria, different species of which
caused tuberculosis and leprosy. They inspired
Christian Gram’s subsequent work on bacterial
staining.
Stains were not involved in Alphonse Lav-
eran’s 1880 discovery of malaria parasites in
blood, however. Malaria was itself named for
the “bad air” thought by many to be its pri-
mary cause; by 1880, several microbiologists
claimed to have identified a causative bac-
terium, but had not made their case. Laveran,
a French military doctor working in Alge-
ria, examined fresh unstained blood, attempt-
ing to discover the origins of a dark pigment
then known for over a century to be present
in the tissues and blood of malaria sufferers.
His observation of motile, pigment-containing
particles substantially larger than bacteria led
him to believe that a highly pleomorphic para-
site was responsible. Laveran’s findings were
viewed skeptically for several years, until more
widespread use of oil immersion objectives
and staining enabled others to confirm the
existence of malaria parasites and identify dif-
ferent stages of their development (Laveran,
1907).
It also became possible to detect subtle dif-
ferences in parasite morphology that corre-
lated with long-known differences in the clin-
ical course of malaria, suggesting that more
than one species of parasite might be involved
in the human disease. Working with a bird
malaria, the British military doctor Ronald
Ross elucidated the complex development of
the parasite and its transmission through the
bites of specific mosquito species. Ross and
Laveran received Nobel Prizes in Medicine in
1902 and 1907, respectively. Ross’s bitter ri-
val, Giovanni Battista Grassi, who, with oth-
ers in Italy, established the causative role of
P. falciparum in the most severe form of
the human disease and its transmission by
mosquitoes of the genus Anopheles, was not
similarly rewarded; the feud, over a century
old, still provides fuel for disputes among
malariologists.
Having found that malaria parasites take
up methylene blue, Ehrlich speculated that the
dye might exert selective toxicity against them
and in 1891 reported antimalarial action in sev-
eral cases. He had already established close
ties to the dye industry in his search for better
stains to facilitate diagnosis; his subsequent
successful demonstration of what he named
chemotherapy motivated companies to modify
molecules to treat diseases. The new drug in-
dustry provided Ehrlich with over six hundred
compounds to test for activity against syphilis;
this first “high-throughput screen” yielded two
effective treatments.
Methylene blue itself is still occasionally
used as an antimalarial, but does not, either
by itself or combined with eosin, produce op-
timal staining of malaria parasites in blood
smears. Between 1891 and 1904, several im-
provements in staining were made, initially
by Malachowski and Romanowsky, and ulti-
mately by Giemsa. All involved the addition
of azure dyes—themselves oxidation products
of methylene blue—to the eosin-methylene
blue mixture. Dye interactions in the azure-
augmented stains color parasite cytoplasm an
intense blue and nuclei a contrasting red, fa-
cilitating identification of the earliest stages
of malaria parasites in RBCs. Giemsa’s dye
combination, still almost universally used for
malaria diagnosis by microscopy, is among the
easiest to prepare and among the most consis-
tent in its staining properties.
This stain has also remained the standard
for morphologic hematology. Over a century
later, we might wonder how the malaria tail
managed to wag the hematology dog. Many
people now have many reasons to look at cells
in blood, in both the clinic and the labora-
tory, and relatively few of us have any occa-
sion to look for or at malaria parasites. That
was not the case at the turn of the twentieth
century, however. To be sure, the anemias and
the leukemias were known by then, as were
elevations in the numbers of WBCs associ-
ated with infection. In addition, the utility of
the first hemacytometers, which counted blood
cells in graduated chambers of defined vol-
ume, was appreciated. However, although mi-
croscopy could provide diagnostic and prog-
nostic information about a range of blood dis-
orders, at that time no treatments were known
for most of them. Malaria, considerably more
widespread than it is today, could be treated
with quinine if diagnosed by microscopy, with
subsequent clearance of parasites from the
blood confirmed by further microscopy. It thus
made sense to optimize staining procedures for
blood to facilitate malaria diagnosis.
THE PARASITES: THEN AND NOW
In 1904 the staining patterns observable
in blood cells and malaria parasites revealed
chemical differences among different cell
types and among different intracellular struc-
tures, but the biological, chemical, and bio-
chemical details were almost completely un-
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molecules of cells were as large as we now
know proteins and nucleic acids to be. In ad-
dition, most of their lower-molecular-weight
building blocks had not been discovered. The
details of cellular and nuclear division had
only been worked out in the previous two
decades; it was clear that cell nuclei contained
an acidic component that would bind basic
dyes such as methylene blue and azure B,
and that both nucleus and cytoplasm contained
varying amounts of proteins, which bound
eosin, and acidic materials, which bound the
basic dyes. The parasites themselves have
changed little since 1904; the acquisition of
genes for resistance to antimalarials, perhaps
the most significant difference, had no dis-
cernible effect on morphology.
By Giemsa’s time, it was known that
malaria parasites go through only part of their
life cycle in the blood. Sporozoites, each con-
taining a single nucleus, are the infective stage
resulting from the parasite reproductive cycle
in the mosquito vector. Sporozoites are intro-
duced into a human or animal host’s blood by
a mosquito’s bite. The sporozoites invade liver
cells, becoming trophozoites, which accumu-
late cytoplasm, and later schizonts, which un-
dergo multiple rounds of asexual nuclear re-
production (schizogony), and segment into
multiple merozoites, each with one nucleus.
Rupture of the infected liver cell releases
merozoites into the blood, where one or more
can infect a RBC.
Within RBCs, merozoites become haploid
“ring stage” trophozoites, and then mature into
schizonts, all the while feeding on the RBCs’
hemoglobin and converting it into hemozoin,
the “malaria pigment.” Like those in the liver,
trophozoites in RBCs initially accumulate cy-
toplasm. Most develop into schizonts, which
segment into uninucleate merozoites, each
of which can initiate additional rounds of
schizogony in a previously uninfected RBC.
A minority of trophozoites develop into male
(micro-) and female (macro-) gametocytes,
which are ingested by mosquitoes to continue
the life cycle, eventually yielding sporozoites.
The overall theme of parasite development
described above has recognizable variations;
among other things, the timing is different for
different species. The development of para-
sites in both the liver and the blood is synchro-
nized, and the release of parasites and cellular
debris produces the characteristic “ague”—a
symptom complex including chills, sweating,
and fever. Although malaria is frequently di-
agnosed based solely on the presenting clin-
ical features and their time course, it is rec-
ommended that parasites be demonstrated in
blood for definitive diagnosis and that density
be monitored by microscopy to establish the
efficacy of treatment in severe cases.
Human Malaria Parasite Species: Now
at Six
Three distinct clinical pictures of malaria
had been known for centuries before the par-
asite was discovered. By 1904, correlations
between these and parasite morphology in pa-
tients’ blood had allowed investigators to dis-
tinguish three species of the genus now called
Plasmodium.
P. falciparum (Pf)
Most malaria deaths result from the “ma-
lignant tertian (i.e., occurring roughly every
third day) malaria” caused by Pf, in which
symptoms may show 36- to 48-hr periodicity
or may occur continuously. The parasite in-
fects RBCs of all ages. Pf also differs from
other parasite species in that RBCs infected
with trophozoites and later intraerythrocytic
stages express surface antigens that bind to
endothelium; these infected cells are thereby
sequestered, i.e., removed from circulating
blood, and may obstruct small blood vessels
in various organs, notably the brain and pla-
centa. Cerebral malaria is involved in most
deaths caused by Pf.
Plasmodium vivax (Pv)
Pv is responsible for “benign tertian
malaria,” a relatively mild disease in which
symptoms occur at intervals of roughly 48 hr.
Pv can produce hypnozoites, a stage that can
remain dormant in the liver for long periods
of time (months to decades). Pv infects young
RBCs (reticulocytes), and was thought to re-
quire the presence of the Duffy blood group
antigen on the host cell for infection. It is now
known, however, that there are Pv strains that
can infect Duffy-negative individuals.
P. malariae (Pm)
Pm causes “benign quartan malaria,” which
is relatively mild but has a cycle of 72 hr, or
every fourth day. Pm infects older RBCs.
Since 1904, three other species of Plasmod-
ium have been demonstrated to cause malaria
in humans.
P. ovale (Po)
Po, identified in the 1920s as the cause
of a mild tertian malaria, has recently been
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P. ovale curtisi and P. ovale wallikeri (Fuehrer
et al., 2012). They are not distinguishable by
morphology and both resemble Pv. Like Pv,
the Po species infect younger RBCs and may
produce long-lived hypnozoites.
P. knowlesi (Pk)
Pk (Cox-Singh, 2012) was identified in the
1920s as a cause of malaria in monkeys; occa-
sional human cases have been reported from
the 1960s on. In the past decade, substantial
numbers of human Pk infections, some severe,
have been recognized to occur in Southeast
Asia; many were initially misdiagnosed as due
to P. malariae. The range into which the para-
site is likely to expand is limited because it is
only transmissible by a small number of geo-
graphically restricted mosquito species. Pk has
a 24-hr cycle and can infect RBCs of all ages.
Pk and Pf can be maintained in long-term
culture in monkey and human RBCs; efforts
are now under way to develop long-term cul-
ture methods for Pv, which has the broadest
geographic distribution and probably infects
the largest number of people. The great ma-
jority of the 600,000 to 1,000,000 malaria
deaths estimated to occur annually however,
are due to Pf. Pm and the Po species, which
altogether account for no more than 10% of





A substantial fraction of malaria mi-
croscopy and almost all malaria cytometry
involve the detection and characterization of
small numbers of parasites or parasitized blood
cells against a background of much larger
numbers of normal blood cells. A necessary
first step in developing an appropriate method-
ology is to identify the physical and chemical
characteristics, or parameters, that are most
useful in distinguishing parasites and para-
sitized cells from other constituents of blood
and in discriminating among parasite species.
In microscopy or cytometry of cultured para-
sites or blood cells from experimental animals
or human subjects, it is generally not neces-
sary to identify the parasite species involved;
in diagnosis, this is critical.
None of the dyes used in the Giemsa stain
and its relatives is specific for any chemical
constituent of a malaria parasite or, indeed, of
any other cell type. For that reason, it is nec-
essary in malaria microscopy, as it is in iden-
tifying different types of WBCs in Giemsa-
stained smears, to discern the sizes, shapes,
colors, and textures of various constituents of
cells and to combine that information to iden-
tify a parasite or cell. In malaria, information
relevant to species identification may come not
only from the size, shape, and texture of the
nucleus or nuclei and cytoplasm, and the pres-
ence or absence of various cytoplasmic struc-
tures, but also from the numbers of different
developmental stages encountered, the modal
number of nuclei per schizont, and the pres-
ence or absence and form of the malaria pig-
ment, hemozoin. Discerning the morphologic
details of both blood cells and parasites either
visually or with interactive or automated im-
age analysis requires that a well-prepared and
-stained smear be examined at high magnifi-




The visual identification of parasite species
relies on morphologic clues that are generally
more subtle than the ones microscopists need
to distinguish among developmental stages.
There is no guarantee, however, that every
example of a given stage of a given parasite
species will match those “textbook pictures” of
that stage and species that are typically found
in instructional materials for microscopists. As
a respected text (Garcia, 2007) puts it: “Note:
Without the appliqué forms, Schüffner’s dots,
multiple rings per cell, and other developing
stages, differentiation among the species can
be very difficult. It is obvious that the early
rings of all four species can mimic one another
very easily.” Simultaneous infection with more
than one parasite species is not uncommon;
such mixed infections are difficult to diagnose
with microscopy.
Sequence information collected to date has
yielded molecular reagents that are usable for
the identification and discrimination of all
six known human malaria parasite species.
Such reagents are frequently employed in
multiplexed bead assays done by flow cytom-
etry and, more recently, by image cytome-
try. Molecular assays using DNA amplifica-
tion can detect very low parasite densities and
are viewed as more reliable than microscopy
for species identification. At present, however,
such assays are too complex and costly for rou-
tine use.
Specific parasite proteins provide the tar-
gets for antibody-based rapid diagnostic tests




Current Protocols in Cytometry Supplement 65
The tests detect parasite antigens with “dip-
sticks” or other simple visual indicators. Al-
though acceptable for the diagnosis and, to
some extent, identification of parasite species,
RDTs are ineffective at densities below 100 to
200/µl, and do not quantify accurately. They
are less effective at detecting Pv than Pf, and
unreliable for the detection of Pm and the Po
species (Murray et al., 2008; McMorrow et al.,
2011). Because they deteriorate when improp-
erly stored, RDTs are reliable only when qual-
ity control can be provided by microscopy.
Pf can be identified by RDTs detecting
histidine-rich protein 2 (HRP2), which is ex-
pressed in and on blood stages. This protein,
however, can remain detectable in blood for
several weeks after an infection has been ad-
equately treated. It has also been established
that some strains of Pf, notably several found
in South America, do not express HRP2 at all;
this further limits the utility of the protein as a
marker.
Nonspecific antibodies to the malaria par-
asite aldolase have been used in RDTs and
combined with HRP2 antibodies in tests that
discriminate Pf infections from mixed infec-
tions and from infections with other parasite
species. There are also RDTs that use mono-
clonal antibodies against parasite lactate dehy-
drogenase (pLDH); levels of this protein cor-
relate sufficiently well with the presence and
level of viable parasites to be used for anti-
malarial drug screening and the assessment of
antimalarial antibody activity as well as for di-
agnosis. The range of available anti-pLDH an-
tibodies now includes some that are monospe-
cific and others that are reactive with all or a
subset of parasite species.
If one accepts the accuracy of species
identification now available using molecular
reagents, cumulative anecdotal evidence sug-
gests that even the best and most experienced
malaria microscopists fall short of infallibil-
ity (Barber et al., 2013). We therefore think
it unlikely that computer processing of high-
resolution images of Giemsa-stained material,
advocated in some quarters, will provide an
effective replacement for malaria microscopy.
Instead, we favor an approach based on sim-
pler but far more reliable quantification of rel-
evant parameters of parasites and parasitized
cells that takes advantage of what has been
learned since Giemsa’s time.
The Cellular and Molecular Ecology
of Blood
By the mid-1800s investigators understood
that counting blood cells could provide clin-
ically useful information. RBCs are the most
abundant (∼5,000,000/µl whole blood); their
very numbers require that a sample be di-
luted a hundredfold or more. This permits
a microscopist to count individual cells in a
known volume using a hemacytometer and
thereafter calculate the RBC concentration in
whole blood from the number counted and the
known dilution factor.
Circulating RBCs do not normally contain
DNA. Like other blood cells, RBCs are formed
in the bone marrow; unlike WBCs, they nor-
mally extrude their nuclei before entering cir-
culation. At this point, some of the ribosomes
used earlier in RBC development for the syn-
thesis of hemoglobin and other proteins remain
in the cytoplasm. Ehrlich himself established
that basic dyes would precipitate a stained net-
work, or reticulum, in these young RBCs, giv-
ing them the name of reticulocytes. The dye-
binding material, which disappears during the
cells’ first day or two in circulation, is now
known to be ribosomal RNA.
Blood platelets (thrombocytes) are actually
cell fragments that break off from large multin-
ucleated megakaryocytes in the bone marrow,
and contain neither nuclei nor detectable DNA.
They may, however, contain small amounts of
ribosomal RNA during their first days in circu-
lation. Platelets, normally present at concen-
trations of 100,000 to 400,000/µl, are much
smaller (volume a few tens of fl) than either
RBCs (typical volume ∼90 fl) or WBCs (typi-
cal volume at least ∼200 fl) and are easily dis-
tinguishable from RBCs and WBCs by their
size.
The typical WBC concentration in nor-
mal blood is 5000 to 10,000/µl, meaning
that only one or two WBCs accompany each
1000 RBCs. Although their hemoglobin con-
tent makes RBCs simple to discriminate from
WBCs by microscopy or cytometry, most
modern automated cell counters, which sim-
ply measure cell size, do not make the distinc-
tion and instead include WBCs in RBC counts,
with negligible effects on accuracy. WBC
counts with either hemacytometers or auto-
mated counters are typically done on whole
blood diluted ∼1:10 with a solution containing
chemicals that lyse the RBCs. WBCs contain
nuclei, each of which carries two copies of the
genome, or approximately 6000 Mbp of DNA
in humans.
Since it is not necessary to distinguish
subcellular details when using hemacytome-
ters to visually count RBCs and WBCs, total
magnifications of 100× or less are typically
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different types of WBCs—the differential
leukocyte count or “diff”—requires substan-
tially higher magnification, as noted above.
Giemsa’s and the related dye mixtures de-
rived from Ehrlich’s work produce charac-
teristic staining patterns in WBCs, defining
five major types. The three types, called gran-
ulocytes, contain cytoplasmic granules and
have lobulated nuclei when mature. The gran-
ules of eosinophils stain most intensely with
acid dyes, and those of basophils stain most
intensely with basic dyes. Those of neu-
trophils, the most common granulocytes, stain
with both acid and basic dyes. Mononuclear
cells include lymphocytes, which typically are
smaller and rounder than granulocytes and
have relatively round nuclei and scanty cy-
toplasm; and monocytes, which generally are
larger than granulocytes, less round, and have
larger and less round nuclei.
Although color information allows differ-
ent types of granulocytes to be identified un-
equivocally, assessment of the maturity of
granulocytes by their degree of nuclear lob-
ularity and discrimination between lympho-
cytes and monocytes require careful examina-
tion of morphologic details. This is typically
done at 1000× on a slide made by smearing
1 to 2 µl of blood in a thin film occupying
an area of 2 to 4 cm2. The quality with which
morphology is preserved varies in different ar-
eas of a smear; in those areas best suited for
cell identification, most WBCs fit within a cir-
cle ∼20 µm in diameter, and most RBCs fit
within a circle <10 µm in diameter.
The relatively small size of malaria
parasites—particularly ring stages, whose de-
tection is critical in diagnosis—also de-
mands high-magnification microscopy of
high-quality smears, which allows an observer
to best appreciate the morphologic character-
istics necessary to detect parasites and distin-
guish species. Ring stages, which are actually
biconcave discs, are typically about 1/3 the di-
ameter of the RBCs in which they are found.
The optical resolution practically attainable
with oil immersion lenses is on the order of
0.25 µm; if this resolution were to be main-
tained in a digitized image of a ring-form par-
asite, the image would contain no more than
200 pixels, many of which would represent
the clear central space and therefore provide
relatively little significant morphologic infor-
mation. The option of making digital images
became available only in the late 1950s; un-
til then, identification of blood cells, parasites,
and any other formed elements that might be
found in blood required microscopy.
Significant Parameters in Malaria
Cytometry
Nucleic Acids: DNA and RNA content
Although the involvement of nuclear repli-
cation in the developmental cycle of malaria
parasites was recognized by 1904, the quan-
tification of RNA and DNA would have been
uninformative at that time; the nature of these
macromolecules and their critical roles in cell
growth were unsuspected then and indeed not
fully appreciated until the 1960s. The stain-
ing characteristics that have made it possible
for microscopists from Ehrlich on to distin-
guish RBCs containing malaria parasites from
unparasitized RBCs depend on the binding of
basic dyes to nucleic acids, but neither methy-
lene blue nor azure B, the basic dyes essen-
tial in Giemsa’s stain, has particularly specific
staining properties. Both of these dyes stain
DNA, without a strong preference for A-T or
G-C base pairs, and also RNA, making precise
quantification of either nucleic acid in Giemsa-
stained material impossible.
By 1952, both UV microspectrophotome-
try and staining with the DNA- and RNA-
specific methyl green-pyronin Y dye combi-
nation had been used to document increases
in both DNA and RNA content during schizo-
gony in RBCs (Lewert, 1952). By 1986, a flow
cytometric method for DNA and RNA quan-
tification using acridine orange was used to
confirm this, and to demonstrate by cell sort-
ing that all parasite developmental stages in
RBCs could be identified based on DNA and
RNA content alone, without recourse to any
morphologic information (Hare, 1986; Hare
and Bahler, 1986). This was again shown in
2008 (Grimberg et al., 2008), using a com-
bination of Hoechst 33342, a compound that
stains DNA stoichiometrically in living cells,
and thiazole orange, originally developed for
flow cytometric reticulocyte counting and es-
tablished to be RNA-specific in the presence
of the Hoechst dye (Jouin et al., 1995, 2004;
Grimberg et al., 2008). A schematic of DNA
and RNA content levels observed in a culture
of P. falciparum (Pf) in human RBCs appears
in Figure 11.20.1.
Uninfected mature RBCs, as noted above,
contain little or no DNA or RNA, and their
Hoechst 33342 and thiazole orange fluores-
cence signals are essentially indistinguishable
from those of unstained RBCs. Cells with one
or two rings contain little RNA (they are esti-
mated to have only ∼10,000 ribosomes) and
one or two copies of the genome (23.3 or





























1 N early trophs






Figure 11.20.1 Typical appearance of a plot of DNA content (UV-excited blue Hoechst 33342
fluorescence) and RNA content (blue-excited green thiazole orange fluorescence) of a popula-
tion of RBCs infected with Pf. Both DNA and RNA content are displayed on logarithmic scales.
Gametocytes are not shown. From Grimberg et al. (2008).
reticulocytes are estimated to contain 50,000
to 100,000 ribosomes, and thus show consid-
erably more thiazole orange fluorescence than
is detected in either uninfected mature RBCs
or RBCs containing ring forms. RBCs con-
taining early trophozoites contain one or two
copies of the genome, and therefore have DNA
content equal to those of the RBCs containing
corresponding ring stages; their RNA content
corresponds to that of uninfected reticulocytes.
Both DNA and RNA content increase as par-
asites pass from the trophozoite to the sch-
izont stage. The overall pattern of increasing
DNA and RNA content with parasite develop-
ment, originally observed by microscopy in Pv
decades ago, and shown in Pf above, is also ap-
parent in flow cytometry of cultured Pk. The
correlation between morphologic features of
these species and those of Pm and the two Po
species strongly suggests that the latter three
species, which thus far do not appear to have
been subjected to multiparameter cytometric
analysis, would manifest similar patterns of
DNA and RNA content during development.
In various contexts, DNA and RNA con-
tent can be used to detect malaria parasites
and/or to determine the effects of drugs and
immune manipulation on their growth and de-
velopment. Any of these tasks can be done
far more effectively by cytometry than by mi-
croscopy, primarily because cytometry is far
more accurate and precise for quantification,
but also because of the limitations of some of
the probes used for detection. DNA could orig-
inally be quantified only by Feulgen staining
(which removed the bases and thus lost se-
quence information) or by its UV absorption
near 260 nm (which required treatment of sam-
ples with RNAse, since RNA absorbs at the
same wavelength). Instrumentation was nec-
essary; visual quantification is imprecise and
260 nm is invisible to humans. The methyl
green/pyronin dye combination (introduced,
ironically enough, by Ehrlich, although its ad-
vantages were not appreciated until well after
his death) stains DNA green and RNA red-
dish purple with great specificity, facilitating
relative comparisons of DNA content by mi-
croscopy, as is done when schizont nuclei are
counted.
In current practice, however, quantification
of DNA and RNA is most frequently done us-
ing fluorescent dyes. Those first demonstrated
to be effective were, for the most part, com-
pounds developed early in the 20th century by
the dye companies that by then had evolved
into drug companies. The Hoechst 33342 dye
now widely preferred for DNA staining in un-
fixed cells, and referred to in Figure 11.20.1, is
one such compound. Many newer dyes, how-
ever, were designed specifically for analyti-
cal purposes, usually by systematic modifica-
tion of the structures of compounds previously
found useful. Thiazole orange, the RNA dye of
Figure 11.20.1, coincidentally exemplifies this
class of dyes; it was made to allow blood retic-
ulocyte counting to be done on the large base of
flow cytometers equipped with 488-nm lasers.
Pyronin Y itself can be used as a fluorescent
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such as Hoechst 33342 (which, incidentally,
has DNA-binding properties nearly identical
to those of methyl green) (Shapiro, 1981).
A single 23 to 27–Mbp malaria para-
site genome can easily bind several million
molecules of a DNA dye; larger genomes,
such as those in human cells, may bind hun-
dreds of millions. A single ribosome can bind
hundreds of molecules of an RNA dye, sug-
gesting that RNA signals from a ring-form-
parasitized cell would come from at least one
million molecules. Thus, DNA and RNA de-
tection can easily be accomplished by simple
fluorescence microscopes and imagers as well
as by flow cytometers.
Hemozoin
The association of the “malaria pigment”
hemozoin (Hz) with the disease (Hänscheid
et al., 2007) antedates the first observation
of the parasites by more than a century, and
played a direct role in Laveran’s initial dis-
covery. It is now known that Hz formation
serves the parasite by detoxifying heme, which
is produced as it feeds on the hemoglobin in
RBCs. The amount of Hz present in para-
sitized cells therefore increases as the para-
site passes through succeeding developmental
stages; little or none is typically detectable in
ring forms, while late-stage schizonts and ga-
metocytes contain large quantities.
Hz can be detected and at least partially
quantified without the use of reagents. It is
paramagnetic, making it possible to use mag-
nets to enrich and separate parasite stages con-
taining the pigment (Karl et al., 2008, 2009;
Kim et al., 2010). Hz is also optically bire-
fringent, i.e., capable of changing the plane of
polarization of incident light. When observed
in unstained or stained blood by transmitted
light microscopy using unpolarized light, it
appears as brownish-yellow particles. Insert-
ing crossed polarizing filters in the illumina-
tion and observation paths of the microscope
darkens the field of view except where Hz is
present; its birefringence produces bright spots
(Lawrence and Olson, 1986). Suitable polar-
izing filters are widely available and relatively
inexpensive; lenses from polarizing sunglasses
have been used successfully (Maude et al.,
2009). Hz particles also appear as relatively
bright spots when observed using dark-field
microscopy without polarization. The most
pronounced contrast with the background is
obtained when polarized light is used for dark-
field illumination and samples are observed
through a filter with a polarization plane per-
pendicular to that of the incident light.
This combination is also employed for
Hz detection in flow cytometers, in which a
side scatter (SSC) signal is measured in a
plane of polarization orthogonal to that of
the illuminating laser beam (conventional SSC
signals are measured in the same plane as
the beam). Until recently, the only flow cy-
tometers equipped to do this were Abbott’s
(http://www.abbott.com/) Cell-Dyn hematol-
ogy analyzers. The depolarized SSC signal in
these analyzers was used to detect eosinophil
WBCs, which have birefringent granules, al-
though they do not contain Hz. A now-lapsed
patent on depolarized SSC measurement, ex-
clusively licensed to Abbott while in effect,
prevented other flow cytometer manufacturers
from implementing the feature in their ma-
chines.
From the 1990s on, several groups of in-
vestigators found that in addition to detecting
eosinophils, the Cell-Dyn instruments would
register depolarized SSC signals from granulo-
cytic and monocytic WBCs that contained Hz
by virtue of having phagocytized parasitized
RBCs (Mendelow et al., 1999; Grobusch et al.,
2003; Hänscheid et al., 2011). Such cells had
previously been visualized on slides; their
relative rarity makes it difficult to estimate
their abundance precisely enough to clarify
their clinical significance. Flow cytometry, in
principle, made it possible to quantify Hz-
containing WBCs more precisely by analyz-
ing much larger blood samples; however, the
hematology analyzers were not readily mod-
ifiable to do this. Depolarized SSC measure-
ments can now be implemented in other flow
cytometers without legal impediment; many
commercially available instruments can be
modified to do them (Frita et al., 2011). In
some cases, e.g., the Accuri (BD Biosciences)
C6 instrument and some from Partec, a user
can make the modification in minutes using
inexpensive optical components.
The use of Hz detection alone in either
blood or tissue for malaria diagnosis, poten-
tially manageable without the use of a reagent,
has attracted numerous investigators, and sub-
stantial funding has been made available for
the approach. Some cautions are in order, how-
ever. It is already known that detectable Hz can
be found in human WBCs for many weeks af-
ter an active malarial infection has resolved,
and that the material can persist in animal tis-
sues for months (Frita et al., 2012). Further-
more, Hz may be produced by parasites other
than malaria, e.g., schistosomes and some fi-
laria. While they are much less common causes
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occur with significant frequency in many
places heavily burdened by malaria.
Lastly, in P. falciparum (Pf) infection,
RBCs harboring the late trophozoite and sch-
izont stages—which contain most of the Hz—
also express surface antigens that adhere to en-
dothelial cells and lead the parasitized cells to
be removed from circulation. As a rule, >95%
of circulating parasitized RBCs in Pf-infected
patients are ring forms containing little or no
detectable Hz, although some will be encoun-
tered in circulating gametocytes. A flow cyto-
metric study measuring depolarized SSC and
DNA in blood from Pf-infected patients found
no parasitized RBC with detectable Hz signals
(Rebelo et al., 2012). Since the use of magnetic
fields to concentrate malaria parasites—in or
outside RBCs—from blood depends entirely
on whether the parasites contain Hz, magnetic
separation would be unlikely to increase the
sensitivity of a solely Hz-based Pf diagnostic.
Cytometric detection and quantification of
Hz can nonetheless be valuable in malaria di-
agnosis when combined with the measurement
of other parameters, notably DNA and RNA
content. Moreover, although the literature now
contains descriptions of several highly com-
plex and expensive measurement methods, Hz
detection using polarized light can, as noted
above, be implemented simply and cheaply in
either image or flow cytometers. As one might
expect, given the established utility of Hz ob-
servation in microscopy, cytometric quantifi-
cation of Hz improves the ability to discrimi-
nate among various developmental stages and
is likely to aid in distinguishing species. It is
already known that a number of antimalari-
als interfere with Hz production in susceptible
parasite strains, and recent evidence suggests
that monitoring this by cytometry may pro-
duce a relatively simple and effective means
of detecting the emergence of drug resistance
(Rebelo et al., 2013).
Mitochondrial Membrane Potential
(!"m) and Other Physiologic
Characteristics; Viability
Malaria parasites contain mitochondria; the
single mitochondrion that enters an RBC
in a merozoite is reproduced during schizo-
gony. Each of the resulting new generation
of merozoites is haploid and contains a sin-
gle mitochondrion. Energized mitochondria in
all cell types maintain a difference in elec-
trical potential of ∼120 mV between their
interior and the cytosol, with the interior neg-
ative; this mitochondrial membrane poten-
tial (!"m) decreases to zero or near zero
in the presence of metabolic inhibitors such
as the proton ionophore carbonyl cyanide m-
chlorophenyl hydrazone (CCCP). The mito-
chondria in blood stages of plasmodia, like
those in trypanosomes and unlike those in
almost all animal cells, are not primarily in-
volved in energy metabolism but instead use
their membrane potential-derivable energy in
biosynthesis, primarily of pyrimidines.
Note that !"m can be measured cyto-
metrically using fluorescent dyes that carry
a single positive charge and are sufficiently
lipid-soluble to be able to pass through cy-
toplasmic and mitochondrial membranes. The
less lipophilic representatives of this class of
dyes, e.g., tetramethylrhodamine ethyl ester
(TMRE), partition across membranes in ac-
cordance with the Nernst equation; at 37◦C,
the ratio of dye concentrations inside and out-
side the membrane increases by a factor of
10 for every 60 mV of membrane potential.
More lipophilic dyes, e.g., rhodamine 123 and
cyanines, exhibit higher ratios of interior to ex-
terior concentrations than would be predicted
by the Nernst equation.
Mitochondrial de-energization and the ac-
companying decrease in !"m occur early
in apoptosis in many cell types, and have
also been observed in parasites exposed
to a number of antimalarial drugs, includ-
ing chloroquine and atovaquone. Both di-
hexyloxacarbocyanine (DiOC6(3)) and hex-
amethylindodicarbocyanine (DiIC1(5)) can be
used as !"m indicators (Shapiro et al.,
1979; Grimberg et al., 2009; Grimberg,
2011). In cells exposed to concentrations of
1 to 10-nM dye, most fluorescence comes
from mitochondria. The dye now in widest
use, however, is 5,5′,6,6′-tetrachloro-1,1′,3,3′-
tetraethylbenzimidazolocarbocyanine iodide
(JC-1). When applied at micromolar concen-
trations, this normally green fluorescent dye
becomes sufficiently concentrated in ener-
gized mitochondria to form red fluorescent
aggregates. Measurements of red and green
fluorescence and the ratio of both provides a
more precise indicator of !"m than can be ob-
tained by measuring a single emission wave-
length. JC-1 has been used to examine !"m
in malaria parasites (Ch’ng et al., 2010).
Most eukaryotic cells have many mitochon-
dria; microscopy or image cytometry would be
necessary to detect a condition in which some
were energized and some not. The mitochon-
dria in RBCs typically lose function as the
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typically contain only one energizable mito-
chondrion for each nucleus, allowing a mea-
surement of DNA content to be used to nor-
malize fluorescence measurements of !"m.
The presence of an energized mitochondrion
in a parasitized cell provides evidence that the
parasite is metabolically viable, but does not
speak to its reproductive viability.
Furthermore, the loss of !"m itself does
not establish that an intracellular parasite is
apoptotic. The characteristics commonly used
in conjunction with !"m as apoptosis indi-
cators in cultured animal cell lines include
membrane phosphatidylserine (PS) exposure,
detected with fluorescent annexin V, and per-
meability to various nucleic acid dyes. The
cytoplasmic membranes of parasitized RBCs,
although known to contain exposed PS and
to therefore bind annexin V, retain sufficient
structural integrity to prevent annexin V from
reaching the parasite cytoplasmic membrane.
Similarly, it is the RBC membrane that de-
termines whether a permeability indicator dye
such as propidium iodide can reach the outside
of the parasite.
Other parameters measurable by cytometry,
e.g., intracellular and intraorganelle pH, con-
tent of ions such as Ca++, and levels of redox-
related metabolites such as reactive oxygen
species (ROS), glutathione, and total –SH
groups, are of interest with respect to the phys-
iology of parasites. The multicompartmental
nature of parasitized RBCs, composed as they
are of RBCs containing membrane-bounded
parasites within which there are a variety
of membrane-bounded organelles, may make
it necessary to use relatively high-resolution
imaging apparatus to distinguish signals from
molecules of the same indicator in different
compartments.
Physiologic parameters such as !"m are
meaningful only in cells that are at least po-
tentially viable. There are some probes that
can be applied to cells in that condition that
will bind covalently and withstand subsequent
fixation, thereby providing at least some in-
dication of the cells’ initial physiologic status
(Jogdand et al., 2012). This approach would
almost certainly be necessary if a parameter
such as !"m were to be considered for diag-
nostic applications.
Activities of some intracellular enzymes
may be detectable however, not only in nonvi-
able cells but also in those that have been per-
meabilized and/or fixed, using chromogenic or
fluorogenic substrates. The fluorogenic sub-
strates most widely used in cytometry are
simple esters of fluorescein and its carboxy-
lated derivatives carboxyfluorescein and cal-
cein; the esters are nonfluorescent and suf-
ficiently lipophilic to diffuse readily through
intact cell membranes. Once inside, they are
hydrolyzed by nonspecific esterases present
in almost all cells, forming fluorescent prod-
ucts containing negatively charged carboxyl
groups, which do not readily cross intact mem-
branes. Although esterases in cells with dam-
aged membranes may hydrolyze the esters,
the resulting products do not accumulate in
sufficient quantity to render these cells fluo-
rescent. Thus, intracellular fluorescence after
exposure to fluorescein esters, although often
described as an indicator of “viability,” actu-
ally only establishes the integrity of the cy-
toplasmic membrane. Other chromogenic and
fluorogenic substrates, e.g., tetrazolium dyes,
have been used to determine metabolic activ-
ity; still others detect the activity of hydrolytic
enzymes unique to unique cell types such as
monocytes and more general classes such as
stem cells.
Protein Structure: Labeled Antibodies
and Fluorescent Proteins
By the late 1960s, when analytical flow cy-
tometers and cell sorters were first applied to
the problem of differential WBC counting, it
was clear that the simple acid-basic dye mix-
tures in Giemsa’s and related stains could not
provide the information necessary to distin-
guish classes of lymphocytes that had been
shown to play different roles in the function of
the immune system. The fluorescent antibody
technique, first developed in the 1940s, pro-
vided an obvious means of identifying small
numbers of protein molecules in and/or on
cells using the high-powered lasers that had re-
cently become available. From the late 1970s
on, initial successes in this area led to the ex-
ploitation of monoclonal antibodies as specific
reagents. When these were used in the early
1980s to define the cellular basis of HIV infec-
tion and AIDS and provide a reliable indicator
of disease progression, flow cytometry became
an essential clinical method, at least for those
who could afford and maintain the apparatus.
Today’s most complex flow cytometers
can simultaneously detect a few thousand
molecules of each of ten or more well-defined
antigens on single cells. Their simpler prede-
cessors facilitated the discovery of effective
antiviral therapies for HIV. From 2000 on,
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patients in resource-poor countries has moti-
vated the development of a range of progres-
sively simpler apparatus for counting CD4+
T lymphocytes. As noted above, such appara-
tus for these regions now includes small field-
portable fluorescence imaging cytometers that
are orders of magnitude smaller, simpler, and
cheaper than the far more elaborate flow sys-
tems that are now used in malaria research.
The imaging instruments can detect signals
from fewer than 5,000 fluorescently labeled
antibody molecules above background; newer
antibody labels should provide even higher
sensitivity.
Monoclonal antibodies that detect species-
specific parasite protein epitopes are now used
in RDTs. Although levels of proteins such as
aldolase, HRP2, and pLDH may vary con-
siderably from case to case, antibodies to
the latter have been detected by fluorescence
microscopy, and biochemical analysis sug-
gests that at least a few tens of thousands of
molecules are expressed even in ring-form-
parasitized cells. They should therefore be de-
tectable by simple imaging systems as well as
by flow cytometers, potentially making it pos-
sible for thousands of instruments now in place
in the field to be adapted for parasite density
determination, diagnostic and otherwise.
The practical development of fluorescent
proteins as research tools was, like that of mon-
oclonal antibodies, facilitated by the availabil-
ity of cytometric apparatus, including high-
resolution imaging and confocal microscopes
as well as flow cytometers. Although the
proteins have proven useful for research ap-
plications in malaria (Tilley et al., 2007;
Vorobjev et al., 2012), they are substantially
less likely than antibodies to be practical for
diagnosis.
Nucleic Acid Sequence and Base
Composition
Complete genome sequences are now avail-
able for three of the six human malaria par-
asites. The P. falciparum genome contains
23.3 Mbp of DNA, with 80.6% in the form
of A-T pairs; few other organisms approach
this A+T percentage. The P. vivax genome
contains 26.8 Mbp of DNA, 57.7% in the
form of A-T pairs. The P. knowlesi genome
contains 23.5 Mbp of DNA, 62.5% as A-T
pairs. The genomes of P. malariae and both
P. ovale species are estimated to be between
25 and 27 Mbp in size; A+T percentages for
these species are not precisely known. Hap-
loid nuclei contain a single copy of the parasite
genome.
Although DNA sequence information is
widely regarded as capable of providing
definitive malaria diagnoses, molecular meth-
ods are not yet sufficiently simple and inex-
pensive enough to replace microscopy. The
earliest molecular reagents demonstrated to
provide highly sensitive malaria species iden-
tification were probes for ribosomal RNA
(rRNA) sequences specific to P. falciparum.
Although autoradiography was initially used
for their detection, it is now relatively com-
monplace to employ fluorescent in situ hy-
bridization (FISH) and flow or image cy-
tometry for the purpose in other contexts.
The FISH probes are typically combined with
DNA stains, allowing nonspecifically clumped
probes to be identified as such by their lack of
association with small amounts of DNA com-
parable in size to the genomes of target or-
ganisms. The principal drawback to the use
of either FISH probes or fluorescent antibod-
ies lies in the relative lack of abundance of
binding sites for them in individual parasites,
which typically contain no more than a few
tens of thousands of copies of either rRNA
sequences or species-specific proteins. Even
ring-form parasites can, by contrast, bind mil-
lions of molecules of DNA dyes and at least
hundreds of thousands of molecules of RNA
dyes, providing much stronger fluorescence
signals, making detection easier and quantifi-
cation more precise. Also, nucleic acid dyes
are, in general, substantially cheaper and more
stable than antibodies and nucleic acid se-
quence probes, and staining procedures are
considerably faster and simpler.
Old and newer cytometric data now suggest
that base composition–selective DNA dyes
could be used to achieve a genome-based
species-specific diagnosis in both flow and im-
age cytometers. Molecular biologists found in
the early 1960s that the melting temperature
at which double-helical DNA could be bro-
ken into single strands depended on the per-
centages of A-T and G-C pairs, which, re-
spectively, are held together by two and three
hydrogen bonds. This allowed the base compo-
sition of the DNA of a variety of organisms to
be determined relatively simply from melting
curves. The nucleic acid binding characteris-
tics of a number of different dyes and drugs
could then be determined by analysis of their
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The Hoechst dyes 33258 and 33342 and
some related compounds, all originally de-
veloped and evaluated as antimalarials, were
found to fluoresce strongly only when bound
to multiple A-T pairs in DNA. Other drugs
such as chromomycin A3 and mithramycin
were found to bind with resultant fluorescence
only to G-C pairs in DNA. The addition of
Hoechst 33258 to mixtures of DNA with sub-
stantially different percentages of A-T pairs
facilitated ultracentrifugal separation, and was
employed in late 1987 to purify P. falciparum
DNA subsequently used to create sequence-
specific probes for the organism (Dame and
McCutchan, 1987).
Hoechst 33258 had also been used earlier
in 1987 to stain human RBCs infected with
P. falciparum and P. vivax for flow cytome-
try (Janse et al., 1987), with the former yield-
ing fluorescence signals >21% higher than the
latter, precisely as would be predicted from the
A-T percentages and genome sizes, neither
of which were known at the time. The pre-
dicted signal intensities from RBCs infected
with P. knowlesi would be almost 27% lower
than those from Pf-infected RBCs. Although
intensity differences of less than 30% are
not reliably detectable by eye, much smaller
differences are routinely measured cytomet-
rically. Breeders now inseminate cattle us-
ing bull sperm sorted into highly enriched
X-chromosome-bearing and Y-chromosome-
bearing fractions based on a difference of less
than 4% in Hoechst dye fluorescence.
Even smaller base composition differences
are detectable using combinations of an A-
T selective dye with one that has a G-C
preference. Two-parameter sorting of human
metaphase chromosomes stained with Hoechst
33258 and chromomycin A3 was used to pre-
pare the first chromosome-specific libraries
used in the Human Genome Project. This dye
combination was also used to identify dif-
ferent bacterial species by base composition
and was shown to provide reliable quantifi-
cation of A+T percentage. Such analyses do
not demand use of high-powered, high-priced
cell sorters; base composition differences be-
tween trypanosomal strains, which would be
expected to yield roughly the same fluores-
cence intensities as would malaria parasites,
can be detected on smears using relatively
modest fluorescence imaging cytometry appa-
ratus (Mühlpfordt et al., 1985; Mühlpfordt and
Berger, 1989, 1990).
The best information now available sug-
gests that base composition measurements
done in such apparatus can reliably discrim-
inate P. falciparum from P. vivax and P.
knowlesi and probably distinguish between
the latter two species, achieving a specificity
equivalent to that obtained with sequence-
specific probes but using only relatively in-
expensive, simple dyes. The imaging instru-
ments could easily be used to measure the
genome sizes and base compositions of the
two P. ovale species and P. malariae by analyz-
ing blood smears from patients with diagnoses
confirmed by molecular methods. The utility
of DNA base composition measurements for
identifying these species could therefore be






Multiparameter Analysis in Stage
Identification and Diagnosis
Cell identifications made on the basis of
morphologic characteristics visualized by mi-
croscopy are of necessity a level removed
from those that are made using flow or im-
age cytometry to quantify specific cellular
constituents. However, both observers and cy-
tometrists, whether identifying cells by stage
and species or determining their functional sta-
tus, typically consider more than one cellu-
lar characteristic. An observer will identify a
malaria parasite as a ring stage because of its
size and shape, relatively scant cytoplasm, the
presence of a single nucleus, and the absence
of Hz. Cytometric identification of tropho-
zoites and schizonts can be made by quan-
tification of DNA and RNA content. The for-
mer is very highly correlated with the number
of nuclei and the latter reflects the amount of
cytoplasm present; Hz might or might not be
measured, but size and shape information are
unnecessary.
The visual identification of gametocytes,
particularly the crescent forms that gave the
species name to P. falciparum, is almost en-
tirely based on morphology, although the pres-
ence of Hz also provides a clue. Cytomet-
ric quantification of DNA and RNA would
reveal a DNA content about twice that of a
single genome (Janse et al., 1988), and also
would demonstrate the presence of a much
larger amount of RNA in female (macro-)
than in male (micro-) gametocytes. The dif-
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pronounced blue color of the cytoplasm in
Giemsa-stained macrogametocytes. Cytome-
try would also detect relatively large depolar-
ized SSC signals from gametocytes because
of their substantial Hz content; they are the
only parasite forms with near-diploid DNA
that contain significant amounts of the pig-
ment. Morphologic information would, as in
the case of ring forms, be unnecessary for cy-
tometric identification of gametocytes.
All of the parameters mentioned above as
relevant to the detection and identification of
malaria parasites, i.e., DNA content, base com-
position, and sequence; and the contents of
RNA, hemozoin, and various specific proteins,
can be measured accurately and precisely by
light transmission, fluorescence, and/or scat-
tering. Whether the measurements are made
on liquid samples in a flowing stream or a
counting chamber, or on dry samples in smears
on slides, the basic analytical problem re-
mains one of detecting and quantifying small
amounts of light originating from small re-
gions of space. In 1904, the detection task
could only be done by a human observer us-
ing a powerful microscope. A century later,
although humans remain severely limited in
their capacity to quantify light intensity, the
more accurate and precise instrumental meth-
ods for doing so do not depend on either high
magnification or high resolution.
Problems with Microscopy 1: The
Sampling Statistics Numbers Game
Even before Giemsa developed what be-
came the definitive stain for blood smears, it
had become clear that malaria diagnosis pre-
sented problems different from those encoun-
tered in blood cell counting, because the levels
of parasites present in blood were frequently
far lower than was the case for even relatively
uncommon types of WBCs and RBCs.
If it is assumed that any malaria para-
sites seen on a patient’s blood smear come
from the patient, detection of even a single
parasite would indicate the presence of par-
asitemia. Reliable quantification of parasite
density, however, requires counting a num-
ber of parasites in a defined volume of blood,
and precision depends on the number actually
counted. The relevant statistical distribution
is Poisson’s: the standard deviation (SD) of a
count of n objects is n1/2 (i.e.,),
n
even in the absence of any other sources of
variability. The percent coefficient of varia-
tion (CV), i.e., 100 times the SD divided by
the count, defines the best attainable precision
of the count. In order to reduce the minimal
attainable CV on a density measurement to 10
percent, it is necessary to count 100 parasites;
at a density of 100/µl, this would require the
examination of 1 µl of blood.
In a modern microscope, the area of a high-
power field (HPF) seen with 10× eyepieces
and a 100× oil immersion lens is ∼0.025 mm2;
in older instruments, a single HPF encom-
passed ∼0.02 mm2. Thus, a 10 × 20–mm
area of a thin smear or film containing 1 µl of
blood would contain 10,000 HPF. At a density
of 100/µl, the target lower level of detection
for microscopy, only 100, or 0.002%, of the
∼5,000,000 RBCs in 1 µl of blood contain
parasites; it would be necessary to examine
0.01 µl of blood, or 100 HPF, to encounter a
single parasite.
Ronald Ross himself, realizing that the de-
tection of parasites at low densities in thin
blood smears would require hours of obser-
vation, suggested in 1903 (Ross, 1903) that in
addition to the thin smear, a thicker one be
made that contained 10 to 20 µl of blood.
He observed that washing an unfixed thick
smear with distilled water would remove the
hemoglobin from most of the RBCs, enabling
parasites to be seen. It remains common prac-
tice to prepare both thin and thick smears, ex-
amining 200 HPF in both and 500 HPF in the
thick smear if no parasites are seen in 200 HPF.
By 1910, Ross had refined his methodology
(Ross and Thomson, 1910), allowing the ac-
tual volume of blood in a thick smear to be
estimated relatively precisely by dispensing it
from a calibrated capillary tube, typically dis-
tributing 1 µl over a 5 × 5–mm area, com-
prising 1250 HPF. Allowing 3 sec/HPF, the
entire volume of blood could be searched in
an hour, although, as Ross noted, “the identi-
fication of the plasmodia [in the thick smear]
requires considerable practice.”
In recent years, it has been established that
the distilled water wash step may remove 60%
to 90% of parasites from an unfixed thick
smear; gametocytes, typically accounting for
only a small percentage of parasites in any
case, appear to be lost preferentially in wash-
ing. Since even the best thick smears typically
do not present parasites in a fashion in which
morphological differences between species are
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smears; however, a good case can be made for
the use of fixed thin smears alone (Ohrt et al.,
2008).
Problems with Microscopy 2: The
Resolution Requirement
The relative nonspecificity of the Giemsa
stain demands that the human observer process
high-magnification, high-resolution images to
extract information about the species and stage
of any parasites encountered on the slide. We
have already noted that equivalent or supe-
rior information, independent of morphology,
can be obtained using flow cytometers, with-
out the need for high magnification or resolu-
tion. Assuming for the moment, however, that
computer image analysis of Giemsa-stained
slides could be made as accurate as flow
cytometry, the collection of data itself would
require relatively complex and expensive hard-
ware. It would be necessary for an automated
stage to move in increments of no more than
a few micrometers in two directions to bring
hundreds of high-power fields into the range
of the objective lens, and for an automated fo-
cusing mechanism to move in submicrometer
increments to acquire a properly focused im-
age of each field. A high-power microscope
made from a mobile phone, using a spring
clip in which to hold a slide and human rather
than binary digits for motion control, is un-
likely to provide any significant improvement
in malaria diagnosis.
Problems with Microscopy 3:
Fluorescence Cannot Be Used
Optimally
Almost all staining procedures for flow cy-
tometry employ fluorescent dyes and/or la-
bels; it is the quantification of multiple cel-
lular constituents by whole-cell fluorescence
measurements in different spectral regions that
provides the information needed to identify
different cell types and characterize their phys-
iologic states.
The light collection lenses used in flow cy-
tometers are similar in their optical charac-
teristics to the “high dry” and oil immersion
lenses used in microscopes. The lens charac-
teristic critical in flow cytometry, however, is
numerical aperture, or light-gathering power.
Although there are flow cytometers available
at premium prices that can provide medium-
resolution images of single cells, a more typi-
cal instrument collects light equally accurately
and precisely from the thin “slice” of a cell on
which it is focused and from the adjacent out-
of-focus areas. These instruments do not form
an image in which cellular details can be rec-
ognized.
Fluorescence measurements of stained cells
using either flow cytometers or imaging sys-
tems typically yield signals high enough above
a background level to make it substantially eas-
ier to detect small numbers of dye molecules
in or on cells than would be the case with ab-
sorption or extinction measurements. Absorp-
tion and extinction by particles near or be-
low the optical resolution limit are essentially
undetectable; fluorescence and light scatter-
ing by particles substantially smaller than the
resolution limit, down to the level of individ-
ual virions, microvesicles, and even single dye
molecules, can be detected in suitably config-
ured apparatus.
Fluorescence microscopes were not avail-
able in 1904; until around 1940, they re-
quired expensive and relatively power-hungry
light sources such as carbon arcs and mer-
cury and xenon arc lamps, and were there-
fore inaccessible in many places with a high
incidence of malaria. From the 1940s on, im-
provements in incandescent lamp technology
made microscopes more affordable and some-
what more energy efficient; since the “Giemsa
Centennial” in 2004, high-power LEDs, effi-
cient enough to be run for hours on batteries,
have become preferred illumination sources
for fluorescence (and other) microscopy as
well as for automotive, home, and industrial
lighting. Although an LED-illuminated fluo-
rescence microscope must still be run in a dark
environment, the addition of a video camera
allows a human observer to work in a lighted
area.
From the 1920s on, fluorescent dyes were
evaluated as stains for blood cells, malaria
parasites, and bacteria. Their most notable re-
cent application to public health problems in
resource-poor countries has been for the diag-
nosis of tuberculosis based on the acid-fast na-
ture of the mycobacterial cell wall. It had been
known for almost 70 years that using the fluo-
rescent dye auramine O rather than the carbol
fuchsin Ziehl-Neelsen absorption method to
stain sputum slides typically allowed smaller
numbers of organisms to be detected more
rapidly using lower (high-dry instead of oil
immersion) magnification. A number of man-
ufacturers offer microscope adapters and in-
expensive fluorescence microscopes that are
equipped with blue LEDs for excitation and
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is suitable for detecting malaria parasites in
acridine orange-stained blood as well as for
TB microscopy with auramine O. At least
one microscope, the CyScope (Partec), can be
equipped with a UV LED for excitation and
a blue emission filter, allowing the detection
of parasites using the relatively DNA-specific
stain DAPI.
Since a human nucleus contains several
hundred times as much DNA as a ring-form
parasite and almost ten times as much as a sch-
izont with 20 to 30 nuclei, it is not a challenge
for a human observer to distinguish parasites
from WBC on the basis of the fluorescence
intensity of a DNA stain. It would be substan-
tially harder to discriminate between DNAs
of different base compositions using a pair of
DNA stains. As long as the human observer is
involved, it is also necessary to work with a
magnified image. Although a single field ob-
served at 40× encompasses 6.25 times the area
of a 100× field, allowing observation time to
be shortened by roughly the same factor, the
human, even dark-adapted and sitting in a dark
room, would be unlikely to be able to detect
fluorescence from a stained ring-form parasite
when looking at a “life-size” (1× magnifica-
tion) slide.
A further disadvantage of fluorescence mi-
croscopy vis-à-vis fluorescence cytometry lies
in the tendency of fluorescent dyes to bleach
and fade, especially when exposed to the high-
intensity excitation used in microscopy and
cytometry. Giemsa and other absorption stains
leave a much larger amount of dye in stained
cells than do typical fluorescence staining pro-
cedures; this in itself often makes it difficult to
quantify stain intensity by absorption because
Beer’s law is violated. The large amounts of
absorption dyes in cells are, however, easily
observable using much less intense illumina-
tion than would typically be optimal for fluo-
rescence excitation, so significant fading does
not occur even after prolonged illumination.
Although there are some chemical treatments
that retard the bleaching and fading of fluores-
cent stains, one typically notices a progressive
decrease in the intensity of cells after even a
minute or two of scanning a slide. This effec-
tively prevents visual quantification of fluores-
cence with any precision. In a flow cytometer,
the sample flow rate is controlled; cells are
not exposed to an illuminating beam until they
pass through it for measurement, and all cells
spend nearly the same time in the beam, al-
lowing fluorescence intensities from different
cells to be compared.
Fluorescence Image Cytometry:
Throughput Going Up, Costs Going
Down
Quantitative fluorescence microscopy at
the whole-cell level can be done by restricting
both the illumination and the microscope field
of view to an area not too much larger than the
area of the cells to be measured, and sequen-
tially positioning individual cells using phase
microscopy or an equivalent dye-independent,
contrast-enhancing technique and illumination
at a wavelength at which the relevant fluores-
cent dyes do not absorb significantly. Fluores-
cence measurements can then be made when
an excitation source is turned on, or its light is
allowed to reach the cell, for only a relatively
brief, defined period of time.
This slow process, typically consuming at
least several seconds for the measurement of
a single cell, was unavoidable when photodi-
odes or photomultiplier tubes (PMTs) were the
only detectors available and extended sources
(e.g., arc lamps) were the only available ex-
citation sources. It is possible to speed up the
analysis process considerably by examining
a larger field of view containing more than
one cell, provided cells are well enough sep-
arated in space for signals from them to be
distinguished. A diode or PMT detector can
be used if a laser, focused to a small spot and
scanned across the area of the field, is used for
illumination; this is analogous to a flow cy-
tometer except that the beam is brought to the
cells instead of the cells being brought to the
beam. Although such laser-scanning cytome-
try reduces analysis time to a small fraction of
a second per cell, the apparatus incorporates
both the costly and complex illumination and
light detection components used in a flow cy-
tometer and the precision stage motion and fo-
cus control hardware needed in an automated
microscope.
If a lamp or LED is used to illuminate a
field containing several cells, it becomes more
logical to use one or more digital cameras as
fluorescence detectors. In this case, it is nec-
essary to use a fluorescence standard such as a
dyed slide to measure variations in excitation
intensity over the field, providing a normal-
ization factor for raw fluorescence intensity
measurements.
This allows reasonably sensitive and pre-
cise measurements to be done in standard flu-
orescence microscopes; it has, moreover, been
established that, as is also the case in flow cy-
tometry, the precision of such measurements
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Using a multimegapixel digital camera chip
as a detector overcomes the limitations of the
human visual system, demonstrably allowing
precise and sensitive quantitative whole-cell
measurements of large numbers of cells dis-
persed on a slide or in a counting chamber to
be made at 1× magnification, with all cells
in the sample being illuminated simultane-
ously. Such wide-field imaging cytometry was
first demonstrated in the early 1990s when the
available digital cameras cost over $10,000
and the laser and arc lamp sources suitable
for excitation were only slightly less expen-
sive, making the apparatus very much simpler
than a flow cytometer but not significantly less
costly. An equivalent instrument could now be
made using LEDs—available at wavelengths
ranging from UV to IR and costing only tens of
dollars—for illumination and similarly priced
camera and microprocessor chips for detection
and the very rudimentary image analysis re-
quired. Wide-field imaging cytometry requires
exposure times no longer than a few seconds;
data from thousands of cells in a field can be
analyzed in minutes.
Based on the well-established relationships
between component costs and finished prod-
uct costs for similar biomedical apparatus, an
image cytometer of the type just described
could be sold for no more than a few thousand
U.S. dollars. The device could examine 1 µl
of blood smeared over a 1 cm2 area of a slide
without requiring either sample movement or
focus adjustment, making detection of one or
more parasites 95% likely even at a density of
5/µl. Obviously, the device could be put to use
for a wide range of other measurements now
made by flow cytometry.
Problems with Flow Cytometry
Reviews of experimental approaches to im-
proving malaria detection, density determina-
tion, and diagnosis frequently describe flow
cytometry as not only complex and expensive,
which it is, but also as imprecise and not par-
ticularly sensitive for detecting low parasite
densities. We regard the latter characterization
as unfair. The small sample of publications
dealing with this application, with the earliest
dating to the 1970s, have used a wide range of
preparative procedures and instruments, with
the choice of dyes restricted more often than
not by the capabilities of the apparatus avail-
able. Much of the earlier work was done using
flow cytometers that had only one light source:
a 488-nm argon ion laser. The flow cytometers
also used nucleic acid dyes that were not par-
ticularly specific for DNA or RNA. This made
it difficult to distinguish cells bearing early-
stage parasites from reticulocytes. As noted
above and illustrated in Figure 11.20.1, the use
of DNA- and RNA-specific dyes facilitates this
distinction. The addition of measurement pa-
rameters, e.g., Hz content, would be expected
to increase the specificity and sensitivity of
detection, and the small amount of data accu-
mulated by the few laboratories now capable
of making such measurements points in this di-
rection. Long ago, flow cytometry was shown
to be capable of detecting tumor cells seeded
into blood at densities of 1/10,000,000 WBC
(Gross et al., 1995); equivalent performance in
malaria would detect 1 parasite/µl.
Although flow cytometers designed for re-
search and relatively sophisticated clinical im-
munophenotyping procedures are reasonably
well suited to measuring cells from human
blood and the immune system, and flow cy-
tometers designed for clinical hematology labs
are optimized for the examination of blood
cells, no production apparatus of either type
comes equipped to measure DNA, RNA, and
hemozoin content, let alone DNA base com-
position and the sequence and content of pro-
teins such as pLDH. Almost all instruments
could measure DNA and a specific protein;
many could also be adapted to measure RNA
and hemozoin. Base composition measure-
ment is problematic because the required base-
sensitive DNA dyes require excitation with
UV or violet light. Neither wavelength is avail-
able on most flow cytometers; adding UV il-
lumination also typically adds at least $10,000
to the cost of an instrument.
The effect of anemia, particularly iron defi-
ciency anemia, on the course of malaria has
been of great interest for some time; a re-
cent paper describes flow cytometric mea-
surement of the labile iron pool in para-
sitized RBCs (Clark et al., 2013), and it
would be of great interest to examine the
growth of parasites in RBCs with differ-
ent hemoglobin contents. However, although
one type of existing flow cytometric hema-
tology analyzer (Advia; Siemens Healthcare)
can measure hemoglobin, the procedure uses
relatively complex optics that cannot readily
be added to any existing research flow cy-
tometer, and the hematology analyzers can-
not readily be adapted for fluorescence mea-
surements of other relevant parameters such
as DNA and RNA. Although an instrument
capable of the combined measurements could
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moderately sophisticated commercial research
flow cytometer, it has been difficult to convince
anybody to pay for it.
At a more mundane level, we note that flow
cytometers, even those adapted to use less fluid
in their specimen transport mechanisms, con-
sume fairly large volumes of clean, particle-
free water or saline, and that access to clean
water is limited in many of the malaria-prone
areas in which affordable cytometric appara-
tus for malaria diagnosis and research is most
needed. Wide-field image cytometry, which is
now capable of measuring the relevant param-
eters, requires minimal quantities of water and
reagents, and the apparatus is less complex
and costly, and more robust and portable, than
flow cytometry, and is likely to remain so for
the foreseeable future.
THE CYTOMETRIC FUTURE IN
MALARIA DIAGNOSIS,
RESEARCH, AND EPIDEMIOLOGY
At this writing, we are unaware of the exis-
tence of any wide-field image cytometers op-
timized for multiparameter measurements of
malaria parasites. We have defined the capa-
bilities of the necessary apparatus during de-
velopment projects targeting other diagnostic
and research applications. Fine-tuning an in-
strument configuration for malaria work could
be accomplished within months, given a sup-
ply of unstained patient blood smears contain-
ing parasite species identified by nucleic acid
sequence and smears from cultured P. falci-
parum, P. knowlesi, and—should it become
available—P. vivax. It would then become pos-
sible to put prototypes into the field.
We have been asked about the feasibility of
using the installed base of flow cytometers for
malaria diagnosis. There are, at present, sev-
eral thousand such instruments now in use in
the field for CD4 counting; most of these rela-
tively simple systems measure fluorescence in
two spectral regions and some add a forward or
side scatter signal. The fluorescence measure-
ments are sufficiently sensitive to detect a few
thousand molecules of each of two antibody
labels. Any more complex fluorescence flow
cytometer used in either a clinical or research
laboratory can almost certainly measure the
same two spectral regions with at least equiv-
alent sensitivity.
As noted above, determination of a para-
site density of 100/µl with a theoretical mini-
mum percent CV of 10% requires counting at
least 100 parasites, which will be distributed
among the roughly 5,000,000 RBCs in 1 µl
of whole blood. The simpler flow cytometers,
e.g., CD4 counters, may count no more than
5,000 “events” per sec, where an “event” is
defined as occurring when a selected “trigger”
signal rises above a preset threshold level. In
almost all malaria cytometry, the trigger sig-
nal is a scatter signal, with the threshold set
to include RBCs, but to exclude platelets and
smaller particles. Analysis of 5,000,000 RBCs
in this case will require 1,000 sec, or 16.7 min.
Since the actual flow rate of diluted sample
through the cytometer is likely to be no more
than 1 µl/sec, the blood sample will have to be
diluted 1:1,000 before it is introduced into the
cytometer.
The BD Biosciences FACSCount CD4
counter measures only two fluorescence sig-
nals. The trigger signal comes from the label
on an antibody against the CD3 antigen, the
presence of which defines a T cell. The CD4+
T cell count is obtained by counting only those
“events,” i.e., T cells, for which there is corre-
sponding signal in the other fluorescence chan-
nel, indicating expression of the CD4 antigen.
The blood sample is not lysed; however, since
the RBCs do not express CD3 antigen, the ap-
paratus is “blind” to them. If the blood sample
is diluted 1:10, and the CD4+ T cell count is
1000/µl, it will take only 10 sec to detect 1000
CD4+ T cells, and, even at a count of 50/µl,
100 cells would be counted in 20 sec.
In attempting to detect malaria parasitemia
at low levels, it would be advantageous to use
a relatively low dilution of blood in order to
be able to analyze 1 µl in a minute or two;
the trigger signal would have to be chosen
to keep the event rate below 5000/sec. The
use of a signal from a DNA-specific fluores-
cent dye would be optimal. RBCs and platelets
do not contain DNA; WBCs and nucleated
RBCs contain several hundred times as much
DNA as do ring-form parasites and almost ten
times as much as do the latest-stage schizonts.
If blood were diluted 1:10, 0.1 µl of blood
would be analyzed each second. With a normal
WBC count, no more than 1000 trigger events
would come from WBCs, whereas, at a para-
site density of 100/µl, only 10 trigger events
would be generated by parasitized RBCs. Al-
though small amounts of free DNA are present
in blood, their size is typically well under
1 Mbp, so a threshold setting of ∼15 Mbp
would prevent either free DNA or any bacte-
ria present in blood from generating trigger
events because of septicemia or contamina-
tion. Nucleated RBCs present at levels of tens
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further diluted; the events they generated, how-
ever, would not be confused with any gener-
ated by parasitized RBCs. DNA events associ-
ated with malaria parasites in the range of 20
Mbp to a few hundred Mbp could also arise
if other parasites, e.g., trypanosomes, were
present in blood; potential interference would,
however, come from micronucleated reticulo-
cytes, which are not normally found in blood.
Micronuclei, also called Howell-Jolly bod-
ies, are chromosomal fragments that remain
in RBCs as they enter circulation after incom-
plete extrusion of the nucleus. Micronucleated
reticulocytes typically contain a few times as
much DNA as does a single malaria parasite
genome; the actual amount is highly variable,
however, whereas ring-form-parasitized RBCs
contain one, sometimes two, and occasion-
ally three copies of a genome of well-defined
size. Many CD4 counters use green (532 or
546–nm) lasers for excitation; these are typi-
cally effective at exciting a number of DNA-
specific dyes, including DRAQ5 and Vybrant
DyeCycle Ruby. Both of these fluoresce at
∼670 nm, allowing the shorter fluorescence
wavelength (∼580 nm) to be used to detect
a weaker signal, e.g., one from a fluorescent
antibody.
Although the signal from a DNA dye would
detect any parasites present in a blood sam-
ple, that signal alone would be unlikely to
permit reliable discrimination among parasite
species; it might also not completely distin-
guish parasitized RBC from micronucleated
reticulocytes. The base composition–specific
dyes thus far shown to be usable for dis-
criminating P. falciparum DNA from P. vivax
and P. knowlesi DNA require UV or violet
excitation—capabilities that are not widely
available in simpler flow cytometers. Although
one could use sequence-specific rRNA probes
for species identification, they are relatively
scarce and expensive, and sample preparation
would require nucleic acid hybridization. It
therefore seems preferable to us to adapt mon-
oclonal antibodies to parasite antigens, which
are already well characterized as components
of RDTs, for species identification by flow cy-
tometry. Since the diagnosis of P. falciparum
takes precedence, one might first run a sam-
ple stained with DNA dye and antibody to the
pLDH of that species, or to HRP2. If specific
antigens were not found, one could stain ad-
ditional aliquots with antibodies to multiple
species. If antigen expression is sufficiently
uniform, it might also be possible to use dif-
ferent dilutions of panspecific and/or species-
specific antibodies together in a multiplex as-
say that would allow detection and species
identification to be done from a single tube.
The strategy just described could be used
with even the simplest flow cytometers for di-
agnosis, for following parasite clearance on
therapy, and for determining low parasite den-
sities for epidemiologic purposes. A simple
flow cytometer could also be used with a com-
bination of DNA- and RNA-specific dyes (the
yellow fluorescent pyronin Y probably repre-
sents a good choice for the latter) to determine
resistance to antimalarials by examining the
growth of patient-derived parasites in short-
term culture. This represents the cytometric
analog of the schizont maturation assay (World
Health Organization, 2001), which was first
developed for P. falciparum, but it was also
subsequently modified to work with P. vivax,
eliminating the drawbacks of the associated
microscopy.
Of course, more complex flow cytome-
ters can be used for more complex assays,
for example, combining DNA, base compo-
sition, RNA, hemozoin, and membrane po-
tential measurements. We have already noted
that several of these measurements could also
be done simultaneously in a much simpler
and less expensive wide-field image cytome-
ter, overcoming the economic and infrastruc-
ture problems associated with flow cytometry
(Basco, 2007), but that no such image cytome-
ters now exist. We should now also point out
that we do not know of more than ten flow
cytometers worldwide that are presently con-
figured for the full range of measurements.
Dozens of these image cytometers could be
built for the cost of a single additional high-
end flow cytometer.
Economic realities have recently forced
substantial reductions in the funds available to
deal with all aspects of malaria; we remain op-
timistic that the right kind of cytometry might
actually make it easier for microscopists to
work within current fiscal constraints, putting
affordable and sustainable technology where
the malaria is and empowering those most di-
rectly affected by the disease to deal with it
more effectively.
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Mühlpfordt, H., Berger, J., and Glaser, N. 1985.
Cytofluorometry as a method for the differen-
tiation of trypanosomes. Trop. Med. Parasitol.
36:135-139.
Murray, C.J.L., Rosenfeld, L.C., Lim, S.S., An-
drews, K.G., Foreman, K.J., Haring, D., Full-
man, N., Naghavi, M., Lozano, R., and Lopez,
A.D. 2012. Global malaria mortality between
1980 and 2010: A systematic analysis. Lancet
379:413-431.
Murray, C.K., Gasser, R.A. Jr., Magill, A.J., and
Miller, R.S. 2008. Update on rapid diagnostic
testing for malaria. Clin. Microbiol. Rev. 21:97-
110.
O’Meara, W.P., Barcus, M., Wongsrichanalai, C.,
Muth, S., Maguire, J.D., Jordan, R.G., Prescott,
W.R., and McKenzie, F.E. 2006. Reader tech-
nique as a source of variability in determining
malaria parasite density by microscopy. Malar.
J. 5:118.
O’Meara, W.P., Hall, B.F., and McKenzie, F.E.
2007. Malaria vaccine efficacy: The difficulty
of detecting and diagnosing malaria. Malar. J.
6:36.
Ohrt, C., O’Meara, W.P., Remich, S., McEvoy, P.,
Ogutu, B., Mtalib, R., and Odera, J.S. 2008. Pilot
assessment of the sensitivity of the malaria thin
film. Malar. J. 7:22.
Pattanapanyasat, K., Udomsangpetch, R., and Web-
ster, H.K. 1993. Two-color flow cytometric anal-
ysis of intraerythrocytic malaria parasite DNA
and surface membrane-associated antigen in
erythrocytes infected with Plasmodium falci-
parum. Cytometry 14:449-454.
Philipp, S., Oberg, H.-H., Janssen, O., Leippe, M.,
and Gelhaus, C. 2012. Isolation of erythrocytes
infected with viable early stages of Plasmod-
ium falciparum by flow cytometry. Cytometry A
81:1048-1054.
Rebelo, M., Shapiro, H.M., Amaral, T., Melo-
Cristino, J., and Hänscheid, T. 2012. Haemozoin
detection in infected erythrocytes for Plasmod-
ium falciparum malaria diagnosis—prospects
and limitations. Acta Trop. 123:58-61.
Rebelo, M., Sousa, C., Shapiro, H.M., Mota, M.M.,
Grobusch, M.P., and Hänscheid, T. 2013. A
novel flow cytometric hemozoin detection assay
for real-time sensitivity testing of Plasmodium
falciparum. PLoS One 8:e61606.
Ross, R. 1903. An improved method for the micro-
scopical diagnosis of intermittent fever. Lancet
161:86.
Ross, R. and Thomson, D. 1910. Some enumera-
tive studies on malarial fever. Proc. Royal Soc.
London B 83:159-173.
Shapiro, H.M. 1981. Flow cytometric estimation of
DNA and RNA content in intact cells stained
with Hoechst 33342 and pyronin Y. Cytometry
2:143-150.
Shapiro, H.M. 2003. Practical Flow Cytometry, 4th
ed. Wiley-Liss, Hoboken, N.J.
Shapiro, H.M., Natale, P.J., and Kamentsky, L.A.
1979. Estimation of membrane potentials of in-
dividual lymphocytes by flow cytometry. Proc.
Natl. Acad. Sci. U.S.A. 76:5728-5730.
Sinnis, P., De La Vega, P., Coppi, A., Krzych, U.,
and Mota, M.M. 2013. Quantification of sporo-
zoite invasion, migration, and development by
microscopy and flow cytometry. Methods Mol.
Biol. 923:385-400.
Tilley, L., McFadden, G., Cowman, A., and Klonis,
N. 2007. Illuminating Plasmodium falciparum-
infected red blood cells. Trends Parasitol.
23:268-277.
Vorobjev, I.A., Buchholz, K., Prabhat, P., Ketman,
K., Egan, E.S., Marti, M., Duraisingh, M.T., and
Barteneva, N.S. 2012. Optimization of flow cy-
tometric detection and cell sorting of transgenic
Plasmodium parasites using interchangeable op-
tical filters. Malar. J. 11:312.
Wongchotigul, V., Suwanna, N., Krudsood, S.,
Chindanond, D., Kano, S., Hanaoka, N., Akai,
Y., Maekawa, Y., Nakayama, S., Kojima, S., and
Looareesuwan, S. 2004. The use of flow cytom-
etry as a diagnostic test for malaria parasites.
Southeast Asian J. Trop. Med. Public Health
35:552-559.
World Health Organization. 2001. In vitro micro-
test (mark III) for the assessment of the re-
sponse of Plasmodium falciparum to chloro-
quine, mefloquine, quinine, amodiaquine, sufa-
doxine/pyrimethamine and artemisinin. World
Health Organization, Geneva.
World Health Organization. 2008. Malaria Mi-
croscopy Quality Assurance Manual, Version 1.
World Health Organization, Geneva.
World Health Organization. 2010. Parasitologi-
cal confirmation of malaria diagnosis: Report
of a WHO technical consultation Geneva, 6-
8 October 2009. World Health Organization,
Geneva.
World Health Organization. 2011. World Malaria
Report 2011. World Health Organization,
Geneva.
Evaluation of a Novel Magneto-Optical Method for the
Detection of Malaria Parasites
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developed a magneto-optical (MO) method which allows high-sensitivity detection of malaria pigment (hemozoin crystals)
in blood via the magnetically induced rotational motion of the hemozoin crystals. Here, we evaluate this MO technique for
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Although research activities aim at developing novel methods
for high-sensitivity diagnosis of malaria, only a few of these
approaches are feasible for clinical and in-field diagnosis. The two
main diagnostic methods currently in practice are the antigen-
based detection of malaria parasites using rapid diagnostic tests
(RDT) and the microscopic observation of infected red blood cells
in blood smears [1–4]. The detection limits of RDT and light
microscopy have been reported to be approximately 100
parasites/mL and 5–50 parasites/mL, respectively [1,5–7], corre-
sponding to parasitemia levels of around 0.002% and 0.0001–
0.001%. RDT are becoming more affordable, however, they
cannot provide a quantitative measure of parasitemia. Presently
they do not possess sufficient sensitivity to detect low-level
infections which are very common in endemic settings along with
the false positive samples due to the presence of parasite protein
(HRP2) even after resolving the infection. On the other hand, light
microscopy is time and labor intensive and the detection threshold
of 5 parasites/mL is rather limited to ideal conditions such as good-
quality blood films, highly trained microscopists and high-powered
microscopes; most of which are rarely present in real life practice.
Most routine diagnostic laboratories achieve approximately 50
parasites/mL and can detect about 50% of malaria cases [6,8,9].
Molecular methods such as polymerase chain reaction (PCR)
assays surpass the performance of RTD and light microscopy
[10,11]. However, they often require expensive equipment and
reagents, highly trained laboratory personnel and are prone to
contamination [12]. Although real-time PCR has a detection limit
corresponding to a few parasites per mL of blood [13,14], it is not
yet a practical method for routine diagnosis under field conditions.
The idea to take advantage of the unique magnetic properties of
malaria pigment (hemozoin) and to use it as an alternative target of
optical diagnosis has been proposed by several groups [15–19].
Hemozoin is a micro-crystalline heme compound produced by
malaria parasites as they detoxify free heme derived from
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hemoglobin digestion [20]. Our recent study using synthetic
hemozoin crystals suspended in blood demonstrated that the
rotating-crystal magneto-optical (MO) diagnostic method can
detect hemozoin concentrations down to 15 pg/mL [15]. Using
data describing the rate of hemoglobin digestion by P. falciparum
available in the literature [21–23], this threshold concentration
was estimated to be equivalent to a parasite density of #30
parasites/mL in infected blood provided that the entire amount of
hemozoin produced by the parasites is released into the lysed cell
suspension.
However, the situation in malaria infection and thus the
requirements for diagnostic applications are different. One aspect
is that in Plasmodium falciparum infections only early developmental
forms, such as rings and early trophozoites, are usually found in
the peripheral circulation, since later developmental stages
sequester in the capillaries [24]. Furthermore, the shape and size
of hemozoin crystals may be different for synthetic and naturally
grown crystals and also depend on the developmental stages of the
parasites as well as the parasite species [25–27]. Since the MO
method detects only hemozoin crystals released into suspension
which can be magnetically rotated, the aggregation of the crystals
or their binding to other components of lysed blood could
influence the sensitivity of this technique.
In the present study we aimed to address these issues by
evaluating the performance of the MO technique using synchro-
nized cultures of P. falciparum and to investigate the limit of
detection in samples with low levels of parasitemia, which would
establish its potential usefulness for field trials. (For a short




We investigated the sensitivity and detection threshold of the
rotating-crystal MO method using two cultures (A and B) with
different maturity distributions of the parasites. The distributions
of the parasites among the different stages – early-ring, late-ring,
early-trophozoite, late-trophozoite, early-schizont and late-schiz-
ont stages – in the two cultures are displayed in Fig. 1 together
with light microscopy images of parasites representative of these
stages.
Culture A had a total parasite density of P&3.16105 parasites/
mL. Parasite stage distribution corresponded to the beginning of
the parasite life cycle following synchronization with mostly ring
stages and some early trophozoites. This culture, referred to as the
ring stage culture in the following, is representative to the distribution
of parasite blood stages most often encountered in natural P.
falciparum infections.
Culture B had a lower total parasite density of P&2.86104
parasites/mL. Parasite stage distribution corresponded to the verge
of the first and second parasite life cycles where some of the
parasites were still in the schizont form but most of them, following
invasion, already turned to early-stage rings of the next generation.
Since the main hemozoin content present in this culture was
formed during the first life cycle with a dominant contribution
from schizont stage parasites [21–23], we will refer to it as the
schizont stage culture. Schizont stage parasites are not normally found
in the peripheral blood during human P. falciparum infection due to
their sequestration in small capillary blood vessels [24]. However,
this stage restriction is not present in other, non-sequestering,
species of human malaria parasites such as P. vivax [28].
Limit of Detection
The MO signal, the measure of hemozoin content within the
lysed cell suspension, is shown in Fig. 2 for dilution series of culture
A and culture B. The 20 serial 2-fold dilutions of the two cultures
using uninfected erythrocytes allowed for the MO signal to be
assessed over 6 orders of magnitude of parasitemia. As a general
trend in Fig. 2A, the MO signal varies proportionally to the
parasitemia level and the signal for each sample shows a gradual
decrease with increasing frequencies of the rotating magnetic field.
This frequency dependence is in agreement with previous results
obtained for synthetic hemozoin crystals suspended in blood and
originates from the viscosity of the lysed cell suspension hindering
fast rotations of the crystals [15].
Samples from the dilution series of culture B exhibited higher
MO signals as compared to dilutions of culture A with the same
level of parasitemia reflecting the increase in intracellular
hemozoin content over the course of the parasite life cycle.
Although the overall frequency dependence of the MO signal is
similar for the two cultures, the more pronounced decrease with
increasing frequency found for the dilutions of culture B is likely
due to the larger crystal size formed in schizont stage parasites.
In order to determine the limit of detection limit for our
method, the MO signal at 20 Hz was plotted versus parasitemia
(and parasite density) in Fig. 2B for the dilution series of the ring
and schizont stage cultures. For reference, we also measured
uninfected blood samples using the same protocol. These showed a
residual MO signal of DT=T&461024 % in average as indicated
in Fig. 2B. This value corresponds to the mean limit of detection of
our method. At low levels of parasite density (P), namely for
samples with P#10 parasites/mL from the dilution series of the
ring stage culture, the signal does not further decrease with
decreasing parasitemia but approaches the residual level observed
for the uninfected samples. Hence, this residual MO signal is not
related to hemozoin. We note that the frequency dependence of
the residual MO signal differs from the hemozoin-dependent MO
signal dominant at higher concentrations. (See curves correspond-
ing to the ring stage sample with P = 9.5 parasites/mL, the schizont
stage sample with P = 0.5 parasites/mL and the uninfected samples
in Fig. 2A.).
For highly diluted ring stage samples with P#10 parasites/mL,
where the MO signal is independent of the parasite density, we
found that the standard deviation of the MO signal from the mean
limit of detection (represented by the signal level of uninfected
samples) is DT=T&1.661024 %. Assuming Gaussian distribution
for the residual MO signal values, the 95% confidence level of the
mean limit of detection for ring stage samples is
DT=T&7.261024 % corresponding to a parasite density of
,40 parasites/mL. This is equivalent to a parasitemia level of
0.0008%. The scattering of the data is larger for schizont stage
samples. In that case we estimated the 95% confidence level of the
mean limit of detection to be DT=T&261023 % corresponding
to a parasite density of ,10 parasites/mL or a parasitemia of
0.0002%.
The presence of a frequency-dependent residual MO signal
indicates that some components of lysed blood can be magnetically
oriented and rotated similarly to the hemozoin crystals. We have
also studied freshly drawn blood following the same lysis protocol.
The residual MO signal observed in that case was considerably
lower than found for either the ring or schizont stage samples,
which were measured following the freeze-thaw-lysis procedure
(see Fig. 2 and also Fig. S1 of the Supporting Information S1). The
noise floor of our equipment, shown for pure water in Fig. 2, is
nearly frequency independent and about one order of magnitude
smaller than the residual signal from fresh blood. This enables
Rotating-Crystal Magneto-Optical Method for Malaria Detection
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Figure 1. Distribution of parasite life cycle stages in the two Plasmodium falciparum cultures used in the present study. Panel A: The
ring stage culture contained early rings, late rings and some early trophozoites of the first generation after synchronization. The schizont stage culture
was on the verge of the first and second life cycles where most of the schizont stages have already turned to early ring stages of the second
generation following invasion. Therefore, the ring stage culture contained only the hemozoin present in the parasites up to the early trophozoite
stage, while the schizont stage culture had the entire hemozoin content formed during one generation of parasites with the largest portion
produced by schizonts. Panel B: Light microscopy images of Giemsa stained thin blood films containing infected red blood cells with parasites in
different stages of maturity (taken from these two cultures). In both panels the labels ER, LR, ET, LT, ES and LS correspond to early-ring, late-ring, early-
trophozoite, late-trophozoite, early-schizont and late-schizont stages, respectively.
doi:10.1371/journal.pone.0096981.g001
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further improvement of the detection limit provided that the
residual MO signal from blood can be reduced by optimizing
blood sample treatment.
Sequential MO measurements performed on the same sample
at different time intervals up to one hour gave identical results. In
several cases we confirmed the reproducibility of the protocol by
repeating the measurement for duplicate samples labeled as
samples #1 and samples #2 in Fig. 2B. When samples were re-
measured after being stored for 24 hours at 4uC and sonicated for
30 minutes prior to the MO measurements, typically an increase
of the MO signal of not more than 10–30% was observed.
Additional data about the effect of sonication on the MO signal,
given in Fig. S1 of the Supporting Information S1, show that
sonication increases the MO signal. We found that the elimination
of the entire freeze-thaw-sonication process from the protocol
reduces the MO signal by 30–40%. In this case, the lowest level of
parasitemia still detectable with a confidence of 95% is approx-
imately 0.0012% for ring stage parasites. Thus, the use of the
clearing solution alone appears to be sufficient if fresh blood
samples are used. Nevertheless, it seems beneficial to use
sonication, where available, especially when screening samples
with very low parasitemias.
Hemozoin Concentration of the Cultures
The hemozoin content of the two cultures can be roughly
estimated from the parasite density and the stages of parasite
development specified in Fig. 1. Ring and early trophozoite stages
respectively convert about 3–5% and 15–20% of the total
hemoglobin in the infected red blood cells to hemozoin [21,22].
Parasites in the schizont stage convert about 50–70% of
hemoglobin to hemozoin [20,29,30]. Using these hemoglobin
conversion rates, we calculated the hemozoin concentrations of the
undiluted ring and schizont stage cultures and compared them to
the amounts estimated based on our MO reference data previously
obtained for synthetic hemozoin [15]. These values are listed in
Table 1. According to the estimate based on the MO signal, the
lowest hemozoin concentration still measurable by our MO setup
using the present protocol is ,20 pg/mL, which is close to the
threshold reported for artificial crystals [15]. (This concentration
refers to the original hemozoin content of blood samples before the
20-fold dilution performed prior to MO measurements.).
The estimate based on the MO signal gives lower values for the
hemozoin content of both cultures than the estimate based on the
hemoglobin conversion rates quoted above. The comparison
between electron microscopy images of natural and synthetic
hemozoin crystals, shown in Fig. 3, implies that this difference
Figure 2. Magneto-optical (MO) detection of parasitemia in synchronized Plasmodium falciparum cultures. Panel A: Red and blue curves
show the frequency dependent MO signal for samples from the ring and schizont stage cultures, respectively, with various levels of parasite density
given in mL21 units on the right of the respective curves. The green curves shows the signal from uninfected reference samples. Data plotted with
triangles and diamonds are the residual signal from freshly hemolyzed uninfected blood and water, respectively. The frequency scale corresponds to
the rotation speed of the magnetic field. Panel B: Red and blue squares in panel B are the MO signal values measured at 20 Hz – indicated by a
vertical solid line in panel A – for the dilution series prepared from the original ring and schizont stage cultures, respectively. Solid and open squares
correspond to the duplicate samples labeled as samples #1 and samples #2. Triangles indicate the results obtained by remeasuring samples #1 with
24 h delay. The solid lines following the trend of the MO signal at higher parasite densities for ring (red line) and schizont (blue line) samples are
guides for the eye. For ring and schizont stage samples with parasite densities lower than 10 parasites/mL and 1 parasites/mL, respectively, the MO
signal does not further decrease. The green horizontal line shows the residual MO signal of uninfected blood, which is the mean detection limit of our
method. The 95% confidence levels of this mean detection limit for the ring and schizont stage samples are indicated by red and blue dashed lines,
respectively. Correspondingly, for ring and schizont stage samples with parasite density higher than 40 parasites/mL and 10 parasites/mL, respectively,
the diagnosis is positive with a confidence of at least 95%. The background signal for freshly hemolyzed uninfected blood and water are also shown
by dark and light grey lines. All these horizontal indicators are also shown in panel A for reference. The upper horizontal scale shows the
corresponding levels of parasitemia.
doi:10.1371/journal.pone.0096981.g002
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arises from the different size of the two types of crystals. The
natural crystallites in this study were considerably smaller (with
typical lengths of ,200–500 nm) than the synthetic ones (,500–
900 nm) used in our former work [15]. The weaker frequency
dependence of the MO signal observed in the present study
indicates that natural crystals are able to follow the rotation of the
magnetic field up to higher frequencies than the synthetic ones due
to their reduced size. Furthermore, the comparison between the
natural crystals within the parasites and those extracted from the
cultures confirms no major change either in the size or in the
morphology of the crystals due to our lysis-sonication protocol.
We have also studied the change in the hemozoin concentration
during the maturation of parasites using additional cultures. Our
preliminary results (displayed in Fig. S2–S4 of the Supporting
Information S1) show the gradual increase of the hemozoin
content during the maturation of the parasites and imply that
hemozoin is present in ring stages in agreement with recent works
[31–33].
Conclusions
The potential of exploiting hemozoin as a magnetic biomarker
for malaria diagnosis has stimulated extended research over the
last few decades. Taking advantage of the paramagnetic nature of
hemozoin, several approaches have been proposed to improve the
sensitivity of existing methods e.g., by magnetic separation of
malaria infected erythrocytes from whole blood prior to diagnosis
[16,34–36]. More recently, new techniques have emerged, which
directly use hemozoin as target material for magnetic diagnosis.
These techniques include detection of depolarized side-scatter in
flow cytometry [37], electrochemical magneto immunoassays [38],
magnetically enriched surface enhanced resonance Raman spec-
troscopy [39,40], acousto-optic detection [31] and magneto-
optical detection using polarized light [17,18,41]. Among them,
to the best of our knowledge, our rotating crystal MO diagnostic
technique is the first realized in a cost-effective and compact
format with excellent sensitivity.
In the present study, the detection limit of our rotating-crystal
MO diagnostic technique was found to be ,40 parasites/mL and
,10 parasites/mL for ring and schizont stage parasites, respec-
tively. These limits of detection are below the threshold currently
achievable with RDT (.100 parasites/mL) and are within the
same range as the limits of expert microscopy for malaria diagnosis
(5–50 parasites/mL) [1]. For the present set of blood samples,
which were kept frozen and thawed before the measurement, the
performance of the method was limited by a residual MO signal
due to some part of the lysed cell suspension. This residual MO
signal obscures the genuine MO signal of hemozoin at parasite
densities lower than the limits quoted above. Preliminary results
indicate that for measurements on freshly lysed blood samples,
which is the condition relevant to instant diagnosis, the detection
limit of our rotating crystal MO platform could be further
improved.
Limitations of our diagnostic technique include i) the possibility
of false positive detections due to the presence of hemozoin in the
blood, e.g. contained within white blood cells [42], for extended
periods of time after an infection has been cleared and ii) the
possibility of false negative results in case an infection only contains
very early ring stage parasites with little or no hemozoin.
Furthermore, methods targeting only hemozoin as a marker for
infection cannot distinguish between different malaria species.
However, the specificity of our MO diagnostic scheme, owing to
variations in the typical size and morphology of hemozoin crystals
produced by different species, needs to be evaluated by a
comparative study on various Plasmodium species. We emphasize
that only studies on field isolates will be able to elucidate the
impact of these possible confounding factors and the present study
is the basis for such field-based trials.
It is currently believed that without active case detection of
asymptomatic malaria infections, malaria eradication will be
impossible or very difficult to achieve [6]. However, there are no
diagnostic tools for rapidly screening hundreds of people per day,
on-site and with high sensitivity [43]. In principle, the rotating-
crystal MO diagnostic method has the potential to fulfill these
requirements as it is cost-effective, rapid and highly sensitive.
However, rigorous field based assessment of the method’s
performance as well as further method development will have to
be conducted in order to judge the value of this method.
Our preliminary results (see the Supporting Information S1)
show that the present methodology may provide an efficient in-
vitro laboratory tool to test the susceptibility of the parasites to
novel or clinically relevant antimalarial drugs by monitoring the
effect of drugs on the rate of hemozoin formation [44]. The scope
of this technique may also cover the study or diagnosis of other
human diseases, such as schistosomiasis, which are also caused by




P. falciparum parasites (laboratory adapted strain 3D7) were
cultured following the method of Trager and Jensen with
modifications [49]. The culture medium was RPMI 1640 with
L-glutamine (GIBCO cat # 31800) supplemented with 2 mg/mL
NaHCO (Merck, cat # 106329), 25 mg/L gentamicin (Pfizer, cat
Table 1. Using the hemozoin conversion rates reported in the literature for the different parasite stages (rings: 3–5%, trophozoites:
15–20%, and schizonts: 50–70%) [20–22,29,30] and the stage distribution of the parasites (Fig. 1), we estimated the hemozoin





Culture A (P = 3.16105 parasites/mL) 17–25 ng/mL 6 ng/mL
Culture B (P = 2.86104 parasites/mL) 14–23 ng/mL hemozoin 9 ng/mL
The lower and upper values of the hemozoin content correspond to the lower and upper values of the conversion rates quoted above. Note that the cultures have
different parasite densities. We also estimated the hemozoin concentration of the two cultures based on MO signal using the conversion factor cHZ = 1 ng/mL R
DT=T = 1.4% between the hemozoin concentration and the low-frequency (,1 Hz) MO signal previously determined for artificial hemozoin crystals suspended in
blood [15].
doi:10.1371/journal.pone.0096981.t001
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# 61022027), 50mg/L hypoxanthine (Calbiochem, cat # 4010),
25 mM HEPES (SAFC, cat # 90909C) and 10% pooled O+
human serum (mixed blood groups, Australian Red Cross Blood
Service). Cultures were maintained at 4% hematocrit with changes
of culture medium every 48 hours and diluted with uninfected O+
red blood cells when the parasitemia exceeded 5%. Parasites were
maintained in an atmosphere of 5% CO2 and 1% O2 in N2.
Parasite cultures were kept in stage synchrony by applying the 5%
Sorbitol method, first described by Lambros and Vanderberg [50].
Hemozoin liberated from late stage parasites by the synchroniza-
Figure 3. Hemozoin crystals observed by electron microscopy in-situ and after isolation. The transmission electron microscopy (TEM)
image in panel A and scanning electron microscopy (SEM) images in panels B, C and D show hemozoin crystals extracted from the samples previously
used for the MO measurements. The granular background of the SEM images comes from the gold coating of the glass substrate. Individual crystals
in panels C and D are marked with asterisks. The length of the black bar at the bottom right corner of each panel is 500 nm. The typical length of the
extracted hemozoin crystals ranges from 200 nm to 500 nm. For comparison, a TEM image of synthetic hemozoin crystals used in our previous MO
study [15] is shown in panel E. These synthetic crystals have more elongated shape with a typical length of 500–900 nm. Panels F and G display TEM
images of intact infected erythrocytes in the schizont stage. Distinct components of the parasite and the erythrocyte can be observed including the
erythrocyte membrane (EM), parasite membrane (PM), food vacuole membrane (FVM), merozoites (M), hemoglobin transport vesicles (HbTV), knobs
(K) and hemozoin (Hz).
doi:10.1371/journal.pone.0096981.g003
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tion process was removed by washing the cells in RPMI medium
after the Sorbitol induced cell lysis and before re-establishment of
the culture. Cultures A and B were harvested ,0 hour and ,40
hours after synchronization of the culture and prepared for the
MO study according to the following protocol.
Parasite stages and densities were determined by counting the
number of parasites in the following 6 stages: early ring (ER), late
ring (LR), early trophozoites (ET), late trophozoites (LT), early
schizonts (ES) and late schizonts (LS). For this determination 5000
red blood cells were counted on Giemsa stained thin blood films.
Parasite density values were calculated from the parasitemia values
based on the assumption that 1 mL of blood contains 56106 red
blood cells at 50% hematocrit [1]. For both cultures, 2-fold
dilution series were prepared in duplicate and adjusted to a
volume of 200 mL at a hematocrit of 50%, using human
erythrocytes (Red Cross blood bank, Royal Melbourne Hospital,
VIC, Australia). Blood lysates were prepared from the dilutions by
freeze-thawing twice and were stored at 280uC until they were
shipped for MO measurement to Hungary. The sample set also
contained uninfected reference samples.
Blood Treatment Prior MO Diagnosis
After thawing the lysates they were diluted 20-fold in distilled
water, to give a final volume of 4 mL. After adding 100 mL of a
red cell lysis buffer (2.5 V/V% Triton X-100 (Sigma-Aldrich,
Budapest, Hungary) in 0.1 M NaOH (Sigma-Aldrich, Budapest,
Hungary)) the sample was sonicated for 30 minutes to dissociate
potential aggregates prior to measurement. MO signals were
recorded on 1 mL volumes taken from the samples immediately
after sonication. The possible effect of storage was assessed by re-
measuring samples after 20 to 120 minutes kept at room
temperature and after 24 hours kept at 4uC.
Magneto-optical Measurements
MO measurements were performed blinded. Signals were
recorded using 1 mL from each lysed sample. The prototype of
the rotating magnet setup as well as the underlying physical
principles of the detection method are described in our previous
study [15]. In brief, the sample is inserted into an assembly of
permanent magnets arranged in a ring. This creates a strong
homogenous magnetic field (B = 1 T) at the center where the
sample is inserted and allows the alignment of the crystals. When
the magnetic ring is rotated, the co-aligned hemozoin crystals
follow this rotation. Polarized light from a laser diode is
transmitted through the sample in the direction perpendicular to
the plane of the rotating magnetic field. The rotation of the co-
aligned dichroic crystals gives rise to a periodic change in the
transmitted intensity (DT ), which – divided by the time-averaged
intensity (T) – corresponds to the MO signal.
In fact, we demonstrated that the MO signal is proportional to
the concentration of synthetic hemozoin crystals in the sample
[15]. The MO signal was measured with increasing rotational
speed values of the magnet, in the range of 1–130 Hertz. Our
previous study showed that a good signal-to-noise ratio is observed
in the range of 10–30 Hertz [15], and thus 20 Hertz was chosen to
investigate the limit of detection. However, the measurement of
the MO signal in the rotation frequency range of 1–130 Hertz was
performed for two reasons: i) the frequency-dependence of the
signal may provide information about the size distribution of the
freely rotating crystals and ii) the frequency-dependence may give
additional information at very low hemozoin concentrations and
help to differentiate between infected samples and uninfected
controls.
Electron Microscopy
For transmission electron microscopy (TEM), parasite samples
were fixed in resin blocks and 70–120 nm thin sections were cut
using a Leica EM UC6 microtome (Leica Microsystems, North
Ryde, NSW, Australia) and brought onto carbon coated copper
TEM grids (ProSciTech, Thuringowa, Qld., Australia). The TEM
grids were then stained with 5% uranyl acetate for 15 minutes and
Reynold’s lead citrate solution for 5 minutes. For synthetic
hemozoin, the aqueous suspension of crystals was dropped onto
formvar membrane (purchased from Sigma-Aldrich) and brought
onto carbon coated copper TEM grids. TEM was conducted on a
JEOL 2100 TEM (JEOL Inc., Tokyo, Japan).
For scanning electron microscopy (SEM), the samples giving the
highest MO signal were used and hemozoin crystals were
extracted following the method of Chen and coworkers [45].
The dark brown pellet obtained by this method was re-suspended
in 80 mL water. For SEM imaging small droplets of the suspension
containing the hemozoin crystals were applied to gold coated glass
slides without further purification or treatment. The droplets were
dried overnight at room temperature. The SEM images were
acquired on a LEO 1540XB electron microscope using the in-lens
detector. The accelerating voltage was set to 3 kV and the viewing
angle was perpendicular to the gold surface. For details of the
method see the Supporting Information S1.
Supporting Information
Supporting Information S1 Supporting information file
containing Figs. S1–S4 and supporting text.
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Paul Drain and colleagues1 proposed 
a standard set of criteria to assess 
the diagnostic accuracy, clinical 
effect, and costs of point-of-care 
(POC) tests in low-income countries 
(LICs). We agree with the authors 
on the need to improve access to 
rapid diagnostics in LICs, and we add 
several factors based on our own 
research on POC testing for common 
infections through our work at the 
Point-of-care tests: 
where is the point?
A recurrent theme in the Review by Paul 
Drain and colleagues1 is the dichotomy 
between point-of-care (POC) tests 
and their laboratory counterparts, 
which implies that these tests can be 
used outside the laboratory. Certainly, 
rapid diagnostic tests (RDTs) for 
malaria are an example of a POC test; 
however, loop-mediated isothermal 
amplification (LAMP) for malaria 
has also been touted as a possible 
POC test.2,3 This discrepancy raises 
an important question: where is the 
point of care? For example, GeneXpert 
(Cepheid, CA, USA) MTB/RIF needs basic 
lab oratory infrastructure, shifting the 
POC from a remote area to a peripheral 
laboratory.4 By contrast, RDTs allow 
effi  cient diagnosis of malaria at the POC, 
even in remote communities, far away 
from laboratories or hospitals. Despite 
the analytical advantage of nucleic acid-
based tests like LAMP, basic laboratory 
infrastructure is needed, meaning that 
it cannot be used at the same proximity 
to the POC as RDTs can.
Authors of one review define the 
setting where POC tests can be used, 
ranging from home to community, 
health post, peripheral laboratory, 
and fi nally hospital.4 Malaria tests are 
deemed POC tests in four of these fi ve 
categories. Oddly, this approach seems 
to turn almost any existing malaria 
diagnostic test into a POC test, and the 
POC into a so-called area of care, which 
is somehow contradictory in itself. The 
eff ect of this approach is the infl ationary 
use of the term POC test because there 
is little, if any, diff erence to a standard 
laboratory-based test.
Where or what is the POC for malaria 
patients, and what defines it? At 
least, tests would need to have some 
quantifiable degree of suitability for 
being a POC test? On the Foundation for 
Innovative New Diagnostics website,5 
LAMP is categorised as a “district and 
sub-district level” test, whereas the 
term POC is mentioned in the context 
of RDTs.
These questions are not mun-
dane because the term point-of-care 
could be no longer useful. The term 
could even be misused in an attempt 
to capture increasingly com petitive 
research funding or could misinform 
implementation strategies in times 
of tight budgets. In conclusion, and 
notwithstanding the many useful 
suggestions, criteria, and definitions 
provided, we believe that the otherwise 
highly valuable review by Drain and 
colleagues should have addressed this 
POC (point of consideration) more 
elaborately.
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First, POC tests are already available 
in some LICs for many infections 
not listed in panel 1 of the Review, 
including hepatitis B virus2 and 
typhoid.3 The cost effectiveness of 
POC tests improves when test kits 
for locally common infections can be 
purchased in bulk, and the positive 
predictive value associated with 
high incidence and prevalence could 
improve assessment of the test’s 
diagnostic accuracy in LIC settings.
Second, we add to the authors’ 
comments on the scarcity of research 
on real-world use of POC tests by calling 
for further comparisons of laboratory-
based with community-based and 
home-based tests. The effectiveness 
of POC tests in all three settings—the 
clinic, community, and home–needs 
further testing and validation. Reports 
of POC test studies need to describe 
environmental factors, such as 
temperature and storage conditions, 
that might aff ect the test results, and 
discuss socioeconomic and educational 
or literacy challenges that could 
have an eff ect on test results in all of 
these venues. 
Third, clear eligibility criteria should 
be included for clinicians, patients, 
and families who might be considering 
use of POC tests so that these users 
will know when use of these tests 
is appropriate. A high number of 
valid positive results will improve 
the perceived value of the tests for 
future POC use. Additionally, test kits 
designed for community-based or 
home-based use should include clear 
instructions on appropriate treatment 
for those with both a positive or 
negative test, who might need to 
consult with a clinician for additional 
tests. The goal of testing outside of care 
centres should be to shorten the time 
to initiation of appropriate treatment, 
which might need the results of several 
diff erent tests, especially if a person 
with an apparent infection or other 
illness has a negative result for an 
infectious disease POC test.
